FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Rodrigues, DAS
   Prestes, EB
   Gama, AMS
   Silva, LD
   Pinheiro, AAS
   Ribeiro, JMC
   Campos, RMP
   Pimentel-Coelho, PM
   De Souza, HS
   Dicko, A
   Duffy, PE
   Fried, M
   Francischetti, IMB
   Saraiva, EM
   Paula-Neto, HA
   Bozza, MT
AF Rodrigues, Danielle A. S.
   Prestes, Elisa B.
   Gama, Andreza M. S.
   Silva, Leandro de Souza
   Pinheiro, Ana Acacia S.
   Ribeiro, Jose Marcos C.
   Campos, Raquel M. P.
   Pimentel-Coelho, Pedro M.
   De Souza, Heitor S.
   Dicko, Alassane
   Duffy, Patrick E.
   Fried, Michal
   Francischetti, Ivo M. B.
   Saraiva, Elvira M.
   Paula-Neto, Heitor A.
   Bozza, Marcelo T.
TI CXCR4 and MIF are required for neutrophil extracellular trap release
   triggered byPlasmodium-infected erythrocytes
SO PLOS PATHOGENS
LA English
DT Article
ID CHROMATIN DECONDENSATION; CEREBRAL MALARIA; HEME OXYGENASE-1;
   PATHOGENESIS; NETOSIS; MYELOPEROXIDASE; ACCUMULATION; PHAGOCYTOSIS;
   ACTIVATION; TOLERANCE
AB Author summary Protozoans of the Plasmodium genre infect red blood cells and cause malaria in humans and various other mammalian species. Estimated malaria cases are at more than 200 million, with 450,000 deaths per year, being cerebral malaria a serious complication that accounts for the majority of deaths. Neutrophils are cells that participate in host defense against pathogens. These cells use various mechanisms to kill invading microrganisms, including the release of webs of DNA, called neutrophil extracellular traps (NETs). These NETs can help control infections but can also induce tissue damage and their role in malaria and the mechanisms of NET production during malaria infection are starting to be understood. Here we show that infected red blood cells produce a cytokine, macrophage migration inhibitory factor (MIF) that stimulates neutrophils to release NETs. These NETs function to limitPlasmodiumdissemination and, thus, digestion of NETs with DNAse treatment causes increased parasitemia and accelerated death in an experimental model of cerebral malaria. Our study uncovers the mechanism by which infected red blood cells stimulate neutrophils to release NETs and suggest an important participation of this process in malaria control.
   Neutrophil extracellular traps (NETs) evolved as a unique effector mechanism contributing to resistance against infection that can also promote tissue damage in inflammatory conditions. Malaria infection can trigger NET release, but the mechanisms and consequences of NET formation in this context remain poorly characterized. Here we show that patients suffering from severe malaria had increased amounts of circulating DNA and increased neutrophil elastase (NE) levels in plasma. We used cultured erythrocytes and isolated human neutrophils to show thatPlasmodium-infected red blood cells release macrophage migration inhibitory factor (MIF), which in turn caused NET formation by neutrophils in a mechanism dependent on the C-X-C chemokine receptor type 4 (CXCR4). NET production was dependent on histone citrullination by peptidyl arginine deiminase-4 (PAD4) and independent of reactive oxygen species (ROS), myeloperoxidase (MPO) or NE. In vitro, NETs functioned to restrain parasite dissemination in a mechanism dependent on MPO and NE activities. Finally, C57/B6 mice infected withP.bergheiANKA, a well-established model of cerebral malaria, presented high amounts of circulating DNA, while treatment with DNAse increased parasitemia and accelerated mortality, indicating a role for NETs in resistance againstPlasmodiuminfection.
C1 [Rodrigues, Danielle A. S.; Prestes, Elisa B.; Gama, Andreza M. S.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Rio De Janeiro, Brazil.
   [Silva, Leandro de Souza; Pinheiro, Ana Acacia S.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Sinalizacao Celular, Rio De Janeiro, Brazil.
   [Ribeiro, Jose Marcos C.; Francischetti, Ivo M. B.] NIAID, Sect Vector Biol, Lab Malaria & Vector Res, Rockville, MD USA.
   [Campos, Raquel M. P.; Pimentel-Coelho, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Neurobiol Celular & Mol, Rio De Janeiro, Brazil.
   [De Souza, Heitor S.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Dept Med Interna, Serv Gastroenterol, Rio De Janeiro, Brazil.
   [De Souza, Heitor S.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Dept Med Interna, Lab Multidisciplinar Pesquisa, Rio De Janeiro, Brazil.
   [De Souza, Heitor S.] Inst DOr Pesquisa & Educ IDOR, Rio De Janeiro, Brazil.
   [Dicko, Alassane] Univ Sci Tech & Technol Bamako, Fac Med Pharm & Dent, Malaria Res & Training Ctr, Bamako, Mali.
   [Duffy, Patrick E.; Fried, Michal] NIAID, Lab Malaria Immunol & Vaccinol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Saraiva, Elvira M.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Imunobiol Leishmanioses, Rio De Janeiro, Brazil.
   [Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Dept Biotecnol Farmaceut, Lab Alvos Mol, Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Rio De Janeiro, Brazil.; Paula-Neto, HA (corresponding author), Univ Fed Rio de Janeiro, Fac Farm, Dept Biotecnol Farmaceut, Lab Alvos Mol, Rio De Janeiro, Brazil.
EM heitorapneto@gmail.com; mbozza@micro.ufrj.br
RI de Souza, Heitor/G-3297-2012
OI de Souza, Heitor/0000-0002-3647-7324; Rodrigues,
   Danielle/0000-0003-2120-3352
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Fundacao de Amparo a Pesquisa do
   Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX This work was financially supported by Conselho Nacional de Pesquisa
   (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES) and Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Baker VS, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-41
   Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497
   Behnen M, 2014, J IMMUNOL, V193, P1954, DOI 10.4049/jimmunol.1400478
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Boxio R, 2004, J LEUKOCYTE BIOL, V75, P604, DOI 10.1189/jlb.0703340
   Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987
   Byrd AS, 2013, J IMMUNOL, V190, P4136, DOI 10.4049/jimmunol.1202671
   Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530
   CELADA A, 1983, J PARASITOL, V69, P49, DOI 10.2307/3281273
   Chen L, 2000, CLIN EXP IMMUNOL, V120, P125, DOI 10.1046/j.1365-2249.2000.01196.x
   Claser C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018720
   Cumnock K, 2018, CURR BIOL, V28, P1635, DOI 10.1016/j.cub.2018.04.009
   de Koning-Ward TF, 2016, NAT REV MICROBIOL, V14, P494, DOI 10.1038/nrmicro.2016.79
   de Oliveira RB, 2014, MBIO, V5, DOI 10.1128/mBio.00949-14
   Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Dwyer M, 2014, J INNATE IMMUN, V6, P765, DOI 10.1159/000363242
   Feintuch CM, 2016, MBIO, V7, DOI 10.1128/mBio.01300-15
   Garcia AB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05041-7
   Gosswein S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02481
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Greve B, 1999, J INFECT DIS, V179, P1584, DOI 10.1086/314780
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Imwong M, 2015, J INFECT DIS, V211, P1128, DOI 10.1093/infdis/jiu590
   Ioannidis LJ, 2016, J IMMUNOL, V196, P1227, DOI 10.4049/jimmunol.1501562
   Karsten E, 2018, CYTOKINE, V102, P34, DOI 10.1016/j.cyto.2017.12.005
   Kho S, 2019, J INFECT DIS, V219, P1994, DOI 10.1093/infdis/jiy661
   Kingston HW, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx169
   Knackstedt SL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0336
   Kumaratilake LM, 2000, CLIN DIAGN LAB IMMUN, V7, P9, DOI 10.1128/CDLI.7.1.9-13.2000
   Ley K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4579
   Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239
   Mantel PY, 2013, CELL HOST MICROBE, V13, P521, DOI 10.1016/j.chom.2013.04.009
   McCormick CJ, 1997, J CLIN INVEST, V100, P2521, DOI 10.1172/JCI119794
   Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171
   Otterdal K, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3593-8
   Pais TF, 2005, J NEUROIMMUNOL, V163, P73, DOI 10.1016/j.jneuroim.2005.02.009
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052
   Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50
   Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675
   Porcherie A, 2011, J EXP MED, V208, P2225, DOI 10.1084/jem.20110845
   Ramos S, 2019, P NATL ACAD SCI USA, V116, P5681, DOI 10.1073/pnas.1822024116
   Ribacke U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069781
   Schumak B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124080
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Sercundes MK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006054
   Sidibe T, 2008, Mali Med, V23, P34
   Thiam HR, 2020, P NATL ACAD SCI USA, V117, P7326, DOI 10.1073/pnas.1909546117
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Villegas-Mendez A, 2012, J IMMUNOL, V189, P968, DOI 10.4049/jimmunol.1200688
   Wang A, 2018, P NATL ACAD SCI USA, V115, P11042, DOI 10.1073/pnas.1806376115
   Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072
   Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847
   Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367
NR 55
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD AUG
PY 2020
VL 16
IS 8
AR e1008230
DI 10.1371/journal.ppat.1008230
PG 23
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NE5SA
UT WOS:000562659700002
PM 32797076
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Silva, RCMC
   Travassos, LH
   Paiva, CN
   Bozza, MT
AF Silva, Rafael C. M. C.
   Travassos, Leonardo H.
   Paiva, Claudia N.
   Bozza, Marcelo T.
TI Heme oxygenase-1 in protozoan infections: A tale of resistance and
   disease tolerance
SO PLOS PATHOGENS
LA English
DT Review
ID TRYPANOSOMA-CRUZI INFECTION; NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE;
   CEREBRAL MALARIA; TNF-ALPHA; METABOLIC ADAPTATION; CONFERS TOLERANCE;
   GENE-EXPRESSION; CELL PROTECTION; BILIVERDIN
AB Heme oxygenase (HO-1) mediates the enzymatic cleavage of heme, a molecule with proinflammatory and prooxidant properties. HO-1 activity deeply impacts host capacity to tolerate infection through reduction of tissue damage or affecting resistance, the ability of the host to control pathogen loads. In this Review, we will discuss the contribution of HO-1 in different and complex protozoan infections, such as malaria, leishmaniasis, Chagas disease, and toxoplasmosis. The complexity of these infections and the pleiotropic effects of HO-1 constitute an interesting area of study and an opportunity for drug development.
C1 [Silva, Rafael C. M. C.; Paiva, Claudia N.; Bozza, Marcelo T.] Univ Fed Rio Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Rio De Janeiro, Brazil.
   [Travassos, Leonardo H.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunoreceptores & Sinalizacao, Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes)CAPES; Fundacao de Amparo a Pesquisa do
   Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX Conselho Nacional de Pesquisa (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (Capes) and Fundacao de Amparo a Pesquisa do
   Rio de Janeiro (FAPERJ). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ademolue TW, 2017, CLIN EXP IMMUNOL, V188, P283, DOI 10.1111/cei.12936
   Agarwal Anupam, 2013, Trans Am Clin Climatol Assoc, V124, P111
   Amoako N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112868
   Andrade SG, 2008, MEM I OSWALDO CRUZ, V103, P21, DOI 10.1590/S0074-02762008005000006
   [Anonymous], 2017, LANCET HIV, V2017, pPE475
   [Anonymous], 2016, THE TOTAL AUDIENCE R
   Araujo ECB, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-89
   Ayres JS, 2008, PLOS BIOL, V6, P2764, DOI 10.1371/journal.pbio.0060305
   Battersby AJ, 2010, PEDIATR BLOOD CANCER, V55, P401, DOI 10.1002/pbc.22461
   Bereswill S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015099
   Blos M, 2003, EUR J IMMUNOL, V33, P1224, DOI 10.1002/eji.200323825
   Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015
   Bundesarztekammer, 2014, DTSCH ARZTEBL, V111, pA1583
   Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105
   Carruthers VB, 2002, ACTA TROP, V81, P111, DOI 10.1016/S0001-706X(01)00201-7
   Cassat JE, 2013, CELL HOST MICROBE, V13, P510, DOI 10.1016/j.chom.2013.04.010
   Chen J, 2014, DIABETES METAB J, V38, P337, DOI 10.4093/dmj.2014.38.5.337
   Chung SW, 2009, CELL MICROBIOL, V11, P199, DOI 10.1111/j.1462-5822.2008.01261.x
   Church J, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-31
   Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643
   Cosentino RO, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001777
   Cunnington AJ, 2012, J IMMUNOL, V189, P5336, DOI 10.4049/jimmunol.1201028
   Das S, 2013, J ANTIMICROB CHEMOTH, V68, P2059, DOI 10.1093/jac/dkt162
   Cataneo AHD, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108745
   Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255
   DRUMMOND GS, 1981, J EXP MED, V153, P245, DOI 10.1084/jem.153.2.245
   Duan X. C., 2015, AM J PHYSIOL-HEART C, V308, pH603
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   El Fadili K, 2008, ANTIMICROB AGENTS CH, V52, P526, DOI 10.1128/AAC.01183-07
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Fatoohi AF, 2004, CLIN EXP IMMUNOL, V136, P535, DOI 10.1111/j.1365-2249.2004.02466.x
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Frade AF, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-587
   Geroldinger G, 2020, BIOCHEM PHARMACOL, V173, DOI 10.1016/j.bcp.2019.113737
   Gonzales S, 2002, DEV NEUROSCI-BASEL, V24, P161, DOI 10.1159/000065686
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Grochot-Przeczek A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005803
   Gutierrez FRS, 2014, MICROBES INFECT, V16, P28, DOI 10.1016/j.micinf.2013.10.007
   Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87
   Issan Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092246
   Jansen T, 2010, J MOL CELL CARDIOL, V49, P186, DOI 10.1016/j.yjmcc.2010.04.011
   Jentho E, 2019, HEME INDUCES INNATE, DOI [10.1101/2019.12.12.874578, DOI 10.1101/2019.12.12.874578]
   Jiang F, 2006, HYPERTENSION, V48, P950, DOI 10.1161/01.HYP.0000242336.58387.1f
   Kapturczak MH, 2004, AM J PATHOL, V165, P1045, DOI 10.1016/S0002-9440(10)63365-2
   Kim SJ, 2013, FREE RADICAL BIO MED, V65, P997, DOI 10.1016/j.freeradbiomed.2013.08.178
   Kirchhoff LV, 2011, ADV PARASIT, V75, P1, DOI 10.1016/B978-0-12-385863-4.00001-0
   Knackstedt SL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0336
   Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425
   Koreny L, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003088
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Kroll-Palhares K, 2008, MEM I OSWALDO CRUZ, V103, P375, DOI 10.1590/S0074-02762008000400011
   Kuesap J, 2010, KOREAN J PARASITOL, V48, P15, DOI 10.3347/kjp.2010.48.1.15
   Lara FA, 2007, BIOCHEM BIOPH RES CO, V355, P16, DOI 10.1016/j.bbrc.2006.12.238
   Larsen K, 2010, TRENDS CARDIOVAS MED, V20, P58, DOI 10.1016/j.tcm.2010.04.001
   Lehmann E, 2010, HEPATOLOGY, V51, P398, DOI 10.1002/hep.23339
   Liao YF, 2013, WORLD J GASTROENTERO, V19, P3555, DOI 10.3748/wjg.v19.i23.3555
   Liu ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034280
   Lopera-Mesa TM, 2013, J INFECT DIS, V207, P1655, DOI 10.1093/infdis/jit082
   Luz NF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02779
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Malta-Santos H, 2017, SCI REP-UK, V7, DOI 10.1038/srep46363
   de Almeida BFM, 2017, IMMUNOBIOLOGY, V222, P693, DOI 10.1016/j.imbio.2016.12.006
   Martins R, 2016, NAT IMMUNOL, V17, P1361, DOI 10.1038/ni.3590
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Mendonca VRR, 2012, INFECT IMMUN, V80, P1445, DOI 10.1128/IAI.05933-11
   Miranda-Sapla MM, 2019, EUR J PHARMACOL, V853, P275, DOI 10.1016/j.ejphar.2019.03.049
   Miu J, 2008, J IMMUNOL, V180, P1217, DOI 10.4049/jimmunol.180.2.1217
   Motaghiannezam Reza, 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P2862
   Motterlini R, 2000, J BIOL CHEM, V275, P13613, DOI 10.1074/jbc.275.18.13613
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   Nagajyothi F, 2012, PARASITOL RES, V110, P2491, DOI 10.1007/s00436-011-2790-9
   Nissapatorn V, 2004, JPN J INFECT DIS, V57, P160
   Nobre LS, 2007, ANTIMICROB AGENTS CH, V51, P4303, DOI 10.1128/AAC.00802-07
   Oliveira LB, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00237
   Otterbein LE, 2000, NAT MED, V6, P422
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Paradkar PN, 2008, BLOOD, V112, P866, DOI 10.1182/blood-2007-12-126854
   Parfenova H, 2012, J CEREBR BLOOD F MET, V32, P1024, DOI 10.1038/jcbfm.2012.13
   Percario S, 2012, INT J MOL SCI, V13, P16346, DOI 10.3390/ijms131216346
   Pereira MLM, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00161
   Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Ferreira LRP, 2014, INT J CARDIOL, V175, P409, DOI 10.1016/j.ijcard.2014.05.019
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Quintela-Carvalho G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01620
   Ramos S, 2019, P NATL ACAD SCI USA, V116, P5681, DOI 10.1073/pnas.1822024116
   Ricchetti GA, 2004, J LEUKOCYTE BIOL, V76, P719, DOI 10.1189/jlb.0104046
   Saha S, 2019, J IMMUNOL, V202, P827, DOI 10.4049/jimmunol.1800958
   SALZMAN TA, 1986, COMP BIOCHEM PHYS B, V85, P537, DOI 10.1016/0305-0491(86)90043-X
   Santangelo R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00036
   Schluesener HJ, 2001, ACTA NEUROPATHOL, V101, P65
   Schulz S, 2015, PEDIATR RES, V77, P640, DOI 10.1038/pr.2015.22
   SCHWARTZMAN J, 1948, J PEDIATR-US, V33, P66, DOI 10.1016/S0022-3476(48)80154-X
   Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Sharma U, 2009, INDIAN J EXP BIOL, V47, P412
   Singh N, 2018, IUBMB LIFE, V70, P869, DOI 10.1002/iub.1868
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063
   Souza CF, 2009, BIOCHEM BIOPH RES CO, V390, P541, DOI 10.1016/j.bbrc.2009.09.135
   STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864
   Suttner DM, 1999, FASEB J, V13, P1800
   Takeda M, 2005, JPN J INFECT DIS, V58, P268
   Tavares A. F., 2013, DFG, V8, DOI 10.1371/joumal.pone.0083157
   Tolosano E, 2010, ANTIOXID REDOX SIGN, V12, P305, DOI 10.1089/ars.2009.2787
   Tomiotto-Pellissier F, 2018, BIOMED PHARMACOTHER, V98, P662, DOI 10.1016/j.biopha.2017.12.083
   Varo R, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2195-7
   VELIMIROVIC B, 1984, INFECTION, V12, P315, DOI 10.1007/BF01651143
   Vijayan V, 2011, J IMMUNOL, V187, P817, DOI 10.4049/jimmunol.1003631
   Vilar-Pereira G, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005947
   Walker DM, 2014, CELL MOL LIFE SCI, V71, P1245, DOI 10.1007/s00018-013-1491-1
   Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579
   Wegiel B, 2014, J CLIN INVEST, V124, P4926, DOI 10.1172/JCI72853
   Weis S, 2017, CELL, V169, P1263, DOI 10.1016/j.cell.2017.05.031
   Wong TH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168919
   World Health Organization, WORLD MAL REP 2018
   World Health Organization, WORLD MAL REP 2019
   WU TW, 1991, BIOCHEM CELL BIOL, V69, P828, DOI 10.1139/o91-123
   Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993
   Zhang LY, 2014, J BIOL CHEM, V289, P26847, DOI 10.1074/jbc.M114.590554
   Zhu ZW, 2010, HEPATOLOGY, V52, P1897, DOI 10.1002/hep.23921
NR 129
TC 1
Z9 1
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD JUL
PY 2020
VL 16
IS 7
AR e1008599
DI 10.1371/journal.ppat.1008599
PG 18
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA MT3IM
UT WOS:000554861900001
PM 32692767
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bozza, MT
   Jeney, V
AF Bozza, Marcelo T.
   Jeney, Viktoria
TI Pro-inflammatory Actions of Heme and Other Hemoglobin-Derived DAMPs
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE hemoglobin; heme; TLR4 (toll-like receptor 4); NLRP3; DAMP; hemolysis
   (red blood cells)
ID RED-BLOOD-CELLS; INTRACEREBRAL HEMORRHAGE; NEUTROPHIL ACTIVATION;
   COMPLEMENT ACTIVATION; SUBARACHNOID HEMORRHAGE; INTRAVASCULAR HEMOLYSIS;
   METABOLIC ADAPTATION; NLRP3 INFLAMMASOME; HYDROGEN-PEROXIDE;
   MASS-SPECTROMETRY
AB Damage associated molecular patterns (DAMPs) are endogenous molecules originate from damaged cells and tissues with the ability to trigger and/or modify innate immune responses. Upon hemolysis hemoglobin (Hb) is released from red blood cells (RBCs) to the circulation and give a rise to the production of different Hb redox states and heme which can act as DAMPs. Heme is the best characterized Hb-derived DAMP that targets different immune and non-immune cells. Heme is a chemoattractant, activates the complement system, modulates host defense mechanisms through the activation of innate immune receptors and the heme oxygenase-1/ferritin system, and induces innate immune memory. The contribution of oxidized Hb forms is much less studied, but some evidence show that these species might play distinct roles in intravascular hemolysis-associated pathologies independently of heme release. This review aims to summarize our current knowledge about the formation and pro-inflammatory actions of heme and other Hb-derived DAMPs.
C1 [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, Rio De Janeiro, Brazil.
   [Jeney, Viktoria] Univ Debrecen, Fac Med, Res Ctr Mol Med, MTA DE Lendulet Vasc Pathophysiol Res Grp, Debrecen, Hungary.
RP Jeney, V (corresponding author), Univ Debrecen, Fac Med, Res Ctr Mol Med, MTA DE Lendulet Vasc Pathophysiol Res Grp, Debrecen, Hungary.
EM jeney.viktoria@med.unideb.hu
FU Hungarian National Research, Development and Innovation Office (NKFIH)
   [K131535]; Hungarian Academy of Sciences, MTA-DE Lendulet Vascular
   Pathophysiology Research Group [96050]; Brazilian agency FAPERJCarlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Brazilian agency CNPqNational Council for Scientific
   and Technological Development (CNPq); Brazilian agency CAPESCAPES
FX This research was funded by the Hungarian National Research, Development
   and Innovation Office (NKFIH), Grant No. K131535 and by the Hungarian
   Academy of Sciences, MTA-DE Lendulet Vascular Pathophysiology Research
   Group, Grant No. 96050. MB received support from the Brazilian agencies
   FAPERJ, CNPq, and CAPES.
CR Alayash AI, 2011, CLIN CHIM ACTA, V412, P493, DOI 10.1016/j.cca.2010.12.011
   Alayash AI, 2001, ANTIOXID REDOX SIGN, V3, P313, DOI 10.1089/152308601300185250
   Andersen CBF, 2012, NATURE, V489, P456, DOI 10.1038/nature11369
   Arruda MA, 2005, MEM I OSWALDO CRUZ, V100, P799, DOI 10.1590/S0074-02762005000700022
   Arruda MA, 2006, EXP CELL RES, V312, P3939, DOI 10.1016/j.yexcr.2006.08.022
   Banerjee S, 2012, FREE RADICAL BIO MED, V53, P1317, DOI 10.1016/j.freeradbiomed.2012.07.023
   Barcellos-de-Souza P, 2013, AM J PHYSIOL-CELL PH, V304, pC170, DOI 10.1152/ajpcell.00078.2012
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200
   Boyle JJ, 2012, CIRC RES, V110, P20, DOI 10.1161/CIRCRESAHA.111.247577
   Boyle JJ, 2009, AM J PATHOL, V174, P1097, DOI 10.2353/ajpath.2009.080431
   Bratosin D, 1998, BIOCHIMIE, V80, P173, DOI 10.1016/S0300-9084(98)80024-2
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Buehler PW, 2009, BLOOD, V113, P2578, DOI 10.1182/blood-2008-08-174466
   Bulters D, 2018, NAT REV NEUROL, V14, P416, DOI 10.1038/s41582-018-0020-0
   Byrnes JR, 2017, BLOOD, V130, P1795, DOI 10.1182/blood-2017-03-745349
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Chen Y, 2015, J CELL MOL MED, V19, P2715, DOI 10.1111/jcmm.12657
   Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
   CONNOR J, 1994, J BIOL CHEM, V269, P2399
   de Back DZ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00009
   de Souza GR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176505
   deCiutiis A C, 1978, J Natl Med Assoc, V70, P503
   Deterding LJ, 2004, J BIOL CHEM, V279, P11600, DOI 10.1074/jbc.M310704200
   Dimitrov JD, 2008, AUTOIMMUN REV, V7, P574, DOI 10.1016/j.autrev.2008.04.009
   Dimitrov JD, 2007, J BIOL CHEM, V282, P26696, DOI 10.1074/jbc.M702751200
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688
   Erdei J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00228
   Erdei J, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4310816
   Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Finn AV, 2012, J AM COLL CARDIOL, V59, P166, DOI 10.1016/j.jacc.2011.10.852
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Frimat M, 2013, BLOOD, V122, P282, DOI 10.1182/blood-2013-03-489245
   Galea J, 2012, J NEUROCHEM, V121, P785, DOI 10.1111/j.1471-4159.2012.07716.x
   Ganz T, 2012, J INNATE IMMUN, V4, P446, DOI 10.1159/000336423
   Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557
   Haldar M, 2014, CELL, V156, P1223, DOI 10.1016/j.cell.2014.01.069
   HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555
   Helms CC, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00125
   Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992
   Hochsmann B, 2019, J CLIN INVEST, V129, P5123, DOI 10.1172/JCI123501
   HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x
   Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185
   Jeney V, 2018, EXPERIENTIA SUPPL, V108, P211, DOI 10.1007/978-3-319-89390-7_9
   Jeney V, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/703571
   Jentho E, 2019, HEME INDUCES INNATE, DOI [10.1101/2019.12.12.874578, DOI 10.1101/2019.12.12.874578]
   Jia YP, 2007, J BIOL CHEM, V282, P4894, DOI 10.1074/jbc.M609955200
   Kassa T, 2016, FEBS OPEN BIO, V6, P876, DOI 10.1002/2211-5463.12103
   Kato GJ, 2017, J CLIN INVEST, V127, P750, DOI 10.1172/JCI89741
   Knackstedt SL, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw0336
   Kohl J, 2006, ADV EXP MED BIOL, V586, P71
   Kono M, 2014, TRANSFUSION, V54, P2811, DOI 10.1111/trf.12700
   Kono M, 2013, BLOOD TRANSFUS-ITALY, V11, P53, DOI 10.2450/2012.0141-11
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Kuck JL, 2018, BIOCHEM BIOPH RES CO, V495, P433, DOI 10.1016/j.bbrc.2017.11.058
   Kwon MS, 2015, INT J MOL SCI, V16, P5028, DOI 10.3390/ijms16035028
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Li YX, 2016, MOL IMMUNOL, V77, P148, DOI 10.1016/j.molimm.2016.07.018
   Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46
   Liu XY, 2003, AM J PHYSIOL-CELL PH, V285, pC1036, DOI 10.1152/ajpcell.00164.2003
   LOGUE GL, 1973, J CLIN INVEST, V52, P1129, DOI 10.1172/JCI107279
   Ma B, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0490-1
   Mai JT, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-61
   Martins R, 2016, NAT IMMUNOL, V17, P1361, DOI 10.1038/ni.3590
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Mendonca R, 2016, INFLAMM RES, V65, P665, DOI 10.1007/s00011-016-0955-9
   Merle NS, 2019, P NATL ACAD SCI USA, V116, P6280, DOI 10.1073/pnas.1814797116
   Merle NS, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96910
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Miller YI, 1997, BIOCHEMISTRY-US, V36, P12189, DOI 10.1021/bi970258a
   Mohanty JG, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00084
   MOLD C, 1995, CLIN IMMUNOL IMMUNOP, V76, P314, DOI 10.1006/clin.1995.1131
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Moraes JA, 2012, ATHEROSCLEROSIS, V224, P394, DOI 10.1016/j.atherosclerosis.2012.07.043
   Muckenthaler MU, 2017, CELL, V168, P344, DOI 10.1016/j.cell.2016.12.034
   MURRAY RK, 1961, BLOOD, V17, P45, DOI 10.1182/blood.V17.1.45.45
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Nyakundi BB, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/8929020
   Nyakundi BB, 2019, BBA-MOL BASIS DIS, V1865, P464, DOI 10.1016/j.bbadis.2018.10.030
   Ohbuchi Ayako, 2017, Biochem Biophys Rep, V11, P147, DOI 10.1016/j.bbrep.2017.07.009
   Opitz B, 2009, THROMB HAEMOSTASIS, V102, P1103, DOI 10.1160/TH09-05-0323
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916
   Pawluczkowycz AW, 2007, J IMMUNOL, V179, P5543, DOI 10.4049/jimmunol.179.8.5543
   Pimenova T, 2010, J PROTEOME RES, V9, P4061, DOI 10.1021/pr100252e
   POHLMAN TH, 1986, J IMMUNOL, V136, P4548
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Posta N, 2020, LAB INVEST, V100, P986, DOI 10.1038/s41374-020-0403-x
   Quintin J, 2014, CURR OPIN IMMUNOL, V29, P1, DOI 10.1016/j.coi.2014.02.006
   Rafikova O, 2018, AM J RESP CELL MOL, V59, P334, DOI 10.1165/rcmb.2017-0308OC
   Ramirez DC, 2003, FREE RADICAL BIO MED, V34, P830, DOI 10.1016/S0891-5849(02)01437-5
   Ramos S, 2019, P NATL ACAD SCI USA, V116, P5681, DOI 10.1073/pnas.1822024116
   Reeder BJ, 2008, FREE RADICAL BIO MED, V44, P274, DOI 10.1016/j.freeradbiomed.2007.06.030
   Rosales C, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1469780
   Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653
   Roumenina LT, 2020, AM J HEMATOL, V95, P456, DOI 10.1002/ajh.25742
   Ruiz-Torres MP, 2005, THROMB HAEMOSTASIS, V93, P443, DOI 10.1160/TH04-07-0450
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354
   Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528
   Schaer DJ, 2006, BLOOD, V107, P373, DOI 10.1182/blood-2005-03-1014
   Schaer DJ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00415
   Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229
   Schallner N, 2015, J CLIN INVEST, V125, P2609, DOI 10.1172/JCI78443
   Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432
   Schneider UC, 2018, CURR NEUROPHARMACOL, V16, P1385, DOI 10.2174/1570159X16666180412110919
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Siems WG, 2000, CLIN NEPHROL, V53, pS9
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   Singla S, 2017, AM J RESP CELL MOL, V57, P307, DOI 10.1165/rcmb.2016-0287OC
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Sparkenbaugh EM, 2020, BLOOD, V135, P1783, DOI 10.1182/blood.2019003543
   Sparkenbaugh EM, 2015, HAEMATOLOGICA, V100, P308, DOI 10.3324/haematol.2014.114728
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   TAPPEL AL, 1955, J BIOL CHEM, V217, P721
   Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Thomas AM, 2019, J IMMUNOL, V203, P1571, DOI 10.4049/jimmunol.1900047
   Travassos LH, 2017, AUTOPHAGY, V13, P625, DOI 10.1080/15548627.2016.1271515
   Vallelian F, 2008, FREE RADICAL BIO MED, V45, P1150, DOI 10.1016/j.freeradbiomed.2008.07.013
   van Bijnen STA, 2015, J THROMB HAEMOST, V13, P2004, DOI 10.1111/jth.13125
   van der Heijden CDCC, 2018, ANTIOXID REDOX SIGN, V29, P1023, DOI 10.1089/ars.2017.7310
   VanderZee J, 1996, FREE RADICAL BIO MED, V20, P199, DOI 10.1016/0891-5849(95)02031-4
   Vasconcellos LRC, 2016, P NATL ACAD SCI USA, V113, pE7474, DOI 10.1073/pnas.1608928113
   Vinchi F, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00094
   Wagener BM, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002522
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038
   Weis S, 2017, CELL, V169, P1263, DOI 10.1016/j.cell.2017.05.031
   Willekens FLA, 2003, BLOOD, V101, P747, DOI 10.1182/blood-2002-02-0500
   Willekens FLA, 2008, BRIT J HAEMATOL, V141, P549, DOI 10.1111/j.1365-2141.2008.07055.x
   Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097
   Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003
NR 146
TC 3
Z9 3
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 30
PY 2020
VL 11
AR 1323
DI 10.3389/fimmu.2020.01323
PG 13
WC Immunology
SC Immunology
GA MQ3CO
UT WOS:000552774700001
PM 32695110
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vidal, VM
   Ferreira, LM
   Gama, AM
   de Farias, JND
   Yilmaz, B
   Raghavan, V
   Littman, D
   do Canto, FB
   de Souza, HS
   Bozza, MT
AF Vidal, Vinicius M.
   Ferreira, Leticia M.
   Gama, Andreza M.
   de Farias, Jose Nazioberto D.
   Yilmaz, Bahtiyar
   Raghavan, Varsha
   Littman, Dan
   do Canto, Fabio B.
   de Souza, Heitor S.
   Bozza, Marcelo T.
TI DANGEROUS LIAISONS: CO-HOUSING WITH MIF-/- MICE TRIGGERS EARLY AND
   SEVERE COLITIS IN IL10-/- MICE
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Crohn's and Colitis Congress
CY JAN 23-25, 2020
CL Austin, TX
NR 0
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2020
VL 158
IS 6
SU 1
MA Tu1236
BP S1029
EP S1029
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA LY2KR
UT WOS:000540349503314
DA 2020-12-01
ER

PT J
AU Bozza, MT
   Lintomen, L
   Kitoko, JZ
   Paiva, CN
   Olsen, PC
AF Bozza, Marcelo T.
   Lintomen, Leticia
   Kitoko, Jamil Z.
   Paiva, Claudia N.
   Olsen, Priscilla C.
TI The Role of MIF on Eosinophil Biology and Eosinophilic Inflammation
SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
LA English
DT Article
DE MIF; Eosinophil; Inflammation; Helminth; Allergy
ID MIGRATION-INHIBITORY FACTOR; ALLERGIC AIRWAY INFLAMMATION; PARASITIC
   NEMATODE; SCHISTOSOMA-MANSONI; CHEMOKINE RECEPTORS; REGULATORY ROLE;
   MURINE MODEL; MACROPHAGE; CYTOKINE; EXPRESSION
AB Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine that participates in innate and adaptive immune responses. MIF contributes to the resistance against infection agents, but also to the cellular and tissue damage in infectious, autoimmune, and allergic diseases. In the past years, several studies demonstrated a critical role for MIF in the pathogenesis of type-2-mediated inflammation, including allergy and helminth infection. Atopic patients have increased MIF amounts in affected tissues, mainly produced by immune cells such as macrophages, Th2 cells, and eosinophils. Increased MIF mRNA and protein are found in activated Th2 cells, while eosinophils stock pre-formed MIF protein and secrete high amounts of MIF upon stimulation. In mouse models of allergic asthma, the lack of MIF causes an almost complete abrogation of the cardinal signs of the disease including mucus secretion, eosinophilic inflammation, and airway hyper-responsiveness. Additionally, blocking the expression of MIF in animal models leads to significant reduction of pathological signs of eosinophilic inflammation such as rhinitis, atopic dermatitis, eosinophilic esophagitis and helminth infection. A number of studies indicate that MIF is important in the effector phase of type-2 immune responses, while its contribution to Th2 differentiation and IgE production is not consensual. MIF has been found to intervene in different aspects of eosinophil physiology including differentiation, survival, activation, and migration. CD4+ T cells and eosinophils express CD74 and CXCR4, receptors able to signal upon MIF binding. Blockage of these receptors with neutralizing antibodies or small molecule antagonists also succeeds in reducing the signals of inflammation in experimental allergic models. Together, these studies demonstrate an important contribution of MIF on eosinophil biology and in the pathogenesis of allergic diseases and helminth infection.
C1 [Bozza, Marcelo T.; Lintomen, Leticia; Kitoko, Jamil Z.; Paiva, Claudia N.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, Inst Microbiol, Rio De Janeiro, RJ, Brazil.
   [Kitoko, Jamil Z.; Olsen, Priscilla C.] Univ Fed Rio de Janeiro, Fac Farm, Dept Anal Clin & Toxicol, Lab Bacteriol & Imunol Clin, Rio De Janeiro, RJ, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, Inst Microbiol, Rio De Janeiro, RJ, Brazil.
EM mbozza@micro.ufrj.br
RI Olsen, Priscilla C/I-8994-2012; Kitoko, Jamil/AAY-1595-2020
OI Olsen, Priscilla C/0000-0002-8795-037X; Kitoko,
   Jamil/0000-0003-0973-5460
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brasil (CAPES)CAPES [001]
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance
   Code 001 to MT Bozza.
CR Amano T, 2007, INFLAMM RES, V56, P24, DOI 10.1007/s00011-007-5184-9
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608
   Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Bozza Marcelo T, 2012, J Parasitol Res, V2012, P413052, DOI 10.1155/2012/413052
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Calandra T, 2017, CRIT REV IMMUNOL, V37, P359, DOI 10.1615/CritRevImmunol.v37.i2-6.90
   Cavalcanti MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025259
   Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384
   Chen PF, 2010, MOL MED, V16, P400, DOI 10.2119/molmed.2009.00128
   Cho MK, 2015, PARASITE IMMUNOL, V37, P180, DOI 10.1111/pim.12172
   Cho MK, 2011, PARASITE IMMUNOL, V33, P265, DOI 10.1111/j.1365-3024.2010.01276.x
   Damle SR, 2017, MUCOSAL IMMUNOL, V10, P205, DOI 10.1038/mi.2016.29
   Das R, 2011, J CLIN IMMUNOL, V31, P666, DOI 10.1007/s10875-011-9541-7
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842
   Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017
   Davis BP, 2018, CLIN REV ALLERG IMMU, V55, P19, DOI 10.1007/s12016-017-8665-9
   de Souza HS, 2015, MUCOSAL IMMUNOL, V8, P1154, DOI 10.1038/mi.2015.6
   Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348
   Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585
   Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC
   Fulkerson PC, 2014, J IMMUNOL, V193, P4043, DOI 10.4049/jimmunol.1400732
   Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160
   Gregory JL, 2006, J IMMUNOL, V177, P8072, DOI 10.4049/jimmunol.177.11.8072
   Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006
   Greven D, 2010, EXPERT OPIN THER TAR, V14, P253, DOI 10.1517/14728220903551304
   Hamasaka A, 2009, J ALLERGY CLIN IMMUN, V124, P90, DOI 10.1016/j.jaci.2009.04.025
   Hart SP, 1998, BIOCHEM SOC T, V26, P650, DOI 10.1042/bst0260650
   HERRIOTT MJ, 1993, J IMMUNOL, V150, P4524
   Hizawa N, 2004, AM J RESP CRIT CARE, V169, P1014, DOI 10.1164/rccm.200307-933OC
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113
   Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x
   Kobayashi M, 2006, EUR RESPIR J, V27, P726, DOI 10.1183/09031936.06.00107004
   Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Li-Kim-Moy JP, 2011, J PEDIATR GASTR NUTR, V52, P147, DOI 10.1097/MPG.0b013e3181ef37a1
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086
   McDermott DH, 2014, BLOOD, V123, P2308, DOI 10.1182/blood-2013-09-527226
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935
   Nagata Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122546
   Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002
   Nakamaru Y, 2004, ANN OTO RHINOL LARYN, V113, P205, DOI 10.1177/000348940411300306
   Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281
   O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065
   Park SK, 2009, J IMMUNOL, V182, P6907, DOI 10.4049/jimmunol.0803533
   Pawig L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00429
   Potolicchio I, 2003, J BIOL CHEM, V278, P30889, DOI 10.1074/jbc.M302854200
   Prieto-Lafuente L, 2009, J LEUKOCYTE BIOL, V85, P844, DOI 10.1189/jlb.0808459
   Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006
   Rieder F, 2007, GASTROENTEROLOGY, V132, P154, DOI 10.1053/j.gastro.2006.10.009
   Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Saglani S, 2015, EUR RESPIR J, V46, P1796, DOI 10.1183/13993003.01196-2014
   Shimizu T, 2005, J DERMATOL SCI, V37, P65, DOI 10.1016/j.jdermsci.2004.08.007
   Shimizu T, 1999, J ALLERGY CLIN IMMUN, V104, P659, DOI 10.1016/S0091-6749(99)70339-8
   Shimizu T, 1997, BIOCHEM BIOPH RES CO, V240, P173, DOI 10.1006/bbrc.1997.7633
   Snider HM, 2007, MIF PARASITIC HELMIN, P133
   Son A, 2009, ANTIOXID REDOX SIGN, V11, P2595, DOI 10.1089/ARS.2009.2522
   Sparkes A, 2017, IMMUNOBIOLOGY, V222, P473, DOI 10.1016/j.imbio.2016.10.006
   Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x
   Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933
   Thiele M, 2005, ANTIOXID REDOX SIGN, V7, P1234, DOI 10.1089/ars.2005.7.1234
   Tilstam PV, 2017, EXPERT OPIN THER TAR, V21, P671, DOI 10.1080/14728222.2017.1336227
   Torii M, 2010, EUR J IMMUNOL, V40, P787, DOI 10.1002/eji.200939724
   Vermeire JJ, 2008, TRENDS PARASITOL, V24, P355, DOI 10.1016/j.pt.2008.04.007
   Vieira-de-Abreu A, 2011, AM J RESP CELL MOL, V44, P509, DOI 10.1165/rcmb.2010-0004OC
   Wang B, 2006, J IMMUNOL, V177, P5779, DOI 10.4049/jimmunol.177.9.5779
   Weidinger S, 2016, LANCET, V387, P1109, DOI 10.1016/S0140-6736(15)00149-X
   WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522
   Wu J, 2009, TISSUE ANTIGENS, V73, P302, DOI 10.1111/j.1399-0039.2008.01206.x
   Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244
   Yasuda C, 2014, EXP DERMATOL, V23, P764, DOI 10.1111/exd.12520
   Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x
   Yoshihisa Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152288
   Yoshihisa Y, 2011, J INVEST DERMATOL, V131, P925, DOI 10.1038/jid.2010.418
   Younis AE, 2012, MICROBES INFECT, V14, P279, DOI 10.1016/j.micinf.2011.09.006
   Zang XX, 2002, J BIOL CHEM, V277, P44261, DOI 10.1074/jbc.M204655200
NR 94
TC 5
Z9 5
U1 3
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1080-0549
EI 1559-0267
J9 CLIN REV ALLERG IMMU
JI Clin. Rev. Allergy Immunol.
PD FEB
PY 2020
VL 58
IS 1
SI SI
BP 15
EP 24
DI 10.1007/s12016-019-08726-z
PG 10
WC Allergy; Immunology
SC Allergy; Immunology
GA KI9US
UT WOS:000511704900002
PM 30680604
DA 2020-12-01
ER

PT J
AU Barbeito-Andres, J
   Pezzuto, P
   Higa, LM
   Dias, AA
   Vasconcelos, JM
   Santos, TMP
   Ferreira, JCCG
   Ferreira, RO
   Dutra, FF
   Rossi, AD
   Barbosa, RV
   Amorim, CKN
   De Souza, MPC
   Chimelli, L
   Aguiar, RS
   Gonzalez, PN
   Lara, FA
   Castro, MC
   Molnar, Z
   Lopes, RT
   Bozza, MT
   Vianez, JLSG
   Barbeito, CG
   Cuervo, P
   Bellio, M
   Tanuri, A
   Garcez, PP
AF Barbeito-Andres, J.
   Pezzuto, P.
   Higa, L. M.
   Dias, A. A.
   Vasconcelos, J. M.
   Santos, T. M. P.
   Ferreira, J. C. C. G.
   Ferreira, R. O.
   Dutra, F. F.
   Rossi, A. D.
   Barbosa, R., V
   Amorim, C. K. N.
   De Souza, M. P. C.
   Chimelli, L.
   Aguiar, R. S.
   Gonzalez, P. N.
   Lara, F. A.
   Castro, M. C.
   Molnar, Z.
   Lopes, R. T.
   Bozza, M. T.
   Vianez, J. L. S. G.
   Barbeito, C. G.
   Cuervo, P.
   Bellio, M.
   Tanuri, A.
   Garcez, P. P.
TI Congenital Zika syndrome is associated with maternal protein
   malnutrition
SO SCIENCE ADVANCES
LA English
DT Article
ID INFECTION; NUTRITION; GROWTH; MODEL; MICE
AB Zika virus (ZIKV) infection during pregnancy is associated with a spectrum of developmental impairments known as congenital Zika syndrome (CZS). The prevalence of this syndrome varies across ZIKV endemic regions, suggesting that its occurrence could depend on cofactors. Here, we evaluate the relevance of protein malnutrition for the emergence of CZS. Epidemiological data from the ZIKV outbreak in the Americas suggest a relationship between undernutrition and cases of microcephaly. To experimentally examine this relationship, we use immunocompetent pregnant mice, which were subjected to protein malnutrition and infected with a Brazilian ZIKV strain. We found that the combination of protein restriction and ZIKV infection leads to severe alterations of placental structure and embryonic body growth, with offspring displaying a reduction in neurogenesis and postnatal brain size. RNA-seq analysis reveals gene expression deregulation required for brain development in infected low-protein progeny. These results suggest that maternal protein malnutrition increases susceptibility to CZS.
C1 [Barbeito-Andres, J.; Ferreira, J. C. C. G.; Ferreira, R. O.; Garcez, P. P.] Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil.
   [Barbeito-Andres, J.; Gonzalez, P. N.] Consejo Nacl Invest Cient & Tecn, Inst Studies Neurosci & Complex Syst ENyS, Buenos Aires, DF, Argentina.
   [Pezzuto, P.; Higa, L. M.; Rossi, A. D.; Aguiar, R. S.; Tanuri, A.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [Dias, A. A.; Dutra, F. F.; Bozza, M. T.; Bellio, M.] Univ Fed Rio de Janeiro, Microbiol Inst Paulo de Goes, Rio De Janeiro, Brazil.
   [Vasconcelos, J. M.] Fed Univ Para, Biol Sci Inst, Belem, Para, Brazil.
   [Santos, T. M. P.; Lopes, R. T.] Univ Fed Rio de Janeiro, Nucl Instrumentat Lab, Rio De Janeiro, Brazil.
   [Barbosa, R., V] CENABIO Natl Ctr Struct Biol & Bioimaging, Rio De Janeiro, Brazil.
   [Amorim, C. K. N.; De Souza, M. P. C.; Vianez, J. L. S. G.] Evandro Chagas Inst, Technol Innovat Ctr, Ananindeua, Brazil.
   [Chimelli, L.] State Inst Brain Paulo Niemeyer, Rio De Janeiro, Brazil.
   [Lara, F. A.; Cuervo, P.] Fiocruz MS, Oswaldo Cruz Inst, Rio De Janeiro, Brazil.
   [Castro, M. C.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA.
   [Molnar, Z.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England.
   [Barbeito, C. G.] Natl Univ La Plata, Fac Vet Sci, Buenos Aires, DF, Argentina.
RP Garcez, PP (corresponding author), Univ Fed Rio de Janeiro, Inst Biomed Sci, Rio De Janeiro, Brazil.
EM ppgarcez@icb.ufrj.br
RI Aguiar, Renato S/G-3542-2015; Rossi, Atila Duque/AAV-6079-2020; Cuervo,
   Patricia/Y-6048-2019; Higa, Luiza/W-2698-2019; Barbeito,
   Claudio/AAM-5227-2020; Ferreira, Raiane/AAZ-5987-2020; BELLIO,
   MARIA/N-8525-2018; Garcez, Patricia/F-8026-2012
OI Aguiar, Renato S/0000-0001-5180-3717; Rossi, Atila
   Duque/0000-0001-6235-8807; Cuervo, Patricia/0000-0002-6245-4185;
   Barbeito, Claudio/0000-0001-9459-138X; BELLIO,
   MARIA/0000-0002-3360-2740; Molnar, Zoltan/0000-0002-6852-6004; Alves
   Dias, Andre/0000-0002-6437-2773; Garcez, Patricia/0000-0002-9107-1335
FU MRC Zika Rapid Response Grant [MC_PC_15102]; FAPERJCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
   [E_03/2017E_03/2017]; Brazilian Ministry of Health [DSAST/SVS
   25380.001612/2017-70]; AAPA Professional Development Grant
FX This work was funded by the MRC Zika Rapid Response Grant (MC_PC_15102),
   FAPERJ (E_03/2017E_03/2017), the Brazilian Ministry of Health (DSAST/SVS
   25380.001612/2017-70), and the AAPA Professional Development Grant.
CR Barbeito-Andres J, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006592
   CAIRESJUNIOR LC, 2018, NAT COMM, V0009
   Carvalho-Sauer R, 2019, INT J INFECT DIS, V82, P44, DOI 10.1016/j.ijid.2019.02.040
   CHANDRA RK, 1992, J NUTR, V122, P754, DOI 10.1093/jn/122.suppl_3.754
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   de Oliveira-Szejnfeld PS, 2016, RADIOLOGY, V281, P203, DOI 10.1148/radiol.2016161584
   de Souza WV, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5039-z
   Dobin A., 2015, CURRENT PROTOCOLS BI
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Garcez PP, 2017, SCI REP-UK, V7, DOI 10.1038/srep40780
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gonzalez PN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152227
   Hedrich A, 2007, VER SALUS GAURAUPUA, V1, P139
   Hirsch AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02499-9
   Institute of Medicine Food and Nutrition Board., 2005, DIETARY REFERENCE IN
   Instituto Brasileiro de Geografia e Estatistica, 2015, IND SOC POP BRAS
   Katona P, 2008, CLIN INFECT DIS, V46, P1582, DOI 10.1086/587658
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Losada-Barragan M, 2017, SCI REP-UK, V7, DOI 10.1038/srep45991
   Lum FM, 2017, CLIN INFECT DIS, V64, P914, DOI 10.1093/cid/ciw878
   Luo HC, 2017, ONCOTARGET, V8, P81295, DOI 10.18632/oncotarget.18333
   Metscher BD, 2009, DEV DYNAM, V238, P632, DOI 10.1002/dvdy.21857
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mourao Junior C. A., 2016, REV EXTENDERE, V4, P85
   Moussaud S, 2010, J NEUROSCI METH, V187, P243, DOI 10.1016/j.jneumeth.2010.01.017
   Naylor C, 2016, TRENDS MOL MED, V22, P88, DOI 10.1016/j.molmed.2015.12.001
   Paul AM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02028
   Prata-Barbos A, 2019, J PEDIAT-BRAZIL, V95, pS30, DOI 10.1016/j.jped.2018.10.016
   R Foundation for Statistical Computing, 2013, LANG ENV STAT COMP
   Rathore APS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3208
   REVILLARD JP, 1990, FOOD ADDIT CONTAM, V7, pS82, DOI 10.1080/02652039009373853
   Rogers I, 1998, EUR J CLIN NUTR, V52, P246, DOI 10.1038/sj.ejcn.1600543
   Rosen S., 2008, FOOD SECURITY ASSESS
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmidt CO, 2008, INT J PUBLIC HEALTH, V53, P165, DOI 10.1007/s00038-008-7068-3
   Silva Gomes V. T., 2015, REV INTERDISCIP, V8, P127
   Szaba FM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006994
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Weger-Lucarelli J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006247
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
   Xavier-Neto J, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005363
   Yockey LJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao1680
NR 47
TC 4
Z9 4
U1 1
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD JAN
PY 2020
VL 6
IS 2
AR eaaw6284
DI 10.1126/sciadv.aaw6284
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KD0JH
UT WOS:000507557500004
PM 31950075
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Figueiredo, CM
   Neris, RLD
   Gavino-Leopoldino, D
   da Silva, MOL
   Almeida, JS
   dos-Santos, JS
   Figueiredo, CP
   Bellio, M
   Bozza, MT
   Assuncao-Miranda, I
AF Figueiredo, Camila Menezes
   da Silva Neris, Romulo Leao
   Gavino-Leopoldino, Daniel
   Lopes da Silva, Mariana Oliveira
   Almeida, Juliana Silva
   dos-Santos, Julio Souza
   Figueiredo, Claudia Pinto
   Bellio, Maria
   Bozza, Marcelo Torres
   Assuncao-Miranda, Iranaia
TI Mayaro Virus Replication Restriction and Induction of Muscular
   Inflammation in Mice Are Dependent on Age, Type-I Interferon Response,
   and Adaptive Immunity
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE mayaro virus; pathogenesis; replication restriction; type-I interferon
   response; adaptive immunity; muscle inflammation
ID CHIKUNGUNYA VIRUS; INFECTION; ARTHRALGIA; ARTHRITIS; DISEASE;
   EXPRESSION; OUTBREAK; HUMANS; MODELS; BRAZIL
AB Mayaro virus (MAYV) is an emergent arbovirus first described in forest regions of the American continent, with recent and increasing notification of urban area circulation. Similar to Chikungunya (CHIKV) and other arthritogenic Alphavirus, MAYV-induced disease shows a high prevalence of persistent arthralgia, and myalgia. Despite this, knowledge regarding pathogenesis and characteristics of host immune response of MAYV infections are still limited. Here, using different ages of wild-type (WT), adult Type I Interferon receptor deficient (IFNAR(-/-)), and adult recombination activation gene-1 deficient (RAG(-/-)) mice, we have investigated the dependence of age, innate and adaptive immunity for the control of MAYV replication, tissue damage, and inflammation in mice. We have found that MAYV induces clinical signal and replicates in young WT mice, which gain the ability to restrict MAYV replication with aging. In addition, we observed that mice age and type I interferon response are related to restriction of MAYV infection and muscular inflammation in mice. Moreover, MAYV continues to replicate persistently in RAG(-/-) mice, being detected at blood and tissues 40 days post infection, indicating that adaptive immunity is essential to MAYV clearance. Despite chronic replication, infected adult RAG(-/-) mice did not develop an apparent signal of muscle damage in early and late infection. On the other hand, MAYV infection in young WT and adult IFNAR-/- mice triggers an increase in the expression of pro-inflammatory mediators, such as TNF, IL-6, KC, IL-1 beta, MCP-1, and RANTES, in muscle tissue, and decreases TGF-beta expression, that were not significantly modulated in adult WT and RAG(-/-) mice. Taken together, our data demonstrated that age, innate and adaptive immunity are important to restrict MAYV replication and that adaptive immunity is also involved in MAYV-induced tissue damage. These results contribute to the comprehension of MAYV pathogenesis, and describe translational mice models for further studies of MAYV infection, vaccine tests, and therapeutic strategies against this virus.
C1 [Figueiredo, Camila Menezes; da Silva Neris, Romulo Leao; Gavino-Leopoldino, Daniel; Lopes da Silva, Mariana Oliveira; Almeida, Juliana Silva; dos-Santos, Julio Souza; Bellio, Maria; Bozza, Marcelo Torres; Assuncao-Miranda, Iranaia] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
   [Figueiredo, Claudia Pinto] Univ Fed Rio de Janeiro, Fac Farm, Rio De Janeiro, Brazil.
RP Assuncao-Miranda, I (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
EM iranaiamiranda@micro.ufrj.br
RI Santos, Julio/AAN-4394-2020; BELLIO, MARIA/N-8525-2018
OI Souza dos Santos, Julio/0000-0002-1165-4232; BELLIO,
   MARIA/0000-0002-3360-2740
FU Brazilian funding agency: Fundacao de Amparo a Pesquisa do Estado do Rio
   de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ); Brazilian funding agency:
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Brazilian funding agency: Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES [001]
FX This work was supported by grants from the Brazilian funding agencies:
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   finance Code 001.
CR Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394
   Esposito DLA, 2017, BRAZ J INFECT DIS, V21, P540, DOI 10.1016/j.bjid.2017.06.002
   Assuncao-Miranda I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/973516
   Auguste AJ, 2015, EMERG INFECT DIS, V21, P1742, DOI 10.3201/eid2110.141660
   Azevedo RSS, 2009, EMERG INFECT DIS, V15, P1830, DOI 10.3201/eid1511.090461
   Brehin AC, 2009, VIROLOGY, V384, P216, DOI 10.1016/j.virol.2008.10.021
   Brunini S, 2017, EMERG INFECT DIS, V23, P1025, DOI 10.3201/eid2306.160929
   Caldas LA, 2018, REV SOC BRAS MED TRO, V51, P584, DOI 10.1590/0037-8682-0235-2018
   Camini FC, 2017, VIRUS RES, V236, P1, DOI 10.1016/j.virusres.2017.04.017
   Carissimo G, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900298
   Cavalheiro MG, 2016, AN ACAD BRAS CIENC, V88, P1485, DOI 10.1590/0001-3765201620150685
   Chow A, 2011, J INFECT DIS, V203, P149, DOI 10.1093/infdis/jiq042
   da Costa VG, 2017, INT J INFECT DIS, V62, P84, DOI 10.1016/j.ijid.2017.07.016
   Deng B, 2012, J IMMUNOL, V189, P3669, DOI 10.4049/jimmunol.1103180
   Fros JJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060166
   Ganesan VK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120368
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603-09
   Mourao MPG, 2012, VECTOR-BORNE ZOONOT, V12, P42, DOI 10.1089/vbz.2011.0669
   Haese NN, 2016, J INFECT DIS, V214, pS482, DOI 10.1093/infdis/jiw284
   Haist KC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006748
   Halsey ES, 2013, EMERG INFECT DIS, V19, P1839, DOI 10.3201/eid1911.130777
   Hawman DW, 2013, J VIROL, V87, P13878, DOI 10.1128/JVI.02666-13
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Kelvin AA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001279
   Labadie K, 2010, J CLIN INVEST, V120, P894, DOI 10.1172/JCI40104
   Lewthwaite P, 2009, EMERG INFECT DIS, V15, P329, DOI 10.3201/eid1502.080902
   Lidbury BA, 2008, J INFECT DIS, V197, P1585, DOI 10.1086/587841
   Long KC, 2011, AM J TROP MED HYG, V85, P750, DOI 10.4269/ajtmh.2011.11-0359
   Alves EDL, 2018, VIRUS RES, V256, P166, DOI 10.1016/j.virusres.2018.08.011
   Mackay IM, 2016, MICROBES INFECT, V18, P724, DOI 10.1016/j.micinf.2016.10.007
   Mavian C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07152-5
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Morrison TE, 2006, J VIROL, V80, P737, DOI 10.1128/JVI.80.2.737-749.2006
   Murillo-Zamora E, 2018, ARCH MED RES, V49, P65, DOI 10.1016/j.arcmed.2018.04.008
   Ng LFP, 2017, ANNU REV VIROL, V4, P413, DOI 10.1146/annurev-virology-101416-041808
   Ng LFP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004261
   Ozden S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000527
   Poddar S, 2016, J VIROL, V90, P8780, DOI 10.1128/JVI.00655-16
   Santiago FW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004104
   Santos FM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007375
   Seymour RL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003800
   Slegers CAD, 2014, J CLIN VIROL, V60, P317, DOI 10.1016/j.jcv.2014.04.020
   Smith JL, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00003-18, 10.1128/msphere.00003-18]
   Soden M, 2000, ARTHRITIS RHEUM, V43, P365, DOI 10.1002/1529-0131(200002)43:2<365::AID-ANR16>3.0.CO;2-E
   Tappe D, 2017, EMERG INFECT DIS, V23, P702, DOI 10.3201/eid2304.160466
   Taylor A, 2015, J GEN VIROL, V96, P221, DOI 10.1099/vir.0.071282-0
   Taylor SF, 2005, SOUTH MED J, V98, P484, DOI 10.1097/01.SMJ.0000145879.14102.F4
   Tesh RB, 1999, CLIN INFECT DIS, V28, P67, DOI 10.1086/515070
   Theilacker C, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-369
   Uhrlaub JL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005891
   Wauquier N, 2011, J INFECT DIS, V204, P115, DOI 10.1093/infdis/jiq006
   Zhang XM, 2017, NAT REV IMMUNOL, V17, P495, DOI 10.1038/nri.2017.54
   Zuchi N, 2014, MEM I OSWALDO CRUZ, V109, P820, DOI 10.1590/0074-0276140108
NR 53
TC 4
Z9 4
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 1
PY 2019
VL 10
AR 2246
DI 10.3389/fmicb.2019.02246
PG 11
WC Microbiology
SC Microbiology
GA JF3GS
UT WOS:000491274900001
PM 31632368
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Barbosa, LA
   Fiuza, PP
   Borges, LJ
   Rolim, FA
   Andrade, MB
   Luz, NF
   Quintela-Carvalho, G
   Lima, JB
   Almeida, RP
   Chan, FK
   Bozza, MT
   Borges, VM
   Prates, DB
AF Barbosa, Laiana A.
   Fiuza, Paloma P.
   Borges, Leticia J.
   Rolim, Fellipe A.
   Andrade, Mayara B.
   Luz, Nivea F.
   Quintela-Carvalho, Graziele
   Lima, Jonilson B.
   Almeida, Roque P.
   Chan, Francis K.
   Bozza, Marcelo T.
   Borges, Valeria M.
   Prates, Deboraci B.
TI RIPK1-RIPK3-MLKL-Associated Necroptosis Drives Leishmania infantum
   Killing in Neutrophils
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Leishmania infantum; neutrophils; necroptosis; cell death; RIPK3; mixed
   lineage kinase domain-like; caspase-8
ID MIXED LINEAGE KINASE; NECROTIC CELL-DEATH; PROGRAMMED NECROSIS; VISCERAL
   LEISHMANIASIS; LUTZOMYIA-LONGIPALPIS; EXTRACELLULAR TRAPS;
   IMMUNE-RESPONSES; RIP1 KINASE; IN-VIVO; INFLAMMATION
AB Necroptosis is a pro-inflammatory cell death, which happens in the context of caspase-8 inhibition, allowing activation of the receptor interacting protein kinase 1-receptor interacting protein kinase 3-mixed lineage kinase domain-like (RIPK1-RIPK3-MLKL) axis. Recently, necroptosis has emerged as a key component of resistance against pathogens including infected macrophage by Leishmania infantum, the ethiologic agent of Visceral leishmaniasis (VL). VL is the most severe form of Leishmaniasis, characterized by systemic inflammation and neutropenia. However, the role of neutrophil cell death in VL has not been characterized. Here, we showed that VL patients exhibited increased lactate dehydrogenase levels in the serum, a hallmark of cell death and tissue damage. We investigated the effect of necroptosis in neutrophil infection in vitro. Human neutrophils pretreated with zVAD-fmk (pan-caspase inhibitor) and zIETD-fmk (caspase-8 inhibitor) increased reactive oxygen species (ROS) level in response to Leishmania infection, which is associated with necroptotic cell death. MLKL, an important effector molecule downstream of necroptosis pathway, was also required for Leishmania killing. Moreover, in absence of caspases-8, murine neutrophils displayed loss of membrane integrity, higher levels of ROS, and decreased L. infantum viability. Pharmacological inhibition of RIPK1 or RIPK3 increased parasite survival when caspase-8 was blocked. Electron microscopy assays revealed morphological features associated with necroptotic death in L. infantum infected-neutrophils pretreated with caspase inhibitor, whereas infected cells pretreated with RIPK1 and RIPK3 inhibitors did not show ultra-structural alterations in membrane integrity and presented viable Leishmania within parasitophorous vacuoles. Taken together, these findings suggest that inhibition of caspase-8 contributes to elimination of L. infantum in neutrophils by triggering necroptosis. Thus, targeting necroptosis may represent a new strategy to control Leishmania replication.
C1 [Barbosa, Laiana A.; Fiuza, Paloma P.; Borges, Leticia J.; Rolim, Fellipe A.; Andrade, Mayara B.; Quintela-Carvalho, Graziele; Borges, Valeria M.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Luz, Nivea F.; Quintela-Carvalho, Graziele; Borges, Valeria M.; Prates, Deboraci B.] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Lab Inflamacao & Biomarcadores, Salvador, BA, Brazil.
   [Quintela-Carvalho, Graziele] Inst Fed Educ Ciencia & Tecnol Baiano, Santa Ines, Brazil.
   [Lima, Jonilson B.] Univ Oeste Bahia, Ctr Ciencias Biol & Saude, Barreiras, Brazil.
   [Almeida, Roque P.] Univ Fed Sergipe, Dept Med, Aracaju, Brazil.
   [Chan, Francis K.] Univ Massachusetts, Med Sch, Dept Pathol Immunol & Microbiol Program, Worcester, MA 01605 USA.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Immunol, Rio De Janeiro, Brazil.
   [Prates, Deboraci B.] Univ Fed Bahia, Inst Ciencias Saude, Dept Biomorfol, Salvador, BA, Brazil.
RP Borges, VM (corresponding author), Univ Fed Bahia, Salvador, BA, Brazil.; Borges, VM; Prates, DB (corresponding author), Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Lab Inflamacao & Biomarcadores, Salvador, BA, Brazil.; Prates, DB (corresponding author), Univ Fed Bahia, Inst Ciencias Saude, Dept Biomorfol, Salvador, BA, Brazil.
EM vborges@bahia.fiocruz.br; debyprates@gmail.com
RI Borges, Valeria/G-2009-2014; Lima, Jonilson Berlink/E-1531-2015; Borges,
   Val/N-6647-2019
OI Lima, Jonilson Berlink/0000-0002-1403-4768; Borges,
   Val/0000-0002-2775-5409
FU Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB [JCB0047/2013,
   5760/2015]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [482722/2013-4, 552721/2011-5, 019.203.02712/2009-8
   FAPITEC/CNPq]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [CAPES: 23038.005304/2011-01]; CAPESCAPES
   [88887.142000/2017-00, 88887.137958/2017-00]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [AI119030]; CNPqNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI119030, R01AI119030, R01AI119030,
   R01AI119030, R01AI119030] Funding Source: NIH RePORTER
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado da Bahia-FAPESB (JCB0047/2013 to DP, 5760/2015 to VB) and from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
   (482722/2013-4 to DP, 552721/2011-5 and 019.203.02712/2009-8
   FAPITEC/CNPq to RA). RA also received a grant from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES:
   23038.005304/2011-01). NFL received funding from CAPES (grants
   88887.142000/2017-00 and 88887.137958/2017-00). FC is supported by NIH
   grant AI119030. LAB and LJB received a fellowship from CNPq. VB, MB, and
   RA are senior investigators from CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P557
   Araujo-Santos T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04595-8
   Belic A, 2000, Med Pregl, V53, P89
   Belizario J, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/128076
   Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785
   Carneiro PP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148084
   Challa S, 2010, CELL MOL LIFE SCI, V67, P3241, DOI 10.1007/s00018-010-0413-8
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Chan FKM, 2015, ANNU REV IMMUNOL, V33, P79, DOI 10.1146/annurev-immunol-032414-112248
   Chan FKM, 2012, CELL, V148, P17, DOI 10.1016/j.cell.2011.12.020
   CHANNON JY, 1984, IMMUNOLOGY, V53, P345
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Chtourou Y, 2015, PHARMACOL REP, V67, P1090, DOI 10.1016/j.pharep.2015.04.002
   Costa PL, 2013, ACTA TROP, V126, P99, DOI 10.1016/j.actatropica.2013.01.011
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Dondelinger Y, 2016, CELL MOL LIFE SCI, V73, P2165, DOI 10.1007/s00018-016-2191-4
   Falcao SAC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003601
   Fox S, 2010, J INNATE IMMUN, V2, P216, DOI 10.1159/000284367
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Gueirard P, 2008, CELL MICROBIOL, V10, P100, DOI 10.1111/j.1462-5822.2007.01018.x
   Guimaraes-Costa AB, 2014, INFECT IMMUN, V82, P1732, DOI 10.1128/IAI.01232-13
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hurrell BP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004929
   Jiao Y, 2018, J LEUKOCYTE BIOL, V103, P175, DOI 10.1189/jlb.3HI0517-173R
   Jorgensen I, 2017, NAT REV IMMUNOL, V17, P151, DOI 10.1038/nri.2016.147
   Karch J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130520
   Kearney CJ, 2017, MOL CELL, V65, P965, DOI 10.1016/j.molcel.2017.02.024
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Luz NF, 2016, J IMMUNOL, V196, P5056, DOI 10.4049/jimmunol.1502492
   Lyon CB, 2016, CELL, V167, P1693, DOI [10.1016/j.cell.2016.11.047, DOI 10.1016/J.CELL.2016.11.047]
   Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021
   Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101
   McComb S, 2014, J IMMUNOL, V192, P5671, DOI 10.4049/jimmunol.1303380
   McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07
   Mihalache CC, 2011, J IMMUNOL, V186, P6532, DOI 10.4049/jimmunol.1004055
   Mocarski ES, 2015, VIROLOGY, V479, P160, DOI 10.1016/j.virol.2015.03.016
   Moreno-Gonzalez G, 2016, AM J RESP CRIT CARE, V194, P415, DOI 10.1164/rccm.201510-2106CI
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Najjar M, 2016, IMMUNITY, V45, P46, DOI 10.1016/j.immuni.2016.06.007
   Ni HM, 2016, AM J PATHOL, V186, P2623, DOI 10.1016/j.ajpath.2016.06.009
   Orzalli MH, 2017, TRENDS CELL BIOL, V27, P810, DOI 10.1016/j.tcb.2017.05.007
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Pfeiffer Thomas, 2014, Front Mol Biosci, V1, P17, DOI 10.3389/fmolb.2014.00017
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Qing DY, 2014, AM J RESP CRIT CARE, V190, P1243, DOI 10.1164/rccm.201406-1095OC
   Quintela-Carvalho G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01620
   Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Rousseau D, 2001, BMC Microbiol, V1, P17, DOI 10.1186/1471-2180-1-17
   Sachet M, 2017, APOPTOSIS, V22, P1189, DOI 10.1007/s10495-017-1413-z
   Sangiuliano B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/821043
   Sharma S, 2016, J INFECT DIS, V214, P1531, DOI 10.1093/infdis/jiw394
   Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni.3206, 10.1038/ni0815-889b]
   Silva EM, 2007, EUR J IMMUNOL, V37, P738, DOI 10.1002/eji.200636790
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Takemoto K, 2014, FEBS OPEN BIO, V4, P777, DOI 10.1016/j.fob.2014.08.007
   Thapa RJ, 2013, P NATL ACAD SCI USA, V110, pE3109, DOI 10.1073/pnas.1301218110
   van den Berg E, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12332
   Van Noorden CJF, 2001, ACTA HISTOCHEM, V103, P241, DOI 10.1078/0065-1281-00601
   van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Wang XL, 2016, J IMMUNOL, V197, P4090, DOI 10.4049/jimmunol.1600051
   Weng D, 2014, P NATL ACAD SCI USA, V111, P7391, DOI 10.1073/pnas.1403477111
   Wu YT, 2008, AUTOPHAGY, V4, P457, DOI 10.4161/auto.5662
   Xia BQ, 2016, CELL RES, V26, P517, DOI 10.1038/cr.2016.26
   Yizengaw E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00517
   Zhang YY, 2016, CELL RES, V26, P643, DOI 10.1038/cr.2016.64
   Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109
NR 75
TC 12
Z9 13
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD AUG 14
PY 2018
VL 9
AR 1818
DI 10.3389/fimmu.2018.01818
PG 10
WC Immunology
SC Immunology
GA GQ4NF
UT WOS:000441648700001
PM 30154785
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Lucas, CGO
   Kitoko, JZ
   Ferreira, FM
   Suzart, VG
   Papa, MP
   Coelho, SVA
   Cavazzoni, CB
   Paula-Neto, HA
   Olsen, PC
   Iwasaki, A
   Pereira, RM
   Pimentel-Coelho, PM
   Vale, AM
   de Arruda, LB
   Bozza, MT
AF Lucas, Carolina G. O.
   Kitoko, Jamil Z.
   Ferreira, Fabricio M.
   Suzart, Vinicius G.
   Papa, Michelle P.
   Coelho, Sharton V. A.
   Cavazzoni, Cecilia B.
   Paula-Neto, Heitor A.
   Olsen, Priscilla C.
   Iwasaki, Akiko
   Pereira, Renata M.
   Pimentel-Coelho, Pedro M.
   Vale, Andre M.
   de Arruda, Luciana B.
   Bozza, Marcelo T.
TI Critical role of CD4(+) T cells and IFN gamma signaling in
   antibody-mediated resistance to Zika virus infection
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GUILLAIN-BARRE-SYNDROME; WEST-NILE-VIRUS; MOUSE MODEL; DENGUE;
   PROTECTION; VACCINE; RESPONSES; IMMUNITY; BRAIN; PATHOGENESIS
AB Protective adaptive immunity to Zika virus (ZIKV) has been mainly attributed to cytotoxic CD8(+) T cells and neutralizing antibodies, while the participation of CD4(+) T cells in resistance has remained largely uncharacterized. Here, we show a neutralizing antibody response, dependent on CD4(+) T cells and IFN gamma signaling, which we detected during the first week of infection and is associated with reduced viral load in the brain, prevention of rapid disease onset and survival. We demonstrate participation of these components in the resistance to ZIKV during primary infection and in murine adoptive transfer models of heterologous ZIKV infection in a background of IFNR deficiency. The protective effect of adoptively transferred CD4(+) T cells requires IFN gamma signaling, CD8(+) T cells and B lymphocytes in recipient mice. Together, this indicates the importance of CD4(+) T cell responses in future vaccine design for ZIKV.
C1 [Lucas, Carolina G. O.; Kitoko, Jamil Z.; Ferreira, Fabricio M.; Suzart, Vinicius G.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Kitoko, Jamil Z.; Olsen, Priscilla C.] Univ Fed Rio de Janeiro, Lab Bacteriol & Imunologia Clin, Fac Farm, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Papa, Michelle P.; Coelho, Sharton V. A.; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Dept Virol, Lab Genet & Imunol Infeccoes Virais, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Cavazzoni, Cecilia B.; Vale, Andre M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Sinalizacao & Imunoreceptores, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Dept Biotecnol Farmaceut, Lab Alvos Mol, Fac Farm, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06519 USA.
   [Pereira, Renata M.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Imunol Mol, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Pimentel-Coelho, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Neurobiol Celular & Mol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM mbozza@micro.ufrj.br
RI Olsen, Priscilla C/I-8994-2012; Pimentel-Coelho, Pedro
   Moreno/AAM-9106-2020; Pimentel-Coelho, Pedro M/K-1994-2015; Arruda,
   Luciana B/N-9086-2013; Pereira, Renata/V-6194-2019; Iwasaki,
   Akiko/Z-1591-2019; Kitoko, Jamil/AAY-1595-2020; Kitoko, JZ/D-1694-2016
OI Olsen, Priscilla C/0000-0002-8795-037X; Pimentel-Coelho, Pedro
   Moreno/0000-0002-2414-3386; Pimentel-Coelho, Pedro
   M/0000-0002-2414-3386; Iwasaki, Akiko/0000-0002-7824-9856; Kitoko,
   Jamil/0000-0003-0973-5460; Kitoko, JZ/0000-0003-0973-5460
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); CAPESCAPES; FINEPCiencia Tecnologia e
   Inovacao (FINEP); ICGEB [CRP/ BRA16-05-EC]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21AI131284] Funding
   Source: NIH RePORTER
FX We thank Dr. Amilcar Tanuri and Dr. Ernesto T.A. Marques Jr. for kindly
   donating the ZIKV strain MR766 and PE243, respectively. Zika EDIII
   recombinant protein was kindly provided by Dr. Michel Nussenzweig. We
   acknowledge Leda R. Castilho, Matheus O. Souza, Renata G. F. Alvim, and
   Tulio M. Lima from Cell Culture Engineering Lab at COPPE/UFRJ for
   providing the purified VLPs used in the ELISA assays. We thank the
   members of the Bozza lab for helpful discussions and suggestions. This
   work was supported by grants from CNPq, FAPERJ, CAPES, FINEP (M.T.B) and
   ICGEB (CRP/ BRA16-05-EC; to R.M.P). C.G.O.L., J.Z.K., F.M.F., and
   V.G.S.S. are supported by fellowships from CAPES, M.P.P., and C.B.C. by
   CNPq and S.V.A.C. by FAPERJ.
CR Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005168
   [Anonymous], 2016, JAMA-J AM MED ASSOC, V316, P2588, DOI [10.1001/jama.2016.19328, 10.1001/jama.2016.18655]
   Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brien JD, 2008, J IMMUNOL, V181, P8568, DOI 10.4049/jimmunol.181.12.8568
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Diamond MS, 2003, J EXP MED, V198, P1853, DOI 10.1084/jem.20031223
   Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   do Rosario MS, 2016, AM J TROP MED HYG, V95, P1157, DOI 10.4269/ajtmh.16-0306
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dowall SD, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005704
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]
   Iijima N, 2016, NATURE, V533, P552, DOI 10.1038/nature17979
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z
   Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2009, J CLIN INVEST, V119, P3266, DOI 10.1172/JCI39387
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lenth RV, 2007, J ANIM SCI, V85, pE24, DOI 10.2527/jas.2006-449
   Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   MuraliKrishna K, 1996, J GEN VIROL, V77, P705, DOI 10.1099/0022-1317-77-4-705
   Nazerai L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00593
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Papa MP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02557
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Prestwood TR, 2012, J VIROL, V86, P12561, DOI 10.1128/JVI.06743-11
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Scott JM, 2018, J VIROL, V92, DOI 10.1128/JVI.00038-18
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   Sitati EM, 2006, J VIROL, V80, P12060, DOI 10.1128/JVI.01650-06
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sumathy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46375
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Winkler CW, 2017, J IMMUNOL, V198, P3526, DOI 10.4049/jimmunol.1601949
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zellweger RM, 2014, J IMMUNOL, V193, P4117, DOI 10.4049/jimmunol.1401597
NR 63
TC 23
Z9 23
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 7
PY 2018
VL 9
AR 3136
DI 10.1038/s41467-018-05519-4
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GP6IG
UT WOS:000440981600013
PM 30087337
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Neris, RLS
   Figueiredo, CM
   Higa, LM
   Araujo, DF
   Carvalho, CAM
   Vercoza, BRF
   Silva, MOL
   Carneiro, FA
   Tanuri, A
   Gomes, AMO
   Bozza, MT
   Da Poian, AT
   Cruz-Oliveira, C
   Assuncao-Miranda, I
AF Neris, Romulo L. S.
   Figueiredo, Camila M.
   Higa, Luiza M.
   Araujo, Daniel F.
   Carvalho, Carlos A. M.
   Vercoza, Brunno R. F.
   Silva, Mariana O. L.
   Carneiro, Fabiana A.
   Tanuri, Amilcar
   Gomes, Andre M. O.
   Bozza, Marcelo T.
   Da Poian, Andrea T.
   Cruz-Oliveira, Christine
   Assuncao-Miranda, Iranaia
TI Co-protoporphyrin IX and Sn-protoporphyrin IX inactivate Zika,
   Chikungunya and other arboviruses by targeting the viral envelope
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TIN-PROTOPORPHYRIN; ANTIVIRAL ACTIVITY; HEME OXYGENASE-1; VIRUSES;
   FUSION; DENGUE; MONOXIDE; AMERICA; COINFECTION; COLOMBIA
AB The global situation of diseases transmitted by arthropod-borne viruses such as Dengue (DENV), Yellow Fever (YFV), Chikungunya (CHIKV) and Zika (ZIKV) viruses is alarming and treatment of human infection by these arboviruses faces several challenges. The discovery of broad-spectrum antiviral molecules, able to inactivate different groups of viruses, is an interesting approach. The viral envelope is a common structure among arboviruses, being a potential target for antivirals. Porphyrins are amphipathic molecules able to interact with membranes and absorb light, being widely used in photodynamic therapy. Previously, we showed that heme, Co-protoporphyrin IX (CoPPIX) and Sn-protoporphyrin IX (SnPPIX) directly inactivate DENV and YFV infectious particles. Here we demonstrate that the antiviral activity of these porphyrins can be broadened to CHIKV, ZIKV, Mayaro virus, Sindbis virus and Vesicular Stomatitis virus. Porphyrin treatment causes viral envelope protein loss, affecting viral morphology, adsorption and entry into target cells. Also, light-stimulation enhanced the SnPPIX activity against all tested arboviruses. In summary, CoPPIX and SnPPIX were shown to be efficient broad-spectrum compounds to inactivate medically and veterinary important viruses.
C1 [Neris, Romulo L. S.; Figueiredo, Camila M.; Araujo, Daniel F.; Silva, Mariana O. L.; Bozza, Marcelo T.; Assuncao-Miranda, Iranaia] Univ Fed Rio de Janeiro UFRJ, Ctr Ciencias Saude, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
   [Carvalho, Carlos A. M.; Gomes, Andre M. O.; Da Poian, Andrea T.; Cruz-Oliveira, Christine] Univ Fed Rio de Janeiro UFRJ, Ctr Ciencias Saude, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, Brazil.
   [Higa, Luiza M.; Tanuri, Amilcar] Univ Fed Rio de Janeiro UFRJ, Inst Biol, Rio De Janeiro, Brazil.
   [Vercoza, Brunno R. F.; Carneiro, Fabiana A.] Univ Fed Rio de Janeiro UFRJ, Polo Avancado Xerem, NUMPEX Nucleo Multidisciplinar Pesquisas, Duque De Caxias, RJ, Brazil.
   [Carvalho, Carlos A. M.] Inst Evandro Chagas IEC, Secao Arbovirol & Febres Hemorrag, Ananindeua, PA, Brazil.
   [Carvalho, Carlos A. M.] Univ Estado Para UEPA, Ctr Ciencias Biol & Saude, Dept Morfol & Ciencias Fisiol, Belem, Para, Brazil.
RP Assuncao-Miranda, I (corresponding author), Univ Fed Rio de Janeiro UFRJ, Ctr Ciencias Saude, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.; Cruz-Oliveira, C (corresponding author), Univ Fed Rio de Janeiro UFRJ, Ctr Ciencias Saude, Inst Bioquim Med Leopoldo de Meis, Rio De Janeiro, Brazil.
EM ccruz@bioqmed.ufrj.br; iranaiamiranda@micro.ufrj.br
RI CARNEIRO, FABIANA A/S-4525-2018; Gomes, Andre/C-4009-2014; Da Poian,
   Andrea T./V-1699-2019; Vercoza, Brunno Renato Farias/AAB-4725-2019;
   Higa, Luiza/W-2698-2019
OI Gomes, Andre/0000-0003-1052-8004; Vercoza, Brunno Renato
   Farias/0000-0001-6117-7879; Cruz-Oliveira,
   Christine/0000-0003-4838-0703; Carneiro, Fabiana/0000-0002-6584-4875;
   Carvalho, Carlos/0000-0001-6615-1387
FU Fundacao de Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Conselho Nacional de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES; Financiadora de Estudos e ProjetosCiencia Tecnologia e
   Inovacao (FINEP)
FX This work was supported by grants from Brazilian funding agencies:
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro, Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior and Financiadora de Estudos
   e Projetos.
CR Akamatsu Y, 2004, FASEB J, V18, P771, DOI 10.1096/fj.03-0921fje
   ANDERSON KE, 1986, CLIN PHARMACOL THER, V39, P510, DOI 10.1038/clpt.1986.88
   Assuncao-Miranda I, 2016, J APPL MICROBIOL, V120, P790, DOI 10.1111/jam.13038
   Bonnett R, 1989, CIBA F SYMP, V146, P40
   Bonnett R, 1989, AM J HYG, V146, P40
   Boriskin YS, 2008, CURR MED CHEM, V15, P997, DOI 10.2174/092986708784049658
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cardona-Ospina JA, 2015, T ROY SOC TROP MED H, V109, P793, DOI 10.1093/trstmh/trv094
   Cruz-Oliveira C, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00053-17
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   DRUMMOND GS, 1986, J CLIN INVEST, V77, P971, DOI 10.1172/JCI112398
   Espinoza JA, 2017, AM J PATHOL, V187, P487, DOI 10.1016/j.ajpath.2016.11.011
   de Figueiredo MLG, 2014, REV SOC BRAS MED TRO, V47, P677, DOI 10.1590/0037-8682-0246-2014
   Hamer DH, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0571-z
   Man D, 2011, J BIOL INORG CHEM, V16, P173, DOI 10.1007/s00775-010-0715-1
   Mardekian SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/834371
   Matanic VCA, 2004, INT J ANTIMICROB AG, V23, P382, DOI 10.1016/j.ijantimicag.2003.07.022
   McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Notario-Perez F, 2017, DRUG DES DEV THER, V11, P1767, DOI 10.2147/DDDT.S133170
   Olivia Lwande Wesula, 2015, Infection Ecology & Epidemiology, V5, P29853, DOI 10.3402/iee.v5.29853
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pushpan S. K., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P187, DOI 10.2174/1568011023354137
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rodriguez-Morales AJ, 2016, TRAVEL MED INFECT DI, V14, P177, DOI 10.1016/j.tmaid.2016.05.004
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Sample CJ, 2013, PEPTIDES, V48, P96, DOI 10.1016/j.peptides.2013.07.014
   Silva P, 2010, PHOTOCHEM PHOTOBIOL, V86, P1147, DOI 10.1111/j.1751-1097.2010.00764.x
   Soumahoro MK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001197
   Sousa IP, 2011, J BIOL CHEM, V286, P1730, DOI 10.1074/jbc.M110.198002
   St Vincent MR, 2010, P NATL ACAD SCI USA, V107, P17339, DOI 10.1073/pnas.1010026107
   Stojiljkovic I, 2001, EXPERT OPIN INV DRUG, V10, P309, DOI 10.1517/13543784.10.2.309
   Vasconcelos PFC, 2016, VECTOR-BORNE ZOONOT, V16, P295, DOI 10.1089/vbz.2016.1952
   Vigant F, 2015, NAT REV MICROBIOL, V13, P426, DOI 10.1038/nrmicro3475
   Vigant F, 2014, J VIROL, V88, P1849, DOI 10.1128/JVI.02907-13
   Vigant F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003297
   Villamil-Gomez WE, 2016, INT J INFECT DIS, V51, P135, DOI 10.1016/j.ijid.2016.07.017
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   WHO, 2017, DENG CONTR EP
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   World Health Organization, 2017, EM ZIK SIT REP
   Zhao HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22008
   Zhu JD, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00517
   Zuchi N, 2014, MEM I OSWALDO CRUZ, V109, P820, DOI 10.1590/0074-0276140108
NR 44
TC 11
Z9 11
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 28
PY 2018
VL 8
AR 9805
DI 10.1038/s41598-018-27855-7
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GK9FC
UT WOS:000436546200026
PM 29955082
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Medei, E
   Bozza, MT
AF Paiva, Claudia N.
   Medei, Emiliano
   Bozza, Marcelo T.
TI ROS and Trypanosoma cruzi: Fuel to infection, poison to the heart
SO PLOS PATHOGENS
LA English
DT Review
ID OXYGEN SPECIES PRODUCTION; CHRONIC CHAGASIC PATIENTS;
   TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; NITRIC-OXIDE; MITOCHONDRIAL
   DYSFUNCTION; VENTRICULAR-ARRHYTHMIAS; INTRACELLULAR PROTOZOA;
   CARDIOVASCULAR-SYSTEM; ADRENERGIC ACTIVITY
AB The activation of macrophage respiratory burst in response to infection with Trypanosoma cruzi inflicts oxidative damage to the host's tissues. For decades, the role of reactive oxygen species (ROS) in the elimination of T. cruzi was taken for granted, but recent evidence suggests parasite growth is stimulated in oxidative environments. It is still a matter of debate whether indeed oxidative environments provide ideal conditions (e.g., iron availability in macrophages) for T. cruzi growth and whether indeed ROS signals directly to stimulate growth. Nitric oxide (NO) and ROS combine to form peroxynitrite, participating in the killing of phagocytosed parasites by activated macrophages. In response to infection, mitochondrial ROS are produced by cardiomyocytes. They contribute to oxidative damage that persists at the chronic stage of infection and is involved in functional impairment of the heart. In this review, we discuss how oxidative stress helps parasite growth during the acute stage and how it participates in the development of cardiomyopathy at the chronic stage.
C1 [Paiva, Claudia N.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Rio De Janeiro, Brazil.
   [Medei, Emiliano] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
   [Medei, Emiliano] Univ Fed Rio de Janeiro, Ctr Nacl Biol Estrutural & Bioimagem, Rio De Janeiro, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Rio De Janeiro, Brazil.
EM cnpaiva@iname.com
OI Medei, Emiliano/0000-0002-0044-1311
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)CAPES
FX Our work was supported by Conselho Nacional de Pesquisa (CNPq), Fundacao
   de Amparo a Pesquisa do Rio de Janeiro (FAPERJ), and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aguiar PHN, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002279
   do Brasil PEAA, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-388
   Ba XQ, 2010, J BIOL CHEM, V285, P11596, DOI 10.1074/jbc.M109.076984
   BAEHNER RL, 1968, SCIENCE, V162, P1277, DOI 10.1126/science.162.3859.1277
   Barbosa JL, 2016, AM J THER, V23, pE1474, DOI 10.1097/MJT.0000000000000137
   Barroso A, 2016, INFECT IMMUN, V84, P3071, DOI 10.1128/IAI.00575-16
   Calderon J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002799
   Campo VA, 2017, INT J PARASITOL-DRUG, V7, P23, DOI 10.1016/j.ijpddr.2016.12.003
   Cutrullis RA, 2017, IMMUNOBIOLOGY, V222, P423, DOI 10.1016/j.imbio.2016.08.007
   Nogueira NPD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025935
   de Souza AP, 2010, MEM I OSWALDO CRUZ, V105, P746, DOI 10.1590/S0074-02762010000600003
   Dey N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111539
   Dhiman M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004516
   Dhiman M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000302
   Dhiman M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028449
   Dhiman M, 2011, J PATHOL, V225, P583, DOI 10.1002/path.2975
   Dias PP, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005852
   Eickhoff CS, 2010, J PARASITOL, V96, P758, DOI 10.1645/GE-2396.1
   Finzi JK, 2004, MOL BIOCHEM PARASIT, V133, P37, DOI 10.1016/j.molbiopara.2003.08.011
   GAZZINELLI RT, 1992, EUR J IMMUNOL, V22, P2501, DOI 10.1002/eji.1830221006
   Goes GR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004555
   Goncalves VM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002469
   Guevara AG, 2000, IMMUNOL LETT, V71, P79, DOI 10.1016/S0165-2478(99)00164-9
   Freire ACG, 2017, PARASITOLOGY, V144, P1498, DOI [10.1017/S0031182017001044, 10.1017/s0031182017001044]
   Guinazu N, 2010, INT J PARASITOL, V40, P1531, DOI 10.1016/j.ijpara.2010.05.012
   Hall BS, 2012, ANTIMICROB AGENTS CH, V56, P115, DOI 10.1128/AAC.05135-11
   Huang BK, 2014, REDOX BIOL, V2, P955, DOI 10.1016/j.redox.2014.08.001
   Hugo M, 2017, P NATL ACAD SCI USA, V114, pE1326, DOI 10.1073/pnas.1618611114
   Imlay James A, 2009, EcoSal Plus, V3, DOI 10.1128/ecosalplus.5.4.4
   Kimura A, 2014, INT IMMUNOL, V26, P209, DOI 10.1093/intimm/dxt067
   Kohler AC, 2014, J MOL CELL CARDIOL, V73, P92, DOI 10.1016/j.yjmcc.2014.03.001
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   LOCKSLEY RM, 1983, J CELL BIOCHEM, V22, P173, DOI 10.1002/jcb.240220306
   Luczak ED, 2014, J MOL CELL CARDIOL, V73, P112, DOI 10.1016/j.yjmcc.2014.02.004
   Macao LB, 2007, INT J CARDIOL, V123, P43, DOI 10.1016/j.ijcard.2006.11.118
   Machado-Silva A, 2016, MUTAT RES-REV MUTAT, V767, P8, DOI 10.1016/j.mrrev.2015.12.003
   Maciel L, 2012, J CARD FAIL, V18, P423, DOI 10.1016/j.cardfail.2012.02.007
   MCCABE RE, 1990, J IMMUNOL, V144, P2384
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x
   Monnerat G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13344
   MORENO SNJ, 1982, ARCH BIOCHEM BIOPHYS, V218, P585, DOI 10.1016/0003-9861(82)90383-6
   Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
   MURRAY HW, 1982, J RETICULOENDOTH SOC, V31, P479
   Nagajyothi F, 2012, PARASITOL RES, V110, P2491, DOI 10.1007/s00436-011-2790-9
   NATHAN C, 1979, J EXP MED, V149, P1057
   Alvarez MN, 2011, J BIOL CHEM, V286, P6627, DOI 10.1074/jbc.M110.167247
   Nogueira NP, 2017, FREE RADICAL BIO MED, V108, P183, DOI 10.1016/j.freeradbiomed.2017.03.027
   Nogueira NP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116712
   Rigalli JP, 2016, TOXICOL APPL PHARM, V304, P90, DOI 10.1016/j.taap.2016.05.007
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pedrosa RC, 2001, REDOX REP, V6, P265, DOI 10.1179/135100001101536328
   Pereira IR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/798078
   Pereira IR, 2014, MEM I OSWALDO CRUZ, V109, P289, DOI 10.1590/0074-0276140033
   Piacenza L, 2013, ANTIOXID REDOX SIGN, V19, P723, DOI 10.1089/ars.2012.4618
   Piacenza L, 2009, CURR OPIN MICROBIOL, V12, P415, DOI 10.1016/j.mib.2009.06.011
   Rowe GC, 2010, CIRC RES, V107, P825, DOI 10.1161/CIRCRESAHA.110.223818
   Ruderman NB, 2010, AM J PHYSIOL-ENDOC M, V298, pE751, DOI 10.1152/ajpendo.00745.2009
   RUSSO M, 1989, PARASITE IMMUNOL, V11, P385, DOI 10.1111/j.1365-3024.1989.tb00675.x
   Salt IP, 2017, CIRC RES, V120, P1825, DOI 10.1161/CIRCRESAHA.117.309633
   Santello FH, 2007, J PINEAL RES, V42, P359, DOI 10.1111/j.1600-079X.2007.00427.x
   Santiago HC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001492
   Sepulveda M, 2017, CRIT CARE MED, V45, pE399, DOI 10.1097/CCM.0000000000002101
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   Slauch JM, 2011, MOL MICROBIOL, V80, P580, DOI 10.1111/j.1365-2958.2011.07612.x
   Soares MP, 2017, NAT REV IMMUNOL, V17, P83, DOI 10.1038/nri.2016.136
   Stempin CC, 2008, ACTA TROP, V106, P119, DOI 10.1016/j.actatropica.2008.02.004
   Tada Y, 2016, CURR PHARM DESIGN, V22, P450, DOI 10.2174/1381612822666151222160559
   TANAKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2584, DOI 10.1073/pnas.79.8.2584
   Tinker A, 2017, INT J CARDIOL, V240, P372, DOI 10.1016/j.ijcard.2017.03.094
   Trochine A, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002844
   Tzima S, 2009, J EXP MED, V206, P1167, DOI 10.1084/jem.20081582
   Vera EAV, 2016, INT J BIOL MACROMOL, V87, P498, DOI 10.1016/j.ijbiomac.2016.03.014
   Jimenez MAV, 2017, INT J CARDIOL, V240, P354, DOI 10.1016/j.ijcard.2017.02.066
   Vilar-Pereira G, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005947
   Wan XX, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005954
   Wen JJ, 2017, ANTIOXID REDOX SIGN, V27, P550, DOI 10.1089/ars.2016.6831
   Wen JJ, 2008, MICROBES INFECT, V10, P1201, DOI 10.1016/j.micinf.2008.06.013
   Wen JJ, 2006, FREE RADICAL BIO MED, V41, P270, DOI 10.1016/j.freeradbiomed.2006.04.009
   Wen Jian-Jun, 2016, JACC Basic Transl Sci, V1, P235
   Wen JJ, 2014, PARASITOL RES, V113, P3159, DOI 10.1007/s00436-014-3977-7
   Wen JJ, 2010, ANTIOXID REDOX SIGN, V12, P27, DOI [10.1089/ars.2008.2418, 10.1089/ARS.2008.2418]
   Wen JJ, 2010, J AM COLL CARDIOL, V55, P2499, DOI 10.1016/j.jacc.2010.02.030
   Wen JJ, 2008, J BIOENERG BIOMEMBR, V40, P587, DOI 10.1007/s10863-008-9184-4
   Wilkinson SR, 2008, P NATL ACAD SCI USA, V105, P5022, DOI 10.1073/pnas.0711014105
   Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827
   Xia N, 2017, BRIT J PHARMACOL, V174, P1633, DOI 10.1111/bph.13492
   Yoon SJ, 2017, J INFECT DIS, V215, P1608, DOI 10.1093/infdis/jix142
NR 90
TC 33
Z9 33
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2018
VL 14
IS 4
AR e1006928
DI 10.1371/journal.ppat.1006928
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA GE3TI
UT WOS:000431135400008
PM 29672619
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vasconcellos, LR
   Siqueira, MS
   Moraes, R
   Carneiro, LA
   Bozza, MT
   Travassos, LH
AF Vasconcellos, L. R.
   Siqueira, M. S.
   Moraes, R.
   Carneiro, L. A.
   Bozza, M. T.
   Travassos, L. H.
TI Heme Oxygenase-1 and Autophagy Linked for Cytoprotection
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE heme oxygenase-1; autophagy; inflammation; cancer; sepsis; diabetes
ID CARBON-MONOXIDE; 5-AMINOLEVULINIC ACID; IRON HOMEOSTASIS; ATG9 VESICLES;
   HOST-DEFENSE; CANCER CELLS; MICE; PROTECTS; MACROPHAGES; INJURY
AB Background: Heme-oxygenase (HO) catalyzes the main enzymatic step of heme degradation and generates anti-inflammatory end products with protective roles in physiological and pathological situations. The importance of HO in pathological conditions is evidenced by its pharmacological inhibition or genetic blockage in different models of stress such as infection, inflammation and oxidative stress. Under these situations, another well-known protective process triggered is autophagy. Autophagy is a homeostatic process that eliminates defective cytosolic components and organelles, allowing cells and tissues to recover through recycling of functional blocks for anabolic reactions. Recently, studies have demonstrated a link between HO activity and autophagy activation.
   Objective: In this review, we focus on the interplay between HO and autophagy, and highlight its importance in homeostasis maintenance under stress conditions.
C1 [Vasconcellos, L. R.; Siqueira, M. S.; Moraes, R.; Travassos, L. H.] Univ Fed Rio de Janeiro, Lab Imunoreceptores & Sinalizacao, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
   [Vasconcellos, L. R.; Carneiro, L. A.; Bozza, M. T.] Univ Fed Rio de Janeiro, Lab Inflamacao & Imunidade, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
RP Travassos, LH (corresponding author), Univ Fed Rio de Janeiro, IBCCF, Lab Intermediario Imunoreceptores & Sinalizacao L, Ave Carlos Chagas Filho 373,Sala G-063 Subsolo, BR-21941902 Rio de Janeiro, RJ, Brazil.
EM leo.travassos@me.com
RI Travassos, Leonardo/G-1925-2012; Carneiro, Leticia/T-8978-2019
OI Travassos, Leonardo/0000-0003-1323-3797; /0000-0002-3877-7013
CR Banerjee P, 2012, J BIOL CHEM, V287, P32113, DOI 10.1074/jbc.M112.393140
   Bilban M, 2008, J MOL MED, V86, P267, DOI 10.1007/s00109-007-0276-0
   Birmingham CL, 2007, AUTOPHAGY, V3, P442, DOI 10.4161/auto.4450
   Birmingham CL, 2006, AUTOPHAGY, V2, P156, DOI 10.4161/auto.2825
   Carchman EH, 2011, HEPATOLOGY, V53, P2053, DOI 10.1002/hep.24324
   Carneiro LAM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00361
   Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Cuervo AM, 2010, NAT CELL BIOL, V12, P735, DOI 10.1038/ncb0810-735
   De Domenico I, 2009, BLOOD, V114, P4546, DOI 10.1182/blood-2009-05-224188
   de Zeeuw D, 2004, KIDNEY INT, V65, P2309, DOI 10.1111/j.1523-1755.2004.00653.x
   Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031
   Dong CL, 2015, EXP CELL RES, V337, P146, DOI 10.1016/j.yexcr.2015.04.005
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Dorsey FC, 2009, J PROTEOME RES, V8, P5253, DOI 10.1021/pr900583m
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5
   Ganley IG, 2013, ESSAYS BIOCHEM, V55, P65, DOI [10.1042/BSE0550065, 10.1042/bse0550065]
   Ganz T, 2015, NAT REV IMMUNOL, V15, P500, DOI 10.1038/nri3863
   Ganz T, 2013, PHYSIOL REV, V93, P1721, DOI 10.1152/physrev.00008.2013
   Geng JF, 2008, AUTOPHAGY, V4, P955, DOI 10.4161/auto.6791
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492
   Hou JG, 2013, AM J PHYSIOL-RENAL, V305, pF1149, DOI 10.1152/ajprenal.00275.2013
   Hussey S, 2009, SEMIN IMMUNOL, V21, P233, DOI 10.1016/j.smim.2009.05.004
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kim HJ, 2017, FREE RADICAL BIO MED, V110, P81, DOI 10.1016/j.freeradbiomed.2017.05.026
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240
   Lee Y, 2015, CELL REP, V13, P223, DOI 10.1016/j.celrep.2015.09.005
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   Mauvezin C, 2014, METHODS, V68, P134, DOI 10.1016/j.ymeth.2014.03.014
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mony VK, 2016, AUTOPHAGY, V12, P619, DOI 10.1080/15548627.2016.1147671
   Moreau K, 2012, J CELL BIOL, V196, P483, DOI 10.1083/jcb.201110114
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   PRZYKLENK K, 1993, CIRCULATION, V87, P893, DOI 10.1161/01.CIR.87.3.893
   Ryter SW, 2016, TRANSL RES, V167, P7, DOI 10.1016/j.trsl.2015.06.011
   Scharn CR, 2016, J IMMUNOL, V196, P4641, DOI 10.4049/jimmunol.1500434
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Shiloh MU, 2008, CELL HOST MICROBE, V3, P323, DOI 10.1016/j.chom.2008.03.007
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silva-Gomes S, 2013, INFECT IMMUN, V81, P2536, DOI 10.1128/IAI.00251-13
   Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Suzuki SW, 2015, P NATL ACAD SCI USA, V112, P3350, DOI 10.1073/pnas.1421092112
   Tan QX, 2015, CANCER SCI, V106, P1023, DOI 10.1111/cas.12712
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Unuma K, 2013, HEPATOL RES, V43, P91, DOI 10.1111/j.1872-034X.2012.01049.x
   Vasconcellos LRC, 2016, P NATL ACAD SCI USA, V113, pE7474, DOI 10.1073/pnas.1608928113
   Walczak M, 2013, AUTOPHAGY, V9, P424, DOI 10.4161/auto.22931
   Waltz P, 2011, AUTOPHAGY, V7, P315, DOI 10.4161/auto.7.3.14044
   Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098834
   Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87
   Yamaguchi M, 2012, STRUCTURE, V20, P1244, DOI 10.1016/j.str.2012.04.018
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180
   Zhao MY, 2016, BIOCHEM BIOPH RES CO, V479, P663, DOI 10.1016/j.bbrc.2016.09.156
   Zhao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075927
NR 72
TC 5
Z9 5
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2018
VL 24
IS 20
BP 2311
EP 2316
DI 10.2174/1381612824666180727100909
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GX5CG
UT WOS:000447758100010
PM 30051776
DA 2020-12-01
ER

PT J
AU Papa, MP
   Meuren, LM
   Coelho, SVA
   Lucas, CGD
   Mustafa, YM
   Matassoli, FL
   Silveira, PP
   Frost, PS
   Pezzuto, P
   Ribeiro, MR
   Tanuri, A
   Nogueira, ML
   Campanati, L
   Bozza, MT
   Neto, HAP
   Pimentel-Coelho, PM
   Figueiredo, CP
   de Aguiar, RS
   de Arruda, LB
AF Papa, Michelle P.
   Meuren, Lana M.
   Coelho, Sharton V. A.
   de Oliveira Lucas, Carolina G.
   Mustafa, Yasmin M.
   Matassoli, Flavio Lemos
   Silveira, Paola P.
   Frost, Paula S.
   Pezzuto, Paula
   Ribeiro, Milene R.
   Tanuri, Amilcar
   Nogueira, Mauricio L.
   Campanati, Loraine
   Bozza, Marcelo T.
   Paula Neto, Heitor A.
   Pimentel-Coelho, Pedro M.
   Figueiredo, Claudia P.
   de Aguiar, Renato S.
   de Arruda, Luciana B.
TI Zika Virus Infects, Activates, and Crosses Brain Microvascular
   Endothelial Cells, without Barrier Disruption
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Zika virus; endothelial cells; blood brain barrier; transcytosis; mouse
   experimental model
ID JAPANESE ENCEPHALITIS-VIRUS; IN-VITRO; NERVOUS-SYSTEM; MODEL;
   TRANSCYTOSIS; ENDOCYTOSIS; INTEGRITY; TRANSPORT; PROTEINS; COMPLEX
AB Zika virus (ZIKV) has been associated to central nervous system (CNS) harm, and virus was detected in the brain and cerebrospinal fluids of microcephaly and meningoencephalitis cases. However, the mechanism by which the virus reaches the CNS is unclear. Here, we addressed the effects of ZIKV replication in human brain microvascular endothelial cells (HBMECs), as an in vitro model of blood brain barrier (BBB), and evaluated virus extravasation and BBB integrity in an in vivo mouse experimental model. HBMECs were productively infected by African and Brazilian ZIKV strains (ZIKV(MR766) and ZIKV(PE243)), which induce increased production of type I and type III IFN, inflammatory cytokines and chemokines. Infection with ZIKV(MR766) promoted earlier cellular death, in comparison to ZIKV(PE243), but infection with either strain did not result in enhanced endothelial permeability. Despite the maintenance of endothelial integrity, infectious virus particles crossed the monolayer by endocytosis/exocytosis-dependent replication pathway or by transcytosis. Remarkably, both viruses' strains infected IFNAR deficient mice, with high viral load being detected in the brains, without BBB disruption, which was only detected at later time points after infection. These data suggest that ZIKV infects and activates endothelial cells, and might reach the CNS through basolateral release, transcytosis or transinfection processes. These findings further improve the current knowledge regarding ZIKV dissemination pathways.
C1 [Papa, Michelle P.; Meuren, Lana M.; Coelho, Sharton V. A.; de Oliveira Lucas, Carolina G.; Mustafa, Yasmin M.; Matassoli, Flavio Lemos; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Virol, Rio De Janeiro, Brazil.
   [de Oliveira Lucas, Carolina G.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Silveira, Paola P.; Pezzuto, Paula; Tanuri, Amilcar; de Aguiar, Renato S.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [Frost, Paula S.; Figueiredo, Claudia P.] Univ Fed Rio de Janeiro, Fac Farm, Nucleo Neurociencias, Rio De Janeiro, Brazil.
   [Ribeiro, Milene R.; Nogueira, Mauricio L.] Fac Med Sao Jose Do Rio Preto, Lab Pesquisas Virol, Sao Jose Do Rio Preto, Brazil.
   [Campanati, Loraine] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil.
   [Paula Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Dept Biotecnol Farmaceut, Lab Alvos Mol, Rio De Janeiro, Brazil.
   [Pimentel-Coelho, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Virol, Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Pimentel-Coelho, Pedro M/K-1994-2015; Arruda, Luciana B/N-9086-2013;
   Pimentel-Coelho, Pedro Moreno/AAM-9106-2020; Figueiredo, Claudia
   P/F-8424-2012; Nogueira, Mauricio L/B-7599-2012; Aguiar, Renato
   S/G-3542-2015; Campanati, Loraine/V-2632-2018
OI Pimentel-Coelho, Pedro M/0000-0002-2414-3386; Pimentel-Coelho, Pedro
   Moreno/0000-0002-2414-3386; Nogueira, Mauricio L/0000-0003-1102-2419;
   Aguiar, Renato S/0000-0001-5180-3717; Campanati,
   Loraine/0000-0001-9172-1951; Figueiredo, Claudia/0000-0001-9467-9891; da
   Silva Frost, Paula/0000-0002-3814-999X
FU CAPESCAPES; CAPES/PVE-Program; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJ-Rede ZIKA; FINEPCiencia
   Tecnologia e Inovacao (FINEP); FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); FAPESPFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/21719-3]
FX This work was supported by CAPES, CAPES/PVE-Program, CNPq, FAPERJ-Rede
   ZIKA, and FINEP. MP was the recipient of a CNPq fellowship. LM and CL
   were the recipient of a CAPES fellowship. SC was the recipient of a
   FAPERJ fellowship. MN is supported by a FAPESP grant #2013/21719-3. MN
   and MB are a CNPq Fellowship recipient.
CR Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bramley JC, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00206-17
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chang CY, 2015, GLIA, V63, P1915, DOI 10.1002/glia.22857
   Chanthick C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31855
   Chen CJ, 2014, J VIROL, V88, P1150, DOI 10.1128/JVI.02738-13
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   da Conceicao TM, 2013, VIROLOGY, V435, P281, DOI 10.1016/j.virol.2012.09.038
   Daniels BP, 2015, CLIN PHARMACOL THER, V97, P372, DOI 10.1002/cpt.75
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Diefenbach RJ, 2008, REV MED VIROL, V18, P35, DOI 10.1002/rmv.560
   Dohgu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039565
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Finke S, 2005, VIRUS RES, V111, P120, DOI 10.1016/j.virusres.2005.04.004
   FUJIWARA T, 1988, J BIOL CHEM, V263, P18545
   Galliez RM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw203
   Harmon B, 2012, J VIROL, V86, P12954, DOI 10.1128/JVI.02242-12
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Liou ML, 1998, CELL TISSUE RES, V293, P389, DOI 10.1007/s004410051130
   Lucey D, 2017, JAMA-J AM MED ASSOC, V317, P1368, DOI 10.1001/jama.2017.1553
   Luethy LN, 2016, VIROLOGY, V487, P1, DOI 10.1016/j.virol.2015.09.019
   Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Miner JJ, 2016, CURR OPIN IMMUNOL, V38, P18, DOI 10.1016/j.coi.2015.10.008
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mladinich MC, 2017, MBIO, V8, DOI [10.1128/mBio.00952-17, 10.1128/mbio.00952-17]
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Morrey JD, 2008, J GEN VIROL, V89, P467, DOI 10.1099/vir.0.83345-0
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JCI27798., 10.1172/JC127798]
   Racaniello VR, 2006, VIROLOGY, V344, P9, DOI 10.1016/j.virol.2005.09.015
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Roach T, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0824-7
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Salinas S, 2010, NAT REV MICROBIOL, V8, P645, DOI 10.1038/nrmicro2395
   Samuel MA, 2007, P NATL ACAD SCI USA, V104, P17140, DOI 10.1073/pnas.0705837104
   Saunders NR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3339/fnins.2015.00385, 10.3389/fnins.2015.00385]
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Singh PK, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92340
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Tugizov SM, 2013, J VIROL, V87, P8179, DOI 10.1128/JVI.00443-13
   Velandia-Romero ML, 2012, J NEUROVIROL, V18, P374, DOI 10.1007/s13365-012-0117-y
   Verma S, 2009, VIROLOGY, V385, P425, DOI 10.1016/j.virol.2008.11.047
   Vermillion MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14575
   Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 62
TC 33
Z9 35
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD DEC 22
PY 2017
VL 8
AR 2557
DI 10.3389/fmicb.2017.02557
PG 17
WC Microbiology
SC Microbiology
GA FQ8DF
UT WOS:000418592400001
PM 29312238
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Quintela-Carvalho, G
   Luz, NF
   Celes, FS
   Zanette, DL
   Andrade, D
   Menezes, D
   Tavares, NM
   Brodskyn, CI
   Prates, DB
   Goncalves, MS
   de Oliveira, CI
   Almeida, RP
   Bozza, MT
   Andrade, BB
   Borges, VM
AF Quintela-Carvalho, Graziele
   Luz, Nivea F.
   Celes, Fabiana S.
   Zanette, Dalila L.
   Andrade, Daniela
   Menezes, Diego
   Tavares, Natalia M.
   Brodskyn, Claudia I.
   Prates, Deboraci B.
   Goncalves, Marilda S.
   de Oliveira, Camila I.
   Almeida, Roque P.
   Bozza, Marcelo T.
   Andrade, Bruno B.
   Borges, Valeria M.
TI Heme Drives Oxidative Stress-Associated Cell Death in Human Neutrophils
   Infected with Leishmania infantum
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE Leishmania infantum; heme; iron; neutrophils; cell death; heme oxygenase
   1
ID NF-KAPPA-B; VISCERAL LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; PARASITE
   BURDEN; INNATE IMMUNITY; MACROPHAGES; SUPEROXIDE; AMAZONENSIS;
   MECHANISMS; APOPTOSIS
AB Free heme is an inflammatory molecule capable of inducing migration and activation of neutrophils. Here, we examine the heme-driven oxidative stress-associated cell death mechanisms in human neutrophils infected with Leishmania infantum, an etiologic agent of visceral leishmaniasis (VL). We first performed exploratory analyses in a population of well characterized treatment-naive VL patients as well as uninfected controls, who were part of previously reported studies. We noted a positive correlation between serum concentrations of heme with heme oxygenase-1 (HO-1) and lactate deydrogenase, as well as, a negative correlation between heme values and peripheral blood neutrophils counts. Moreover, in vitro infection with L. infantum in the presence of heme enhanced parasite burden in neutrophils, while increasing the production of reactive oxygen species and release of neutrophilic enzymes. Additional experiments demonstrated that treatment of infected neutrophils with ferrous iron (Fe+2), a key component of the heme molecule, resulted in increased parasite survival without affecting neutrophil activation status. Furthermore, stimulation of infected neutrophils with heme triggered substantial increases in HO-1 mRNA expression as well as in superoxide dismutase-1 enzymatic activity. Heme, but not Fe+2, induced oxidative stress-associated cell death. These findings indicate that heme promotes intracellular L. infantum survival via activation of neutrophil function and oxidative stress. This study opens new perspectives for the understanding of immunopathogenic mechanisms involving neutrophils in VL.
C1 [Quintela-Carvalho, Graziele; Luz, Nivea F.; Celes, Fabiana S.; Zanette, Dalila L.; Andrade, Daniela; Menezes, Diego; Tavares, Natalia M.; Brodskyn, Claudia I.; Goncalves, Marilda S.; de Oliveira, Camila I.; Andrade, Bruno B.; Borges, Valeria M.] IGM, Fundacao Oswaldo Cruz FIOCRUZ, Salvador, BA, Brazil.
   [Quintela-Carvalho, Graziele; Celes, Fabiana S.; Tavares, Natalia M.; Brodskyn, Claudia I.; Goncalves, Marilda S.; de Oliveira, Camila I.; Borges, Valeria M.] Univ Fed Bahia UFBA, Fac Med, Salvador, BA, Brazil.
   [Quintela-Carvalho, Graziele] Inst Fed Educ Ciencia & Tecnol Baiano IFBaiano, Santa Ines, Brazil.
   [Menezes, Diego] ITP, Aracaju, Brazil.
   [Prates, Deboraci B.] Univ Fed Bahia UFBA, Inst Cienc Saude, Dept Biomorfol, Salvador, BA, Brazil.
   [Almeida, Roque P.] UFS, Hosp Univ, Dept Med, Aracaju, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Rio de Janeiro, RJ, Brazil.
   [Andrade, Bruno B.] MONSTER Initiat, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil.
   [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
RP Andrade, BB; Borges, VM (corresponding author), IGM, Fundacao Oswaldo Cruz FIOCRUZ, Salvador, BA, Brazil.; Borges, VM (corresponding author), Univ Fed Bahia UFBA, Fac Med, Salvador, BA, Brazil.; Andrade, BB (corresponding author), MONSTER Initiat, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil.; Andrade, BB (corresponding author), Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
EM bruno.andrade@bahia.fiocruz.br; vborges@bahia.fiocruz.br
RI Andrade, Bruno/AAI-2248-2020; Menezes, Diego/T-4794-2019; Borges,
   Valeria/G-2009-2014; de Oliveira, Camila I/B-4358-2009; Tavares,
   Natalia/AAQ-1527-2020; Borges, Val/N-6647-2019
OI de Oliveira, Camila I/0000-0002-7868-5164; Borges,
   Val/0000-0002-2775-5409; zanette, dalila l./0000-0001-9397-4127; Machado
   Tavares, Natalia/0000-0002-4026-679X; Andrade,
   Bruno/0000-0001-6833-3811; Farias Luz, Nivea/0000-0003-1958-7043
FU Fundacao de Amparo a Pesquisa do Estado da Bahia-FAPESB [RED0018/2013];
   Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico-CNPqNational Council for Scientific and Technological
   Development (CNPq) [478480/2013-0, 552721/2011-5, 019.203.02712/2009-8
   FAPITEC/CNPq]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES [CAPES: 23038.005304/2011-01]; FAPESB; CAPESCAPES
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado da Bahia-FAPESB (RED0018/2013 to VB) and from Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico-CNPq (478480/2013-0 to VB,
   552721/2011-5 and 019.203.02712/2009-8 FAPITEC/CNPq to RA). RA also
   received a grant from Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES: 23038.005304/2011-01). GQ-C received a fellowship from
   FAPESB. NL received a fellowship from CAPES. VB, MB, RA, CO, CB, and MG
   are senior investigators from CNPq. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelmoula Mohamed Slim, 2003, Tunis Med, V81, P535
   Afonso L, 2008, J LEUKOCYTE BIOL, V84, P389, DOI 10.1189/jlb.0108018
   Almeida BFM, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12494
   Amaral EP, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0872-7
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Araujo-Santos T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04595-8
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Ballas SK, 2013, BLOOD, V121, P243, DOI 10.1182/blood-2012-10-462135
   Belic A, 2000, Med Pregl, V53, P89
   Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002
   Boukhris I, 2015, PAN AFR MED J, V22, DOI 10.11604/pamj.2015.22.96.5662
   Carvalho MOS, 2018, BRIT J HAEMATOL, V182, P933, DOI 10.1111/bjh.14896
   Carvalho S, 2009, ACTA TROP, V109, P131, DOI 10.1016/j.actatropica.2008.10.007
   Cassat JE, 2013, CELL HOST MICROBE, V13, P510, DOI 10.1016/j.chom.2013.04.010
   Celes FS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38330
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Huynh C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002795
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Dey S, 2012, J BIOL CHEM, V287, P26630, DOI 10.1074/jbc.M112.341255
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Falcao SAC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003601
   Fenton H. J. H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Fukai T, 2011, ANTIOXID REDOX SIGN, V15, P1583, DOI 10.1089/ars.2011.3999
   Gardinassi LG, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2222-5
   Gardinassi LG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005123
   Goto Y, 2017, PARASITOL RES, V116, P457, DOI 10.1007/s00436-016-5313-x
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Hurrell BP, 2016, TRENDS PARASITOL, V32, P392, DOI 10.1016/j.pt.2016.02.003
   Kapitulnik J, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00026
   Kedzierski L, 2011, HUM VACCINES, V7, P1204, DOI 10.4161/hv.7.11.17752
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Luz NF, 2016, J IMMUNOL, V196, P5056, DOI 10.4049/jimmunol.1502492
   Miralda I, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00217
   Mittra B, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005340
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Nauseef WM, 2014, CELL MICROBIOL, V16, P1146, DOI 10.1111/cmi.12312
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Prates DB, 2011, J LEUKOCYTE BIOL, V90, P575, DOI 10.1189/jlb.0211105
   Ribeiro-Gomes FL, 2004, J IMMUNOL, V172, P4454, DOI 10.4049/jimmunol.172.7.4454
   Ribeiro-Gomes FL, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00059
   SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Tavares N, 2016, J IMMUNOL, V196, P1865, DOI 10.4049/jimmunol.1502224
   Tavares NM, 2014, J INFECT DIS, V210, P656, DOI 10.1093/infdis/jiu158
   Thakur AK, 2013, EXP PARASITOL, V135, P595, DOI 10.1016/j.exppara.2013.09.008
   Whyte M, 1999, BIOCHEM SOC T, V27, P802, DOI 10.1042/bst0270802
NR 56
TC 9
Z9 9
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 23
PY 2017
VL 8
AR 1620
DI 10.3389/fimmu.2017.01620
PG 12
WC Immunology
SC Immunology
GA FN4YS
UT WOS:000416013600002
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Barbosa, MGD
   Prata, RBD
   Andrade, PR
   Ferreira, H
   Silva, BJD
   de Oliveira, JAD
   Assis, TQ
   de Toledo-Pinto, TG
   Bezerra, OCD
   Nery, JAD
   Rosa, PS
   Bozza, MT
   Lara, FA
   Moraes, MO
   Schmitz, V
   Sarno, EN
   Pinheiro, RO
AF de Mattos Barbosa, Mayara Garcia
   da Silva Prata, Rhana Berto
   Andrade, Priscila Ribeiro
   Ferreira, Helen
   de Andrade Silva, Bruno Jorge
   da Paixao de Oliveira, Jessica Araujo
   Assis, Tayna Quintella
   de Toledo-Pinto, Thiago Gomes
   de Lima Bezerra, Ohanna Cavalcanti
   da Costa Nery, Jose Augusto
   Rosa, Patricia Sammarco
   Bozza, Marcelo Torres
   Lara, Flavio Alves
   Moraes, Milton Ozorio
   Schmitz, Veronica
   Sarno, Euzenir Nunes
   Pinheiro, Roberta Olmo
TI Indoleamine 2,3-dioxygenase and iron are required for Mycobacterium
   leprae survival
SO MICROBES AND INFECTION
LA English
DT Article
DE Leprosy; Macrophages; Iron; Indoleamine 2,3-dioxygenase; Mycobacterium
   leprae
ID MACROPHAGE POLARIZATION; EXPRESSION; GAMMA; HOMEOSTASIS; PATHWAYS; CD163
AB Our previous study has demonstrated that IL-10 may modulate both indoleamine 2,3-dioxygenase (IDO) and CD163 expression in lepromatous leprosy (LL) cells, favoring Mycobacterium leprae persistence through induction of regulatory pathways and iron storage. Here, we observed that in LL lesion cells there is an increase in the expression of proteins involved in iron metabolism such as hemoglobin (Hb), haptoglobin, heme oxygenase 1 and transferrin receptor 1 (TfR1) when compared to tuberculoid leprosy (BT) cells. We also found increased iron deposits and diminished expression of the iron exporter ferroportin 1 in LL lesion cells. Hemin, but not FeSO4 stimulation, was able to enhance M. leprae viability by a mechanism that involves IDO. Analysis of cell phenotype in lesions demonstrated a predominance of M2 markers in LL when compared with BT lesion cells. A positive correlation between CD163 and PPARG with the bacillary index (BI) was observed. In contrast, TNF, STAT1 and CSF2 presented a negative correlation with the BI. In summary, this study demonstrates that iron may regulate IDO expression by a mechanism that involves IL-10, which may contribute for the predominance of M2-like phenotype in LL lesions that favors the phagocytosis and maintenance of M. leprae in host cells. (C) 2017 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [de Mattos Barbosa, Mayara Garcia; da Silva Prata, Rhana Berto; Andrade, Priscila Ribeiro; Ferreira, Helen; de Andrade Silva, Bruno Jorge; da Paixao de Oliveira, Jessica Araujo; Assis, Tayna Quintella; de Toledo-Pinto, Thiago Gomes; de Lima Bezerra, Ohanna Cavalcanti; da Costa Nery, Jose Augusto; Moraes, Milton Ozorio; Schmitz, Veronica; Sarno, Euzenir Nunes; Pinheiro, Roberta Olmo] Fundacao Oswaldo Cruz, Leprosy Lab, Oswaldo Cruz Inst, Rio De Janeiro, RJ, Brazil.
   [da Silva Prata, Rhana Berto; Bozza, Marcelo Torres] Univ Fed Rio de Janeiro, Inflammat & Immun Lab, Rio De Janeiro, RJ, Brazil.
   [Lara, Flavio Alves] Fundacao Oswaldo Cruz, Cellular Microbiol Lab, Rio De Janeiro, RJ, Brazil.
   [Rosa, Patricia Sammarco] Lauro de Souza Lima Inst, Lab Anim House, Bauru, SP, Brazil.
RP Pinheiro, RO (corresponding author), Fundacao Oswaldo Cruz, Leprosy Lab, Ave Brasil,4365, BR-21040360 Rio De Janeiro, RJ, Brazil.
EM roberta.olmo@pq.cnpq.br
RI Pinheiro, R O/A-2525-2013; Lara, Flavio Alves/L-1861-2013; Schmitz,
   Veronica P/D-2458-2013; Moraes, Milton Ozorio/G-9753-2011
OI Pinheiro, R O/0000-0001-8471-4227; Schmitz, Veronica
   P/0000-0002-0865-133X; Moraes, Milton Ozorio/0000-0003-2653-0037; Nunes
   Sarno, Euzenir/0000-0003-0129-2159
FU Brazilian National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [311488/2009-9, 311489/2009-9]; Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ) [203675]; Brazilian Coordination for the Improvement of
   Higher Education Personnel (CAPES)CAPES
FX This work was supported by the Brazilian National Council for Scientific
   and Technological Development (CNPq) [grant numbers 311488/2009-9 and
   311489/2009-9]; the Carlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ) [grant number 203675]; and the
   Brazilian Coordination for the Improvement of Higher Education Personnel
   (CAPES).
CR Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Araujo JA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00119
   ARNOLDI J, 1990, AM J PATHOL, V137, P749
   de Souza VNB, 2012, MEM I OSWALDO CRUZ, V107, P183, DOI 10.1590/S0074-02762012000900026
   Cairo G, 2010, HAEMATOL-HEMATOL J, V95, P1801, DOI 10.3324/haematol.2010.030239
   de Sousa JR, 2016, ACTA TROP, V157, P108, DOI 10.1016/j.actatropica.2016.01.008
   Sales JD, 2011, CLIN EXP IMMUNOL, V165, P251, DOI 10.1111/j.1365-2249.2011.04412.x
   Delaby C, 2005, BLOOD, V106, P3979, DOI 10.1182/blood-2005-06-2398
   ERMAKOVA Nina, 1936, International Journal of Leprosy, V4, P445
   Fallows D, 2016, J INFLAMM-LOND, V13, DOI 10.1186/s12950-016-0117-4
   Fulco TD, 2014, INFECT IMMUN, V82, P3968, DOI 10.1128/IAI.02194-14
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graversen JH, 2012, MOL THER, V20, P1550, DOI 10.1038/mt.2012.103
   HAYAISHI O, 1985, BIKEN J, V28, P39
   Hummon AB, 2007, BIOTECHNIQUES, V42, P467, DOI 10.2144/000112401
   Jung ID, 2010, BIOCHEM PHARMACOL, V80, P491, DOI 10.1016/j.bcp.2010.04.025
   Krausse-Opatz B, 2009, MICROB PATHOGENESIS, V46, P289, DOI 10.1016/j.micpath.2009.03.001
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Mattos KA, 2014, CELL MICROBIOL, V16, P797, DOI 10.1111/cmi.12279
   Mattos KA, 2010, J LEUKOCYTE BIOL, V87, P371, DOI 10.1189/jlb.0609433
   Meneghetti F, 2016, CURR MED CHEM, V23, P4009, DOI 10.2174/0929867323666160607223747
   Montoya D, 2009, CELL HOST MICROBE, V6, P343, DOI 10.1016/j.chom.2009.09.002
   Moura DF, 2012, EUR J IMMUNOL, V42, P2925, DOI 10.1002/eji.201142198
   Muraille E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00603
   Nairz M, 2009, CELL MICROBIOL, V11, P1365, DOI 10.1111/j.1462-5822.2009.01337.x
   Olakanmi O, 2002, J BIOL CHEM, V277, P49727, DOI 10.1074/jbc.M209768200
   Pereira-Suarez Ana Laura, 2015, Indian J Dermatol Venereol Leprol, V81, P594, DOI 10.4103/0378-6323.168345
   Recalcati S, 2010, EUR J IMMUNOL, V40, P824, DOI 10.1002/eji.200939889
   Reeve I, 2002, P NATL ACAD SCI USA, V99, P8608, DOI 10.1073/pnas.142287699
   Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255
   Schaible ME, 2004, NAT REV MICROBIOL, V2, P946, DOI 10.1038/nrmicro1046
   Silva LM, 2015, HUM PATHOL, V46, P746, DOI 10.1016/j.humpath.2015.01.015
   Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016
   Theurl I, 2008, BLOOD, V111, P2392, DOI 10.1182/blood-2007-05-090019
   Trombone APF, 2014, JOVE-J VIS EXP, P85
   Widner B, 1997, CLIN CHEM, V43, P2424
   Williams DL, 2004, J MOL MICROB BIOTECH, V8, P58, DOI 10.1159/000082081
   YOSHIDA R, 1987, METHOD ENZYMOL, V142, P188
NR 38
TC 8
Z9 8
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD NOV
PY 2017
VL 19
IS 11
BP 505
EP 514
DI 10.1016/j.micinf.2017.06.006
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FL6MV
UT WOS:000414360300003
PM 28684130
DA 2020-12-01
ER

PT J
AU Pinheiro, CD
   Monteiro, APT
   Dutra, FF
   Bozza, MT
   Peters-Golden, M
   Benjamim, CF
   Canetti, C
AF Pinheiro, Carla da S.
   Monteiro, Ana Paula T.
   Dutra, Fabiano F.
   Bozza, Marcelo T.
   Peters-Golden, Marc
   Benjamim, Claudia F.
   Canetti, Claudio
TI Short-Term Regulation of Fc gamma R-Mediated Phagocytosis by TLRs in
   Macrophages: Participation of 5-Lipoxygenase Products
SO MEDIATORS OF INFLAMMATION
LA English
DT Article
ID TOLL-LIKE RECEPTORS; LEUKOTRIENE B-4; ACTIVATION; KINASE; CELLS; INNATE;
   RECOGNITION; MECHANISMS; MIGRATION; BINDING
AB TLRs recognize a broad spectrum of microorganism molecules, triggering a variety of cellular responses. Among them, phagocytosis is a critical process for host defense. Leukotrienes (LTs), lipid mediators produced from 5-lipoxygenase (5-LO) enzyme, increase Fc gamma R-mediated phagocytosis. Here, we evaluated the participation of TLR2, TLR3, TLR4, and TLR9 in Fc gamma R-mediated phagocytosis and whether this process is modulated by LTs. Rat alveolar macrophages (AMs), murine bone marrow-derived macrophages (BMDMs), and peritoneal macrophages (PMs) treated with TLR2, TLR3, and TLR4 agonists, but not TLR9, enhanced IgG-opsonized sheep red blood cell (IgG-sRBC) phagocytosis. Pretreatment of AMs or BMDMs with drugs that block LT synthesis impaired the phagocytosis promoted by TLR ligands, and TLR potentiation was also abrogated in PMs and BMDMs from 5-LO-/- mice. LTB4 production induced by IgG engagement was amplified by TLR ligands, while cys-LTs were amplified by activation of TLR2 and TLR4, but not by TLR3. We also noted higher ERK1/2 phosphorylation in IgG-RBC-challenged cells when preincubated with TLR agonists. Furthermore, ERK1/2 inhibition by PD98059 reduced the phagocytic activity evoked by TLR agonists. Together, these data indicate that TLR2, TLR3, and TLR4 ligands, but not TLR9, amplify IgG-mediated phagocytosis by a mechanism which requires LT production and ERK-1/2 pathway activation.
C1 [Pinheiro, Carla da S.; Monteiro, Ana Paula T.; Canetti, Claudio] Biophys Inst Carlos Chagas Filho, Lab Inflammat, Rio De Janeiro, RJ, Brazil.
   [Dutra, Fabiano F.; Bozza, Marcelo T.] Inst Microbiol Prof Paulo de Goes, Dept Immunol, Rio De Janeiro, RJ, Brazil.
   [Peters-Golden, Marc] Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
   [Benjamim, Claudia F.] Univ Fed Rio de Janeiro, Biophys Inst Carlos Chagas Filho, Lab Immunopharmacol, BR-22541900 Rio De Janeiro, RJ, Brazil.
RP Canetti, C (corresponding author), Biophys Inst Carlos Chagas Filho, Lab Inflammat, Rio De Janeiro, RJ, Brazil.
EM ccanetti@biof.ufrj.br
RI Monteiro, Ana Paula T/L-9540-2013; Benjamim, Claudia/T-5090-2019;
   Claudio, Canetti A/C-2774-2009
OI Benjamim, Claudia/0000-0001-6247-9596; 
FU Fundacao Carlos Chagas Filho de Amparo a pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao Carlos Chagas Filho de Amparo a
   pesquisa do Estado do Rio de Janeiro (FAPERJ) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Akula S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096903
   Amiel E, 2009, J LEUKOCYTE BIOL, V85, P595, DOI 10.1189/jlb.1008631
   Anand RJ, 2007, J PEDIATR SURG, V42, P927, DOI 10.1016/j.jpedsurg.2007.01.023
   Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249
   Bailie MB, 1996, J IMMUNOL, V157, P5221
   Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103
   Bu HF, 2010, J CELL PHYSIOL, V222, P658, DOI 10.1002/jcp.21985
   Campos MRM, 2009, MOL IMMUNOL, V46, P1204, DOI 10.1016/j.molimm.2008.11.024
   Canetti C, 2001, BRIT J PHARMACOL, V134, P1619, DOI 10.1038/sj.bjp.0704403
   Canetti C, 2003, BLOOD, V102, P1877, DOI 10.1182/blood-2003-02-0534
   Canetti C, 2007, J IMMUNOL, V179, P8350, DOI 10.4049/jimmunol.179.12.8350
   CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0
   Crowley M. T., 2007, J EXP MED, V186, P1027
   De Nardo D, 2015, CYTOKINE, V74, P181, DOI 10.1016/j.cyto.2015.02.025
   Doyle SE, 2004, J EXP MED, V199, P81, DOI 10.1084/jem.20031237
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0
   Haralambieva IH, 2004, J MED MICROBIOL, V53, P1187, DOI 10.1099/jmm.0.45758-0
   Hirayama T, 2011, J ORTHOP RES, V29, P984, DOI 10.1002/jor.21369
   Hu B, 2000, J IMMUNOL, V165, P2124, DOI 10.4049/jimmunol.165.4.2124
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   JONSSON EW, 1994, J PHARMACOL EXP THER, V271, P615
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kumagai Y, 2010, J ALLERGY CLIN IMMUN, V125, P985, DOI 10.1016/j.jaci.2010.01.058
   Lee CW, 2004, AM J PHYSIOL-LUNG C, V286, pL921, DOI 10.1152/ajplung.00124.2003
   Lefebvre JS, 2010, FASEB J, V24, P637, DOI 10.1096/fj.09-135624
   Liu SR, 2012, J IMMUNOL, V188, P1098, DOI 10.4049/jimmunol.1101121
   Mansfield PJ, 2000, BLOOD, V95, P2407, DOI 10.1182/blood.V95.7.2407.007k02_2407_2412
   Mortaz E, 2007, EUR J PHARMACOL, V561, P214, DOI 10.1016/j.ejphar.2006.12.038
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Peter ME, 2009, J IMMUNOL, V182, P7690, DOI 10.4049/jimmunol.0900819
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11
   Radmark O, 2005, BIOCHEM BIOPH RES CO, V338, P102, DOI 10.1016/j.bbrc.2005.08.013
   Richardson ET, 2015, INFECT IMMUN, V83, P2242, DOI 10.1128/IAI.00135-15
   Serezani CH, 2011, J CLIN INVEST, V121, P671, DOI 10.1172/JCI43302
   Silva RC, 2010, CELL PHYSIOL BIOCHEM, V26, P319, DOI 10.1159/000320555
   Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605
   Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959
   Wu TT, 2011, CYTOKINE, V55, P40, DOI 10.1016/j.cyto.2011.03.005
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986
   Yin Q, 2015, ANNU REV IMMUNOL, V33, P393, DOI 10.1146/annurev-immunol-032414-112258
   Zou JX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136843
NR 46
TC 6
Z9 6
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2017
VL 2017
AR 2086840
DI 10.1155/2017/2086840
PG 10
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA FE4BX
UT WOS:000408160500001
PM 28894350
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Travassos, LH
   Vasconcellos, LRC
   Bozza, MT
   Carneiro, LAM
AF Travassos, Leonardo H.
   Vasconcellos, Luiz R. C.
   Bozza, Marcelo T.
   Carneiro, Leticia A. M.
TI Heme and iron induce protein aggregation
SO AUTOPHAGY
LA English
DT Editorial Material
DE aggregation; ALIS; autophagy; ferritin; heme; iron; NRF2; oxidative
   stress; protein
AB Heme is an essential molecule expressed in many tissues where it plays key roles as the prosthetic group of several proteins involved in vital physiological and metabolic processes such as gas and electron transport. Structurally, heme is a tetrapyrrole ring containing an atom of iron (Fe) in its center. When released into the extracellular milieu, heme exerts several deleterious effects, which make it an important player in infectious and noninfectious hemolytic diseases where large amounts of free heme are observed such as malaria, dengue fever, beta-thalassemia, sickle cell disease and ischemia-reperfusion. Our recent work has uncovered an unappreciated cellular response triggered by heme or Fe, one of its degradation products, on macrophages, which is the formation of protein aggregates known as aggresome-like induced structres (ALIS). This response was shown to be fully dependent on ROS production and the activation of the transcription factor NFE2L2/NRF2. In addition, we have demonstrated that heme degradation by HMOX1/HO-1 (heme oxygenase 1) is required and that Fe is essential for the formation of ALIS, as heme analogs lacking the central atom of Fe are not able to induce these structures. ALIS formation is also observed in vivo, in a model of phenylhydrazine (PHZ)-induced hemolysis, indicating that it is an integral part of the host response to excessive free heme and that it may play a role in cellular homeostasis.
C1 [Travassos, Leonardo H.; Vasconcellos, Luiz R. C.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunoreceptores Sinalizacao, BR-21941 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.; Carneiro, Leticia A. M.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Lab Inflamacao Imunidade, BR-21941 Rio De Janeiro, Brazil.
   [Travassos, Leonardo H.] LIRS, Lab Intermediario Imunoreceptores Sinalizacao, Carlos Chagas Filho, Rio De Janeiro, Brazil.
RP Travassos, LH (corresponding author), LIRS, Lab Intermediario Imunoreceptores Sinalizacao, Carlos Chagas Filho, Rio De Janeiro, Brazil.
EM leo.travassos@me.com
RI Travassos, Leonardo/G-1925-2012; Carneiro, Leticia/T-8978-2019
OI Travassos, Leonardo/0000-0003-1323-3797; /0000-0002-3877-7013
NR 0
TC 6
Z9 6
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PY 2017
VL 13
IS 3
BP 625
EP 626
DI 10.1080/15548627.2016.1271515
PG 2
WC Cell Biology
SC Cell Biology
GA EO7BJ
UT WOS:000396845900014
PM 28055290
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Monnerat, G
   Alarcon, ML
   Vasconcellos, LR
   Hochman-Mendez, C
   Brasil, G
   Bassani, RA
   Casis, O
   Malan, D
   Travassos, LH
   Sepulveda, M
   Burgos, JI
   Vila-Petroff, M
   Dutra, FF
   Bozza, MT
   Paiva, CN
   Carvalho, AB
   Bonomo, A
   Fleischmann, BK
   Carvalho, ACC
   Medei, E
AF Monnerat, Gustavo
   Alarcon, Micaela L.
   Vasconcellos, Luiz R.
   Hochman-Mendez, Camila
   Brasil, Guilherme
   Bassani, Rosana A.
   Casis, Oscar
   Malan, Daniela
   Travassos, Leonardo H.
   Sepulveda, Marisa
   Ignacio Burgos, Juan
   Vila-Petroff, Martin
   Dutra, Fabiano F.
   Bozza, Marcelo T.
   Paiva, Claudia N.
   Carvalho, Adriana Bastos
   Bonomo, Adriana
   Fleischmann, Bernd K.
   Campos de Carvalho, Antonio Carlos
   Medei, Emiliano
TI Macrophage-dependent IL-1 beta production induces cardiac arrhythmias in
   diabetic mice
SO NATURE COMMUNICATIONS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; NLRP3 INFLAMMASOME; SARCOPLASMIC-RETICULUM;
   VENTRICULAR REPOLARIZATION; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE;
   NALP3 INFLAMMASOME; CONVERTING-ENZYME; HUMAN MONOCYTES; ACTIVATION
AB Diabetes mellitus (DM) encompasses a multitude of secondary disorders, including heart disease. One of the most frequent and potentially life threatening disorders of DM-induced heart disease is ventricular tachycardia (VT). Here we show that toll-like receptor 2 (TLR2) and NLRP3 inflammasome activation in cardiac macrophages mediate the production of IL-1 beta in DM mice. IL-1 beta causes prolongation of the action potential duration, induces a decrease in potassium current and an increase in calcium sparks in cardiomyocytes, which are changes that underlie arrhythmia propensity. IL-1 beta-induced spontaneous contractile events are associated with CaMKII oxidation and phosphorylation. We further show that DM-induced arrhythmias can be successfully treated by inhibiting the IL-1 beta axis with either IL-1 receptor antagonist or by inhibiting the NLRP3 inflammasome. Our results establish IL-1 beta as an inflammatory connection between metabolic dysfunction and arrhythmias in DM.
C1 [Monnerat, Gustavo; Alarcon, Micaela L.; Hochman-Mendez, Camila; Brasil, Guilherme; Carvalho, Adriana Bastos; Campos de Carvalho, Antonio Carlos; Medei, Emiliano] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.
   [Vasconcellos, Luiz R.; Travassos, Leonardo H.] Univ Fed Rio de Janeiro, LIRS Lab Immunoreceptors & Signaling, BR-21941902 Rio De Janeiro, Brazil.
   [Vasconcellos, Luiz R.; Dutra, Fabiano F.; Bozza, Marcelo T.; Paiva, Claudia N.; Bonomo, Adriana] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941902 Rio De Janeiro, Brazil.
   [Bassani, Rosana A.] Univ Estadual Campinas, Ctr Biomed Engn, BR-13083970 Campinas, SP, Brazil.
   [Casis, Oscar] Univ Pais Vasco UPV EHU, Fac Farm, Dept Fisiol, Vitoria 01006, Spain.
   [Malan, Daniela] Univ Bonn, Life & Brain Ctr, Inst Physiol 1, D-53127 Bonn, Germany.
   [Sepulveda, Marisa; Ignacio Burgos, Juan; Vila-Petroff, Martin] Univ Nacl La Plata, Fac Ciencias Med, Conicet La Plata, Ctr Invest Cardiovasc, RA-1900 La Plata, Buenos Aires, Argentina.
   [Bonomo, Adriana] FIOCRUZ Manguinhos, FIOCANCER VPPLR FIOCRUZ, BR-21040360 Rio De Janeiro, Brazil.
   [Campos de Carvalho, Antonio Carlos; Medei, Emiliano] Natl Ctr Struct Biol & Bioimaging CENABIO UFRJ, BR-21941902 Rio De Janeiro, Brazil.
RP Medei, E (corresponding author), Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.; Medei, E (corresponding author), Natl Ctr Struct Biol & Bioimaging CENABIO UFRJ, BR-21941902 Rio De Janeiro, Brazil.
EM emedei70@biof.ufrj.br
RI BRASIL, GUILHERME VISCONDE/M-7286-2019; Travassos, Leonardo/G-1925-2012;
   Carvalho, Adriana B/E-4427-2011; monnerat, gustavo/E-3398-2015; Bassani,
   Rosana/O-7906-2014; cahli, gustavo monnerat/J-6907-2019; de Carvalho,
   Antonio Campos/A-3152-2008
OI BRASIL, GUILHERME VISCONDE/0000-0002-4695-4710; Travassos,
   Leonardo/0000-0003-1323-3797; Carvalho, Adriana B/0000-0002-7830-7868;
   monnerat, gustavo/0000-0002-1010-6314; Bassani,
   Rosana/0000-0002-6453-1359; de Carvalho, Antonio
   Campos/0000-0002-0062-3043; Medei, Emiliano/0000-0002-0044-1311; CASIS
   SAENZ, OSCAR/0000-0002-6219-3317
FU Brazilian National Research Council (CNPq), BrazilNational Council for
   Scientific and Technological Development (CNPq) [308168/2012-7,
   475218/2012-4]; Carlos Chagas Filho Rio de Janeiro State Research
   Foundation (FAPERJ), Brazil [E-26/103.222/2011, E-26/111.171/2011];
   National Institutes of Science and Technology for Biology Structural and
   Bioimaging, Brazil [573767/2008-4]; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [FL 276/7-2];
   Stem Cell Factory II; FONCYTFONCyT [PICT 1678]; FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ) [PDR 10]; CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This work was funded by the Brazilian National Research Council (CNPq,
   grants: 308168/2012-7 and 475218/2012-4), the Carlos Chagas Filho Rio de
   Janeiro State Research Foundation (FAPERJ, grants: E-26/103.222/2011 and
   E-26/111.171/2011) and National Institutes of Science and Technology for
   Biology Structural and Bioimaging (grant: 573767/2008-4), Brazil and by
   grants of the Deutsche Forschungsgemeinschaft (FL 276/7-2 to B.K.F.) and
   by the Stem Cell Factory II co-founded by the European Union (European
   Regional Development Fund-Investing in your future) and the German
   federal state North Rhine-Westphalia (NRW) (to D.M. and B.K.F.).
   Additionally, the work was funded by PICT 1678 from FONCYT to M.V.-P..
   G.M. has a postdoctoral fellowship from FAPERJ (PDR 10), F.F.D has a
   postdoctoral fellowship from CAPES, L.R.V. has a PhD fellowship from
   FAPERJ, M.L.A has a PhD fellowship from CNPq.
CR Aurora AB, 2014, J CLIN INVEST, V124, P1382, DOI 10.1172/JCI72181
   BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130
   BASSANI RA, 1995, BIOPHYS J, V68, P2015, DOI 10.1016/S0006-3495(95)80378-4
   Bassani RA, 2012, GEN PHYSIOL BIOPHYS, V31, P401, DOI 10.4149/gpb_2012_042
   Bierhaus A, 2012, NAT MED, V18, P926, DOI 10.1038/nm.2750
   Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576
   Casis O, 2000, DIABETOLOGIA, V43, P101, DOI 10.1007/s001250050013
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Coutinho DCO, 2014, EUROPACE, V16, P1689, DOI 10.1093/europace/euu070
   CURTIS MJ, 1988, CARDIOVASC RES, V22, P656, DOI 10.1093/cvr/22.9.656
   Dasu MR, 2008, DIABETES, V57, P3090, DOI 10.2337/db08-0564
   Dasu MR, 2007, AM J PHYSIOL-ENDOC M, V293, pE337, DOI 10.1152/ajpendo.00718.2006
   Dasu MR, 2010, LAB INVEST, V90, P1628, DOI 10.1038/labinvest.2010.158
   De Nardo D, 2011, TRENDS IMMUNOL, V32, P373, DOI 10.1016/j.it.2011.05.004
   Devaraj S, 2008, J CLIN ENDOCR METAB, V93, P578, DOI 10.1210/jc.2007-2185
   Devaraj S, 2011, METABOLISM, V60, P256, DOI 10.1016/j.metabol.2010.01.005
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Ehses JA, 2010, DIABETOLOGIA, V53, P1795, DOI 10.1007/s00125-010-1747-3
   El-Atat Fadi A, 2004, Curr Diab Rep, V4, P187, DOI 10.1007/s11892-004-0022-8
   Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019
   Erickson JR, 2013, NATURE, V502, P372, DOI 10.1038/nature12537
   Ferraz SA, 2001, J MOL CELL CARDIOL, V33, P711, DOI 10.1006/jmcc.2001.1337
   Frangogiannis N. G., 2015, DISCOVERIES CRAIOVA, V3, pe41, DOI [DOI 10.15190/D.2015.33, 10.15190/d.2015.33]
   Gonano LA, 2011, CIRC-ARRHYTHMIA ELEC, V4, P947, DOI 10.1161/CIRCEP.111.964908
   Grishman EK, 2012, PEDIATR RES, V71, P626, DOI 10.1038/pr.2012.24
   Higashikuni Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000267
   KAHN JK, 1987, J CLIN ENDOCR METAB, V64, P751, DOI 10.1210/jcem-64-4-751
   KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8
   Kehat I, 2002, CIRC RES, V91, P659, DOI 10.1161/01.RES.0000039084.30342.9B
   Khoo MSC, 2005, HEART RHYTHM, V2, P634, DOI 10.1016/j.hrthm.2005.03.019
   Kim HY, 2014, NAT MED, V20, P54, DOI 10.1038/nm.3423
   Koenen TB, 2011, DIABETES, V60, P517, DOI 10.2337/db10-0266
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Laliberte RE, 2003, J BIOL CHEM, V278, P16567, DOI 10.1074/jbc.M211596200
   Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206
   Larsen L, 2007, DIABETOLOGIA, V50, P779, DOI 10.1007/s00125-006-0562-3
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee HM, 2013, DIABETES, V62, P194, DOI 10.2337/db12-0420
   LI YH, 1993, CARDIOVASC RES, V27, P525, DOI 10.1093/cvr/27.3.525
   Lopez-Izquierdo A, 2014, AM J PHYSIOL-HEART C, V306, pH747, DOI 10.1152/ajpheart.00849.2013
   Lu ZJ, 2013, DIABETES, V62, P4257, DOI 10.2337/db13-0420
   Luheshi NM, 2012, EUR J IMMUNOL, V42, P716, DOI 10.1002/eji.201142079
   Luo M, 2013, J CLIN INVEST, V123, P1262, DOI 10.1172/JCI65268
   MAGYAR J, 1992, J MOL CELL CARDIOL, V24, P841, DOI 10.1016/0022-2828(92)91098-P
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mersmann J, 2010, CRIT CARE MED, V38, P1927, DOI 10.1097/CCM.0b013e3181ef455b
   Mitrokhin VM, 2015, INT IMMUNOPHARMACOL, V28, P780, DOI 10.1016/j.intimp.2015.08.006
   Monnerat-Cahli G, 2014, J MOL CELL CARDIOL, V76, P116, DOI 10.1016/j.yjmcc.2014.08.012
   Monnerat-Cahli G, 2014, INT J CARDIOL, V171, P199, DOI 10.1016/j.ijcard.2013.12.013
   Niu JL, 2014, EXP MOL PATHOL, V96, P71, DOI 10.1016/j.yexmp.2013.11.001
   Perez BF, 2004, REV MED CHILE, V132, P413, DOI 10.4067/S0034-98872004000400002
   Perregaux DG, 2001, J PHARMACOL EXP THER, V299, P187
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Preis SR, 2009, CIRCULATION, V120, P212, DOI 10.1161/CIRCULATIONAHA.108.846519
   Rossing P, 2001, DIABETIC MED, V18, P199, DOI 10.1046/j.1464-5491.2001.00446.x
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Singh MV, 2012, J MOL CELL CARDIOL, V52, P1135, DOI 10.1016/j.yjmcc.2012.01.021
   Sordillo PP, 2015, IN VIVO, V29, P619
   Stettler C, 2007, DIABETOLOGIA, V50, P186, DOI 10.1007/s00125-006-0483-1
   Sumpter KM, 2011, PEDIATR DIABETES, V12, P656, DOI 10.1111/j.1399-5448.2011.00761.x
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127
   Tu E, 2010, INT J CARDIOL, V138, P91, DOI 10.1016/j.ijcard.2008.06.021
   van Rooijen N, 2010, METHODS MOL BIOL, V605, P189, DOI 10.1007/978-1-60327-360-2_13
   Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279
   Vilaysane A, 2010, J AM SOC NEPHROL, V21, P1732, DOI 10.1681/ASN.2010020143
   Volders PGA, 1998, CIRCULATION, V98, P1136, DOI 10.1161/01.CIR.98.11.1136
NR 68
TC 81
Z9 84
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 24
PY 2016
VL 7
AR 13344
DI 10.1038/ncomms13344
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ED2EZ
UT WOS:000388657900001
PM 27882934
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Vasconcellos, LRC
   Dutra, FF
   Siqueira, MS
   Paula-Neto, HA
   Dahan, J
   Kiarely, E
   Carneiro, LAM
   Bozza, MT
   Travassos, LH
AF Vasconcellos, Luiz R. C.
   Dutra, Fabianno F.
   Siqueira, Mariana S.
   Paula-Neto, Heitor A.
   Dahan, Jennifer
   Kiarely, Ellen
   Carneiro, Leticia A. M.
   Bozza, Marcelo T.
   Travassos, Leonardo H.
TI Protein aggregation as a cellular response to oxidative stress induced
   by heme and iron
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE autophagy; p62/SQSTM1; ALIS; heme; iron
ID DEGRADATION; ACTIVATION; HEMOGLOBIN; P62/SQSTM1; EXPRESSION; MOLECULES;
   MIGRATION; OXYGENASE; HEMOLYSIS; IMMUNITY
AB Hemolytic diseases include a variety of conditions with diverse etiologies in which red blood cells are destroyed and large amounts of hemeproteins are released. Heme has been described as a potent proinflammatory molecule that is able to induce multiple innate immune responses, such as those triggered by TLR4 and the NLRP3 inflammasome, as well as necroptosis in macrophages. The mechanisms by which eukaryotic cells respond to the toxic effects induced by heme to maintain homeostasis are not fully understood, however. Here we describe a previously uncharacterized cellular response induced by heme: the formation of p62/SQTM1 aggregates containing ubiquitinated proteins in structures known as aggresome-like induced structures (ALIS). This action is part of a response driven by the transcription factor NRF2 to the excessive generation of reactive oxygen species induced by heme that results in the expression of genes involved in antioxidant responses, including p62/SQTM1. Furthermore, we show that heme degradation by HO-1 is required for ALIS formation, and that the free iron released on heme degradation is necessary and sufficient to induce ALIS. Moreover, ferritin, a key protein in iron metabolism, prevents excessive ALIS formation. Finally, in vivo, hemolysis promotes an increase in ALIS formation in target tissues. Our data unravel a poorly understood aspect of the cellular responses induced by heme that can be explored to better understand the effects of free heme and free iron during hemolytic diseases such as sickle cell disease, dengue fever, malaria, and sepsis.
C1 [Vasconcellos, Luiz R. C.; Siqueira, Mariana S.; Kiarely, Ellen; Travassos, Leonardo H.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunoreceptores & Sinalizacao, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Dutra, Fabianno F.; Dahan, Jennifer; Carneiro, Leticia A. M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Lab Alvos Mol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Travassos, LH (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunoreceptores & Sinalizacao, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM leo.travassos@biof.ufrj.br
RI Travassos, Leonardo/G-1925-2012; Carneiro, Leticia/T-8978-2019
OI Travassos, Leonardo/0000-0003-1323-3797; /0000-0002-3877-7013
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); CAPESCAPES; CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX We thank N. Mizushima (Tokyo Medical and Dental Center) for the
   Atg5<SUP>-/-</SUP> MEFs; C. Munz (University of Zurich) for
   pHR-SIN-CSGWNotI-GFP-LC3; M. Soares (Instituto Gulbenkian de Ciencia)
   for femurs from Nrf2<SUP>-/-</SUP>, FtH<SUP>-/-</SUP>, and
   Hmox1<SUP>-/-</SUP> mice; and Clarissa Damaso (Instituto de Biofisica
   Carlos Chagas Filho, Universidade Federal do Rio de Janeiro) for
   anti-p62. L.R.V. and J.D. were supported by fellowships from the
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ). E. K. and F.F.D. received fellowships from the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES).
   M.S.S. was supported by a fellowship from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). Work in the L.H.T.,
   L.A.M.C., and M.T.B. laboratories was supported by grants from FAPERJ,
   CAPES, and CNPq.
CR AFT RL, 1983, J BIOL CHEM, V258, P2069
   AFT RL, 1984, J BIOL CHEM, V259, P301
   Barcellos-de-Souza P, 2013, AM J PHYSIOL-CELL PH, V304, pC170, DOI 10.1152/ajpcell.00078.2012
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Carneiro LAM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00361
   Chiu DTY, 1996, FREE RADICAL BIO MED, V21, P89, DOI 10.1016/0891-5849(96)00035-4
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Fujita KI, 2011, P NATL ACAD SCI USA, V108, P1427, DOI 10.1073/pnas.1014156108
   Garcia-Arencibia M, 2010, SEMIN CELL DEV BIOL, V21, P691, DOI 10.1016/j.semcdb.2010.02.008
   Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kim CH, 2010, INT J ONCOL, V37, P97, DOI 10.3892/ijo_00000657
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Lelouard H, 2002, NATURE, V417, P177, DOI 10.1038/417177a
   Lim SK, 1998, BLOOD, V92, P1870, DOI 10.1182/blood.V92.6.1870.418k38_1870_1877
   Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200
   Lyoumi S, 1999, EUR J BIOCHEM, V261, P190, DOI 10.1046/j.1432-1327.1999.00254.x
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Moraes JA, 2012, ATHEROSCLEROSIS, V224, P394, DOI 10.1016/j.atherosclerosis.2012.07.043
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Soares MP, 2016, CURR OPIN IMMUNOL, V38, P94, DOI 10.1016/j.coi.2015.11.006
   Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5
   Szeto J, 2006, AUTOPHAGY, V2, P189, DOI 10.4161/auto.2731
   VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2
   Vinchi F, 2013, CIRCULATION, V127, P1317, DOI 10.1161/CIRCULATIONAHA.112.130179
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
NR 37
TC 37
Z9 37
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 22
PY 2016
VL 113
IS 47
BP E7474
EP E7482
DI 10.1073/pnas.1608928113
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ED4OY
UT WOS:000388830700017
PM 27821769
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Vilar-Pereira, G
   Carneiro, VC
   Mata-Santos, H
   Vicentino, ARR
   Ramos, IP
   Giarola, NLL
   Feijo, DF
   Meyer-Fernandes, JR
   Paula-Neto, HA
   Medei, E
   Bozza, MT
   Lannes-Vieira, J
   Paiva, CN
AF Vilar-Pereira, Glaucia
   Carneiro, Vitor C.
   Mata-Santos, Hilton
   Vicentino, Amanda R. R.
   Ramos, Isalira P.
   Giarola, Naira L. L.
   Feijo, Daniel F.
   Meyer-Fernandes, Jose R.
   Paula-Neto, Heitor A.
   Medei, Emiliano
   Bozza, Marcelo T.
   Lannes-Vieira, Joseli
   Paiva, Claudia N.
TI Resveratrol Reverses Functional Chagas Heart Disease in Mice
SO PLOS PATHOGENS
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; TRYPANOSOMA-CRUZI INFECTION; OXIDATIVE STRESS;
   ANTIARRHYTHMIC EFFICACY; CARDIOMYOPATHY; METFORMIN; BENZNIDAZOLE;
   MECHANISMS; FAILURE; BIOAVAILABILITY
AB Chronic chagasic cardiomyopathy (CCC) develops years after acute infection by Trypanosoma cruzi and does not improve after trypanocidal therapy, despite reduction of parasite burden. During disease, the heart undergoes oxidative stress, a potential causative factor for arrhythmias and contractile dysfunction. Here we tested whether antioxidants/cardioprotective drugs could improve cardiac function in established Chagas heart disease. We chose a model that resembles B1-B2 stage of human CCC, treated mice with resveratrol and performed electrocardiography and echocardiography studies. Resveratrol reduced the prolonged PR and QTc intervals, increased heart rates and reversed sinus arrhythmia, atrial and atrioventricular conduction disorders; restored a normal left ventricular ejection fraction, improved stroke volume and cardiac output. Resveratrol activated the AMPK-pathway and reduced both ROS production and heart parasite burden, without interfering with vascularization or myocarditis intensity. Resveratrol was even capable of improving heart function of infected mice when treatment was started late after infection, while trypanocidal drug benznidazole failed. We attempted to mimic resveratrol's actions using metformin (AMPK-activator) or tempol (SOD-mimetic). Metformin and tempol mimicked the beneficial effects of resveratrol on heart function and decreased lipid peroxidation, but did not alter parasite burden. These results indicate that AMPK activation and ROS neutralization are key strategies to induce tolerance to Chagas heart disease. Despite all tissue damage observed in established Chagas heart disease, we found that a physiological dysfunction can still be reversed by treatment with resveratrol, metformin and tempol, resulting in improved heart function and representing a starting point to develop innovative therapies in CCC.
C1 [Vilar-Pereira, Glaucia; Lannes-Vieira, Joseli] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Interacoes, Rio De Janeiro, RJ, Brazil.
   [Carneiro, Vitor C.; Vicentino, Amanda R. R.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Programa Biol Mol & Tecnol, Rio de Janeiro, RJ, Brazil.
   [Mata-Santos, Hilton; Feijo, Daniel F.; Bozza, Marcelo T.; Paiva, Claudia N.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunologial, Rio de Janeiro, RJ, Brazil.
   [Mata-Santos, Hilton] Univ Fed Rio de Janeiro, Fac Farm, Dept Anal Clin & Toxicol, Rio de Janeiro, RJ, Brazil.
   [Ramos, Isalira P.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Dept Radiol, Rio de Janeiro, RJ, Brazil.
   [Ramos, Isalira P.; Medei, Emiliano] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio de Janeiro, RJ, Brazil.
   [Ramos, Isalira P.; Medei, Emiliano] Univ Fed Rio de Janeiro, Ctr Nacl Biol Estrutural & Bioimagem, Rio de Janeiro, RJ, Brazil.
   [Giarola, Naira L. L.; Meyer-Fernandes, Jose R.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio de Janeiro, RJ, Brazil.
   [Meyer-Fernandes, Jose R.] Inst Nacl Ciencia & Tecnol Biol Estrutural Bioima, Rio De Janeiro, RJ, Brazil.
   [Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Dept Farmacos, Rio de Janeiro, RJ, Brazil.
   [Feijo, Daniel F.] Ctr Pesquisa Goncalo Moniz, Lab Imunoparasitol, Lab Imunoregulacao, Rua Valdemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunologial, Rio de Janeiro, RJ, Brazil.
EM claudianpaiva@mail.com
RI Ferreira Feijo, Daniel/Y-6067-2018
OI Carneiro, Vitor/0000-0003-1518-7667; Peroba Rezende Ramos,
   Isalira/0000-0003-3577-0403; Medei, Emiliano/0000-0002-0044-1311
FU DECIT Conselho Nacional de Pesquisa (CNPq); CNPq UniversalNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal (CAPES)CAPES; Fundacao de Amparo a
   Pesquisa do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Instituto
   Oswaldo Cruz (IOC, Fiocruz); CNPqNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by DECIT Conselho Nacional de Pesquisa (CNPq),
   CNPq Universal, Coordenacao de Aperfeicoamento de Pessoal (CAPES), and
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ), Instituto
   Oswaldo Cruz (IOC, Fiocruz). CNP, JLV, EM, JRMF and MTB received
   personal CNPq grants. All funding institutions are located in Brazil.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amri A, 2012, J CONTROL RELEASE, V158, P182, DOI 10.1016/j.jconrel.2011.09.083
   Baczko I, 2014, BRIT J PHARMACOL, V171, P92, DOI 10.1111/bph.12409
   Baez A, 2011, T ROY SOC TROP MED H, V105, P239, DOI 10.1016/j.trstmh.2011.01.007
   Britton RG, 2015, ANN NY ACAD SCI, V1348, P124, DOI 10.1111/nyas.12796
   de Carvalho ACC, 2011, ADV PARASIT, V75, P49, DOI 10.1016/B978-0-12-385863-4.00003-4
   Chan AYM, 2008, J BIOL CHEM, V283, P24194, DOI 10.1074/jbc.M802869200
   Chen WP, 2007, EUR J PHARMACOL, V554, P196, DOI 10.1016/j.ejphar.2006.10.016
   Cunha-Neto E, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/683230
   Dhiman M, 2011, J PATHOL, V225, P583, DOI 10.1002/path.2975
   Eickhoff CS, 2010, J PARASITOL, V96, P758, DOI 10.1645/GE-2396.1
   Falasca C A, 1991, Arq Bras Cardiol, V56, P287
   FEDERICI EE, 1964, AM J TROP MED HYG, V13, P272, DOI 10.4269/ajtmh.1964.13.272
   Francischetti IMB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087140
   Garcia S, 2005, ANTIMICROB AGENTS CH, V49, P1521, DOI 10.1128/AAC.49.4.1521-1528.2005
   Gundewar S, 2009, CIRC RES, V104, P403, DOI 10.1161/CIRCRESAHA.108.190918
   Guzman Mentesana Gustavo, 2010, Rev Fac Cien Med Univ Nac Cordoba, V67, P150
   Hao EK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069452
   Healy Chris, 2015, Card Electrophysiol Clin, V7, P251, DOI 10.1016/j.ccep.2015.03.016
   Jamieson AM, 2013, SCIENCE, V340, P1230, DOI 10.1126/science.1233632
   Jelicks LA, 1999, AM J TROP MED HYG, V61, P207, DOI 10.4269/ajtmh.1999.61.207
   Johnson JJ, 2011, MOL NUTR FOOD RES, V55, P1169, DOI 10.1002/mnfr.201100117
   Kayama Y, 2015, INT J MOL SCI, V16, P25234, DOI 10.3390/ijms161025234
   Kim TT, 2015, TRENDS ENDOCRIN MET, V26, P40, DOI 10.1016/j.tem.2014.11.001
   Li W, 2013, ACTA PHARMACOL SIN, V34, P1164, DOI 10.1038/aps.2013.82
   Ma H, 2010, CIRCULATION, V122, P282, DOI 10.1161/CIRCULATIONAHA.110.953208
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Mello DB, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003945
   Molina I, 2014, NEW ENGL J MED, V370, P1899, DOI 10.1056/NEJMoa1313122
   Morillo CA, 2015, NEW ENGLAND J MED
   Mukherjee S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016959
   Paiva CN, 2014, ANTIOXID REDOX SIGN, V20, P1000, DOI 10.1089/ars.2013.5447
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Park EJ, 2015, BBA-MOL BASIS DIS, V1852, P1071, DOI 10.1016/j.bbadis.2015.01.014
   Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017
   Pereira IR, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003659
   Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003
   Raj P, 2014, LIFE SCI, V95, P63, DOI 10.1016/j.lfs.2013.12.011
   Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X
   Ribeiro AL, 2012, NAT REV CARDIOL, V9, P576, DOI 10.1038/nrcardio.2012.109
   Rocha NN, 2006, PARASITOLOGY, V133, P729, DOI 10.1017/S0031182006001193
   Sasaki H, 2009, CIRCULATION, V119, P2568, DOI 10.1161/CIRCULATIONAHA.108.798561
   Sin TK, 2015, J PHYSIOL-LONDON, V593, P1887, DOI 10.1113/jphysiol.2014.270101
   Vera EAV, 2016, INT J BIOL MACROMOL, V87, P498, DOI 10.1016/j.ijbiomac.2016.03.014
   Viotti R, 2006, ANN INTERN MED, V144, P724, DOI 10.7326/0003-4819-144-10-200605160-00006
   Wen JJ, 2010, J AM COLL CARDIOL, V55, P2499, DOI 10.1016/j.jacc.2010.02.030
   Wen JJ, 2008, J BIOENERG BIOMEMBR, V40, P587, DOI 10.1007/s10863-008-9184-4
   Xin P, 2010, EUR J PHARMACOL, V649, P293, DOI 10.1016/j.ejphar.2010.09.036
   Zaidenberg A, 2006, BASIC CLIN PHARMACOL, V98, P351, DOI 10.1111/j.1742-7843.2006.pto_253.x
   Zhang L, 2007, AM J PHYSIOL-HEART C, V293, pH457, DOI 10.1152/ajpheart.00002.2007
   Zhang Y, 2006, BIOCHEM BIOPH RES CO, V340, P1192, DOI 10.1016/j.bbrc.2005.12.124
NR 51
TC 21
Z9 21
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2016
VL 12
IS 10
AR e1005947
DI 10.1371/journal.ppat.1005947
PG 19
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA EB8UO
UT WOS:000387666900046
PM 27788262
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Luz, NF
   Balaji, S
   Okuda, K
   Barreto, AS
   Bertin, J
   Gough, PJ
   Gazzinelli, R
   Almeida, RP
   Bozza, MT
   Borges, VM
   Chan, FKM
AF Luz, Nivea Farias
   Balaji, Sakthi
   Okuda, Kendi
   Barreto, Aline Silva
   Bertin, John
   Gough, Peter J.
   Gazzinelli, Ricardo
   Almeida, Roque P.
   Bozza, Marcelo T.
   Borges, Valeria M.
   Chan, Francis Ka-Ming
TI RIPK1 and PGAM5 Control Leishmania Replication through Distinct
   Mechanisms
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PROGRAMMED NECROSIS; NLRP3 INFLAMMASOME; HEME OXYGENASE-1;
   KINASE-ACTIVITY; NITRIC-OXIDE; VISCERAL LEISHMANIASIS; IMMUNE-RESPONSES;
   MOLECULAR SWITCH; INNATE IMMUNITY; CELL-DEATH
AB Leishmaniasis is an important parasitic disease found in the tropics and subtropics. Cutaneous and visceral leishmaniasis affect an estimated 1.5 million people worldwide. Despite its human health relevance, relatively little is known about the cell death pathways that control Leishmania replication in the host. Necroptosis is a recently identified form of cell death with potent antiviral effects. Receptor interacting protein kinase 1 (RIPK1) is a critical kinase that mediates necroptosis downstream of death receptors and TLRs. Heme, a product of hemoglobin catabolism during certain intracellular pathogen infections, is also a potent inducer of macrophage necroptosis. We found that human visceral leishmaniasis patients exhibit elevated serum levels of heme. Therefore, we examined the impact of heme and necroptosis on Leishmania replication. Indeed, heme potently inhibited Leishmania replication in bone marrow-derived macrophages. Moreover, we found that inhibition of RIPK1 kinase activity also enhanced parasite replication in the absence of heme. We further found that the mitochondrial phosphatase phosphoglycerate mutase family member 5 (PGAM5), a putative downstream effector of RIPK1, was also required for inhibition of Leishmania replication. In mouse infection, both PGAM5 and RIPK1 kinase activity are required for IL-1 beta expression in response to Leishmania. However, PGAM5, but not RIPK1 kinase activity, was directly responsible for Leishmania-induced IL-1b secretion and NO production in bone marrow-derived macrophages. Collectively, these results revealed that RIPK1 and PGAM5 function independently to exert optimal control of Leishmania replication in the host.
C1 [Luz, Nivea Farias; Balaji, Sakthi; Chan, Francis Ka-Ming] Univ Massachusetts, Sch Med, Dept Pathol, 368 Plantat St, Worcester, MA 01605 USA.
   [Luz, Nivea Farias; Borges, Valeria M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40110060 Salvador, BA, Brazil.
   [Okuda, Kendi; Gazzinelli, Ricardo] Univ Massachusetts, Div Infect Dis & Immunol, Sch Med, Worcester, MA 01605 USA.
   [Barreto, Aline Silva; Almeida, Roque P.] Univ Fed Sergipe, Univ Hosp, Dept Med, BR-49010390 Aracaju, Brazil.
   [Bertin, John; Gazzinelli, Ricardo] Fundacao Oswaldo Cruz, Ctr Pesquisa Rene Rachou, Lab Imunopatol, BR-30190002 Belo Horizonte, MG, Brazil.
   [Gough, Peter J.] GlaxoSmithKline, Pattern Recognit Receptor Discovery Performance U, Immunoinflammat Therapeut Area, Collegeville, PA 19422 USA.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Chan, Francis Ka-Ming] Univ Massachusetts, Sch Med, Immunol & Microbiol Program, Worcester, MA 01605 USA.
RP Chan, FKM (corresponding author), Univ Massachusetts, Sch Med, Dept Pathol, 368 Plantat St, Worcester, MA 01605 USA.; Borges, VM (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40110060 Salvador, BA, Brazil.
EM vborges@bahia.fiocruz.br; francis.chan@umassmed.edu
RI Chan, Francis Ka-Ming/E-9647-2014; Borges, Valeria/G-2009-2014; Borges,
   Val/N-6647-2019
OI Chan, Francis Ka-Ming/0000-0002-4803-8353; Borges,
   Val/0000-0002-2775-5409; Gough, Peter/0000-0002-5110-9300; Farias Luz,
   Nivea/0000-0003-1958-7043; Gazzinelli, Ricardo/0000-0003-2427-7699
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI119030]; Fundacao
   de Amparo a Pesquisa do Estado da Bahia; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI083497, R01AI083497,
   R01AI119030, R01AI083497, R01AI119030, R01AI119030, R01AI119030,
   R01AI119030, R01AI083497] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grant AI119030
   (to F.K.-M.C.), the Fundacao de Amparo a Pesquisa do Estado da Bahia (to
   V.M.B.), and a postdoctoral fellowship from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (to N.F.L.). V.M.B., R.P.A.,
   R.G., and M.T.B. are senior investigators at Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico.
CR Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Sampaio MJAD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000877
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Berger SB, 2014, J IMMUNOL, V192, P5476, DOI 10.4049/jimmunol.1400499
   Calegari-Silva TC, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150118
   Calegari-Silva TC, 2009, IMMUNOL LETT, V127, P19, DOI 10.1016/j.imlet.2009.08.009
   Challa S, 2010, J VIROL, V84, P10467, DOI 10.1128/JVI.00983-10
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Chan FKM, 2015, ANNU REV IMMUNOL, V33, P79, DOI 10.1146/annurev-immunol-032414-112248
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Huynh C, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002795
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Dannappel M, 2014, NATURE, V513, P90, DOI 10.1038/nature13608
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 1999, J BIOL CHEM, V274, P9673, DOI 10.1074/jbc.274.14.9673
   Gurung P, 2015, J CLIN INVEST, V125, P1329, DOI 10.1172/JCI79526
   Kang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8515
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kang YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9371
   Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200
   LIEW FY, 1990, J IMMUNOL, V145, P4306
   Lima DS, 2013, NAT MED, V19, P909, DOI 10.1038/nm.3221
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021
   MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73
   Mocarski ES, 2015, VIROLOGY, V479, P160, DOI 10.1016/j.virol.2015.03.016
   Moriwaki K, 2016, J IMMUNOL, V196, P407, DOI 10.4049/jimmunol.1501662
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361
   Olekhnovitch R, 2014, J CLIN INVEST, V124, P1711, DOI 10.1172/JCI72058
   Polykratis A, 2014, J IMMUNOL, V193, P1539, DOI 10.4049/jimmunol.1400590
   Roca FJ, 2013, CELL, V153, P521, DOI 10.1016/j.cell.2013.03.022
   Saha S, 2006, INDIAN J MED RES, V123, P245
   Sigala PA, 2014, ANNU REV MICROBIOL, V68, P259, DOI 10.1146/annurev-micro-091313-103537
   Silva-Gomes S, 2013, INFECT IMMUN, V81, P2536, DOI 10.1128/IAI.00251-13
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Xu WJ, 2015, ONCOTARGET, V6, P30017, DOI 10.18632/oncotarget.5013
   Zamboni DS, 2015, IMMUNOL REV, V265, P156, DOI 10.1111/imr.12291
NR 44
TC 10
Z9 10
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 15
PY 2016
VL 196
IS 12
BP 5056
EP 5063
DI 10.4049/jimmunol.1502492
PG 8
WC Immunology
SC Immunology
GA DO7BP
UT WOS:000377937500023
PM 27183605
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Galvao, I
   Dias, ACF
   Tavares, LD
   Rodrigues, IPS
   Queiroz, CM
   Costa, VV
   Reis, AC
   Oliveira, RDR
   Louzada, P
   Souza, DG
   Leng, L
   Bucala, R
   Sousa, LP
   Bozza, MT
   Teixeira, MM
   Amaral, FA
AF Galvao, Izabela
   Fialho Dias, Ana Carolina
   Tavares, Livia Duarte
   Stopa Rodrigues, Irla Paula
   Queiroz-Junior, Celso Martins
   Costa, Vivian Vasconcelos
   Reis, Alesandra Corte
   Ribeiro Oliveira, Rene Donizeti
   Louzada-Junior, Paulo
   Souza, Daniele Gloria
   Leng, Lin
   Bucala, Richard
   Sousa, Lirlandia Pires
   Bozza, Marcelo Torres
   Teixeira, Mauro Martins
   Amaral, Flavio Almeida
TI Macrophage migration inhibitory factor drives neutrophil accumulation by
   facilitating IL-1 beta production in a murine model of acute gout
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
ID TAUTOMERASE ACTIVE-SITE; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS;
   CHEMOKINE RECEPTORS; SYNOVIAL-FLUID; MIF; MICE; INTERLEUKIN-1-BETA;
   INFLAMMASOME; ACTIVATION
AB This study evaluated the role of macrophage migration inhibitory factor in inflammation caused by monosodium urate crystals. The concentration of macrophage migration inhibitory factor was increased in synovial fluid of patients with acute gout, and there was a positive correlation between intra-articular macrophage migration inhibitory factor and IL-1 beta concentrations. In mice, the injection of monosodium urate crystals into the knee joint increased the levels of macrophage migration inhibitory factor in macrophages and in inflamed tissue. The injection of recombinant macrophage migration inhibitory factor into the joint of mice reproduced the inflammatory response observed in acute gout, including histologic changes, the recruitment of neutrophils, and increased levels of IL-1 beta and CXCL1. Importantly, the accumulation of neutrophils and the amount IL-1 beta in the joints were reduced in macrophage migration inhibitory factor-deficient mice when injected with monosodium urate crystals. We observed a similar effect when we blocked macrophage migration inhibitory factor with (S,R)-3-(4hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid or anti -macrophage migration inhibitory factor. In addition, the blockade of IL-1R and CXCR2 reduced recombinant macrophage migration inhibitory factor-induced neutrophil recruitment. Mechanistically, recombinant macrophage migration inhibitory factor is important for the synthesis of iv mRNA in vivo and in isolated macrophages. Altogether, macrophage migration inhibitory factor promotes neutrophil accumulation and is important for IL -1p production, which are 2 crucial events contributing to the pathogenesis of acute gout.
C1 [Galvao, Izabela; Fialho Dias, Ana Carolina; Stopa Rodrigues, Irla Paula; Teixeira, Mauro Martins; Amaral, Flavio Almeida] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG, Brazil.
   [Tavares, Livia Duarte; Costa, Vivian Vasconcelos; Souza, Daniele Gloria] Univ Fed Minas Gerais, Inst Biol Sci, Dept Microbiol, Belo Horizonte, MG, Brazil.
   [Queiroz-Junior, Celso Martins; Reis, Alesandra Corte] Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Belo Horizonte, MG, Brazil.
   [Sousa, Lirlandia Pires] Univ Fed Minas Gerais, Fac Pharm, Dept Clin Anal & Toxicol, Belo Horizonte, MG, Brazil.
   [Ribeiro Oliveira, Rene Donizeti; Louzada-Junior, Paulo] Univ Sao Paulo, Sch Med Ribeirao Preto, Div Rheumatol, BR-05508 Sao Paulo, Brazil.
   [Bozza, Marcelo Torres] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, Lab Inflammat & Immun, BR-21941 Rio De Janeiro, Brazil.
   [Leng, Lin; Bucala, Richard] Yale Univ, Sch Med, Dept Med Rheumatol, Anlyan Ctr, New Haven, CT USA.
RP Teixeira, MM; Amaral, FA (corresponding author), Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Inst Biol Sc, Av Antidade Fed Minas Gerais, Belo Horizonte, MG, Brazil.
EM mmtex@icb.ufmg.br; famaral@icb.ufmg.br
RI Costa, Vivian VVC/I-2499-2018; Amaral, Flavio Almeida/C-3768-2018;
   Teixeira, Mauro M/A-4587-2008; Louzada-Junior, Paulo/E-4132-2012;
   Queiroz-Junior, Celso/L-5438-2013; Oliveira, Rene/C-4467-2012
OI Costa, Vivian VVC/0000-0002-0175-642X; Amaral, Flavio
   Almeida/0000-0002-1695-0612; Teixeira, Mauro M/0000-0002-6944-3008;
   Louzada-Junior, Paulo/0000-0003-2585-3870; Queiroz-Junior,
   Celso/0000-0002-7884-7709; Oliveira, Rene/0000-0003-0229-6864; Leng,
   Lin/0000-0002-0605-358X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG, Brazil)Minas Gerais State Research Foundation (FAPEMIG);
   European Community's Seventh Framework Programme (TIMER consortium)
   [HEALTH-F4-2011-281608]; U.S. National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [NIH-AR049610]; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
   [R01AR049610, R01AR049610, R01AR049610, R01AR049610, R01AR049610,
   R01AR049610, R01AR049610, R01AR049610, R01AR049610, R01AR049610,
   R01AR049610, R01AR049610, R01AR049610, R01AR049610, R01AR049610,
   R01AR049610] Funding Source: NIH RePORTER
FX The authors thank the funding agencies, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil); Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil); and
   European Community's Seventh Framework Programme (FP7-2007-2013, TIMER
   consortium), under Grant Agreement No. HEALTH-F4-2011-281608, for
   financial support. R.B. and L.L. are supported by U.S. National
   Institutes of Health Grant NIH-AR049610. The authors thank Ilma Marcal
   for technical assistance.
CR Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200
   Alexander JK, 2012, EXP NEUROL, V236, P351, DOI 10.1016/j.expneurol.2012.04.018
   Amaral FA, 2012, ARTHRITIS RHEUM-US, V64, P474, DOI 10.1002/art.33355
   Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Coelho FM, 2008, ARTHRITIS RHEUM-US, V58, P2329, DOI 10.1002/art.23622
   Daryadel A, 2006, J BIOL CHEM, V281, P27653, DOI 10.1074/jbc.M604051200
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   de Souza HS, 2015, MUCOSAL IMMUNOL, V8, P1154, DOI 10.1038/mi.2015.6
   Gomes MTR, 2013, J IMMUNOL, V190, P3629, DOI 10.4049/jimmunol.1202817
   Gregory JL, 2004, ARTHRITIS RHEUM-US, V50, P3023, DOI 10.1002/art.20470
   Gregory JL, 2006, J IMMUNOL, V177, P8072, DOI 10.4049/jimmunol.177.11.8072
   Klasen C, 2014, J IMMUNOL, V192, P5273, DOI 10.4049/jimmunol.1302209
   Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
   Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO;2-E
   Liu MH, 2012, CLIN BIOCHEM, V45, P737, DOI 10.1016/j.clinbiochem.2012.03.012
   Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   Martin WJ, 2009, ARTHRITIS RHEUM-US, V60, P281, DOI 10.1002/art.24185
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Meazza C, 2002, ARTHRITIS RHEUM, V46, P232, DOI 10.1002/1529-0131(200201)46:1<232::AID-ART10059>3.0.CO;2-B
   Mitroulis I, 2013, SEMIN IMMUNOPATHOL, V35, P501, DOI 10.1007/s00281-013-0361-0
   Nuki G, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1906
   Onodera S, 1999, CYTOKINE, V11, P163, DOI 10.1006/cyto.1998.0402
   Onodera S, 2004, ARTHRITIS RHEUM-US, V50, P1437, DOI 10.1002/art.20190
   Perez-Ruiz F, 2014, RHEUM DIS CLIN N AM, V40, P193, DOI 10.1016/j.rdc.2014.01.003
   Popa-Nita O, 2010, IMMUNOL CELL BIOL, V88, P32, DOI 10.1038/icb.2009.98
   Queiroz CM, 2011, J IMMUNOL, V187, P3821, DOI 10.4049/jimmunol.1101195
   Reber LL, 2014, ARTHRITIS RHEUMATOL, V66, P2881, DOI 10.1002/art.38747
   Robinson PC, 2014, MATURITAS, V78, P245, DOI 10.1016/j.maturitas.2014.05.001
   Roddy E, 2014, RHEUM DIS CLIN N AM, V40, P155, DOI 10.1016/j.rdc.2014.01.001
   Sachs D, 2011, BRIT J PHARMACOL, V162, P72, DOI 10.1111/j.1476-5381.2010.00895.x
   Santos LL, 2011, ARTHRITIS RHEUM-US, V63, P960, DOI 10.1002/art.30203
   Santos LL, 2009, CLIN CHIM ACTA, V399, P1, DOI 10.1016/j.cca.2008.09.014
   Scanu A, 2012, ANN RHEUM DIS, V71, P621, DOI 10.1136/annrheumdis-2011-200711
   Toh ML, 2006, J IMMUNOL, V177, P4818, DOI 10.4049/jimmunol.177.7.4818
NR 42
TC 22
Z9 24
U1 3
U2 15
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JUN
PY 2016
VL 99
IS 6
BP 1035
EP 1043
DI 10.1189/jlb.3MA0915-418R
PG 9
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA DN2IN
UT WOS:000376887400023
PM 26868525
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Assuncao-Miranda, I
   Cruz-Oliveira, C
   Neris, RLS
   Figueiredo, CM
   Pereira, LPS
   Rodrigues, D
   Araujo, DFF
   Da Poian, AT
   Bozza, MT
AF Assuncao-Miranda, I.
   Cruz-Oliveira, C.
   Neris, R. L. S.
   Figueiredo, C. M.
   Pereira, L. P. S.
   Rodrigues, D.
   Araujo, D. F. F.
   Da Poian, A. T.
   Bozza, M. T.
TI Inactivation of Dengue and Yellow Fever viruses by heme,
   cobalt-protoporphyrin IX and tin-protoporphyrin IX
SO JOURNAL OF APPLIED MICROBIOLOGY
LA English
DT Article
DE antiviral; Dengue Virus; inactivation; metalloporphyrins; Yellow Fever
   Virus
ID CARBON-MONOXIDE; IN-VITRO; INFECTION; REPLICATION; INHIBITION;
   PORPHYRINS; PROTEIN; ENTRY; MACROPHAGES; OXYGENASE-1
AB AimsTo investigate the effect of heme, cobalt-protoporphyrin IX and tin-protoporphyrin IX (CoPPIX and SnPPIX), macrocyclic structures composed by a tetrapyrrole ring with a central metallic ion, on Dengue Virus (DENV) and Yellow Fever Virus (YFV) infection.
   Methods and ResultsTreatment of HepG2 cells with heme, CoPPIX and SnPPIX after DENV infection reduced infectious particles without affecting viral RNA contents in infected cells. The reduction of viral load occurs only with the direct contact of DENV with porphyrins, suggesting a direct effect on viral particles. Previously incubation of DENV and YFV with heme, CoPPIX and SnPPIX resulted in viral particles inactivation in a dose-dependent manner. Biliverdin, a noncyclical porphyrin, was unable to inactivate the viruses tested. Infection of HepG2 cells with porphyrin-pretreated DENV2 results in a reduced or abolished viral protein synthesis, RNA replication and cell death. Treatment of HepG2 or THP-1 cell lineage with heme or CoPPIX after DENV infection with a very low MOI resulted in a decreased DENV replication and protection from death.
   ConclusionsHeme, CoPPIX and SnPPIX possess a marked ability to inactivate DENV and YFV, impairing its ability to infect and induce cytopathic effects on target cells.
   Significance and Impact of the StudyThese results open the possibility of therapeutic application of porphyrins or their use as models to design new antiviral drugs against DENV and YFV.
C1 [Assuncao-Miranda, I.; Neris, R. L. S.; Figueiredo, C. M.; Rodrigues, D.; Araujo, D. F. F.; Bozza, M. T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.
   [Cruz-Oliveira, C.; Pereira, L. P. S.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo Meis, Rio De Janeiro, Brazil.
RP Assuncao-Miranda, I; Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Rio De Janeiro, Brazil.
EM iranaiamiranda@micro.ufrj.br; mbozza@micro.ufrj.br
RI Da Poian, Andrea T./V-1699-2019
OI Rodrigues, Danielle/0000-0003-2120-3352; Da Poian,
   Andrea/0000-0002-3969-704X; Cruz-Oliveira, Christine/0000-0003-4838-0703
CR Benati FJ, 2009, LETT APPL MICROBIOL, V49, P791, DOI 10.1111/j.1472-765X.2009.02744.x
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Chen-Collins ARM, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-9
   Cheng Y, 2010, ANTIMICROB AGENTS CH, V54, P197, DOI 10.1128/AAC.01206-09
   Chu JJH, 2007, P NATL ACAD SCI USA, V104, P3520, DOI 10.1073/pnas.0611681104
   Chung SW, 2009, CELL MICROBIOL, V11, P199, DOI 10.1111/j.1462-5822.2008.01261.x
   Conceicao TM, 2010, J VIROL METHODS, V163, P1, DOI 10.1016/j.jviromet.2009.10.001
   Costa L, 2012, VIRUSES-BASEL, V4, P1034, DOI 10.3390/v4071034
   Courageot MP, 2000, J VIROL, V74, P564, DOI 10.1128/JVI.74.1.564-572.2000
   Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668
   De La Guardia C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/825039
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Guo HT, 2011, ANTIMICROB AGENTS CH, V55, P478, DOI 10.1128/AAC.00989-10
   Hou WH, 2010, GASTROENTEROLOGY, V138, P1909, DOI 10.1053/j.gastro.2009.11.001
   Ichiyama K, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002188
   Lawrence S P, 2000, Adv Intern Med, V45, P65
   Lee JC, 2015, ANTIVIR RES, V116, P1, DOI 10.1016/j.antiviral.2015.01.002
   Lehmann E, 2010, HEPATOLOGY, V51, P398, DOI 10.1002/hep.23339
   Lim SP, 2015, ANTIVIR RES, V119, P57, DOI 10.1016/j.antiviral.2015.04.010
   Lin YL, 2002, ANTIVIR RES, V56, P93, DOI 10.1016/S0166-3542(02)00095-5
   Mazzola S, 2005, FASEB J, V19, P2045, DOI 10.1096/fj.05-3782fje
   Mazzucco MB, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0134-2
   Osorio JE, 2014, LANCET INFECT DIS, V14, P830, DOI 10.1016/S1473-3099(14)70811-4
   Otterbein LE, 2000, NAT MED, V6, P422
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Perera R, 2008, ANTIVIR RES, V80, P11, DOI 10.1016/j.antiviral.2008.05.004
   Pushpan S. K., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P187, DOI 10.2174/1568011023354137
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Schmidt WN, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00129
   Silva EFF, 2010, CHEM-EUR J, V16, P9273, DOI 10.1002/chem.201000111
   Staudinger R, 1996, P ASSOC AM PHYSICIAN, V108, P47
   Stojiljkovic I, 2001, EXPERT OPIN INV DRUG, V10, P309, DOI 10.1517/13543784.10.2.309
   Vigant F, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003297
   Vzorov AN, 2002, ANTIMICROB AGENTS CH, V46, P3917, DOI 10.1128/AAC.46.12.3917-3925.2002
   Wang QY, 2009, ANTIMICROB AGENTS CH, V53, P1823, DOI 10.1128/AAC.01148-08
   Wegiel B, 2014, ANTIOXID REDOX SIGN, V20, P1709, DOI 10.1089/ars.2013.5667
   Wen WH, 2009, J MED CHEM, V52, P4903, DOI 10.1021/jm900515g
   Wolf MC, 2010, P NATL ACAD SCI USA, V107, P3157, DOI 10.1073/pnas.0909587107
   Woodland DL, 2015, VIRAL IMMUNOL, V28, P75, DOI 10.1089/vim.2015.1502
   Zaitseva E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001131
   Zhu ZW, 2010, HEPATOLOGY, V52, P1897, DOI 10.1002/hep.23921
NR 45
TC 16
Z9 17
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1364-5072
EI 1365-2672
J9 J APPL MICROBIOL
JI J. Appl. Microbiol.
PD MAR
PY 2016
VL 120
IS 3
BP 790
EP 804
DI 10.1111/jam.13038
PG 15
WC Biotechnology & Applied Microbiology; Microbiology
SC Biotechnology & Applied Microbiology; Microbiology
GA DF1JB
UT WOS:000371094600024
PM 26759117
OA Bronze
DA 2020-12-01
ER

PT J
AU Soares, MP
   Bozza, MT
AF Soares, Miguel P.
   Bozza, Marcelo T.
TI Red alert: labile heme is an alarmin
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Review
ID NF-KAPPA-B; REGULATORY T-CELLS; TOLL-LIKE RECEPTORS; CARBON-MONOXIDE;
   NEUTROPHIL MIGRATION; CONFERS TOLERANCE; INDUCED APOPTOSIS; JNK
   ACTIVATION; HEMOGLOBIN; PATHOGENESIS
AB Alarmins are a heterogeneous group of endogenous molecules that signal cellular damage when sensed extracellularly. Heme is an endogenous molecule that acts as a prosthetic group of hemoproteins, such as hemoglobin and myoglobin. When released from damaged red blood cells or muscle cells, oxidized hemoglobin and myoglobin release their prosthetic heme groups, respectively. This generates labile heme, which is sensed by pattern recognition receptors (PRR) expressed by innate immune cells and possibly regulatory T cells (TREG). The ensuing adaptive response, which alerts for the occurrence of red blood cell or muscle cell damage, regulates the pathologic outcome of hemolysis or rhabdomyolysis, respectively. In conclusion, we propose that labile heme is an alarmin.
C1 [Soares, Miguel P.] Inst Gulbenkian Ciencias, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Av Carlos Chagas Filho 373,Cidade Univ, BR-21941902 Rio De Janeiro, Brazil.
RP Soares, MP (corresponding author), Inst Gulbenkian Ciencias, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.; Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Av Carlos Chagas Filho 373,Cidade Univ, BR-21941902 Rio De Janeiro, Brazil.
EM mpsosares@igc.gulbenkian.pt; mbozza@micro.ufrj.br
OI Soares, Miguel/0000-0002-9314-4833
FU Fundacao Calouste Gulbenkian; Fundacao para a Ciencia e
   TecnologiaPortuguese Foundation for Science and Technology [PTDC/SAU
   TOX/116627/2010, HMSP-ICT/0022/2010, RECI/IMI-IMU/0038/2012]; European
   Community 7th Framework Grant ERC-AdG [294709-DAMAGECONTROL]; Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Conselho Nacional de Pesquisa (CNPq)National Council for
   Scientific and Technological Development (CNPq); INCTDengue; Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrazilCAPES
FX The authors thank Luis Ferreira Moita (Instituto Gulbenkian de Ciencia)
   for critical review of the manuscript and Zelia Gouveia for producing
   the heme structures in Figure 1. MPS is supported by Fundacao Calouste
   Gulbenkian and by grants from the Fundacao para a Ciencia e Tecnologia
   (PTDC/SAU TOX/116627/2010, HMSP-ICT/0022/2010, RECI/IMI-IMU/0038/2012)
   and by the European Community 7th Framework Grant ERC-2011-AdG.
   294709-DAMAGECONTROL. MTB is supported by Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Pesquisa
   (CNPq), INCTDengue, and Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES), Brazil. While preparing this manuscript another
   manuscript putting forward similar notions was published elsewhere:
   "Heme as a danger molecule in pathogen recognition" By Barbara Wegiel,
   Carl J. Hauser, Leo E. Otterbein, Free Radical Biology and Medicine.
   Volume 89, Received 13 July 2015, Accepted 8 August 2015, Available
   online 9 October 2015.
CR Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Anzaldi LL, 2010, INFECT IMMUN, V78, P4977, DOI 10.1128/IAI.00613-10
   Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Ascenzi P, 2005, IUBMB LIFE, V57, P749, DOI 10.1080/15216540500380871
   BALLA G, 1992, J BIOL CHEM, V267, P18148
   BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Belcher JD, 2006, J CLIN INVEST, V116, P808, DOI 10.1172/JCI26857
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69
   Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054
   Cai Y, 2011, J IMMUNOL, V187, P1314, DOI 10.4049/jimmunol.1002925
   Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Du RJ, 2010, EMBO J, V29, P632, DOI 10.1038/emboj.2009.380
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Fenton H. J. H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Fernandez AZ, 2001, ATHEROSCLEROSIS, V158, P103, DOI 10.1016/S0021-9150(01)00422-1
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   GEORGE P, 1952, BIOCHEM J, V51, P103, DOI 10.1042/bj0510103
   Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578
   Gozzelino R, 2014, ANTIOXID REDOX SIGN, V20, P1754, DOI 10.1089/ars.2013.5666
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1
   Jiang N, 2007, NAT IMMUNOL, V8, P1114, DOI 10.1038/ni1501
   KACA W, 1994, J BIOL CHEM, V269, P25078
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Korolnek T, 2015, BLOOD, V125, P2893, DOI 10.1182/blood-2014-12-567776
   Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010
   Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Lee SK, 2013, DNA CELL BIOL, V32, P36, DOI 10.1089/dna.2012.1897
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847
   ORJIH AU, 1981, SCIENCE, V214, P667, DOI 10.1126/science.7027441
   Otterbein LE, 2000, NAT MED, V6, P422
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017
   Piazza M, 2011, INNATE IMMUN-LONDON, V17, P293, DOI 10.1177/1753425910369020
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002
   Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229
   Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   Soares MP, 2015, EMBO REP, V16, P1482, DOI 10.15252/embr.201540558
   Soares MP, 2014, TRENDS IMMUNOL, V35, P483, DOI 10.1016/j.it.2014.08.001
   Soares MP, 2009, CURR OPIN PHARMACOL, V9, P482, DOI 10.1016/j.coph.2009.05.008
   Soares MP, 2009, TRENDS MOL MED, V15, P50, DOI 10.1016/j.molmed.2008.12.004
   Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607
   Vinchi F, 2008, AM J PATHOL, V173, P289, DOI 10.2353/ajpath.2008.071130
   Wegiel B, 2014, J CLIN INVEST, V124, P4926, DOI 10.1172/JCI72853
NR 69
TC 56
Z9 56
U1 2
U2 12
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0952-7915
EI 1879-0372
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD FEB
PY 2016
VL 38
BP 94
EP 100
DI 10.1016/j.coi.2015.11.006
PG 7
WC Immunology
SC Immunology
GA DC4RL
UT WOS:000369207900014
PM 26741528
DA 2020-12-01
ER

PT J
AU Righy, C
   Bozza, MT
   Oliveira, MF
   Bozza, FA
AF Righy, Cassia
   Bozza, Marcelo T.
   Oliveira, Marcus F.
   Bozza, Fernando A.
TI Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage:
   Are the Enemies Within?
SO CURRENT NEUROPHARMACOLOGY
LA English
DT Article
DE Heme; hemorrhagic stroke; inflammatory response; intracranial bleeding;
   iron; reactive oxygen species; subarachnoid hemorrhage
ID ACTIVATED-RECEPTOR-GAMMA; BLOOD-BRAIN-BARRIER; EXPERIMENTAL SUBARACHNOID
   HEMORRHAGE; HEME OXYGENASE-1 INDUCTION; PRIOR STATIN USE; RAT MODEL;
   AGONIST ROSIGLITAZONE; HEMATOMA RESOLUTION; INDUCED ATTENUATION;
   PERIHEMATOMA EDEMA
AB Hemorrhagic stroke is a disease with high incidence and mortality rates. In addition to the mass lesions that result from hemorrhagic stroke, substances such as the blood-derived products (BDP) (hemoglobin (Hb), heme and iron) induce a potent inflammatory response and exert direct toxic effects on neurons, astrocytes, and microglia. In the present review, we discuss the mechanisms of brain injury secondary to hemorrhagic stroke, focusing on the involvement of BDP as major players of cellular redox imbalance, inflammation, and glutamate excitotoxicity. Potential natural mechanisms of protection against free Hb and heme such as haptoglobin and hemopexin, respectively, are highlighted. We finally discuss the experimental and clinical trials targeting free iron and heme scavenging as well as inflammation, as potential new therapies to minimize the devastating effects of hemorrhagic stroke on brain structure and function.
C1 [Righy, Cassia; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Lab Med Intens, Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Resposta Ao Estresse, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.] Univ Fed Rio de Janeiro, Inst Nacl Ciencia & Tecnol Biol Estrutural & Bioi, Lab Inflamacao & Metab, Rio De Janeiro, Brazil.
   [Bozza, Fernando A.] DOr Inst Res & Educ, Rio De Janeiro, Brazil.
RP Righy, C (corresponding author), Ave Brasil 4-365, BR-21040900 Rio De Janeiro, RJ, Brazil.
EM cassiarighy@gmail.com
RI Bozza, Fernando A/A-2618-2013; Shinotsuka, Cassia Righy/H-9181-2013;
   Oliveira, Marcus/G-3158-2011
OI Bozza, Fernando A/0000-0003-4878-0256; Shinotsuka, Cassia
   Righy/0000-0002-9206-9552; Oliveira, Marcus/0000-0002-9890-8425
CR AFT RL, 1983, J BIOL CHEM, V258, P2069
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   ANTONINI E, 1966, J BIOL CHEM, V241, P3236
   Auriat AM, 2012, EXP NEUROL, V234, P136, DOI 10.1016/j.expneurol.2011.12.030
   Ayer RE, 2013, ACTA NEUROCHIR SUPPL, V115, P259, DOI 10.1007/978-3-7091-1192-5_46
   Biffi A, 2011, NEUROLOGY, V76, P1581, DOI 10.1212/WNL.0b013e3182194be9
   Caliaperumal J, 2012, EXP NEUROL, V237, P363, DOI 10.1016/j.expneurol.2012.07.001
   Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002
   Chen CW, 2012, AUTOPHAGY, V8, P1510, DOI 10.4161/auto.21289
   Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577
   Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187
   Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861
   Chen-Roetling J, 2006, BIOCHEM BIOPH RES CO, V350, P233, DOI 10.1016/j.bbrc.2006.09.036
   Cui JJ, 2012, CELL BIOCHEM BIOPHYS, V62, P87, DOI 10.1007/s12013-011-9264-7
   DAVIES MJ, 1988, BIOCHIM BIOPHYS ACTA, V964, P28, DOI 10.1016/0304-4165(88)90063-3
   Diguet E, 2004, EUR J NEUROSCI, V19, P3266, DOI 10.1111/j.0953-816X.2004.03372.x
   Dowlatshahi D, 2012, STROKE, V43, P1518, DOI 10.1161/STROKEAHA.111.645978
   DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3
   Duan Shu-rong, 2007, Zhonghua Yi Xue Za Zhi, V87, P1904
   Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g
   Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   FitzMaurice E, 2008, STROKE, V39, P2151, DOI 10.1161/STROKEAHA.107.508861
   Flaherty ML, 2010, SEMIN NEUROL, V30, P565, DOI 10.1055/s-0030-1268866
   Frantzias J, 2011, ANN NEUROL, V69, P389, DOI 10.1002/ana.22243
   Galea J, 2012, J NEUROCHEM, V121, P785, DOI 10.1111/j.1471-4159.2012.07716.x
   Germano A, 2007, J NEUROTRAUM, V24, P732, DOI 10.1089/neu.2006.0181
   Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633
   Gonzales NR, 2013, INT J STROKE, V8, P388, DOI 10.1111/j.1747-4949.2011.00761.x
   Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Hahl P, 2013, J NEUROCHEM, V125, P89, DOI 10.1111/jnc.12165
   HESS JR, 1993, J APPL PHYSIOL, V74, P1769
   HILLERED L, 1983, J CEREBR BLOOD F MET, V3, P207, DOI 10.1038/jcbfm.1983.28
   Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185
   Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025
   Im DS, 2012, BRAIN RES, V1455, P114, DOI 10.1016/j.brainres.2012.03.025
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681
   Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85
   Kirkpatrick PJ, 2014, LANCET NEUROL, V13, P666, DOI 10.1016/S1474-4422(14)70084-5
   Koeppen AH, 1995, J NEUROL SCI, V134, P102, DOI 10.1016/0022-510X(95)00215-N
   Koeppen AH, 1995, J NEUROL SCI, V134, P1, DOI 10.1016/0022-510X(95)00202-D
   Lara FA, 2009, J CEREBR BLOOD F MET, V29, P1109, DOI 10.1038/jcbfm.2009.34
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Li H, 2009, J NEUROCHEM, V110, P1774, DOI 10.1111/j.1471-4159.2009.06271.x
   Liu X, 2010, NEUROL SCI, V31, P699, DOI 10.1007/s10072-010-0241-5
   Lou M, 2009, CEREBROVASC DIS, V27, P266, DOI 10.1159/000199464
   Mairuae N, 2011, NEUROSCI LETT, V500, P36, DOI 10.1016/j.neulet.2011.06.001
   Mantle D, 2001, CLIN CHIM ACTA, V312, P185, DOI 10.1016/S0009-8981(01)00623-4
   MARLET JM, 1982, J FORENSIC SCI, V27, P880
   Mehdiratta M, 2008, STROKE, V39, P1165, DOI 10.1161/STROKEAHA.107.501213
   Merlo L, 2011, J NEUROTRAUM, V28, P2493, DOI 10.1089/neu.2010.1624
   Nagy E, 2010, ARTERIOSCL THROM VAS, V30, P1347, DOI 10.1161/ATVBAHA.110.206433
   Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672
   Naval NS, 2008, NEUROCRIT CARE, V8, P6, DOI 10.1007/s12028-007-0080-2
   Naval NS, 2008, NEUROCRIT CARE, V8, P13, DOI 10.1007/s12028-007-0081-1
   Pan H, 2011, NEUROCHEM RES, V36, P2434, DOI 10.1007/s11064-011-0571-6
   Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553
   Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902
   Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236
   Rincon F, 2012, TRANSL STROKE RES, V3, pS10, DOI 10.1007/s12975-012-0175-8
   Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Sabri M, 2011, J CEREBR BLOOD F MET, V31, P190, DOI 10.1038/jcbfm.2010.76
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   SADRZADEH SMH, 1988, J CLIN INVEST, V82, P1510, DOI 10.1172/JCI113759
   SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865
   SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354
   Schalinske KL, 1998, J BIOL CHEM, V273, P3740, DOI 10.1074/jbc.273.6.3740
   Schipper HM, 2009, CURR ALZHEIMER RES, V6, P424, DOI 10.2174/156720509789207985
   Selim M, 2011, STROKE, V42, P3067, DOI 10.1161/STROKEAHA.111.617589
   Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104
   Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066
   Song LY, 2007, J NEUROSCI RES, V85, P2186, DOI 10.1002/jnr.21367
   Song S, 2008, ACTA NEUROCHIR SUPPL, V105, P13
   Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Vellimana AK, 2011, STROKE, V42, P776, DOI 10.1161/STROKEAHA.110.607200
   Vesely MJJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1087
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703
   Wang GQ, 2011, ACTA NEUROCHIR, V153, P319, DOI 10.1007/s00701-010-0750-2
   Wang J, 2008, NEUROSCIENCE, V155, P1133, DOI 10.1016/j.neuroscience.2008.07.004
   Wang J, 2005, CIRC RES, V97, P821, DOI 10.1161/01.RES.0000185833.42544.06
   Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020
   Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009
   Wang L, 2012, TRANSL STROKE RES, V3, P107, DOI 10.1007/s12975-011-0099-8
   Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x
   Warkentin LM, 2010, BRAIN RES, V1309, P95, DOI 10.1016/j.brainres.2009.10.058
   Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025
   Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209
   Wu JM, 2009, NEUROL RES, V31, P183, DOI 10.1179/174313209X385680
   Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45
   Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7
   Wu Y, 2011, J NEUROL SCI, V305, P85, DOI 10.1016/j.jns.2011.03.006
   Wu Y, 2010, BRAIN RES, V1322, P102, DOI 10.1016/j.brainres.2010.01.073
   Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991
   Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820
   Xue MZ, 2010, AM J PATHOL, V176, P1193, DOI 10.2353/ajpath.2010.090361
   Yabluchanskiy A, 2012, CRIT CARE MED, V40, P544, DOI 10.1097/CCM.0b013e31822f0d64
   Yu J, 2009, BRAIN RES, V1257, P102, DOI 10.1016/j.brainres.2008.12.030
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
   Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011
   Zhang X, 2006, GLIA, V54, P795, DOI 10.1002/glia.20416
   Zhao F, 2011, STROKE, V42, P3587, DOI 10.1161/STROKEAHA.111.623926
   Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506
   Zhao XR, 2007, ANN NEUROL, V61, P352, DOI 10.1002/ana.21097
   Zhao XR, 2006, J CEREBR BLOOD F MET, V26, P811, DOI 10.1038/sj.jcbfm.9600233
   Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009
   Zhou Q, 2010, CIRC J, V74, P818, DOI 10.1253/circj.CJ-10-0110
NR 114
TC 22
Z9 22
U1 1
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-159X
EI 1875-6190
J9 CURR NEUROPHARMACOL
JI Curr. Neuropharmacol.
PY 2016
VL 14
IS 4
BP 392
EP 402
DI 10.2174/1570159X14666151230110058
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DK4HN
UT WOS:000374878300011
PM 26714583
OA Green Published
DA 2020-12-01
ER

PT J
AU de Souza, HS
   Tortori, CA
   Lintomen, L
   Figueiredo, RT
   Bernardazzi, C
   Leng, L
   Bucala, R
   Madi, K
   Buongusto, F
   Elia, CCS
   Castelo-Branco, MTL
   Bozza, MT
AF de Souza, H. S.
   Tortori, C. A.
   Lintomen, L.
   Figueiredo, R. T.
   Bernardazzi, C.
   Leng, L.
   Bucala, R.
   Madi, K.
   Buongusto, F.
   Elia, C. C. S.
   Castelo-Branco, M. T. L.
   Bozza, M. T.
TI Macrophage migration inhibitory factor promotes eosinophil accumulation
   and tissue remodeling in eosinophilic esophagitis
SO MUCOSAL IMMUNOLOGY
LA English
DT Article
ID GASTROESOPHAGEAL-REFLUX DISEASE; FACTOR MIF; CHEMOKINE RECEPTORS;
   EXPRESSION PROFILE; CXCR4; CHILDREN; ACTIVATION; ESTROGEN; FIBROSIS;
   IL-5
AB Macrophage migration inhibitory factor (MIF) is involved in eosinophil biology and in type 2 inflammation, contributing to allergic and helminthic diseases. We hypothesized that MIF participates in the pathogenesis of eosinophilic esophagitis (EoE), an allergic condition characterized by esophageal eosinophilic inflammation. MIF is highly expressed in esophageal mucosa of patients with EoE, compared with gastro-esophageal reflux disease and control patients, where it co-localizes predominantly with eosinophils. In vitro, recombinant MIF promotes human eosinophil chemotaxis, while MIF antagonist and CXCR4 antagonist, AMD3100, revert this effect. In a model of EoE induced by ovalbumin, Mif-deficient mice have reduced inflammation and collagen deposition compared with wild-type (WT) mice. Importantly, treatment of WT mice with anti-MIF or with AMD3100 during the challenge phase prevents accumulation of eosinophils and tissue remodeling. Conversely, recombinant MIF promoted tissue eosinophil inflammation in allergic mice. Together, these results implicate MIF in the pathogenesis of esophageal inflammation and suggest that targeting MIF might represent a novel therapy for EoE.
C1 [de Souza, H. S.; Tortori, C. A.; Bernardazzi, C.; Madi, K.; Buongusto, F.; Elia, C. C. S.] Univ Fed Rio de Janeiro, Serv Gastroenterol, Rio De Janeiro, Brazil.
   [de Souza, H. S.; Tortori, C. A.; Bernardazzi, C.; Madi, K.; Buongusto, F.; Elia, C. C. S.] Univ Fed Rio de Janeiro, Dept Internal Med, Univ Hosp, Lab Multidisciplinar Pesquisa, Rio De Janeiro, Brazil.
   [de Souza, H. S.; Elia, C. C. S.] DOr Inst Res & Educ IDOR, Rio De Janeiro, Brazil.
   [Lintomen, L.; Bozza, M. T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941 Rio De Janeiro, Brazil.
   [Figueiredo, R. T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Polo Xerem, Rio De Janeiro, Brazil.
   [Leng, L.; Bucala, R.] Yale Univ, Sch Med, Anlyan Ctr, Dept Med Rheumatol, New Haven, CT USA.
   [Castelo-Branco, M. T. L.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Imunol Celular, Rio De Janeiro, Brazil.
RP de Souza, HS (corresponding author), Univ Fed Rio de Janeiro, Serv Gastroenterol, Rio De Janeiro, Brazil.
EM hsouza@hucff.ufrj.br
RI de Souza, Heitor Siffert Pereira/G-3297-2012; Figueiredo, Rodrigo
   T./F-5176-2016
OI de Souza, Heitor Siffert Pereira/0000-0002-3647-7324; Figueiredo,
   Rodrigo T./0000-0002-7551-8782; Bozza, Marcelo/0000-0003-3683-7550
FU Brazilian Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq); FAPERJ (Fundacao Carlos Chagas Filho
   de Amparo a Pesquisa do Estado do Rio de Janeiro)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   [AR050498]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R01AR050498, R01AR050498,
   R01AR050498, R01AR050498, R01AR050498, R01AR050498, R01AR050498,
   R01AR050498, R01AR050498, R01AR050498] Funding Source: NIH RePORTER
FX This work was supported by grants from the Brazilian Research Council
   (CNPq) and the FAPERJ (Fundacao Carlos Chagas Filho de Amparo a Pesquisa
   do Estado do Rio de Janeiro). Drs Bucala and Leng are supported by
   AR050498. We acknowledge the technical assistance of Dr Monica Monerat
   and Grasiella Matioszek.
CR Aloisi AM, 2005, PAIN, V115, P142, DOI 10.1016/j.pain.2005.02.019
   Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218
   Ashcroft GS, 2003, J CLIN INVEST, V111, P1309, DOI 10.1172/KCO200316288
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679
   Blanchard Carine, 2008, Gastrointest Endosc Clin N Am, V18, P133, DOI 10.1016/j.giec.2007.09.016
   Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024
   Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Bozza Marcelo T, 2012, J Parasitol Res, V2012, P413052, DOI 10.1155/2012/413052
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Cavalcanti MG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025259
   Chehade M, 2007, J PEDIATR GASTR NUTR, V45, P319, DOI 10.1097/MPG.0b013e31806ab384
   Cho JY, 2014, J PEDIATR GASTR NUTR, V59, P10, DOI 10.1097/MPG.0000000000000343
   Fitzgerald RC, 2002, GUT, V50, P451, DOI 10.1136/gut.50.4.451
   Franciosi JP, 2009, CLIN GASTROENTEROL H, V7, P415, DOI 10.1016/j.cgh.2008.10.006
   Houdeau E, 2007, GASTROENTEROLOGY, V132, P982, DOI 10.1053/j.gastro.2006.12.028
   Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113
   Li-Kim-Moy JP, 2011, J PEDIATR GASTR NUTR, V52, P147, DOI 10.1097/MPG.0b013e3181ef37a1
   Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040
   Lue HQ, 2011, CELL SIGNAL, V23, P135, DOI 10.1016/j.cellsig.2010.08.013
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   McDermott DH, 2014, BLOOD, V123, P2308, DOI 10.1182/blood-2013-09-527226
   Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007
   Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464
   Mishra A, 2007, J LEUKOCYTE BIOL, V81, P916, DOI 10.1189/jlb.1106653
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Mueller S, 2006, J CLIN PATHOL, V59, P1175, DOI 10.1136/jcp.2005.031922
   Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935
   Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002
   Nakamaru Y, 2004, ANN OTO RHINOL LARYN, V113, P205, DOI 10.1177/000348940411300306
   Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924
   Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281
   Rieder F, 2007, GASTROENTEROLOGY, V132, P154, DOI 10.1053/j.gastro.2006.10.009
   Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003
   Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524
   Rothenberg MA, 2001, J ALLERGY CLIN IMMUN, V108, P891, DOI 10.1067/mai.2001.120095
   Shimizu T, 2005, J DERMATOL SCI, V37, P65, DOI 10.1016/j.jdermsci.2004.08.007
   Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x
   Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024
   Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x
   Vera PL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003898
   Verdu EF, 2002, AM J PHYSIOL-GASTR L, V283, pG27, DOI 10.1152/ajpgi.00460.2001
   Vieira-de-Abreu A, 2011, AM J RESP CELL MOL, V44, P509, DOI 10.1165/rcmb.2010-0004OC
   Wang B, 2006, J IMMUNOL, V177, P5779, DOI 10.4049/jimmunol.177.9.5779
   Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244
NR 50
TC 17
Z9 17
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1933-0219
EI 1935-3456
J9 MUCOSAL IMMUNOL
JI Mucosal Immunol.
PD SEP
PY 2015
VL 8
IS 5
BP 1154
EP 1165
DI 10.1038/mi.2015.6
PG 12
WC Immunology
SC Immunology
GA CP5WB
UT WOS:000359954600019
PM 25712805
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Molinaro, R
   Pecli, C
   Guilherme, RF
   Alves-Filho, JC
   Cunha, FQ
   Canetti, C
   Kunkel, SL
   Bozza, MT
   Benjamim, CF
AF Molinaro, Raphael
   Pecli, Cyntia
   Guilherme, Rafael F.
   Alves-Filho, Jose Carlos
   Cunha, Fernando Q.
   Canetti, Claudio
   Kunkel, Steven L.
   Bozza, Marcelo T.
   Benjamim, Claudia F.
TI CCR4 Controls the Suppressive Effects of Regulatory T Cells on Early and
   Late Events during Severe Sepsis
SO PLOS ONE
LA English
DT Article
ID MURINE POLYMICROBIAL SEPSIS; CHEMOKINE RECEPTOR 4; NITRIC-OXIDE;
   NEUTROPHIL MIGRATION; SEPTIC SHOCK; PULMONARY-FIBROSIS; IMMUNE
   DYSFUNCTION; TUMOR-GROWTH; FAILURE; EXPRESSION
AB Sepsis is a deadly disease characterized by an overwhelming release of inflammatory mediators and the activation of different types of cells. This altered state of cell activation, termed leukocyte reprogramming, contributes to patient outcome. However, the understanding of the process underlying sepsis and the role of regulatory T cells (Tregs) in sepsis remains to be elucidated. In this study, we investigated the role of CCR4, the CCL17/CCL22 chemokine receptor, in the innate and acquired immune responses during severe sepsis and the role of Tregs in effecting the outcome. In contrast with wild-type (WT) mice subjected to cecal ligation and puncture (CLP) sepsis, CCR4-deficient (CCR4(-/-)) septic mice presented an increased survival rate, significant neutrophil migration toward the infection site, a low bacterial count in the peritoneum, and reduced lung inflammation and serum cytokine levels. Thus, a better early host response may favor an adequate long-term response. Consequently, the CCR4(-/-) septic mice were not susceptible to secondary fungal infection, in contrast with the WT septic mice. Furthermore, Tregs cells from the CCR4(-/-) septic mice showed reduced suppressive effects on neutrophil migration (both in vivo and in vitro), lymphocyte proliferation and ROS production from activated neutrophils, in contrast with what was observed for Tregs from the WT septic mice. These data show that CCR4 is involved in immunosuppression after severe sepsis and suggest that CCR4(+) Tregs negatively modulate the short and long-term immune responses.
C1 [Molinaro, Raphael; Pecli, Cyntia; Guilherme, Rafael F.; Benjamim, Claudia F.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941 Rio De Janeiro, RJ, Brazil.
   [Alves-Filho, Jose Carlos; Cunha, Fernando Q.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Farmacol, Ribeirao Preto, SP, Brazil.
   [Canetti, Claudio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, RJ, Brazil.
   [Kunkel, Steven L.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, RJ, Brazil.
RP Benjamim, CF (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941 Rio De Janeiro, RJ, Brazil.
EM cbenjamim@icb.ufrj.br
RI Alves-Filho, Jose Carlos/B-5814-2008; Claudio, Canetti A/C-2774-2009;
   Benjamim, Claudia/T-5090-2019; Cunha, Fernando Q/M-3090-2014
OI Alves-Filho, Jose Carlos/0000-0002-9918-8714; Benjamim,
   Claudia/0000-0001-6247-9596; Bozza, Marcelo/0000-0003-3683-7550; Cunha,
   Fernando Queiroz/0000-0003-4755-1670
FU Universal- CNPqNational Council for Scientific and Technological
   Development (CNPq); APQ1- FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); CAPESCAPES
FX Funding provided by Universal- CNPq, APQ1- FAPERJ and Fellowship -
   CAPES.
CR Alves-Filho J. C., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P151
   Annane D, 2009, CRIT CARE MED, V37, pS117, DOI 10.1097/CCM.0b013e318192078b
   Baatar D, 2007, J IMMUNOL, V178, P4891, DOI 10.4049/jimmunol.178.8.4891
   Belperio JA, 2004, J IMMUNOL, V173, P4692, DOI 10.4049/jimmunol.173.7.4692
   Benjamim CF, 2003, AM J PATHOL, V163, P2605, DOI 10.1016/S0002-9440(10)63615-2
   Benjamim CF, 2002, INFECT IMMUN, V70, P3602, DOI 10.1128/IAI.70.7.3602-3610.2002
   Benjamim CF, 2000, J INFECT DIS, V182, P214, DOI 10.1086/315682
   Benjamim CF, 2005, BLOOD, V105, P3588, DOI 10.1182/blood-2004-08-3251
   BONE RC, 1992, CHEST, V101, P320, DOI 10.1378/chest.101.2.320
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Cavaillon JM, 2005, J ENDOTOXIN RES, V11, P311, DOI 10.1179/096805105X58733
   Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755
   Cuenca AG, 2010, BLOOD, V115, P4324, DOI 10.1182/blood-2010-03-271379
   Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093
   Doerschug KC, 2004, CRIT CARE MED, V32, P489, DOI 10.1097/01.CCM.0000109450.66450.23
   Guilherme RF, 2013, AM J RESP CELL MOL, V49, P1029, DOI 10.1165/rcmb.2012-0462OC
   HOYT DB, 1988, J SURG RES, V45, P342, DOI 10.1016/0022-4804(88)90129-1
   Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847
   Inoue T, 2004, EUR RESPIR J, V24, P49, DOI 10.1183/09031936.04.00110203
   Ishii M, 2008, EUR J IMMUNOL, V38, P2290, DOI 10.1002/eji.200838360
   Jakubzick C, 2004, AM J PATHOL, V165, P1211, DOI 10.1016/S0002-9440(10)63381-0
   Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772
   Katoh S, 2003, ALLERGY, V58, P518, DOI 10.1034/j.1398-9995.2003.00149.x
   Kim SH, 2002, J CLIN INVEST, V110, P1675, DOI 10.1172/JCI200215547
   Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080
   Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129
   Landelle C, 2008, INFECT CONT HOSP EP, V29, P1054, DOI 10.1086/591859
   Lee I, 2005, J EXP MED, V201, P1037, DOI 10.1084/jem.20041709
   Lewkowicz P, 2006, J IMMUNOL, V177, P7155, DOI 10.4049/jimmunol.177.10.7155
   LIN RY, 1993, CHEST, V104, P847, DOI 10.1378/chest.104.3.847
   Margry B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088869
   Monneret G, 2003, CRIT CARE MED, V31, P2068, DOI 10.1097/01.CCM.0000069345.78884.0F
   Monneret G, 2008, MOL MED, V14, P64, DOI 10.2119/2007-00102.Monneret
   Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102
   Nascimento DC, 2010, CRIT CARE MED, V38, P1718, DOI 10.1097/CCM.0b013e3181e78ad0
   Neill DR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002660
   Ness TL, 2006, J IMMUNOL, V177, P7531, DOI 10.4049/jimmunol.177.11.7531
   NISHIJIMA MK, 1986, CRIT CARE MED, V14, P87, DOI 10.1097/00003246-198602000-00002
   Ocuin LM, 2011, J LEUKOCYTE BIOL, V89, P423, DOI 10.1189/jlb.0810479
   Paula-Neto HA, 2011, SHOCK, V35, P17, DOI 10.1097/SHK.0b013e3181e37ea8
   PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338
   Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058
   Rios-Santos F, 2007, AM J RESP CRIT CARE, V175, P490, DOI 10.1164/rccm.200601-103OC
   Rudensky AY, 2006, J EXP MED, V203, P489, DOI 10.1084/jem.20060214
   Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018
   Scumpia PO, 2007, BLOOD, V110, P3673, DOI 10.1182/blood-2007-04-087171
   Scumpia PO, 2006, J IMMUNOL, V177, P7943, DOI 10.4049/jimmunol.177.11.7943
   Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4
   Suratt BT, 2001, AM J PHYSIOL-LUNG C, V281, pL913
   Tavares-Murta BM, 2002, CRIT CARE MED, V30, P1056, DOI 10.1097/00003246-200205000-00017
   Torres-Duenas D, 2006, SHOCK, V25, P267, DOI 10.1097/01.shk.0000208804.34292.38
   Traeger T, 2008, INFECT IMMUN, V76, P5285, DOI 10.1128/IAI.00310-08
   Valenca SS, 2004, TOXICOL PATHOL, V32, P351, DOI 10.1080/01926230490431466
   Venet F, 2004, CRIT CARE MED, V32, P2329, DOI 10.1097/01.CCM.0000145999.42971.4B
   Walley ER, 1996, INFECT IMMUN, V64, P4733, DOI 10.1128/IAI.64.11.4733-4738.1996
   Weighardt H, 2000, SURGERY, V127, P309, DOI 10.1067/msy.2000.104118
   Wisnoski N, 2007, SHOCK, V27, P251, DOI 10.1097/01.shk.0000239780.33398.e4
   Wysocka M, 2001, J IMMUNOL, V166, P7504, DOI 10.4049/jimmunol.166.12.7504
   Yoneyama H, 1998, J CLIN INVEST, V102, P1933, DOI 10.1172/JCI4619
   Yuan Q, 2007, J EXP MED, V204, P1327, DOI 10.1084/jem.20062076
   ZHANG XK, 1993, J LEUKOCYTE BIOL, V54, P444
NR 61
TC 17
Z9 17
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 21
PY 2015
VL 10
IS 7
AR e0133227
DI 10.1371/journal.pone.0133227
PG 21
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN6LZ
UT WOS:000358547600074
PM 26197455
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Cunha-Neto, E
   Chevillard, C
   Rodrigues, MM
   Bozza, MT
AF Cunha-Neto, Edecio
   Chevillard, Christophe
   Rodrigues, Mauricio Martins
   Bozza, Marcelo T.
TI Immunology and Infection by Protozoan Parasites
SO MEDIATORS OF INFLAMMATION
LA English
DT Editorial Material
C1 [Cunha-Neto, Edecio] Univ Sao Paulo, Sch Med, Heart Inst Incor, BR-05403000 Sao Paulo, SP, Brazil.
   [Chevillard, Christophe] INSERM, Marseille, France.
   [Chevillard, Christophe] Univ Aix Marseille, Marseille, France.
   [Rodrigues, Mauricio Martins] Univ Fed Sao Paulo, Escola Paulista Med, BR-04044010 Sao Paulo, SP, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Cunha-Neto, E (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst Incor, BR-05403000 Sao Paulo, SP, Brazil.
EM edecunha@gmail.com
RI chevillard, christophe/A-7087-2015; Cunha-Neto, Edecio/B-4157-2009
OI chevillard, christophe/0000-0002-5269-8813; Cunha-Neto,
   Edecio/0000-0002-3699-3345; Bozza, Marcelo/0000-0003-3683-7550
NR 0
TC 0
Z9 0
U1 1
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 0962-9351
EI 1466-1861
J9 MEDIAT INFLAMM
JI Mediat. Inflamm.
PY 2015
VL 2015
AR 504951
DI 10.1155/2015/504951
PG 2
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CF3OO
UT WOS:000352458600001
PM 25873762
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Dutra, FF
   Alves, LS
   Rodrigues, D
   Fernandez, PL
   de Oliveira, RB
   Golenbock, DT
   Zamboni, DS
   Bozza, MT
AF Dutra, Fabianno F.
   Alves, Leticia S.
   Rodrigues, Danielle
   Fernandez, Patricia L.
   de Oliveira, Rosane B.
   Golenbock, Douglas T.
   Zamboni, Dario S.
   Bozza, Marcelo T.
TI Hemolysis-induced lethality involves inflammasome activation by heme
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE inflammation; mitochondria; ROS; NOX2; Syk
ID NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; NEUTROPHIL MIGRATION; OXIDATIVE
   STRESS; CELL ACTIVATION; NADPH OXIDASE; OXYGENASE; MICE; IRON;
   EXPRESSION
AB The increase of extracellular heme is a hallmark of hemolysis or extensive cell damage. Heme has prooxidant, cytotoxic, and inflammatory effects, playing a central role in the pathogenesis of malaria, sepsis, and sickle cell disease. However, the mechanisms by which heme is sensed by innate immune cells contributing to these diseases are not fully characterized. We found that heme, but not porphyrins without iron, activated LPS-primed macrophages promoting the processing of IL-1 beta dependent on nucleotide-binding domain and leucine rich repeat containing family, pyrin domain containing 3 (NLRP3). The activation of NLRP3 by heme required spleen tyrosine kinase, NADPH oxidase-2, mitochondrial reactive oxygen species, and K+ efflux, whereas it was independent of heme internalization, lysosomal damage, ATP release, the purinergic receptor P2X7, and cell death. Importantly, our results indicated the participation of macrophages, NLRP3 inflammasome components, and IL-1R in the lethality caused by sterile hemolysis. Thus, understanding the molecular pathways affected by heme in innate immune cells might prove useful to identify new therapeutic targets for diseases that have heme release.
C1 [Dutra, Fabianno F.; Alves, Leticia S.; Rodrigues, Danielle; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, Brazil.
   [Fernandez, Patricia L.] Inst Invest Cient Serv Alta Tecnol, Ctr Biol Celular & Mol Enfermedades, Panama City 084301103, Panama.
   [de Oliveira, Rosane B.; Golenbock, Douglas T.] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA.
   [Zamboni, Dario S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular, BR-14049900 Sao Paulo, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Dutra, Fabianno F/C-1387-2015; Zamboni, Dario S/D-3024-2012
OI Dutra, Fabianno F/0000-0003-3106-7585; Zamboni, Dario
   S/0000-0002-7856-7512; Rodrigues, Danielle/0000-0003-2120-3352; Llanes
   Fernandez, Patricia/0000-0002-0762-0566; Bozza,
   Marcelo/0000-0003-3683-7550
FU Conselho Nacional de Pesquisa; Fundacao de Amparo a Pesquisa do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Instituto Nacional de Ciencia e
   Tecnologia em Dengue (Brazil); Programa de Apoio ao Pos-Doutorado no Rio
   de Janeiro, Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior/FAPERJ.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI079293, R01AI079293, R01AI079293,
   R01AI079293, R01AI079293, R01AI079293, R01AI079293, R01AI079293,
   R01AI079293, R01AI079293, R01AI079293] Funding Source: NIH RePORTER
FX We thank Dr. Miguel Soares for providing tibias and femurs of WT,
   Hmox1<SUP>-/-</SUP>, and Fth<SUP>-/-</SUP> mice; Dr. Leda Vieira for
   providing tibias and femurs of WT and gp91phox<SUP>-/-</SUP>; Dr. Pedro
   Persechini for providing P2X7 mice; and Dr. Miriam Werneck for critical
   reading of the manuscript. M. T. B. received financial support from
   Conselho Nacional de Pesquisa, Fundacao de Amparo a Pesquisa do Rio de
   Janeiro (FAPERJ), and Instituto Nacional de Ciencia e Tecnologia em
   Dengue (Brazil). F. F. D. has a postdoctoral fellowship from Programa de
   Apoio ao Pos-Doutorado no Rio de Janeiro, Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior/FAPERJ.
CR Abais JM, 2013, ANTIOXID REDOX SIGN, V18, P1537, DOI 10.1089/ars.2012.4666
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Ataide MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003885
   Balla J, 2007, ANTIOXID REDOX SIGN, V9, P2119, DOI 10.1089/ars.2007.1787
   Barcellos-de-Souza P, 2013, AM J PHYSIOL-CELL PH, V304, pC170, DOI 10.1152/ajpcell.00078.2012
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   BAYSAL E, 1990, FREE RADICAL BIO MED, V9, P5, DOI 10.1016/0891-5849(90)90043-I
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Bezbradica JS, 2012, CURR OPIN IMMUNOL, V24, P58, DOI 10.1016/j.coi.2011.12.010
   Cassat JE, 2013, CELL HOST MICROBE, V13, P510, DOI 10.1016/j.chom.2013.04.010
   CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520
   Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200
   Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P281, DOI 10.1089/ars.2012.4918
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Hara H, 2013, NAT IMMUNOL, V14, P1247, DOI 10.1038/ni.2749
   Hasan RN, 2008, CIRC RES, V102, P42, DOI 10.1161/CIRCRESAHA.107.155143
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Kalantari P, 2014, CELL REP, V6, P196, DOI 10.1016/j.celrep.2013.12.014
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Leemans JC, 2011, IMMUNOL REV, V243, P152, DOI 10.1111/j.1600-065X.2011.01043.x
   Li HF, 2009, J IMMUNOL, V183, P1528, DOI 10.4049/jimmunol.0901080
   Li QW, 2014, CELL BIOCHEM BIOPHYS, V69, P495, DOI 10.1007/s12013-014-9823-9
   Lim SK, 1998, BLOOD, V92, P1870, DOI 10.1182/blood.V92.6.1870.418k38_1870_1877
   Lu NH, 2012, TOXICOL IN VITRO, V26, P732, DOI 10.1016/j.tiv.2012.03.006
   Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Moraes JA, 2012, ATHEROSCLEROSIS, V224, P394, DOI 10.1016/j.atherosclerosis.2012.07.043
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847
   Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Setty BNY, 2008, J THROMB HAEMOST, V6, P2202, DOI 10.1111/j.1538-7836.2008.03177.x
   Shio MT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000559
   Simoes RL, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/946878
   Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Tolosano E, 1999, BLOOD, V94, P3906, DOI 10.1182/blood.V94.11.3906
   Tolosano E, 2002, BLOOD, V100, P4201, DOI 10.1182/blood-2002-04-1270
   van Bruggen R, 2010, BLOOD, V115, P5398, DOI 10.1182/blood-2009-10-250803
   Vinchi F, 2008, AM J PATHOL, V173, P289, DOI 10.2353/ajpath.2008.071130
   Vinchi F, 2013, CIRCULATION, V127, P1317, DOI 10.1161/CIRCULATIONAHA.112.130179
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 66
TC 142
Z9 143
U1 3
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 30
PY 2014
VL 111
IS 39
BP E4110
EP E4118
DI 10.1073/pnas.1405023111
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AP8SW
UT WOS:000342350200010
PM 25225402
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Dutra, FF
   Bozza, MT
AF Dutra, Fabianno F.
   Bozza, Marcelo T.
TI Heme on innate immunity and inflammation
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE heme; iron; hemolysis; ROS; inflammation; innate immunity; programed
   cell death; cytotoxicity
ID SICKLE-CELL-DISEASE; ACUTE CHEST SYNDROME; NF-KAPPA-B; HEMOGLOBIN
   SCAVENGER RECEPTOR; ISCHEMIA-REPERFUSION INJURY; OXYGEN SPECIES
   GENERATION; HEMOLYTIC-UREMIC SYNDROME; ALPHA-INDUCED APOPTOSIS;
   TUMOR-NECROSIS-FACTOR; EARLY BRAIN-INJURY
AB Heme is an essential molecule expressed ubiquitously all through our tissues. Heme plays major functions in cellular physiology and metabolism as the prosthetic group of diverse proteins. Once released from cells and from hemeproteins free heme causes oxidative damage and inflammation, thus acting as a prototypic damage-associated molecular pattern. In this context, free heme is a critical component of the pathological process of sterile and infectious hemolytic conditions including malaria, hemolytic anemias, ischemia-reperfusion, and hemorrhage. The plasma scavenger proteins hemopexin and albumin reduce heme toxicity and are responsible for transporting free heme to intracellular compartments where it is catabolized by heme-oxygenase enzymes. Upon hemolysis or severe cellular damage the serum capacity to scavenge heme may saturate and increase free heme to sufficient amounts to cause tissue damage in various organs. The mechanism by which heme causes reactive oxygen generation, activation of cells of the innate immune system and cell death are not fully understood. Although heme can directly promote lipid peroxidation by its iron atom, heme can also induce reactive oxygen species generation and production of inflammatory mediators through the activation of selective signaling pathways. Heme activates innate immune cells such as macrophages and neutrophils through activation of innate immune receptors. The importance of these events has been demonstrated in infectious and non-infectious diseases models. In this review, we will discuss the mechanisms behind heme-induced cytotoxicity and inflammation and the consequences of these events on different tissues and diseases.
C1 [Dutra, Fabianno F.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, Brazil.
RP Dutra, FF (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Ave Carlos Chagas Filho 373, BR-21941902 Rio De Janeiro, Brazil.
EM fabianno44@yahoo.com.br; mbozza@micro.ufrj.br
RI Dutra, Fabianno F/C-1387-2015
OI Dutra, Fabianno F/0000-0003-3106-7585; Bozza,
   Marcelo/0000-0003-3683-7550
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); INCT Dengue,
   Brazil; Programa Nacional de Pos-Doutorado (PNPD) CAPES/FAPERJ
FX We thank Miriam Werneck for critical reading of the manuscript. Marcelo
   T. Bozza received financial support from Conselho Nacional de Pesquisa
   (CNPq), Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ), and INCT Dengue, Brazil, Fabianno F. Dutra has a postdoctoral
   fellowship from Programa Nacional de Pos-Doutorado (PNPD) CAPES/FAPERJ.
CR Adisa OA, 2013, BRIT J HAEMATOL, V162, P702, DOI 10.1111/bjh.12445
   AFT RL, 1983, J BIOL CHEM, V258, P2069
   AFT RL, 1984, J BIOL CHEM, V259, P301
   Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004
   Arroyo LH, 1999, CARDIOVASC RES, V41, P369, DOI 10.1016/S0008-6363(98)00308-3
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Arruda MA, 2006, EXP CELL RES, V312, P3939, DOI 10.1016/j.yexcr.2006.08.022
   BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700
   BALLA G, 1991, LAB INVEST, V64, P648
   BALLA G, 1992, J BIOL CHEM, V267, P18148
   BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285
   Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999
   Barcellos-de-Souza P, 2013, AM J PHYSIOL-CELL PH, V304, pC170, DOI 10.1152/ajpcell.00078.2012
   BAYSAL E, 1990, FREE RADICAL BIO MED, V9, P5, DOI 10.1016/0891-5849(90)90043-I
   Bean CJ, 2012, BLOOD, V120, P3822, DOI 10.1182/blood-2011-06-361642
   Belcher JD, 2000, BLOOD, V96, P2451, DOI 10.1182/blood.V96.7.2451.h8002451_2451_2459
   Belcher JD, 2003, BLOOD, V101, P3953, DOI 10.1182/blood-2002-10-3313
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje
   Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870
   Boyle JJ, 2012, CIRC RES, V110, P20, DOI 10.1161/CIRCRESAHA.111.247577
   Boyle JJ, 2009, AM J PATHOL, V174, P1097, DOI 10.2353/ajpath.2009.080431
   Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Browne P, 1998, FREE RADICAL BIO MED, V24, P1040, DOI 10.1016/S0891-5849(97)00391-2
   BROXMEYER HE, 1991, P NATL ACAD SCI USA, V88, P770, DOI 10.1073/pnas.88.3.770
   Bunyaratvej A, 1995, Southeast Asian J Trop Med Public Health, V26 Suppl 1, P257
   Cai Y, 2011, J IMMUNOL, V187, P1314, DOI 10.4049/jimmunol.1002925
   CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Chen JM, 2011, BLOOD, V117, P3680, DOI 10.1182/blood-2010-08-302539
   Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861
   Chen Z, 2011, STROKE, V42, P465, DOI 10.1161/STROKEAHA.110.602755
   Cheng C, 2013, TRENDS CARDIOVAS MED, V23, P153, DOI 10.1016/j.tcm.2012.10.004
   Chiabrando D, 2012, J CLIN INVEST, V122, P4569, DOI 10.1172/JCI62422
   Chies JAB, 2001, MED HYPOTHESES, V57, P46, DOI 10.1054/mehy.2000.1310
   CHIU D, 1989, SEMIN HEMATOL, V26, P128
   Chiu DTY, 1996, FREE RADICAL BIO MED, V21, P89, DOI 10.1016/0891-5849(96)00035-4
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003
   Correa-Costa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014298
   Cozzi A, 2003, FEBS LETT, V537, P187, DOI 10.1016/S0014-5793(03)00114-5
   Cunnington AJ, 2012, J IMMUNOL, V189, P5336, DOI 10.4049/jimmunol.1201028
   Cunnington AJ, 2012, NAT MED, V18, P120, DOI 10.1038/nm.2601
   DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128
   deCiutiis A C, 1978, J Natl Med Assoc, V70, P503
   Devey L, 2009, MOL THER, V17, P65, DOI 10.1038/mt.2008.237
   Dong BB, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-58
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Dunmore BJ, 2007, J VASC SURG, V45, P155, DOI 10.1016/j.jvs.2006.08.072
   EDELSTEIN SJ, 1973, P NATL ACAD SCI USA, V70, P1104, DOI 10.1073/pnas.70.4.1104
   EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688
   ENGLE MA, 1964, CIRCULATION, V30, P698, DOI 10.1161/01.CIR.30.5.698
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Eskew JD, 1999, J BIOL CHEM, V274, P638, DOI 10.1074/jbc.274.2.638
   EVANS SV, 1988, J BIOL CHEM, V263, P4263
   FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657
   Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27
   Fenton H. J. H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Ferris CD, 1999, NAT CELL BIOL, V1, P152
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97
   Frimat M, 2013, BLOOD, V122, P282, DOI 10.1182/blood-2013-03-489245
   Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200
   Georgel P, 2007, VIROLOGY, V362, P304, DOI 10.1016/j.virol.2006.12.032
   Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578
   Gladwin MT, 2008, NEW ENGL J MED, V359, P2254, DOI 10.1056/NEJMra0804411
   Gozzelino R, 2012, CELL HOST MICROBE, V12, P693, DOI 10.1016/j.chom.2012.10.011
   Gozzelino R, 2011, ADV EXP MED BIOL, V691, P211, DOI 10.1007/978-1-4419-6612-4_22
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Gu YX, 2009, STROKE, V40, P2241, DOI 10.1161/STROKEAHA.108.539536
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   Hahalis G, 2008, ATHEROSCLEROSIS, V198, P448, DOI 10.1016/j.atherosclerosis.2007.09.030
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   HAREL S, 1988, FREE RADICAL RES COM, V5, P21, DOI 10.3109/10715768809068555
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   HEBBEL RP, 1991, BLOOD, V77, P214
   HEINLE RW, 1948, BLOOD, V3, P449, DOI 10.1182/blood.V3.4.449.449
   Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hovav T, 1999, BRIT J HAEMATOL, V106, P178
   Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185
   INGRAM VM, 1957, NATURE, V180, P326, DOI 10.1038/180326a0
   Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   JUCKETT MB, 1995, AM J PATHOL, V147, P782
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023
   Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225
   Keel SB, 2008, SCIENCE, V319, P825, DOI 10.1126/science.1151133
   Khandros E, 2012, BLOOD, V119, P5265, DOI 10.1182/blood-2011-12-397729
   Kim SJ, 2013, FREE RADICAL BIO MED, V65, P997, DOI 10.1016/j.freeradbiomed.2013.08.178
   Kolodgie FD, 2003, NEW ENGL J MED, V349, P2316, DOI 10.1056/NEJMoa035655
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200
   Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238
   Krishnamurthy PC, 2006, NATURE, V443, P586, DOI 10.1038/nature05125
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004
   Kwon HM, 1998, J CLIN INVEST, V101, P1551, DOI 10.1172/JCI1568
   Lad L, 2003, J BIOL CHEM, V278, P7834, DOI 10.1074/jbc.M211450200
   Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003
   Larsen R, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00077
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   Latunde-Dada GO, 2006, FEBS LETT, V580, P6865, DOI 10.1016/j.febslet.2006.11.048
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee JY, 2010, J CEREBR BLOOD F MET, V30, P1793, DOI 10.1038/jcbfm.2010.137
   LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591
   Li QW, 2014, CELL BIOCHEM BIOPHYS, V69, P495, DOI 10.1007/s12013-014-9823-9
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   LIGHT WR, 1990, J BIOL CHEM, V265, P15632
   LIGHT WR, 1990, J BIOL CHEM, V265, P15623
   Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46
   Lin TA, 2010, J INFECT DIS, V202, P624, DOI 10.1086/654929
   Liu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071366
   Loirat C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-60
   Lu NH, 2012, TOXICOL IN VITRO, V26, P732, DOI 10.1016/j.tiv.2012.03.006
   Luo YP, 2014, INT IMMUNOPHARMACOL, V20, P24, DOI 10.1016/j.intimp.2014.02.017
   Lyoumi S, 1999, EUR J BIOCHEM, V261, P190, DOI 10.1046/j.1432-1327.1999.00254.x
   Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070
   MAO GD, 1994, FREE RADICAL BIO MED, V16, P493, DOI 10.1016/0891-5849(94)90127-9
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184
   Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963
   Matsui NM, 2001, BLOOD, V98, P1955, DOI 10.1182/blood.V98.6.1955
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693
   Michel JB, 2011, EUR HEART J, V32, P1977, DOI 10.1093/eurheartj/ehr054
   Mocsai A, 2013, J EXP MED, V210, P1283, DOI 10.1084/jem.20122220
   MOLD C, 1995, CLIN IMMUNOL IMMUNOP, V76, P314, DOI 10.1006/clin.1995.1131
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Moraes JA, 2012, ATHEROSCLEROSIS, V224, P394, DOI 10.1016/j.atherosclerosis.2012.07.043
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   MULLEREBERHARD U, 1970, NEW ENGL J MED, V283, P1090, DOI 10.1056/NEJM197011122832007
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612
   Nagy E, 2010, ARTERIOSCL THROM VAS, V30, P1347, DOI 10.1161/ATVBAHA.110.206433
   Nan YM, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-124
   Natarajan R, 2007, MICROVASC RES, V73, P163, DOI 10.1016/j.mvr.2007.01.002
   Nath KA, 2000, AM J PATHOL, V156, P1527, DOI 10.1016/S0002-9440(10)65024-9
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992
   Oliveira JHM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001320
   Oliveira MF, 1999, NATURE, V400, P517, DOI 10.1038/22910
   OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897
   Oliyier M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00025
   Otterbein LE, 2000, NAT MED, V6, P422
   Paes MC, 2001, ARCH INSECT BIOCHEM, V48, P63, DOI 10.1002/arch.1058
   Paiva-Silva GO, 2006, P NATL ACAD SCI USA, V103, P8030, DOI 10.1073/pnas.0602224103
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pandey AV, 1996, FEBS LETT, V393, P189, DOI 10.1016/0014-5793(96)00881-2
   Paoli M, 1999, NAT STRUCT BIOL, V6, P926
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Park SY, 2006, J MOL BIOL, V360, P690, DOI 10.1016/j.jmb.2006.05.036
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Paszty C, 1997, SCIENCE, V278, P876, DOI 10.1126/science.278.5339.876
   Patel RP, 1996, FREE RADICAL RES, V25, P117, DOI 10.3109/10715769609149916
   PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543
   Pawluczkowycz AW, 2007, J IMMUNOL, V179, P5543, DOI 10.4049/jimmunol.179.8.5543
   Pereira LOR, 2007, BIOCHEMISTRY-US, V46, P6822, DOI 10.1021/bi700011d
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017
   Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9
   Piazza M, 2011, INNATE IMMUN-LONDON, V17, P293, DOI 10.1177/1753425910369020
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Potor L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/676425
   Qiu AD, 2006, CELL, V127, P917, DOI 10.1016/j.cell.2006.09.041
   Quaye IK, 2008, T ROY SOC TROP MED H, V102, P735, DOI 10.1016/j.trstmh.2008.04.010
   Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014
   Rajagopal A, 2008, NATURE, V453, P1127, DOI 10.1038/nature06934
   Regan RF, 2001, J NEUROCHEM, V79, P545, DOI 10.1046/j.1471-4159.2001.00590.x
   Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799
   ROSE MY, 1985, J BIOL CHEM, V260, P6632
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Ruiz-Torres MP, 2005, THROMB HAEMOSTASIS, V93, P443, DOI 10.1160/TH04-07-0450
   Ryan TM, 1997, SCIENCE, V278, P873, DOI 10.1126/science.278.5339.873
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Sansing LH, 2011, ANN NEUROL, V70, P646, DOI 10.1002/ana.22528
   Schimmel M, 2013, HAEMATOLOGICA, V98, P1797, DOI 10.3324/haematol.2013.088021
   Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919
   SCHMITT TH, 1993, ARCH BIOCHEM BIOPHYS, V307, P96, DOI 10.1006/abbi.1993.1566
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Shio MT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000559
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   Silva-Gomes S, 2013, INFECT IMMUN, V81, P2536, DOI 10.1128/IAI.00251-13
   SIMIONATTO CS, 1988, AM J MED, V85, P538
   Sindrilaru A, 2011, J CLIN INVEST, V121, P985, DOI 10.1172/JCI44490
   SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325
   SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4
   Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025
   Sluimer JC, 2009, J AM COLL CARDIOL, V53, P1517, DOI 10.1016/j.jacc.2008.12.056
   SPIRITO P, 1990, J AM COLL CARDIOL, V15, P1521, DOI 10.1016/0735-1097(90)92820-R
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003
   TAPPEL AL, 1955, J BIOL CHEM, V217, P721
   TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3
   Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200
   Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Tolosano E, 1999, BLOOD, V94, P3906, DOI 10.1182/blood.V94.11.3906
   Tolosano E, 2010, ANTIOXID REDOX SIGN, V12, P305, DOI 10.1089/ars.2009.2787
   TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554
   Turnbull IR, 2005, J EXP MED, V202, P363, DOI 10.1084/jem.20050986
   Underhill DM, 2007, TRENDS IMMUNOL, V28, P66, DOI 10.1016/j.it.2006.12.004
   VanderZee J, 1996, FREE RADICAL BIO MED, V20, P199, DOI 10.1016/0891-5849(95)02031-4
   VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607
   VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2
   VINCENT SH, 1989, SEMIN HEMATOL, V26, P105
   Vinchi F, 2008, AM J PATHOL, V173, P289, DOI 10.2353/ajpath.2008.071130
   Vinchi F, 2013, CIRCULATION, V127, P1317, DOI 10.1161/CIRCULATIONAHA.112.130179
   Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18
   Vojtechovsky J, 1999, BIOPHYS J, V77, P2153, DOI 10.1016/S0006-3495(99)77056-6
   von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322
   Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Wagener FADTG, 2003, BLOOD, V102, P521, DOI 10.1182/blood-2002-07-2248
   Wagener FADTG, 2001, TRENDS PHARMACOL SCI, V22, P52, DOI 10.1016/S0165-6147(00)01609-6
   Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802
   Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095
   Wang YC, 2013, STROKE, V44, P2545, DOI 10.1161/STROKEAHA.113.001038
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1
   Wu ML, 2011, AM J CARDIOVASC DIS, V1, P150
   Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0
   Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60
   Xue H, 2007, WORLD J GASTROENTERO, V13, P5384, DOI 10.3748/wjg.v13.i40.5384
   Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yanai H, 2009, CURR OPIN IMMUNOL, V21, P17, DOI 10.1016/j.coi.2009.01.005
   Yang H, 2002, SHOCK, V17, P485, DOI 10.1097/00024382-200206000-00008
   Yoriki H, 2013, J GASTROEN HEPATOL, V28, P632, DOI 10.1111/jgh.12074
   Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x
   Zawrotniak M, 2013, ACTA BIOCHIM POL, V60, P277
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 260
TC 126
Z9 131
U1 1
U2 33
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 27
PY 2014
VL 5
AR 115
DI 10.3389/fphar.2014.00115
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AX7JH
UT WOS:000347091900001
PM 24904418
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Albuquerque, PC
   Fonseca, FL
   Dutra, FF
   Bozza, MT
   Frases, S
   Casadevall, A
   Rodrigues, ML
AF Albuquerque, P. C.
   Fonseca, F. L.
   Dutra, F. F.
   Bozza, M. T.
   Frases, S.
   Casadevall, A.
   Rodrigues, M. L.
TI Cryptococcus neoformans glucuronoxylomannan fractions of different
   molecular masses are functionally distinct
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Albuquerque, P. C.; Fonseca, F. L.; Dutra, F. F.; Bozza, M. T.; Frases, S.; Rodrigues, M. L.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Casadevall, A.] Albert Einstein Coll Med, New York, NY USA.
   [Rodrigues, M. L.] Fiocruz MS, CDTS, BR-21045900 Rio De Janeiro, Brazil.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
PD MAY
PY 2014
VL 57
SU 1
SI SI
BP 53
EP 53
PG 1
WC Dermatology; Mycology
SC Dermatology; Mycology
GA AG0FL
UT WOS:000335090600114
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Bozza, MT
AF Paiva, Claudia N.
   Bozza, Marcelo T.
TI Are Reactive Oxygen Species Always Detrimental to Pathogens?
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID FOAM CELL-FORMATION; CHRONIC GRANULOMATOUS-DISEASE; NF-KAPPA-B;
   HUMAN-IMMUNODEFICIENCY-VIRUS; INNATE IMMUNE-RESPONSE; NITRIC-OXIDE
   SYNTHASE; NEUTROPHIL EXTRACELLULAR TRAPS; TRYPANOSOMA-CRUZI INFECTION;
   LEISHMANIA-MAJOR INFECTION; NADPH PHAGOCYTE OXIDASE
AB Reactive oxygen species (ROS) are deadly weapons used by phagocytes and other cell types, such as lung epithelial cells, against pathogens. ROS can kill pathogens directly by causing oxidative damage to biocompounds or indirectly by stimulating pathogen elimination by various nonoxidative mechanisms, including pattern recognition receptors signaling, autophagy, neutrophil extracellular trap formation, and T-lymphocyte responses. Thus, one should expect that the inhibition of ROS production promote infection. Increasing evidences support that in certain particular infections, antioxidants decrease and prooxidants increase pathogen burden. In this study, we review the classic infections that are controlled by ROS and the cases in which ROS appear as promoters of infection, challenging the paradigm. We discuss the possible mechanisms by which ROS could promote particular infections. These mechanisms are still not completely clear but include the metabolic effects of ROS on pathogen physiology, ROS-induced damage to the immune system, and ROS-induced activation of immune defense mechanisms that are subsequently hijacked by particular pathogens to act against more effective microbicidal mechanisms of the immune system. The effective use of antioxidants as therapeutic agents against certain infections is a realistic possibility that is beginning to be applied against viruses.
C1 [Paiva, Claudia N.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Paulo de Goes, CCS Bloco D,Ave Carlos Chagas Filho, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM cnpaiva@iname.com
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Pesquisa (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); INCTDengue
FX The authors received financial support from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Conselho Nacional
   de Pesquisa (CNPq), Fundacao de Amparo a Pesquisa do Rio de Janeiro
   (FAPERJ) and INCTDengue. "Figures were made with the help of Motifolio
   (www.motifolio.com)''.
CR Adamson S, 2011, CURR OPIN LIPIDOL, V22, P335, DOI 10.1097/MOL.0b013e32834a97e4
   Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183
   Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005
   Almeida TF, 2012, PARASITE IMMUNOL, V34, P492, DOI 10.1111/j.1365-3024.2012.01384.x
   Alvarez MN, 2004, ARCH BIOCHEM BIOPHYS, V432, P222, DOI 10.1016/j.abb.2004.09.015
   Andersson H, 2006, J MED MICROBIOL, V55, P1023, DOI 10.1099/jmm.0.46553-0
   Aratani Y, 2004, JPN J INFECT DIS, V57, pS15
   Ashida H, 2011, J CELL BIOL, V195, P931, DOI 10.1083/jcb.201108081
   Auerbuch V, 2004, J EXP MED, V200, P527, DOI 10.1084/jem.20040976
   Bahia AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057014
   Baillie L, 2005, FEMS MICROBIOL LETT, V245, P33, DOI 10.1016/j.femsle.2005.02.016
   Balstad TR, 2011, MOL NUTR FOOD RES, V55, P185, DOI 10.1002/mnfr.201000204
   BARUCHEL S, 1992, J LEUKOCYTE BIOL, V52, P111
   Ben-Ari J, 2012, EXPERT REV ANTI-INFE, V10, P881, DOI [10.1586/ERI.12.77, 10.1586/eri.12.77]
   Bereswill S, 2010, PLOS ONE, V5
   Bergeron M, 2008, PARASITE IMMUNOL, V30, P280, DOI 10.1111/j.1365-3024.2008.01022.x
   Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606
   Bisti S, 2006, MICROBES INFECT, V8, P1464, DOI 10.1016/j.micinf.2006.01.014
   Blanchard TG, 2003, J INFECT DIS, V187, P1609, DOI 10.1086/374780
   Blessing E, 2002, CIRCULATION, V105, P1976, DOI 10.1161/01.CIR.0000015062.41860.5B
   Blos M, 2003, EUR J IMMUNOL, V33, P1224, DOI 10.1002/eji.200323825
   Boyle JJ, 2012, CURR OPIN LIPIDOL, V23, P453, DOI 10.1097/MOL.0b013e328356b145
   Boyle JJ, 2012, CIRC RES, V110, P20, DOI 10.1161/CIRCRESAHA.111.247577
   Breuer W, 1996, FEBS LETT, V382, P304, DOI 10.1016/0014-5793(96)00190-1
   Breuer W, 2008, INT J BIOCHEM CELL B, V40, P350, DOI 10.1016/j.biocel.2007.03.010
   Brigelius-Flohe R, 2011, ANTIOXID REDOX SIGN, V15, P2335, DOI 10.1089/ars.2010.3534
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   BUCHMEIER NA, 1993, MOL MICROBIOL, V7, P933, DOI 10.1111/j.1365-2958.1993.tb01184.x
   Buommino E, 2012, HELICOBACTER, V17, P417, DOI 10.1111/j.1523-5378.2012.00973.x
   Burke MF, 2010, CIRC RES, V106, P627, DOI 10.1161/CIRCRESAHA.109.215855
   Bustamante J, 2007, J ALLERGY CLIN IMMUN, V120, P32, DOI 10.1016/j.jaci.2007.04.034
   Bustamante J, 2011, NAT IMMUNOL, V12, P213, DOI 10.1038/ni.1992
   Cairo G, 2011, TRENDS IMMUNOL, V32, P241, DOI 10.1016/j.it.2011.03.007
   Calderon J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002799
   Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   Carneiro LAM, 2009, CELL HOST MICROBE, V5, P123, DOI 10.1016/j.chom.2008.12.011
   Carvajal-Yepes M, 2011, J BIOL CHEM, V286, P8941, DOI 10.1074/jbc.M110.186684
   Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
   Castro SM, 2006, AM J RESP CRIT CARE, V174, P1361, DOI 10.1164/rccm.200603-319OC
   Challa S, 2010, CELL MOL LIFE SCI, V67, P3241, DOI 10.1007/s00018-010-0413-8
   Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006
   CHANG C, 2011, FILM COMMENT, V47, P6
   Charron AJ, 2002, J CELL SCI, V115, P3049
   Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1493, DOI 10.1152/ajpcell.00016.2006
   Chen XX, 2012, VIROLOGY, V426, P66, DOI 10.1016/j.virol.2012.01.023
   Chlosta S, 2006, INFECT IMMUN, V74, P3065, DOI 10.1128/IAI.74.5.3065-3067.2006
   Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC
   Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730
   Conner GE, 2002, AM J RESP CRIT CARE, V166, pS57, DOI 10.1164/rccm.2206018
   Corleis B, 2012, CELL MICROBIOL, V14, P1109, DOI 10.1111/j.1462-5822.2012.01783.x
   Costa-Mattioli M, 2008, NAT IMMUNOL, V9, P1097, DOI 10.1038/ni1008-1097
   Cox JV, 2012, CELL MICROBIOL, V14, P1497, DOI 10.1111/j.1462-5822.2012.01823.x
   Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189
   Cruz KK, 2008, PARASITE IMMUNOL, V30, P171, DOI 10.1111/j.1365-3024.2007.01014.x
   Cybulski RJ, 2009, INFECT IMMUN, V77, P274, DOI 10.1128/IAI.00515-08
   D'Archivio M, 2008, FEBS LETT, V582, P2291, DOI 10.1016/j.febslet.2008.05.029
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2011, J INFECT DIS, V204, P951, DOI 10.1093/infdis/jir432
   Das NK, 2009, CELL MICROBIOL, V11, P83, DOI 10.1111/j.1462-5822.2008.01241.x
   Nogueira NPD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025935
   De Luca A, 2012, J CLIN INVEST, V122, P1816, DOI 10.1172/JCI60862
   Devadas K, 2006, J IMMUNOL, V176, P4252, DOI 10.4049/jimmunol.176.7.4252
   Devadas K, 2010, J LEUKOCYTE BIOL, V87, P915, DOI 10.1189/jlb.0307172
   Dhiman M, 2011, J PATHOL, V225, P583, DOI 10.1002/path.2975
   Dinauer MC, 1997, J IMMUNOL, V158, P5581
   Dorn BR, 2001, INFECT IMMUN, V69, P5698, DOI 10.1128/IAI.69.9.5698-5708.2001
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Drakesmith H, 2012, SCIENCE, V338, P768, DOI 10.1126/science.1224577
   Drummond RA, 2011, CURR OPIN MICROBIOL, V14, P392, DOI 10.1016/j.mib.2011.07.001
   Endres R, 1997, IMMUNITY, V7, P419, DOI 10.1016/S1074-7613(00)80363-5
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Fang FC, 2011, MBIO, V2, DOI 10.1128/mBio.00141-11
   Feeney ER, 2013, J INFECT DIS, V207, P628, DOI 10.1093/infdis/jis723
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189
   Finn AV, 2012, J AM COLL CARDIOL, V59, P166, DOI 10.1016/j.jacc.2011.10.852
   Finzi JK, 2004, MOL BIOCHEM PARASIT, V133, P37, DOI 10.1016/j.molbiopara.2003.08.011
   Fortes GB, 2012, BLOOD, V119, P2368, DOI 10.1182/blood-2011-08-375303
   Fraternale A, 2009, MOL ASPECTS MED, V30, P99, DOI 10.1016/j.mam.2008.09.001
   Freigang S, 2011, EUR J IMMUNOL, V41, P2040, DOI 10.1002/eji.201041316
   Fujita M, 2010, CLIN EXP IMMUNOL, V160, P457, DOI 10.1111/j.1365-2249.2010.04092.x
   Gallois A, 2001, J IMMUNOL, V166, P5741, DOI 10.4049/jimmunol.166.9.5741
   Garofalo RP, 2013, ANTIOXID REDOX SIGN, V18, P186, DOI 10.1089/ars.2011.4307
   Geiler J, 2010, BIOCHEM PHARMACOL, V79, P413, DOI 10.1016/j.bcp.2009.08.025
   Gilmour MI, 2012, TOXICOL PATHOL, V40, P312, DOI 10.1177/0192623311431949
   Gordon MA, 2008, J INFECTION, V56, P413, DOI 10.1016/j.jinf.2008.03.012
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729
   Grant PR, 2000, J MED VIROL, V61, P439, DOI 10.1002/1096-9071(200008)61:4&lt;439::AID-JMV5&gt;3.0.CO;2-L
   Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Guerra C, 2012, CLIN EXP IMMUNOL, V168, P142, DOI 10.1111/j.1365-2249.2011.04552.x
   Guevara AG, 2000, IMMUNOL LETT, V71, P79, DOI 10.1016/S0165-2478(99)00164-9
   Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x
   Guimaraes-Costa Anderson B, 2012, J Parasitol Res, V2012, P929743, DOI 10.1155/2012/929743
   Guinazu N, 2010, INT J PARASITOL, V40, P1531, DOI 10.1016/j.ijpara.2010.05.012
   Gurbuz AK, 2005, SOUTH MED J, V98, P1095, DOI 10.1097/01.smj.0000182486.39913.da
   Gutierrez MG, 2005, CELL MICROBIOL, V7, P981, DOI 10.1111/j.1462-5822.2005.00527.x
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Gutierrez-Grobe Y, 2011, ANN HEPATOL, V10, P105
   GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993
   Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI 10.1038/NCHEMBIO.496
   Halliwell B, 2006, TRENDS BIOCHEM SCI, V31, P509, DOI 10.1016/j.tibs.2006.07.005
   Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3
   HANNA PC, 1994, MOL MED, V1, P7
   Hara H, 2007, NAT IMMUNOL, V8, P619, DOI 10.1038/ni1466
   Harvey CJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002042
   Hashiba T, 2001, GENE THER, V8, P1499, DOI 10.1038/sj.gt.3301540
   Hayashi K, 2012, ARCH VIROL, V157, P1377, DOI 10.1007/s00705-012-1306-y
   HERRMANN M, 1990, J CLIN INVEST, V86, P942, DOI 10.1172/JCI114796
   Hider RC, 2011, BIOMETALS, V24, P1179, DOI 10.1007/s10534-011-9476-8
   Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102
   Ho HY, 2009, J AGR FOOD CHEM, V57, P6140, DOI 10.1021/jf901128u
   Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557
   Hosakote YM, 2012, AM J PHYSIOL-LUNG C, V303, pL991, DOI 10.1152/ajplung.00192.2012
   Hou WH, 2010, HEPATOLOGY, V51, P1494, DOI 10.1002/hep.23401
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106
   HUANG TT, 1992, FREE RADICAL RES COM, V17, P59, DOI 10.3109/10715769209061089
   Hybiske K, 2008, NAT REV MICROBIOL, V6, P99, DOI 10.1038/nrmicro1821
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45
   Jackson KE, 2004, MOL MICROBIOL, V54, P109, DOI 10.1111/j.1365-2958.2004.04284.x
   JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751
   James J S, 1997, AIDS Treat News, P1
   James J S, 2000, AIDS Treat News, P2
   Jankowski A, 2002, ANTIOXID REDOX SIGN, V4, P61, DOI 10.1089/152308602753625861
   Jasper H, 2008, CELL, V132, P915, DOI 10.1016/j.cell.2008.03.002
   Jiang H, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-69
   Johnson EE, 2012, MICROBES INFECT, V14, P207, DOI 10.1016/j.micinf.2011.10.001
   Johnson EE, 2010, INFECT IMMUN, V78, P5099, DOI 10.1128/IAI.00498-10
   JONES GS, 1990, J INFECT DIS, V162, P700, DOI 10.1093/infdis/162.3.700
   Joseph SB, 2004, CELL, V119, P299, DOI 10.1016/j.cell.2004.09.032
   Joubert PE, 2012, AUTOPHAGY, V8, P1261, DOI 10.4161/auto.20751
   Kakhlon O, 2002, FREE RADICAL BIO MED, V33, P1037, DOI 10.1016/S0891-5849(02)01006-7
   Kalayoglu MV, 1998, INFECT IMMUN, V66, P5067, DOI 10.1128/IAI.66.11.5067-5072.1998
   Kedzierski L, 2007, PARASITOL RES, V102, P91, DOI 10.1007/s00436-007-0729-y
   Keenan JI, 2005, FREE RADICAL BIO MED, V38, P1188, DOI 10.1016/j.freeradbiomed.2004.12.025
   Kesic MJ, 2011, FREE RADICAL BIO MED, V51, P444, DOI 10.1016/j.freeradbiomed.2011.04.027
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Kima PE, 2000, J EXP MED, V191, P1063, DOI 10.1084/jem.191.6.1063
   Kinter CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050016
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Koarai A, 2010, AM J RESP CELL MOL, V42, P651, DOI 10.1165/rcmb.2008-0345OC
   Kong XN, 2011, AM J RESP CRIT CARE, V184, P928, DOI 10.1164/rccm.201102-0271OC
   Kosmider B, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-43
   Kotsias F, 2013, ANTIOXID REDOX SIGN, V18, P714, DOI 10.1089/ars.2012.4557
   Kou MC, 2013, MOL NUTR FOOD RES, V57, P1598, DOI 10.1002/mnfr.201200227
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Kozarov EV, 2005, ARTERIOSCL THROM VAS, V25, pE17, DOI 10.1161/01.ATV.0000155018.67835.1a
   Kuhn AM, 2011, FREE RADICAL BIO MED, V50, P1382, DOI 10.1016/j.freeradbiomed.2011.02.036
   Kumagai Y, 2010, J ALLERGY CLIN IMMUN, V125, P985, DOI 10.1016/j.jaci.2010.01.058
   Kumar C, 2011, EMBO J, V30, P2044, DOI 10.1038/emboj.2011.105
   KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841
   KuoLee R, 2011, MICROBES INFECT, V13, P447, DOI 10.1016/j.micinf.2011.01.010
   Kurz T, 2011, FREE RADICAL BIO MED, V50, P1647, DOI 10.1016/j.freeradbiomed.2011.03.014
   Kusuhara K, 2009, EUR J PEDIATR, V168, P745, DOI 10.1007/s00431-008-0824-9
   Labbe K, 2008, CELL DEATH DIFFER, V15, P1339, DOI 10.1038/cdd.2008.91
   Lam GY, 2010, SEMIN IMMUNOPATHOL, V32, P415, DOI 10.1007/s00281-010-0221-0
   Lamkanfi M, 2010, CELL HOST MICROBE, V8, P44, DOI 10.1016/j.chom.2010.06.007
   Lanceta L, 2013, BIOCHEM J, V449, P189, DOI 10.1042/BJ20120936
   Lang PA, 2013, CELL DEATH DIFFER, V20, P649, DOI 10.1038/cdd.2012.167
   Larson JA, 2004, MOL MICROBIOL, V53, P807, DOI 10.1111/j.1365-2958.2004.04169.x
   Lee PPW, 2008, PEDIATR INFECT DIS J, V27, P224, DOI 10.1097/INF.0b013e31815b494c
   Lee SM, 2005, VIROLOGY, V342, P47, DOI 10.1016/j.virol.2005.07.034
   Lehmann E, 2010, HEPATOLOGY, V51, P398, DOI 10.1002/hep.23339
   LEHRER RI, 1975, J CLIN INVEST, V55, P338, DOI 10.1172/JCI107937
   Lekstrom-Himes JA, 2000, NEW ENGL J MED, V343, P1703, DOI 10.1056/NEJM200012073432307
   Leto TL, 2009, ANTIOXID REDOX SIGN, V11, P2607, DOI [10.1089/ars.2009.2637, 10.1089/ARS.2009.2637]
   Li M, 2010, CELL SIGNAL, V22, P1469, DOI 10.1016/j.cellsig.2010.05.015
   Lim MBH, 2011, J LEUKOCYTE BIOL, V90, P771, DOI 10.1189/jlb.1010549
   Lipinski S, 2009, J CELL SCI, V122, P3522, DOI 10.1242/jcs.050690
   Liu GY, 2005, J EXP MED, V202, P209, DOI 10.1084/jem.20050846
   Liu Q, 2009, AM J PATHOL, V174, P153, DOI 10.2353/ajpath.2009.080555
   Liu W, 2010, MICROBES INFECT, V12, P1226, DOI 10.1016/j.micinf.2010.09.004
   Lu CC, 2008, J LEUKOCYTE BIOL, V83, P1028, DOI 10.1189/jlb.0907647
   Luz NF, 2012, J IMMUNOL, V188, P4460, DOI 10.4049/jimmunol.1103072
   Ma CY, 2012, J BIOL CHEM, V287, P18359, DOI 10.1074/jbc.M112.367060
   Mantegazza AR, 2008, BLOOD, V112, P4712, DOI 10.1182/blood-2008-01-134791
   Mantena RKR, 2008, CELL MICROBIOL, V10, P1058, DOI 10.1111/j.1462-5822.2007.01105.x
   Marcil V, 2006, CARDIOVASC RES, V72, P473, DOI 10.1016/j.cardiores.2006.08.024
   Marriott HM, 2008, AM J RESP CRIT CARE, V177, P887, DOI 10.1164/rccm.200707-990OC
   Marriott HM, 2007, VACCINE, V25, P2485, DOI 10.1016/j.vaccine.2006.09.024
   Marro S, 2010, HAEMATOL-HEMATOL J, V95, P1261, DOI 10.3324/haematol.2009.020123
   Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237
   Mata M, 2011, BIOCHEM PHARMACOL, V82, P548, DOI 10.1016/j.bcp.2011.05.014
   Matsue H, 2003, J IMMUNOL, V171, P3010, DOI 10.4049/jimmunol.171.6.3010
   MCCABE RE, 1990, J IMMUNOL, V144, P2384
   McCaffrey RL, 2006, J LEUKOCYTE BIOL, V80, P1224, DOI 10.1189/jlb.0406287
   Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935
   Melo RCN, 2003, CELL BIOL INT, V27, P853, DOI 10.1016/S1065-6995(03)00173-2
   METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x
   Michalek RD, 2008, VIROLOGY, V379, P205, DOI 10.1016/j.virol.2008.07.004
   Miller EW, 2010, P NATL ACAD SCI USA, V107, P15681, DOI 10.1073/pnas.1005776107
   Miller J, 2010, NY TIMES BK REV, P6
   Millonig G, 2012, J BIOL CHEM, V287, P37472, DOI 10.1074/jbc.M112.358911
   Mimche PN, 2012, J ANTIMICROB CHEMOTH, V67, P1895, DOI 10.1093/jac/dks132
   Mittra B, 2013, J EXP MED, V210, P401, DOI 10.1084/jem.20121368
   Mladenka P, 2006, FREE RADICAL RES, V40, P263, DOI 10.1080/10715760500511484
   Moazed TC, 1997, J INFECT DIS, V175, P883, DOI 10.1086/513986
   Moghaddam AE, 2011, J IMMUNOL, V187, P1626, DOI 10.4049/jimmunol.1003906
   Monfregola J, 2012, J BIOL CHEM, V287, P44603, DOI 10.1074/jbc.M112.414029
   Monteiro MC, 2008, PARASITOL RES, V102, P801, DOI 10.1007/s00436-007-0827-x
   Moore SF, 2009, J IMMUNOL, V183, P3302, DOI 10.4049/jimmunol.0900394
   Morris D, 2013, BBA-GEN SUBJECTS, V1830, P3329, DOI 10.1016/j.bbagen.2012.10.012
   MOUY R, 1989, J PEDIATR-US, V114, P555, DOI 10.1016/S0022-3476(89)80693-6
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   MULLER PK, 1989, INFECT IMMUN, V57, P2591
   MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B
   Murray HW, 1999, J EXP MED, V189, P741, DOI 10.1084/jem.189.4.741
   MURRAY HW, 1982, J RETICULOENDOTH SOC, V31, P479
   Murray James L., 2012, Antiviral Chemistry & Chemotherapy, V22, P205, DOI 10.3851/IMP2080
   Mydel P, 2006, PLOS PATHOG, V2, P712, DOI 10.1371/journal.ppat.0020076
   Myers JT, 2003, J IMMUNOL, V171, P5447, DOI 10.4049/jimmunol.171.10.5447
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Nagajyothi F, 2012, PARASITOL RES, V110, P2491, DOI 10.1007/s00436-011-2790-9
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   NATHAN C, 1979, J EXP MED, V149, P1057
   Nathan C, 2010, CELL, V140, DOI 10.1016/j.cell.2010.03.008
   Newcomb WW, 2012, J VIROL, V86, P11931, DOI 10.1128/JVI.01349-12
   Nicolaou G, 2012, J ATHEROSCLER THROMB, V19, P137, DOI 10.5551/jat.10249
   Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119
   Nimmerjahn F, 2004, J GEN VIROL, V85, P2347, DOI 10.1099/vir.0.79958-0
   Alvarez MN, 2011, J BIOL CHEM, V286, P6627, DOI 10.1074/jbc.M110.167247
   Nygren H, 2004, WORLD J SURG, V28, P337, DOI 10.1007/s00268-003-7402-0
   O'Rourke EJ, 2003, P NATL ACAD SCI USA, V100, P2789, DOI 10.1073/pnas.0337641100
   Oberley-Deegan RE, 2010, FREE RADICAL BIO MED, V49, P1666, DOI 10.1016/j.freeradbiomed.2010.08.026
   Oberley-Deegan RE, 2009, AM J RESP CELL MOL, V41, P170, DOI 10.1165/rcmb.2008-0138OC
   Ohga S, 1997, J INFECTION, V34, P147, DOI 10.1016/S0163-4453(97)92509-3
   Okahashi N, 2011, FEMS MICROBIOL LETT, V323, P164, DOI 10.1111/j.1574-6968.2011.02375.x
   Olagnier D, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002254
   Onyiah JC, 2013, GASTROENTEROLOGY, V144, P789, DOI 10.1053/j.gastro.2012.12.025
   Paiva CN, 2012, J CLIN INVEST, V122, P2531, DOI 10.1172/JCI58525
   Palanisamy GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026254
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Papp D, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002673
   Park DW, 2009, EXP MOL MED, V41, P171, DOI 10.3858/emm.2009.41.3.020
   Parker H, 2012, J LEUKOCYTE BIOL, V91, P369, DOI 10.1189/jlb.0711387
   PARRY MF, 1977, J CLIN MICROBIOL, V5, P58
   Paul-Clark MJ, 2009, AM J RESP CRIT CARE, V179, P299, DOI 10.1164/rccm.200707-1019OC
   Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071
   Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Piacenza L, 2013, ANTIOXID REDOX SIGN, V19, P723, DOI 10.1089/ars.2012.4618
   Piacenza L, 2009, CURR OPIN MICROBIOL, V12, P415, DOI 10.1016/j.mib.2009.06.011
   Piao ZH, 2012, CELL IMMUNOL, V280, P1, DOI 10.1016/j.cellimm.2012.11.003
   Pinheiro RO, 2009, MICROBES INFECT, V11, P181, DOI 10.1016/j.micinf.2008.11.006
   Pohanka M, 2012, J MICROBIOL, V50, P401, DOI 10.1007/s12275-012-1621-8
   POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202
   Polvani S, 2012, PPAR RES, V2012, DOI 10.1155/2012/641087
   Portugal S, 2011, NAT MED, V17, P732, DOI 10.1038/nm.2368
   Potter SM, 2005, INFECT IMMUN, V73, P4941, DOI 10.1128/IAI.73.8.4941-4947.2005
   Pratico D, 2001, LIPIDS, V36, pS45, DOI 10.1007/s11745-001-0681-0
   Protzer U, 2007, GASTROENTEROLOGY, V133, P1156, DOI 10.1053/j.gastro.2007.07.021
   Puertollano MA, 2011, CURR TOP MED CHEM, V11, P1752
   Py BF, 2007, AUTOPHAGY, V3, P117, DOI 10.4161/auto.3618
   Qi MS, 2003, MICROB PATHOGENESIS, V35, P259, DOI 10.1016/j.micpath.2003.07.002
   Qin ZQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000742
   Qiu HY, 2009, INFECT IMMUN, V77, P1015, DOI 10.1128/IAI.01029-08
   Rabhi I, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001763
   RAGERZISMAN B, 1982, INFECT IMMUN, V36, P1229, DOI 10.1128/IAI.36.3.1229-1237.1982
   Rayamajhi M, 2010, J EXP MED, V207, P327, DOI 10.1084/jem.20091746
   Reddy NM, 2009, J IMMUNOL, V183, P4601, DOI 10.4049/jimmunol.0901754
   Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a
   Reeves EP, 2003, J MED MICROBIOL, V52, P643, DOI 10.1099/jmm.0.05181-0
   Riva DA, 2006, INTERVIROLOGY, V49, P294, DOI 10.1159/000094245
   Roca FJ, 2013, CELL, V153, P521, DOI 10.1016/j.cell.2013.03.022
   Rocha-Vieira E, 2003, IMMUNOLOGY, V108, P401, DOI 10.1046/j.1365-2567.2003.01582.x
   Rockwell CE, 2012, J IMMUNOL, V188, P1630, DOI 10.4049/jimmunol.1101712
   Rodrigues WF, 2010, MEM I OSWALDO CRUZ, V105, P137, DOI 10.1590/S0074-02762010000200005
   Rodriguez-Acosta A, 1998, J SUBMICR CYTOL PATH, V30, P299
   ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884
   Romano PS, 2009, AUTOPHAGY, V5, P6, DOI 10.4161/auto.5.1.7160
   Romao PRT, 1999, PARASITOLOGY, V118, P559, DOI 10.1017/S0031182099004278
   Rosen H, 2002, J BIOL CHEM, V277, P30463, DOI 10.1074/jbc.M202331200
   Rubartelli A, 2011, TRENDS IMMUNOL, V32, P559, DOI 10.1016/j.it.2011.08.005
   Ruotsalainen AK, 2013, CARDIOVASC RES, V98, P107, DOI 10.1093/cvr/cvt008
   Rutter K, 2011, ANTIVIR THER, V16, P1327, DOI 10.3851/IMP1942
   Rybicka JM, 2010, P NATL ACAD SCI USA, V107, P10496, DOI 10.1073/pnas.0914867107
   Sadikot RT, 2004, J IMMUNOL, V172, P1801, DOI 10.4049/jimmunol.172.3.1801
   Saeed O, 2012, ARTERIOSCL THROM VAS, V32, P299, DOI 10.1161/ATVBAHA.111.240101
   Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008
   Santello FH, 2007, J PINEAL RES, V42, P359, DOI 10.1111/j.1600-079X.2007.00427.x
   Santiago HC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001492
   Sapra R, 2006, MICROB PATHOGENESIS, V41, P157, DOI 10.1016/j.micpath.2006.07.002
   Schachtele SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036216
   Schaper M, 2003, INFECT IMMUN, V71, P4087, DOI 10.1128/IAI.71.7.4087-4092.2003
   Schmidt WN, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00129
   Schnaith A, 2007, J BIOL CHEM, V282, P2695, DOI 10.1074/jbc.M609784200
   Schulert GS, 2009, INFECT IMMUN, V77, P1324, DOI 10.1128/IAI.01318-08
   Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653
   Serghides L, 2001, J IMMUNOL, V166, P6742, DOI 10.4049/jimmunol.166.11.6742
   Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002
   Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje
   Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7
   Shin DM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001230
   Singh V, 2012, CELL HOST MICROBE, V12, P669, DOI 10.1016/j.chom.2012.09.012
   Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930
   Skulachev VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1438
   Slauch JM, 2011, MOL MICROBIOL, V80, P580, DOI 10.1111/j.1365-2958.2011.07612.x
   Soler-Palacin P, 2007, ALLERGOL IMMUNOPATH, V35, P83, DOI 10.1157/13106774
   Soucy-Faulkner A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000930
   Sousa-Franco J, 2006, MICROBES INFECT, V8, P390, DOI 10.1016/j.micinf.2005.07.007
   SPEERT DP, 1994, J INFECT DIS, V170, P1524, DOI 10.1093/infdis/170.6.1524
   Speir E, 1996, CIRC RES, V79, P1143, DOI 10.1161/01.RES.79.6.1143
   Spooner R, 2011, INT J MOL SCI, V12, P334, DOI 10.3390/ijms12010334
   STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943
   Starr T, 2012, CELL HOST MICROBE, V11, P33, DOI 10.1016/j.chom.2011.12.002
   Staudinger BJ, 2002, J CLIN INVEST, V110, P1151, DOI 10.1172/JCI200215268
   Stecher B, 2007, PLOS BIOL, V5, P2177, DOI 10.1371/journal.pbio.0050244
   Stefanska J, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/106507
   Stempin CC, 2004, EUR J IMMUNOL, V34, P200, DOI 10.1002/eji.200324313
   Stempin CC, 2008, ACTA TROP, V106, P119, DOI 10.1016/j.actatropica.2008.02.004
   Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719
   Tal MC, 2009, P NATL ACAD SCI USA, V106, P2770, DOI 10.1073/pnas.0807694106
   Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883
   Tavakoli S, 2012, ANTIOXID REDOX SIGN, V17, P1785, DOI 10.1089/ars.2012.4638
   Teles RMB, 2013, SCIENCE, V339, P1448, DOI 10.1126/science.1233665
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Thao TDH, 2008, BIOCHEM PHARMACOL, V75, P2135, DOI 10.1016/j.bcp.2008.03.008
   Tilton C, 2011, J VIROL, V85, P12585, DOI 10.1128/JVI.05572-11
   Tung WH, 2011, J CELL PHYSIOL, V226, P3316, DOI 10.1002/jcp.22677
   Ueno N, 2012, TRENDS PARASITOL, V28, P335, DOI 10.1016/j.pt.2012.05.002
   UMEZAWA K, 1995, INFECT IMMUN, V63, P4402, DOI 10.1128/IAI.63.11.4402-4408.1995
   Van Assche T, 2011, FREE RADICAL BIO MED, V51, P337, DOI 10.1016/j.freeradbiomed.2011.05.011
   van Diepen A, 2002, INFECT IMMUN, V70, P2614, DOI 10.1128/IAI.70.5.2614-2621.2002
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Vardhan H, 2010, BIOCHEM CELL BIOL, V88, P835, DOI [10.1139/O10-027, 10.1139/o10-027]
   Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655
   Venketaraman V, 2005, INFECT IMMUN, V73, P1886, DOI 10.1128/IAI.73.3.1886-1889.2005
   Venketaraman V, 2003, INFECT IMMUN, V71, P1864, DOI 10.1128/IAI.71.4.1864-1871.2003
   Vlahos R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001271
   Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216
   Wang GD, 2012, TOXICOLOGY, V292, P113, DOI 10.1016/j.tox.2011.12.001
   Wang JP, 2012, AM J PATHOL, V180, P221, DOI 10.1016/j.ajpath.2011.09.007
   Wang YB, 2009, J BIOL CHEM, V284, P1694, DOI 10.1074/jbc.M807890200
   WASHBURN RG, 1987, INFECT IMMUN, V55, P2088, DOI 10.1128/IAI.55.9.2088-2092.1987
   Weichhart T, 2009, TRENDS IMMUNOL, V30, P218, DOI 10.1016/j.it.2009.02.002
   WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969
   Wen JJ, 2010, J AM COLL CARDIOL, V55, P2499, DOI 10.1016/j.jacc.2010.02.030
   West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973
   Winter SE, 2010, NATURE, V467, P426, DOI 10.1038/nature09415
   Winterbourn CC, 2013, ANTIOXID REDOX SIGN, V18, P642, DOI 10.1089/ars.2012.4827
   Wu K. C., 2012, PLOS ONE, V7
   Wu WH, 2009, NAT IMMUNOL, V10, P1208, DOI 10.1038/ni.1788
   Wyde PR, 1996, ANTIVIR RES, V31, P173, DOI 10.1016/0166-3542(95)06967-4
   Xu M, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-104
   Yanagisawa S, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-50
   Yanaka A, 2009, CANCER PREV RES, V2, P353, DOI 10.1158/1940-6207.CAPR-08-0192
   Yang CS, 2009, J IMMUNOL, V182, P3696, DOI 10.4049/jimmunol.0802217
   Yang HC, 2011, MICROBES INFECT, V13, P109, DOI 10.1016/j.micinf.2010.10.008
   Yasir M, 2011, INFECT IMMUN, V79, P4019, DOI 10.1128/IAI.05308-11
   Ye FC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002054
   Yi L, 2012, AM J PATHOL, V180, P1049, DOI 10.1016/j.ajpath.2011.11.019
   Yoo SK, 2011, NATURE, V480, P109, DOI 10.1038/nature10632
   Yoon JH, 2011, BMB REP, V44, P165, DOI 10.5483/BMBRep.2011.44.3.165
   Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96
   Yvan-Charvet L, 2007, J CLIN INVEST, V117, P3900, DOI 10.1172/JCI33372
   Zaki MH, 2009, J IMMUNOL, V182, P3746, DOI 10.4049/jimmunol.0803363
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
   Zhao JF, 2012, MOL NUTR FOOD RES, V56, P691, DOI 10.1002/mnfr.201100735
   Zhu XW, 2012, CIRC RES, V111, P1398, DOI 10.1161/CIRCRESAHA.112.269043
   Zhu ZW, 2008, HEPATOLOGY, V48, P1430, DOI 10.1002/hep.22491
   Zhu ZW, 2010, HEPATOLOGY, V52, P1897, DOI 10.1002/hep.23921
NR 366
TC 164
Z9 167
U1 2
U2 36
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD FEB 20
PY 2014
VL 20
IS 6
BP 1000
EP 1037
DI 10.1089/ars.2013.5447
PG 38
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AA7PR
UT WOS:000331289900012
PM 23992156
OA Green Published
DA 2020-12-01
ER

PT J
AU Albuquerque, PC
   Fonseca, FL
   Dutra, FF
   Bozza, MT
   Frases, S
   Casadevall, A
   Rodrigues, ML
AF Albuquerque, Priscila C.
   Fonseca, Fernanda L.
   Dutra, Fabianno F.
   Bozza, Marcelo T.
   Frases, Susana
   Casadevall, Arturo
   Rodrigues, Marcio L.
TI Cryptococcus neoformans glucuronoxylomannan fractions of different
   molecular masses are functionally distinct
SO FUTURE MICROBIOLOGY
LA English
DT Article
DE Cryptococcus neoformans; glucuronoxylomannan; host response; molecular
   mass; polysaccharides
ID CAPSULAR POLYSACCHARIDE; MONOCLONAL-ANTIBODY; HOST RESPONSE; IN-VIVO;
   BINDING; VIRULENCE; CHITIN; PHAGOCYTOSIS; PATHOGEN; TOLL-LIKE-RECEPTOR-4
AB Aims: Glucuronoxylomannan (GXM) is the major polysaccharide component of Cryptococcus neoformans. We evaluated in this study whether GXM fractions of different molecular masses were functionally distinct. Materials & methods: GXM samples isolated from C. neoformans cultures were fractionated to generate polysaccharide preparations differing in molecular mass. These fractions were used in experiments focused on the association of GXM with cell wall components of C. neoformans, as well as on the interaction of the polysaccharide with host cells. Results & conclusion: GXM fractions of variable molecular masses bound to the surface of a C. neoformans acapsular mutant in a punctate pattern that is in contrast to the usual annular pattern of surface coating observed when GXM samples containing the full molecular mass range were used. The polysaccharide samples were also significantly different in their ability to stimulate cytokine production by host cells. Our findings indicate that GXM fractions are functionally distinct depending on their mass.
C1 [Albuquerque, Priscila C.; Fonseca, Fernanda L.; Rodrigues, Marcio L.] CTDS Fiocruz, Ctr Desenvolvimento Tecnol Saude, BR-21040361 Rio De Janeiro, RJ, Brazil.
   [Albuquerque, Priscila C.; Fonseca, Fernanda L.; Dutra, Fabianno F.; Bozza, Marcelo T.; Rodrigues, Marcio L.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Frases, Susana] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
   [Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY USA.
   [Casadevall, Arturo] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY USA.
RP Rodrigues, ML (corresponding author), CTDS Fiocruz, Ctr Desenvolvimento Tecnol Saude, Ave Brazil 4036,Predio Expansao,8 Andar,Sala 814, BR-21040361 Rio De Janeiro, RJ, Brazil.
EM marciolr@cdts.fiocruz.br
RI Rodrigues, Marcio/J-3727-2013; Dutra, Fabianno F/C-1387-2015; Fonseca,
   Fernanda/V-3446-2019; Frases, Susana/W-9502-2019; Albuquerque, Priscila
   C/L-4884-2015
OI Rodrigues, Marcio/0000-0002-6081-3439; Dutra, Fabianno
   F/0000-0003-3106-7585; Frases, Susana/0000-0001-5875-9886; Albuquerque,
   Priscila C/0000-0001-8185-024X; Bozza, Marcelo/0000-0003-3683-7550
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ); National
   Institute for Science and Technology on Innovation on Neglected Diseases
   (INCT/IDN, CNPq); NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI033142, AI033774,
   AI052733, HL059842]; Center for AIDS Research at Einstein; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052733, R01AI033774, R01AI033774, R01AI052733, R01AI033774,
   R37AI033142, R01AI052733, R01AI033774, R01AI033142, R37AI033142,
   R01AI052733, R01AI033774, R01AI033774, R01AI052733, R01AI033142,
   R01AI033774, R01AI033774, R01AI052733, R37AI033142, R01AI052733,
   R01AI052733, R01AI052733, R01AI052733, R01AI033142, R37AI033142,
   R01AI033774, R01AI033774, R01AI033774, R01AI033774, R37AI033142,
   R01AI033142, R01AI033774, R37AI033142, R37AI033142, R37AI033142,
   R01AI033774, R37AI033142, R01AI033142, R01AI052733, R01AI052733,
   R37AI033142, R01AI033142, R01AI033774, R37AI033142, R01AI033774,
   R01AI033774, R01AI033774, R01AI033142, R37AI033142, R01AI033774,
   R01AI033142, R01AI033774, R01AI052733, R01AI033142, R01AI033142,
   R37AI033142, R01AI033142, R01AI033774, R37AI033142, R01AI033774,
   R01AI052733, R01AI052733, R01AI033142, R01AI033142] Funding Source: NIH
   RePORTER
FX ML Rodrigues, MT Bozza, FF Dutra, S Frases, PC Albuquerque and FL
   Fonseca are supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES, Brazil), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil) and Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil). ML
   Rodrigues, PC Albuquerque and FL Fonseca were also supported by the
   National Institute for Science and Technology on Innovation on Neglected
   Diseases (INCT/IDN, CNPq). A Casadevall is supported by NIH Grants
   AI033142, AI033774, AI052733 and HL059842, and the Center for AIDS
   Research at Einstein. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The authors have no other relevant affiliations or financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript apart from those disclosed.
CR Albuquerque PC, 2012, FUNGAL GENET BIOL, V49, P943, DOI 10.1016/j.fgb.2012.09.002
   Barbosa FM, 2007, CLIN VACCINE IMMUNOL, V14, P94, DOI 10.1128/CVI.00296-06
   Broad Institute of Health and Massachusetts Institute of Technology, CRYPT NEOF GRUB H99
   Casadevall A, 1998, ANTIMICROB AGENTS CH, V42, P1437, DOI 10.1128/AAC.42.6.1437
   CASADEVALL A, 1992, J IMMUNOL METHODS, V154, P27, DOI 10.1016/0022-1759(92)90209-C
   Chang ZL, 2006, INFECT IMMUN, V74, P144, DOI 10.1128/IAI.74.1.144-151.2006
   Chun CD, 2011, CELL HOST MICROBE, V9, P243, DOI 10.1016/j.chom.2011.02.003
   Cleare W, 1998, CLIN DIAGN LAB IMMUN, V5, P125, DOI 10.1128/CDLI.5.2.125-129.1998
   Da Silva CA, 2008, J IMMUNOL, V181, P4279, DOI 10.4049/jimmunol.181.6.4279
   Da Silva CA, 2009, J IMMUNOL, V182, P3573, DOI 10.4049/jimmunol.0802113
   Doering TL, 2009, ANNU REV MICROBIOL, V63, P223, DOI 10.1146/annurev.micro.62.081307.162753
   DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0
   Fonseca FL, 2010, INFECT IMMUN, V78, P3861, DOI 10.1128/IAI.00111-10
   Fonseca FL, 2009, EUKARYOT CELL, V8, P1543, DOI 10.1128/EC.00142-09
   Frases S, 2008, EUKARYOT CELL, V7, P319, DOI 10.1128/EC.00378-07
   Frases S, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00207
   Frases S, 2009, P NATL ACAD SCI USA, V106, P1228, DOI 10.1073/pnas.0808995106
   Guo H, 2008, CURR TOP MED CHEM, V8, P141
   Kumar P, 2011, CURR OPIN STRUC BIOL, V21, P597, DOI 10.1016/j.sbi.2011.08.006
   Larsen RA, 2005, ANTIMICROB AGENTS CH, V49, P952, DOI 10.1128/AAC.49.3.952-958.2005
   Lee CG, 2008, CURR OPIN IMMUNOL, V20, P684, DOI 10.1016/j.coi.2008.10.002
   Lester SJ, 2011, VET CLIN PATH, V40, P4, DOI 10.1111/j.1939-165X.2010.00281.x
   Levitz SA, 2004, MICROBES INFECT, V6, P1351, DOI 10.1016/j.micinf.2004.08.014
   Luberto C, 2003, J CLIN INVEST, V112, P1080, DOI [10.1172/JCI200318309, 10.1172/JCI18309]
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   Nakamura K, 2006, FEMS IMMUNOL MED MIC, V47, P148, DOI 10.1111/j.1574-695X.2006.00078.x
   Nimrichter L, 2007, EUKARYOT CELL, V6, P1400, DOI 10.1128/EC.00122-07
   Nosanchuk JD, 1997, INFECT IMMUN, V65, P1836, DOI 10.1128/IAI.65.5.1836-1841.1997
   Nussbaum G, 1997, J EXP MED, V185, P685, DOI 10.1084/jem.185.4.685
   Park BJ, 2009, AIDS, V23, P525, DOI 10.1097/QAD.0b013e328322ffac
   Ramos CL, 2012, EUKARYOT CELL, V11, P1086, DOI 10.1128/EC.00001-12
   Reese AJ, 2003, MOL MICROBIOL, V50, P1401, DOI 10.1046/j.1365-2958.2003.03780.x
   Reese AJ, 2007, MOL MICROBIOL, V63, P1385, DOI 10.1111/j.1365-2958.2006.05551.x
   Rivera J, 1998, INFECT IMMUN, V66, P5027, DOI 10.1128/IAI.66.10.5027-5030.1998
   Rodrigues ML, 2008, EUKARYOT CELL, V7, P602, DOI 10.1128/EC.00307-07
   Rodrigues ML, 2007, EUKARYOT CELL, V6, P48, DOI 10.1128/EC.00318-06
   Rodrigues ML, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00171
   Rodrigues ML, 2009, MED MYCOL, V47, P783, DOI 10.3109/13693780902788621
   Rodrigues ML, 1999, MICROBES INFECT, V1, P293, DOI 10.1016/S1286-4579(99)80025-2
   Rodrigues ML, 1997, INFECT IMMUN, V65, P4937, DOI 10.1128/IAI.65.12.4937-4942.1997
   Stano P, 2009, J IMMUNOL, V182, P84, DOI 10.4049/jimmunol.182.1.84
   Taylor Clare M., 2005, V12, P55, DOI 10.1159/000081689
   Yauch LE, 2005, INFECT IMMUN, V73, P8429, DOI 10.1128/IAI.73.12.8429-8432.2005
   Yauch LE, 2004, INFECT IMMUN, V72, P5373, DOI 10.1128/IAI.72.9.5373-5382.2004
   Zaragoza O, 2009, ADV APPL MICROBIOL, V68, P133, DOI 10.1016/S0065-2164(09)01204-0
NR 45
TC 13
Z9 14
U1 0
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0913
EI 1746-0921
J9 FUTURE MICROBIOL
JI Future Microbiol.
PD FEB
PY 2014
VL 9
IS 2
BP 147
EP 161
DI 10.2217/fmb.13.163
PG 15
WC Microbiology
SC Microbiology
GA AB6CJ
UT WOS:000331874900009
PM 24571070
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Rodrigues, GC
   Feijo, DF
   Bozza, MT
   Pan, PW
   Vullo, D
   Parkkila, S
   Supuran, CT
   Capasso, C
   Aguiar, AP
   Vermelho, AB
AF Rodrigues, Giseli Capaci
   Feijo, Daniel Ferreira
   Bozza, Marcelo Torres
   Pan, Peiwen
   Vullo, Daniela
   Parkkila, Seppo
   Supuran, Claudiu T.
   Capasso, Clemente
   Aguiar, Alcino Palermo
   Vermelho, Alane Beatriz
TI Design, Synthesis, and Evaluation of Hydroxamic Acid Derivatives as
   Promising Agents for the Management of Chagas Disease
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TRYPANOSOMA-CRUZI; CARBONIC-ANHYDRASE; AMERICAN TRYPANOSOMIASIS;
   CYSTEINE PROTEINASE; ORAL-TRANSMISSION; INHIBITION; EXPRESSION; PHASE;
   ASSAY
AB Today, there are approximately 8 million cases of Chagas disease in the southern cone of South America alone, and about 100 million people are living with the risk of becoming infected. The present pharmacotherapy is sometimes ineffective and has serious side effects. Here, we report a series of 4,5 ''. -dihydroisoxazoles incorporating hydroxamate moieties, which act as effective inhibitors of the carbonic anhydrase (CA) from Trypanosoma cruzi (TcCA). One compound (5g)was evaluated in detail and shows promising features as an antitrypanosomal agent. Excellent values for the inhibition of growth for all three developmental forms of the parasite were observed at low concentrations of 5g (IC50 values from 7.0 to <1 mu M). The compound has a selectivity index (SI) of 6.7 and no cytotoxicity to macrophage cells. Preliminary in vivo data showed that 5g reduces bloodstream parasites and that all treated mice survived; it was also more effective than the standard drug benznidazole.
C1 [Rodrigues, Giseli Capaci; Aguiar, Alcino Palermo] IME, Dept Quim, Lab Sintese Organ, Rio De Janeiro, Brazil.
   [Rodrigues, Giseli Capaci; Vermelho, Alane Beatriz] Univ Fed Rio de Janeiro, IMPG, Dept Microbiol, Lab Proteases Microrganismos, Rio De Janeiro, Brazil.
   [Rodrigues, Giseli Capaci] Univ Grande Rio, Escola Ciencia & Tecnol, Rio De Janeiro, Brazil.
   [Rodrigues, Giseli Capaci] Univ Grande Rio, Programa Posgrad Ensino Ciencias, Rio De Janeiro, Brazil.
   [Feijo, Daniel Ferreira; Bozza, Marcelo Torres] Univ Fed Rio de Janeiro, IMPPG, Inst Microbiol Paulo Goes, Lab Inflamacao & Imunidade,Dept Imunol, Rio De Janeiro, Brazil.
   [Pan, Peiwen; Parkkila, Seppo] Univ Tampere, Inst Biomed Technol, Fimlab Ltd, Sch Med & BioMediTech, Tampere 33520, Finland.
   [Pan, Peiwen] Tampere Univ Hosp, Tampere 33520, Finland.
   [Vullo, Daniela; Supuran, Claudiu T.] Univ Firenze, Lab Chim Bioinorgan, I-50019 Florence, Italy.
   [Supuran, Claudiu T.] Univ Florence, Dipartimento NEIROFARBA, Sez Sci Farmaceut, I-50019 Florence, Italy.
   [Capasso, Clemente] CNR, Ist Biochim Proteine, I-80131 Naples, Italy.
   [Vermelho, Alane Beatriz] Univ Fed Rio de Janeiro, Unidade Bioenergia Biocatalise & Bioprod, Rio De Janeiro, Brazil.
RP Vermelho, AB (corresponding author), Univ Fed Rio de Janeiro, IMPG, Dept Microbiol, Lab Proteases Microrganismos, Rio De Janeiro, Brazil.
EM abvermelho@micro.ufrj.br
RI , Alcino/AAG-1283-2020; Capasso, Clemente/P-3522-2016; Ferreira Feijo,
   Daniel/Y-6067-2018; VERMELHO/J-8803-2013; de Aguiar, Alcino
   P/H-4405-2017
OI , Alcino/0000-0002-0559-1546; Capasso, Clemente/0000-0003-3314-2411;
   VERMELHO/0000-0001-5926-4172; de Aguiar, Alcino P/0000-0002-0559-1546;
   Parkkila, Seppo/0000-0001-7323-8536; VULLO, Daniela/0000-0002-1352-1900;
   Bozza, Marcelo/0000-0003-3683-7550
FU Coordenacao de Aperfeicoamento Pessoal de Nivel Superior (CAPES)CAPES;
   Instituto Militar de Engenharia (IME); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (MCT/CNPq)National Council for
   Scientific and Technological Development (CNPq); Conselho de Ensino para
   Graduados e Pesquisas (CEPG/UFRJ); Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); EUEuropean Union (EU)
FX This study was supported by grants from Coordenacao de Aperfeicoamento
   Pessoal de Nivel Superior (CAPES), Instituto Militar de Engenharia
   (IME), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (MCT/CNPq), Conselho de Ensino para Graduados e Pesquisas (CEPG/UFRJ),
   and Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio
   de Janeiro (FAPERJ) as well as by two EU grants (Metoxia and Dynano). We
   are grateful to Ieda Coleto Miguel de Castro and Silva Rocha de Souza
   for technical support and Marcelo Rosado Fantappie and Amanda Roberta
   Revoredo Vicentino for western blot assay support.
CR Abdel-Hamid MK, 2007, BIOORGAN MED CHEM, V15, P6975, DOI 10.1016/j.bmc.2007.07.044
   Alterio V, 2012, CHEM REV, V112, P4421, DOI 10.1021/cr200176r
   Andres JI, 2006, BIOORGAN MED CHEM, V14, P4361, DOI 10.1016/j.bmc.2006.02.043
   Barbosa G. A. D., 2011, REV MIL CIEN TEC, V2, P57
   Basappa, 2004, BIOORG MED CHEM LETT, V14, P3679, DOI 10.1016/j.bmcl.2004.05.012
   Basappa, 2003, BIOORGAN MED CHEM, V11, P4539, DOI 10.1016/j.bmc.2003.08.007
   BONALDO MC, 1991, EXP PARASITOL, V73, P44, DOI 10.1016/0014-4894(91)90006-I
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   Capaci-Rodrigues G., 2010, CURR ENZ INHIB, V6, P183
   Carabarin-Lima A, 2013, ACTA TROP, V127, P126, DOI 10.1016/j.actatropica.2013.04.007
   Codd R, 2008, COORDIN CHEM REV, V252, P1387, DOI 10.1016/j.ccr.2007.08.001
   Coura JR, 2010, NATURE, V465, pS6, DOI 10.1038/nature09221
   Cuevas IC, 2003, INFECT IMMUN, V71, P5739, DOI 10.1128/IAI.71.10.5739-5749.2003
   d'Avila-Levy CM, 2003, ARCH BIOCHEM BIOPHYS, V420, P1, DOI 10.1016/j.abb.2003.09.033
   Ramirez JD, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002041
   de Melo ACN, 2004, HEPATOL RES, V28, P49, DOI 10.1016/j.hepres.2003.09.002
   De Simone G, 2012, J INORG BIOCHEM, V111, P117, DOI 10.1016/j.jinorgbio.2011.11.017
   DEVLIN JP, 1975, J CHEM SOC PERK T 1, P846, DOI 10.1039/p19750000846
   Di Fiore A, 2012, CHEM COMMUN, V48, P8838, DOI 10.1039/c2cc34275h
   Farkas E, 2000, POLYHEDRON, V19, P1727, DOI 10.1016/S0277-5387(00)00453-8
   Fauro R, 2013, PARASITOLOGY, V140, P917, DOI 10.1017/S0031182013000103
   KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561
   Little S. E., 2013, VET PARASITOL, pS0304
   Lowndes CM, 1996, PARASITOLOGY, V112, P393, DOI 10.1017/S0031182000066622
   Ortiz AM, 2013, AN SIST SANIT NAVAR, V36, P115, DOI 10.4321/s1137-66272013000100011
   MEIRELLES MNL, 1984, J SUBMICR CYTOL PATH, V16, P533
   Munoz-Calderon A, 2013, INFECT GENET EVOL, V17, P113, DOI 10.1016/j.meegid.2013.03.036
   Muri EMF, 2002, CURR MED CHEM, V9, P1631, DOI 10.2174/0929867023369402
   Niemirowicz G, 2008, MOL MICROBIOL, V70, P853, DOI 10.1111/j.1365-2958.2008.06444.x
   Niemirowicz G, 2007, BIOCHEM J, V401, P399, DOI 10.1042/BJ20060973
   de Melo ACN, 2010, EXP PARASITOL, V125, P256, DOI 10.1016/j.exppara.2010.01.023
   Pan PW, 2013, J MED CHEM, V56, P1761, DOI 10.1021/jm4000616
   Petroianu GA, 2012, PHARMAZIE, V67, P874, DOI 10.1691/ph.2012.2519
   Pirrung MC, 2002, J MED CHEM, V45, P4359, DOI 10.1021/jm020183v
   Vicentino ARR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039104
   Rodrigues CM, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000846
   Rodrigues RD, 2001, SYNTHETIC COMMUN, V31, P3075, DOI 10.1081/SCC-100105879
   Rolon M, 2006, PARASITOL RES, V99, P103, DOI 10.1007/s00436-006-0126-y
   Gutierrez FRS, 2008, J INFECT DIS, V197, P1468, DOI 10.1086/587487
   Salomon CJ, 2012, J PHARM SCI-US, V101, P888, DOI 10.1002/jps.23010
   Schneider Monika, 2013, Methods Mol Biol, V1031, P37, DOI 10.1007/978-1-62703-481-4_4
   SOUTOPADRON T, 1990, J CELL SCI, V96, P485
   Tapadar S, 2009, BIOORG MED CHEM LETT, V19, P3023, DOI 10.1016/j.bmcl.2009.04.058
   Verma Rajeshwar P, 2012, Exp Suppl, V103, P137, DOI 10.1007/978-3-0348-0364-9_5
   Sanchez LV, 2013, PARASITOLOGY, V140, P147, DOI 10.1017/S0031182012001394
   Weidner-Wells MA, 2004, BIOORG MED CHEM LETT, V14, P3069, DOI 10.1016/j.bmcl.2004.04.037
   Werner M, 2013, BIOTECHNOL PROGR, V29, P986, DOI 10.1002/btpr.1734
   WOODWARD RB, 1965, J AM CHEM SOC, V87, P395, DOI 10.1021/ja01080a054
   World Health Organization, CHAG DIS AM TRYP FAC
NR 49
TC 51
Z9 53
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 23
PY 2014
VL 57
IS 2
BP 298
EP 308
DI 10.1021/jm400902y
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 297JU
UT WOS:000330252500004
PM 24299463
DA 2020-12-01
ER

PT J
AU Hottz, ED
   Lopes, JF
   Freitas, C
   Valls-de-Souza, R
   Oliveira, MF
   Bozza, MT
   Da Poian, AT
   Weyrich, AS
   Zimmerman, GA
   Bozza, FA
   Bozza, PT
AF Hottz, Eugenio D.
   Lopes, Juliana F.
   Freitas, Carla
   Valls-de-Souza, Rogerio
   Oliveira, Marcus F.
   Bozza, Marcelo T.
   Da Poian, Andrea T.
   Weyrich, Andrew S.
   Zimmerman, Guy A.
   Bozza, Fernando A.
   Bozza, Patricia T.
TI Platelets mediate increased endothelium permeability in dengue through
   NLRP3-inflammasome activation
SO BLOOD
LA English
DT Article
ID HEMORRHAGIC-FEVER; CELL-DEATH; VIRUS-INFECTIONS; SHOCK-SYNDROME;
   MICROPARTICLES; INFLAMMASOME; LIPOPOLYSACCHARIDE; SEVERITY; PROTEIN;
   IMMUNOPATHOGENESIS
AB Dengue is the most frequent hemorrhagic viral disease and re-emergent infection in the world. Although thrombocytopenia is characteristically observed in mild and severe forms of dengue, the role of platelet activation in dengue pathogenesis has not been fully elucidated. We hypothesize that platelets have major roles in inflammatory amplification and increased vascular permeability during severe forms of dengue. Here we investigate interleukin (IL)-1 beta synthesis, processing, and secretion in platelets during dengue virus (DV) infection and potential contribution of these events to endothelial permeability during infection. We observed increased expression of IL-1 beta in platelets and platelet-derived microparticles from patients with dengue or after platelet exposure to DV in vitro. We demonstrated that DV infection leads to assembly of nucleotide-binding domain leucine rich repeat containing protein (NLRP3) inflammasomes, activation of caspase-1, and caspase-1-dependent IL-1 beta secretion. Our findings also indicate that platelet-derived IL-1 beta is chiefly released in microparticles through mechanisms dependent on mitochondrial reactive oxygen species-triggered NLRP3 inflammasomes. Inflammasome activation and platelet shedding of IL-1 beta-rich microparticles correlated with signs of increased vascular permeability. Moreover, microparticles from DV-stimulated platelets induced enhanced permeability in vitro in an IL-1-dependent manner. Our findings provide new evidence that platelets contribute to increased vascular permeability in DV infection by inflammasome-dependent release of IL-1 beta.
C1 [Hottz, Eugenio D.; Lopes, Juliana F.; Freitas, Carla; Zimmerman, Guy A.; Bozza, Patricia T.] Inst Oswaldo Cruz, Lab Immunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Hottz, Eugenio D.; Valls-de-Souza, Rogerio; Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Oliveira, Marcus F.; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
   [Weyrich, Andrew S.; Zimmerman, Guy A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA.
   [Weyrich, Andrew S.] Univ Utah, Program Mol Med, Salt Lake City, UT USA.
RP Bozza, FA (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Ave Brasil 4365, Rio De Janeiro, Brazil.
EM bozza.fernando@gmail.com; pbozza@ioc.fiocruz.br
RI Oliveira, Marcus/G-3158-2011; Bozza, Fernando A/A-2618-2013; Da Poian,
   Andrea T./V-1699-2019; Hottz, Eugenio D/I-9850-2014
OI Oliveira, Marcus/0000-0002-9890-8425; Bozza, Fernando
   A/0000-0003-4878-0256; Da Poian, Andrea/0000-0002-3969-704X; Weyrich,
   Andrew/0000-0001-9622-4647; Bozza, Marcelo/0000-0003-3683-7550; Bozza,
   Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Programa Estrategico de Apoio a Pesquisa em Saude/Fiocruz; Instituto
   Nacional de Ciencia e Tecnologia de Biologia Estrutural e Bioimagem;
   Programa de Apoio a Nucleos de Excelencia Dengue; National Institute of
   Science and Technology in Dengue; National Institutes of Health,
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HL066277, HL091754,
   HL044525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091754,
   R01HL066277, R01HL091754, R01HL091754, R01HL066277, R01HL066277,
   R01HL066277, R37HL044525, R01HL044525, R01HL066277, R01HL066277,
   R37HL044525, R01HL044525, R01HL044525, R01HL044525, R37HL044525,
   R37HL044525, R01HL066277, R01HL044525, R37HL044525, R01HL066277,
   R01HL044525, R01HL044525, R01HL044525, R01HL044525, R37HL044525,
   R01HL044525, R37HL044525, R01HL044525, R37HL044525, R01HL066277,
   R37HL044525, R01HL066277, R01HL066277, R01HL044525, R01HL044525,
   R37HL044525, R01HL091754, R01HL044525, R01HL066277] Funding Source: NIH
   RePORTER
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Fundacao de Amparo a Pesquisa
   do Estado do Rio de Janeiro, Programa Estrategico de Apoio a Pesquisa em
   Saude/Fiocruz, Instituto Nacional de Ciencia e Tecnologia de Biologia
   Estrutural e Bioimagem, Programa de Apoio a Nucleos de Excelencia
   Dengue, and National Institute of Science and Technology in Dengue, and
   the National Institutes of Health, National Heart, Lung, and Blood
   Institute grants (HL066277, HL091754, and HL044525 to A. S. W. and
   G.A.Z).
CR Aggrey AA, 2013, J IMMUNOL, V190, P4685, DOI 10.4049/jimmunol.1202672
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brown GT, 2011, J IMMUNOL, V186, P5489, DOI 10.4049/jimmunol.1001623
   Burdette D, 2012, J GEN VIROL, V93, P235, DOI 10.1099/vir.0.034033-0
   Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   DACHARYPRIGENT J, 1993, BLOOD, V81, P2554
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Denis MM, 2005, CELL, V122, P379, DOI 10.1016/j.cell.2005.06.015
   Falconar AKI, 2006, CLIN VACCINE IMMUNOL, V13, P1044, DOI 10.1128/CVI.00105-06
   HAMBURGER SA, 1990, BLOOD, V75, P550
   Hottz E., 2011, DRUG DISCOV TODAY DI, V8, pe33, DOI DOI 10.1016/J.DDMEC.2011.09.001
   Hottz ED, 2013, J THROMB HAEMOST, V11, P951, DOI 10.1111/jth.12178
   Houghton-Trivino N, 2010, BIOMEDICA, V30, P587
   Jaiyen Y, 2009, MICROBIOL IMMUNOL, V53, P442, DOI 10.1111/j.1348-0421.2009.00148.x
   KAPLANSKI G, 1993, BLOOD, V81, P2492
   Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   Lamkanfi M, 2011, J IMMUNOL, V187, P597, DOI 10.4049/jimmunol.1100229
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mause SF, 2005, ARTERIOSCL THROM VAS, V25, P1512, DOI 10.1161/01.ATV.0000170133.43608.37
   MITRAKUL C, 1977, AM J TROP MED HYG, V26, P975, DOI 10.4269/ajtmh.1977.26.975
   Nasirudeen AMA, 2009, J MED VIROL, V81, P1069, DOI 10.1002/jmv.21486
   Noisakran S, 2009, ANN NY ACAD SCI, V1171, pE24, DOI 10.1111/j.1749-6632.2009.05050.x
   Noisakran S, 2009, SE ASIAN J TROP MED, V40, P253
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Schexneider Katherine I, 2005, Curr Hematol Rep, V4, P145
   Schmidt AC, 2010, NEW ENGL J MED, V363, P484, DOI 10.1056/NEJMcibr1005904
   Schwertz H, 2006, J EXP MED, V203, P2433, DOI 10.1084/jem.20061302
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shashkin PN, 2008, J IMMUNOL, V181, P3495, DOI 10.4049/jimmunol.181.5.3495
   Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231
   Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3
   Shcherbina A, 1999, BLOOD, V93, P2128
   Shu PY, 2003, CLIN DIAGN LAB IMMUN, V10, P622, DOI 10.1128/CDLI.10.4.622-630.2003
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138
   Vaughn DW, 1997, J INFECT DIS, V176, P322, DOI 10.1086/514048
   Vieira-de-Abreu A, 2012, SEMIN IMMUNOPATHOL, V34, P5, DOI 10.1007/s00281-011-0286-4
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Wang JG, 2011, BLOOD, V118, P2366, DOI 10.1182/blood-2011-01-330878
   WANG SG, 1995, VIROLOGY, V213, P254, DOI 10.1006/viro.1995.1567
   Weyrich AS, 2003, J THROMB HAEMOST, V1, P1897, DOI 10.1046/j.1538-7836.2003.00304.x
   World Health Organization, 2009, DENG GUID DIAGN TREA
   Wu MF, 2013, BLOOD, V121, P95, DOI 10.1182/blood-2012-05-430090
   Yu CY, 2010, J VIROL, V84, P2421, DOI 10.1128/JVI.02174-09
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 50
TC 142
Z9 145
U1 1
U2 18
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 14
PY 2013
VL 122
IS 20
BP 3405
EP 3414
DI 10.1182/blood-2013-05-504449
PG 10
WC Hematology
SC Hematology
GA 261LM
UT WOS:000327666500010
PM 24009231
OA Green Published
DA 2020-12-01
ER

PT J
AU Fonseca, FL
   Guimaraes, AJ
   Kmetzsch, L
   Dutra, FF
   Silva, FD
   Taborda, CP
   Araujo, GD
   Frases, S
   Staats, CC
   Bozza, MT
   Schrank, A
   Vainstein, MH
   Nimrichter, L
   Casadevall, A
   Rodrigues, ML
AF Fonseca, Fernanda L.
   Guimaraes, Allan J.
   Kmetzsch, Livia
   Dutra, Fabianno F.
   Silva, Fernanda D.
   Taborda, Carlos P.
   Araujo, Glauber de S.
   Frases, Susana
   Staats, Charley C.
   Bozza, Marcelo T.
   Schrank, Augusto
   Vainstein, Marilene H.
   Nimrichter, Leonardo
   Casadevall, Arturo
   Rodrigues, Marcio L.
TI Binding of the wheat germ lectin to Cryptococcus neoformans
   chitooligomers affects multiple mechanisms required for fungal
   pathogenesis
SO FUNGAL GENETICS AND BIOLOGY
LA English
DT Article
DE Cryptococcus neoformans; Virulence; Lectin binding; Capsule; Chitin
   oligosaccharides
ID CAPSULE-ASSOCIATED GENE; MONOCLONAL-ANTIBODY; PSEUDALLESCHERIA-BOYDII;
   POLYSACCHARIDE CAPSULE; ENCODING GENE; HOST RESPONSE; IN-VIVO;
   VIRULENCE; GLUCURONOXYLOMANNAN; EXPRESSION
AB The principal capsular component of Cryptococcus neoformans, glucuronoxylomannan (GXM), interacts with surface glycans, including chitin-like oligomers. Although the role of GXM in cryptococcal infection has been well explored, there is no information on how chitooligomers affect fungal pathogenesis. In this study, surface chitooligomers of C neoformans were blocked through the use of the wheat germ lectin (WGA) and the effects on animal pathogenesis, interaction with host cells, fungal growth and capsule formation were analyzed. Treatment of C neoformans cells with WGA followed by infection of mice delayed mortality relative to animals infected with untreated fungal cells. This observation was associated with reduced brain colonization by lectin-treated cryptococci. Blocking chitooligomers also rendered yeast cells less efficient in their ability to associate with phagocytes. WGA did not affect fungal viability, but inhibited GXM release to the extracellular space and capsule formation. In WGA-treated yeast cells, genes that are involved in capsule formation and GXM traffic had their transcription levels decreased in comparison with untreated cells. Our results suggest that cellular pathways required for capsule formation and pathogenic mechanisms are affected by blocking chitin-derived structures at the cell surface of C neoformans. Targeting chitooligomers with specific ligands may reveal new therapeutic alternatives to control cryptococcosis. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Fonseca, Fernanda L.; Dutra, Fabianno F.; Bozza, Marcelo T.; Nimrichter, Leonardo; Rodrigues, Marcio L.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro, Brazil.
   [Guimaraes, Allan J.] Univ Fed Fluminense, Inst Biomed, Dept Microbiol Imunol & Parasitol, BR-24220000 Niteroi, RJ, Brazil.
   [Kmetzsch, Livia; Staats, Charley C.; Schrank, Augusto; Vainstein, Marilene H.] Univ Fed Rio Grande do Sul, Ctr Biotecnol, BR-90046900 Porto Alegre, RS, Brazil.
   [Kmetzsch, Livia; Staats, Charley C.; Schrank, Augusto; Vainstein, Marilene H.] Univ Fed Rio Grande do Sul, Dept Biol Mol & Biotecnol, BR-90046900 Porto Alegre, RS, Brazil.
   [Silva, Fernanda D.; Taborda, Carlos P.] Univ Sao Paulo, Inst Ciencias Biomed, BR-05508 Sao Paulo, Brazil.
   [Araujo, Glauber de S.; Frases, Susana] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Ultraestrutura Celular Hertha Meyer, BR-21941 Rio De Janeiro, Brazil.
   [Araujo, Glauber de S.; Frases, Susana] Inst Nacl Metrol Normalizacao & Qualidade Ind INM, Biol Lab, Rio De Janeiro, Brazil.
   [Casadevall, Arturo] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
   [Casadevall, Arturo] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA.
   [Rodrigues, Marcio L.] Fundacao Oswaldo Cruz Fiocruz, Ctr Desenvolvimento Tecnol Saude, Rio De Janeiro, Brazil.
RP Rodrigues, ML (corresponding author), Fiocruz MS, Ctr Desenvolvimento Tecnol Saude, Av Brasil 4-365, BR-21040360 Rio De Janeiro, Brazil.
EM marciolr@cdts.fiocruz.br
RI Guimaraes, Allan J/E-2160-2014; Taborda, Carlos P/K-1660-2016; Silva,
   Fernanda D./F-2723-2012; Dutra, Fabianno F/C-1387-2015; Schrank,
   Augusto/G-4688-2012; Frases, Susana/W-9502-2019; Staats, Charley
   C/J-4283-2014; Kmetzsch, Livia/H-4033-2015; Guimaraes,
   Allan/AAQ-2343-2020; Nimrichter, Leonardo/L-3545-2014; Vainstein,
   Marilene H/J-5452-2014; Taborda, Carlos Pelleschi/AAH-7031-2020;
   Rodrigues, Marcio/J-3727-2013; Fonseca, Fernanda/V-3446-2019
OI Guimaraes, Allan J/0000-0002-2856-9667; Taborda, Carlos
   P/0000-0001-9928-9809; Silva, Fernanda D./0000-0002-3508-6241; Dutra,
   Fabianno F/0000-0003-3106-7585; Schrank, Augusto/0000-0002-5248-4620;
   Frases, Susana/0000-0001-5875-9886; Staats, Charley
   C/0000-0002-2433-6903; Kmetzsch, Livia/0000-0003-3766-5869; Guimaraes,
   Allan/0000-0002-2856-9667; Nimrichter, Leonardo/0000-0001-9281-6856;
   Vainstein, Marilene H/0000-0002-3914-2300; Rodrigues,
   Marcio/0000-0002-6081-3439; Araujo, Glauber Ribeiro de
   Sousa/0000-0002-5478-9006; Bozza, Marcelo/0000-0003-3683-7550
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP, Brazil)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [AI033142, AI033774, AI052733, HL059842]; Center for
   AIDS Research at Einstein; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37AI033142, R01AI052733,
   R01AI033774, R01AI033142, R01AI033774, R01AI033142, R37AI033142,
   R37AI033142, R37AI033142, R37AI033142, R01AI033142, R01AI033142,
   R37AI033142, R01AI033774, R01AI033774, R01AI033142, R01AI052733,
   R01AI052733, R01AI052733, R01AI033774, R01AI052733, R01AI033142,
   R01AI033774, R01AI033774, R01AI033774, R01AI033142, R01AI052733,
   R37AI033142, R01AI033774, R01AI033774, R01AI033774, R01AI052733,
   R01AI052733, R01AI033774, R01AI033142, R01AI052733, R01AI033142,
   R01AI033142, R01AI033774, R01AI033774, R01AI033774, R37AI033142,
   R01AI052733, R01AI052733, R37AI033142, R01AI052733, R37AI033142,
   R37AI033142, R01AI033774, R01AI033774, R01AI052733, R37AI033142,
   R01AI033774, R01AI033774, R37AI033142, R01AI033142, R01AI033774,
   R01AI033142, R01AI033774, R01AI052733, R01AI033774, R01AI052733,
   R37AI033142, R01AI033142] Funding Source: NIH RePORTER
FX We thank Radames Cordero, Julian Munoz, Antonio Nakouzi and Lorena
   Derengowski for suggestions and help with animal experimentation.
   M.L.R., A.S., C.C.S., M.H.V., F.L.F., C.P.T., A.J.G., M.T.B., C.P.T.,
   and L.N. are supported by grants from Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES, Brazil), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil) and Fundacao
   de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil). A.C.
   is supported by NIH Grants AI033142, AI033774, AI052733, and HL059842
   and the Center for AIDS Research at Einstein. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The authors declare no reported conflicts
   of interest.
CR Albuquerque PC, 2012, FUTURE MICROBIOL, V7, P319, DOI [10.2217/FMB.11.162, 10.2217/fmb.11.162]
   Alspaugh JA, 1997, GENE DEV, V11, P3206, DOI 10.1101/gad.11.23.3206
   Barbosa FM, 2006, MICROBES INFECT, V8, P493, DOI 10.1016/j.micinf.2005.07.027
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Casadevall A, 1998, ANTIMICROB AGENTS CH, V42, P1437, DOI 10.1128/AAC.42.6.1437
   CASADEVALL A, 1992, J IMMUNOL METHODS, V154, P27, DOI 10.1016/0022-1759(92)90209-C
   Casadevall A, 2010, J CLIN INVEST, V120, P1389, DOI 10.1172/JCI42949
   Casadevall A, 2009, TRENDS MICROBIOL, V17, P158, DOI 10.1016/j.tim.2008.12.005
   Chang YC, 1995, GENE, V167, P179, DOI 10.1016/0378-1119(95)00640-0
   Chang YC, 1999, J BACTERIOL, V181, P5636, DOI 10.1128/JB.181.18.5636-5643.1999
   Chang YC, 1996, INFECT IMMUN, V64, P1977, DOI 10.1128/IAI.64.6.1977-1983.1996
   Chang YC, 1998, INFECT IMMUN, V66, P2230, DOI 10.1128/IAI.66.5.2230-2236.1998
   Chang YC, 1997, INFECT IMMUN, V65, P1584, DOI 10.1128/IAI.65.5.1584-1592.1997
   Charlier C, 2009, INFECT IMMUN, V77, P120, DOI 10.1128/IAI.01065-08
   Chen C, 2004, ANN NY ACAD SCI, V1019, P355, DOI 10.1196/annals.1297.061
   Ciopraga J, 1999, BBA-GEN SUBJECTS, V1428, P424, DOI 10.1016/S0304-4165(99)00085-9
   Cordero RJB, 2013, J IMMUNOL, V190, P317, DOI 10.4049/jimmunol.1202324
   D'Souza CA, 2001, MOL CELL BIOL, V21, P3179, DOI 10.1128/MCB.21.9.3179-3191.2001
   Da Silva CA, 2008, J IMMUNOL, V181, P4279, DOI 10.4049/jimmunol.181.6.4279
   Da Silva CA, 2009, J IMMUNOL, V182, P3573, DOI 10.4049/jimmunol.0802113
   Del Poeta M, 2004, EUKARYOT CELL, V3, P1067, DOI 10.1128/EC.3.5.1067-1075.2004
   Doering TL, 2009, ANNU REV MICROBIOL, V63, P223, DOI 10.1146/annurev.micro.62.081307.162753
   Feldmesser M, 2001, TRENDS MICROBIOL, V9, P273, DOI 10.1016/S0966-842X(01)02035-2
   Figueiredo RT, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00248
   Figueiredo RT, 2010, J BIOL CHEM, V285, P40714, DOI 10.1074/jbc.M110.181255
   Fonseca FL, 2009, EUKARYOT CELL, V8, P1543, DOI 10.1128/EC.00142-09
   Garcia-Rivera J, 2004, EUKARYOT CELL, V3, P385, DOI 10.1128/EC.3.2.385-392.2004
   Gillece JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028550
   GOLDMAN D, 1994, INFECT IMMUN, V62, P4755, DOI 10.1128/IAI.62.11.4755-4761.1994
   Kechichian TB, 2007, INFECT IMMUN, V75, P4792, DOI 10.1128/IAI.00587-07
   Klutts JS, 2006, FEMS YEAST RES, V6, P499, DOI 10.1111/j.1567-1364.2006.00054.x
   Kmetzsch L, 2011, MOL MICROBIOL, V81, P206, DOI 10.1111/j.1365-2958.2011.07686.x
   Kmetzsch Livia, 2011, Commun Integr Biol, V4, P186, DOI 10.4161/cib.4.2.14271
   Kmetzsch L, 2011, FUNGAL GENET BIOL, V48, P192, DOI 10.1016/j.fgb.2010.07.011
   Kmetzsch L, 2010, EUKARYOT CELL, V9, P1798, DOI 10.1128/EC.00114-10
   Levitz SA, 2004, MICROBES INFECT, V6, P1351, DOI 10.1016/j.micinf.2004.08.014
   Levitz Stuart M, 2002, Nihon Ishinkin Gakkai Zasshi, V43, P133, DOI 10.3314/jjmm.43.133
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loftus BJ, 2005, SCIENCE, V307, P1321, DOI 10.1126/science.1103773
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   McClelland EE, 2010, J CLIN INVEST, V120, P1355, DOI 10.1172/JCI38322
   MIRELMAN D, 1975, NATURE, V256, P414, DOI 10.1038/256414a0
   Nakamura K, 2006, FEMS IMMUNOL MED MIC, V47, P148, DOI 10.1111/j.1574-695X.2006.00078.x
   O'Brien XM, 2012, J BIOL CHEM, V287, P3337, DOI 10.1074/jbc.M111.298307
   ORGAD U, 1984, LAB INVEST, V50, P294
   Park BJ, 2009, AIDS, V23, P525, DOI 10.1097/QAD.0b013e328322ffac
   Ramos CL, 2012, EUKARYOT CELL, V11, P1086, DOI 10.1128/EC.00001-12
   Rodrigues ML, 2008, EUKARYOT CELL, V7, P602, DOI 10.1128/EC.00307-07
   Rodrigues ML, 2007, CLIN VACCINE IMMUNOL, V14, P1372, DOI 10.1128/CVI.00202-07
   Rodrigues ML, 2007, EUKARYOT CELL, V6, P48, DOI 10.1128/EC.00318-06
   Rodrigues ML, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00249
   Roy Monika, 2011, Expert Rev Anti Infect Ther, V9, P715, DOI 10.1586/eri.11.86
   Sommer U, 2003, J BIOL CHEM, V278, P47724, DOI 10.1074/jbc.M307223200
   Wills EA, 2001, MOL MICROBIOL, V40, P610, DOI 10.1046/j.1365-2958.2001.02401.x
   Wozniak KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017204
   Yauch LE, 2005, INFECT IMMUN, V73, P8429, DOI 10.1128/IAI.73.12.8429-8432.2005
   Yauch LE, 2004, INFECT IMMUN, V72, P5373, DOI 10.1128/IAI.72.9.5373-5382.2004
   Yoneda A, 2006, MOL BIOL CELL, V17, P5131, DOI 10.1091/mbc.E06-08-0701
   Zaragoza 0., 2004, BIOL PROCED ONLINE, V6, P10
   Zaragoza O, 2006, MOL MICROBIOL, V59, P67, DOI 10.1111/j.1365-2958.2005.04928.x
   Zaragoza O, 2009, ADV APPL MICROBIOL, V68, P133, DOI 10.1016/S0065-2164(09)01204-0
   Zou C., 2012, FRONT IMMUNOL, P3
NR 62
TC 18
Z9 18
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1087-1845
EI 1096-0937
J9 FUNGAL GENET BIOL
JI Fungal Genet. Biol.
PD NOV
PY 2013
VL 60
SI SI
BP 64
EP 73
DI 10.1016/j.fgb.2013.04.005
PG 10
WC Genetics & Heredity; Mycology
SC Genetics & Heredity; Mycology
GA 256DP
UT WOS:000327290200008
PM 23608320
OA Green Published, Green Accepted
DA 2020-12-01
ER

PT J
AU Lima, DS
   Costa, DL
   Carregaro, V
   Cunha, LD
   Silva, ALN
   Mineo, TWP
   Gutierrez, FRS
   Bellio, M
   Bortoluci, KR
   Flavell, RA
   Bozza, MT
   Silva, JS
   Zamboni, DS
AF Lima-Junior, Djalma S.
   Costa, Diego L.
   Carregaro, Vanessa
   Cunha, Larissa D.
   Silva, Alexandre L. N.
   Mineo, Tiago W. P.
   Gutierrez, Fredy R. S.
   Bellio, Maria
   Bortoluci, Karina R.
   Flavell, Richard A.
   Bozza, Marcelo T.
   Silva, Joao S.
   Zamboni, Dario S.
TI Inflammasome-derived IL-1 beta production induces nitric oxide-mediated
   resistance to Leishmania
SO NATURE MEDICINE
LA English
DT Article
ID NALP3 INFLAMMASOME; MAJOR AMASTIGOTES; IMMUNE-RESPONSES; SUSCEPTIBILITY;
   ACTIVATION; RECEPTOR; MICE; MACROPHAGES; INNATE; INTERLEUKIN-1-BETA
AB Parasites of the Leishmania genus are the causative agents of leishmaniasis in humans, a disease that affects more than 12 million people worldwide. These parasites replicate intracellularly in macrophages, and the primary mechanisms underlying host resistance involve the production of nitric oxide (NO). In this study we show that the Nlrp3 inflammasome is activated in response to Leishmania infection and is important for the restriction of parasite replication both in macrophages and in vivo as demonstrated through the infection of inflammasome-deficient mice with Leishmania amazonensis, Leishmania braziliensis and Leishmania infantum chagasi. Inflammasome-driven interleukin-1 beta (IL-1 beta) production facilitated host resistance to infection, as signaling through IL-1 receptor (IL-1R) and MyD88 was necessary and sufficient to trigger inducible nitric oxide synthase (NOS2)-mediated production of NO. In this manuscript we identify a major signaling platform for host resistance to Leishmania spp. infection and describe the molecular mechanisms underlying Leishmania-induced NO production.
C1 [Lima-Junior, Djalma S.; Cunha, Larissa D.; Silva, Alexandre L. N.; Zamboni, Dario S.] Univ Sao Paulo, Dept Biol Celular Mol & Bioagentes Patogencios, BR-14049 Ribeirao Preto, SP, Brazil.
   [Lima-Junior, Djalma S.; Costa, Diego L.; Carregaro, Vanessa; Mineo, Tiago W. P.; Gutierrez, Fredy R. S.; Silva, Joao S.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, BR-14049 Ribeirao Preto, SP, Brazil.
   [Bellio, Maria; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Rio De Janeiro, Brazil.
   [Bortoluci, Karina R.] Univ Fed Sao Paulo, Dept Ciencias Biol, Sao Paulo, Brazil.
   [Bortoluci, Karina R.] Univ Fed Sao Paulo, Ctr Terapia Celular & Mol, Sao Paulo, Brazil.
   [Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
   [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA.
RP Zamboni, DS (corresponding author), Univ Sao Paulo, Dept Biol Celular Mol & Bioagentes Patogencios, BR-14049 Ribeirao Preto, SP, Brazil.
EM dszamboni@fmrp.usp.br
RI Bortoluci, Karina/P-9296-2019; Gutierrez, Fredy R.S./C-3911-2009;
   Carregaro, Vanessa/D-2913-2012; Costa, Diego Luis/F-7168-2019; Zamboni,
   Dario S/D-3024-2012; Bortoluci, Karina R/C-6018-2012; Mineo, Tiago W.
   P./B-4153-2009; Silva, Joao S/A-4484-2008; Lima-Junior,
   Djalma/H-4833-2013; Cunha, Larissa D/I-4204-2012; BELLIO,
   MARIA/N-8525-2018
OI Bortoluci, Karina/0000-0001-6780-5397; Gutierrez, Fredy
   R.S./0000-0001-9873-8342; Costa, Diego Luis/0000-0002-9440-2814;
   Zamboni, Dario S/0000-0002-7856-7512; Bortoluci, Karina
   R/0000-0001-6780-5397; Mineo, Tiago W. P./0000-0002-2339-2743; Silva,
   Joao S/0000-0002-3410-3927; Lima-Junior, Djalma/0000-0002-2092-8047;
   BELLIO, MARIA/0000-0002-3360-2740; Bozza, Marcelo/0000-0003-3683-7550;
   Carregaro, Vanessa/0000-0002-8435-0766
FU Instituto Nacional de Ciencia e Tecnologia de Vacinas
   (INCTV/CNPq)National Council for Scientific and Technological
   Development (CNPq); Nucleo de Apoio a Pesquisa em Doencas Inflamatorias
   (NAPDIN) [11.1.21625.01.0]; Fundacao de Amparo ao Ensino, Pesquisa e
   Assistencia do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto da Universidade de Sao Paulo (FAEPA); Special Programme
   for Research and Training in Tropical Diseases/World Health Organization
   (TDR/WHO) [A60999]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2006/52867-4, 2009/05054-6]
FX We are grateful to M. Nakamura for technical assistance, F. Cunha
   (Universidade de Sao Paulo, Brazil) for providing IL-1Ra and V. Dixit
   (Genentech, USA) for providing us with the Nlrp3<SUP>-/-</SUP> mice and
   the antibody to caspase-1 p20. This work was supported by grants from
   Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV/CNPq),
   Nucleo de Apoio a Pesquisa em Doencas Inflamatorias (NAPDIN, grant
   11.1.21625.01.0), Fundacao de Amparo ao Ensino, Pesquisa e Assistencia
   do Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da
   Universidade de Sao Paulo (FAEPA), Special Programme for Research and
   Training in Tropical Diseases/World Health Organization (TDR/WHO, grant
   A60999 to D.S.Z.) and Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP, grant 2006/52867-4 to D.S.Z.). D. L. C., V. C., L. D. C.,
   A.L.N.S. and D.S.L.-J. (grant 2009/05054-6) are supported by fellowships
   from FAPESP. R. A. F. is an Investigator of the Howard Hughes Medical
   Institute. D.S.Z., M. B., M. T. B. and J.S.S. are Research Fellows from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil.
CR AFONSO LCC, 1993, INFECT IMMUN, V61, P2952, DOI 10.1128/IAI.61.7.2952-2959.1993
   ANDRADE ZA, 1984, AM J PATHOL, V114, P137
   Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969
   Bosque F, 2000, SCAND J IMMUNOL, V51, P533
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Debus A, 2003, INFECT IMMUN, V71, P7215, DOI 10.1128/IAI.71.12.7215-7218.2003
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Fernandez-Figueroa EA, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001533
   FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0
   Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200
   GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927
   GREEN SJ, 1990, J IMMUNOL, V145, P4290
   GREEN SJ, 1990, J IMMUNOL, V144, P278
   Gregory DJ, 2005, PARASITOLOGY, V130, pS27, DOI 10.1017/S0031182005008139
   Hamon MA, 2011, INFECT IMMUN, V79, P2839, DOI 10.1128/IAI.01243-10
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Kautz-Neu K, 2011, EXP DERMATOL, V20, P77, DOI 10.1111/j.1600-0625.2010.01172.x
   Kostka SL, 2006, J INVEST DERMATOL, V126, P1582, DOI 10.1038/sj.jid.5700309
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206
   LIEW FY, 1991, EUR J IMMUNOL, V21, P3009, DOI 10.1002/eji.1830211216
   Liu D, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00083
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147
   Moravej A, 2012, MOL BIOL REP, V39, P6907, DOI 10.1007/s11033-012-1517-z
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mukbel RM, 2007, AM J TROP MED HYG, V76, P669, DOI 10.4269/ajtmh.2007.76.669
   Muraille E, 2003, J IMMUNOL, V170, P4237, DOI 10.4049/jimmunol.170.8.4237
   NATHAN C, 1992, FASEB J, V6, P3051
   Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8
   Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933
   Satoskar AR, 1998, EUR J IMMUNOL, V28, P2066, DOI 10.1002/(SICI)1521-4141(199807)28:07<2066::AID-IMMU2066>3.0.CO;2-X
   Shio MT, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/819512
   Soong L, 2008, J IMMUNOL, V180, P4355, DOI 10.4049/jimmunol.180.7.4355
   Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656
   STENGER S, 1994, J EXP MED, V180, P783, DOI 10.1084/jem.180.3.783
   Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239
   Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111
   Wen HT, 2012, NAT IMMUNOL, V13, P352, DOI 10.1038/ni.2228
   WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599
   Xin LJ, 2008, MOL IMMUNOL, V45, P3371, DOI 10.1016/j.molimm.2008.04.018
   Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305
NR 51
TC 197
Z9 200
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD JUL
PY 2013
VL 19
IS 7
BP 909
EP +
DI 10.1038/nm.3221
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA 179YB
UT WOS:000321557700035
PM 23749230
DA 2020-12-01
ER

PT J
AU Mietto, BS
   Jurgensen, S
   Alves, L
   Pecli, C
   Narciso, MS
   Assuncao-Miranda, I
   Villa-Verde, DMS
   Lima, FRD
   de Menezes, JRL
   Benjamim, CF
   Bozza, MT
   Martinez, AMB
AF Mietto, Bruno Siqueira
   Jurgensen, Sofia
   Alves, Lucineia
   Pecli, Cyntia
   Narciso, Marcelo Sampaio
   Assuncao-Miranda, Iranaia
   Serra Villa-Verde, Dea Maria
   de Souza Lima, Flavia Regina
   Lacerda de Menezes, Joao Ricardo
   Benjamim, Claudia Farias
   Bozza, Marcelo Torres
   Blanco Martinez, Ana Maria
TI Lack of galectin-3 speeds Wallerian degeneration by altering TLR and
   pro-inflammatory cytokine expressions in injured sciatic nerve
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE macrophages; mice; neuroinflammation; Schwann cells; sciatic nerve
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; TOLL-LIKE RECEPTORS;
   PERIPHERAL-NERVE; FUNCTIONAL RECOVERY; SCHWANN-CELLS; MACROPHAGE
   ACTIVATION; SIGNALING PATHWAYS; PHAGOCYTOSIS; REGENERATION;
   INTERLEUKIN-1-BETA
AB Wallerian degeneration (WD) comprises a series of events that includes activation of non-neuronal cells and recruitment of immune cells, creating an inflammatory milieu that leads to extensive nerve fragmentation and subsequent clearance of the myelin debris, both of which are necessary prerequisites for effective nerve regeneration. Previously, we documented accelerated axon regeneration in animals lacking galectin-3 (Gal-3), a molecule associated with myelin clearance. To clarify the mechanisms underlying this enhanced regeneration, we focus here on the early steps of WD following sciatic nerve crush in Gal-3/ mice. Using an in vivo model of nerve degeneration, we observed that removal of myelin debris is more efficient in Gal-3/ than in wild-type (WT) mice; we next used an in vitro phagocytosis assay to document that the phagocytic potential of macrophages and Schwann cells was enhanced in the Gal-3/ mice. Moreover, both RNA and protein levels for the pro-inflammatory cytokines IL-1 and TNF-, as well as for Toll-like receptor (TLR)-2 and -4, show robust increases in injured nerves from Gal-3/mice compared to those from WT mice. Collectively, these data indicate that the lack of Gal-3 results in an augmented inflammatory profile that involves the TLRcytokine pathway, and increases the phagocytic capacity of Schwann cells and macrophages, which ultimately contributes to speeding the course of WD.
C1 [Mietto, Bruno Siqueira; Jurgensen, Sofia; Alves, Lucineia; Narciso, Marcelo Sampaio; Blanco Martinez, Ana Maria] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Pesquisa Neurociencia Basica & Clin, Lab Neurodegeneracao & Reparo, Rio De Janeiro, RJ, Brazil.
   [Pecli, Cyntia; Benjamim, Claudia Farias] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Assuncao-Miranda, Iranaia] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Lab Resposta Celular Infeccoes Virais, Rio De Janeiro, RJ, Brazil.
   [Serra Villa-Verde, Dea Maria] Fiocruz MS, Inst Oswaldo Cruz, Lab Pesquisas Timo, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [de Souza Lima, Flavia Regina] Univ Fed Rio de Janeiro, Programa Biol Celular & Desenvolvimento, Lab Morfogenese Celular, Rio De Janeiro, RJ, Brazil.
   [Lacerda de Menezes, Joao Ricardo] Univ Fed Rio de Janeiro, Programa Anat, Lab Neuroanat Celular, Rio De Janeiro, RJ, Brazil.
   [Bozza, Marcelo Torres] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Lab Inflamacao & Imunidade, Rio De Janeiro, RJ, Brazil.
RP Martinez, AMB (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Pesquisa Neurociencia Basica & Clin, Lab Neurodegeneracao & Reparo, Rio De Janeiro, RJ, Brazil.
EM martinez@histo.ufrj.br
RI Martinez, Ana/C-6318-2014; Mietto, Bruno/J-1261-2016; Villa-Verde, Dea
   M.S./Q-1238-2016; Menezes, Joao R. L./D-5668-2012; Benjamim,
   Claudia/T-5090-2019
OI Mietto, Bruno/0000-0002-4172-2670; Villa-Verde, Dea
   M.S./0000-0002-2685-5512; Benjamim, Claudia/0000-0001-6247-9596; Souza
   Lima, Flavia Regina/0000-0003-0799-9235; Bozza,
   Marcelo/0000-0003-3683-7550
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX The authors declare no competing financial interests. This work was
   supported by CNPq, CAPES and FAPERJ. We are grateful to Jose Eduardo
   Goncalves dos Santos for technical assistance with the nanoliter
   microinjector.
CR Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007
   Bruck W, 1997, BRAIN PATHOL, V7, P741, DOI 10.1111/j.1750-3639.1997.tb01060.x
   Chattopadhyay S, 2007, BRAIN BEHAV IMMUN, V21, P561, DOI 10.1016/j.bbi.2006.10.015
   Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020
   Ferraz LC, 2008, EUR J IMMUNOL, V38, P2762, DOI 10.1002/eji.200737986
   Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195
   Filer A, 2009, ARTHRITIS RHEUM, V60, P1604, DOI 10.1002/art.24574
   Gaudet AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-110
   Goethals S, 2010, GLIA, V58, P1701, DOI 10.1002/glia.21041
   Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200
   Henderson NC, 2009, IMMUNOL REV, V230, P160, DOI 10.1111/j.1600-065X.2009.00794.x
   Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9
   Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108
   Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LUBINSKA L, 1977, BRAIN RES, V130, P47, DOI 10.1016/0006-8993(77)90841-1
   MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650
   Martini R, 2008, GLIA, V56, P1566, DOI 10.1002/glia.20766
   MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10
   Nadeau S, 2011, J NEUROSCI, V31, P12533, DOI 10.1523/JNEUROSCI.2840-11.2011
   Narciso MS, 2009, EXP NEUROL, V217, P7, DOI 10.1016/j.expneurol.2009.01.008
   Ochieng J, 2002, GLYCOCONJUGATE J, V19, P527, DOI 10.1023/B:GLYC.0000014082.99675.2f
   Okun E, 2009, BRAIN RES REV, V59, P278, DOI 10.1016/j.brainresrev.2008.09.001
   Oliveira JT, 2010, NEUROSCIENCE, V170, P1295, DOI 10.1016/j.neuroscience.2010.08.042
   Ousman SS, 2000, GLIA, V30, P92, DOI 10.1002/(SICI)1098-1136(200003)30:1<92::AID-GLIA10>3.0.CO;2-W
   Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407
   PERRY VH, 1995, EUR J NEUROSCI, V7, P271, DOI 10.1111/j.1460-9568.1995.tb01063.x
   REICHERT F, 1994, J NEUROSCI, V14, P3231
   Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9
   Rotshenker S, 2008, GLIA, V56, P1607, DOI 10.1002/glia.20713
   Rotshenker S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-109
   Ruas LP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004519
   Sano H, 2003, J CLIN INVEST, V112, P389, DOI 10.1172/JCI200317592
   Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002
   STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086
   Subang MC, 2001, EUR J NEUROSCI, V13, P521, DOI 10.1046/j.1460-9568.2001.01425.x
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Vargas ME, 2010, P NATL ACAD SCI USA, V107, P11993, DOI 10.1073/pnas.1001948107
   Winzeler AM, 2011, J NEUROSCI, V31, P6481, DOI 10.1523/JNEUROSCI.3004-10.2011
NR 44
TC 23
Z9 23
U1 2
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0953-816X
EI 1460-9568
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD MAY
PY 2013
VL 37
IS 10
BP 1682
EP 1690
DI 10.1111/ejn.12161
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 148AK
UT WOS:000319213900013
PM 23406314
DA 2020-12-01
ER

PT J
AU Asensi, GF
   de Sales, NFF
   Dutra, FF
   Feijo, DF
   Bozza, MT
   Ulrich, RG
   Miyoshi, A
   de Morais, K
   Azevedo, VAD
   Silva, JT
   Le Loir, Y
   Paschoalin, VMF
AF Asensi, Giselli Fernandes
   Fonseca de Sales, Nathalia Ferrari
   Dutra, Fabiano Ferreira
   Feijo, Daniel Ferreira
   Bozza, Marcelo Torres
   Ulrich, Robert G.
   Miyoshi, Anderson
   de Morais, Katia
   de Carvalho Azevedo, Vasco Ariston
   Silva, Joab Trajano
   Le Loir, Yves
   Flosi Paschoalin, Vania Margaret
TI Oral immunization with Lactococcus lactis secreting attenuated
   recombinant staphylococcal enterotoxin B induces a protective immune
   response in a murine model
SO MICROBIAL CELL FACTORIES
LA English
DT Article
DE Recombinant enterotoxin B (rSEB); Staphylococcus aureus; Oral mice
   immunization; Lactococcus lactis; Intestinal IgA antibodies; Serum IgG
   antibodies; Live vaccine
ID FIBRONECTIN-BINDING PROTEIN; CLUMPING FACTOR; CAPSULAR POLYSACCHARIDE;
   BIOLOGICAL-WARFARE; MUCOSAL DELIVERY; AUREUS; VACCINE; MASTITIS;
   EXPRESSION; INFECTION
AB Background: Staphylococcus aureus is unrestrictedly found in humans and in animal species that maintain thermal homeostasis. Inadequate cleaning of processing equipment or inappropriate handling can contaminate processed food and cause severe food poisoning. Staphylococcal enterotoxin B (SEB), a potent superantigenic exotoxin, is produced by 50% of clinical isolates of S. aureus and is associated with massive food poisoning and with the induction of toxic shock syndrome.
   Results: A gene sequence encoding a recombinant SEB (rSEB), devoid of superantigenic activity, was successfully cloned and expressed in a cytoplasmic or a secreted form in the food-grade lactic acid bacterium Lactococcus lactis. The recombinant protein detected in the cytoplasm or in the culture medium exhibited the expected molecular mass and was recognized by a SEB-polyclonal antibody. Oral immunization with the recombinant L. lactis strains induced a protective immune response in a murine model of S. aureus infection. Immunized mice survived intraperitoneal challenge with an S. aureus SEB-producer strain. Counts of S. aureus in the spleen of rSEB-immunized mice were significantly reduced. The rSEB-immunized mice showed significant titers of anti-SEB IgA and IgG in stools and serum, respectively. Both recombinant L. lactis strains were able to elicit cellular or systemic immune responses in mice, with no significant difference if rSEB was produced in its cytoplasmic or secreted form. However, recombinant L. lactis expressing the cytoplasmic rSEB increased the survival rate of the challenged mice by 43%.
   Conclusions: These findings show the vaccine efficacy of L. lactis carrying an attenuated SEB, in a murine model, following lethal S. aureus challenge.
C1 [Asensi, Giselli Fernandes; Fonseca de Sales, Nathalia Ferrari; Dutra, Fabiano Ferreira; Feijo, Daniel Ferreira; Bozza, Marcelo Torres; Silva, Joab Trajano; Flosi Paschoalin, Vania Margaret] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Ulrich, Robert G.] USAMRIID, Lab Mol Immunol, Frederick, MD USA.
   [Miyoshi, Anderson; de Morais, Katia; de Carvalho Azevedo, Vasco Ariston] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Le Loir, Yves] INRA, STLO UMR1253, F-35042 Rennes, France.
   [Le Loir, Yves] Agrocampus Ouest, STLO UMR1253, F-35042 Rennes, France.
RP Paschoalin, VMF (corresponding author), Univ Fed Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
EM paschv@iq.ufrj.br
RI Paschoalin, Vania/Q-4997-2019; Azevedo, Vasco A.C/F-4315-2011;
   Paschoalin, Vania M F/J-1746-2014; Dutra, Fabianno F/C-1387-2015;
   Ferreira Feijo, Daniel/Y-6067-2018; Azevedo, Vasco A/B-1556-2019
OI Paschoalin, Vania/0000-0001-6093-134X; Azevedo, Vasco
   A.C/0000-0002-4775-2280; Dutra, Fabianno F/0000-0003-3106-7585; Azevedo,
   Vasco A/0000-0002-4775-2280; Bozza, Marcelo/0000-0003-3683-7550
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); CAPES - COFECUBCAPES [359-09]; CNPq
   grant PVE Nivel1
FX This work was supported by FAPERJ, CNPq, and CAPES - COFECUB project
   359-09. GFA received a CNPq scholarship, and YLL is the recipient of
   CNPq grant PVE Nivel1.
CR Ahanotu E., 2006, APPL BIOSAF, V11, P120, DOI DOI 10.1177/153567600601100303
   Bavari S, 1996, J INFECT DIS, V174, P338, DOI 10.1093/infdis/174.2.338
   Bermudez-Humaran LG, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S4
   Bermudez-Humaran LG, 2009, HUM VACCINES, V5, P264, DOI 10.4161/hv.5.4.7553
   Boles JW, 2003, CLIN IMMUNOL, V108, P51, DOI 10.1016/S1521-6616(03)00066-4
   Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R
   Casey AL, 2007, INT J ANTIMICROB AG, V29, pS23, DOI 10.1016/S0924-8579(07)72175-1
   Castagliuolo I, 2006, VACCINE, V24, P4393, DOI 10.1016/j.vaccine.2006.02.055
   Chang BS, 2008, VACCINE, V26, P2081, DOI 10.1016/j.vaccine.2008.02.043
   Clarke SR, 2009, INFECT IMMUN, V77, P2408, DOI 10.1128/IAI.01304-08
   Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399
   Frossard CP, 2007, J ALLERGY CLIN IMMUN, V119, P952, DOI 10.1016/j.jaci.2006.12.615
   Harro CD, 2012, VACCINE, V30, P1729, DOI 10.1016/j.vaccine.2011.12.045
   Innocentin S, 2009, APPL ENVIRON MICROB, V75, P4870, DOI 10.1128/AEM.00825-09
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANGELLA P, 1993, J BACTERIOL, V175, P5806, DOI 10.1128/JB.175.18.5806-5813.1993
   Le Loir Y, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-2
   Le Loir Y, 1998, J BACTERIOL, V180, P1895, DOI 10.1128/JB.180.7.1895-1903.1998
   Leggiadro RJ, 2000, INFECT CONT HOSP EP, V21, P53, DOI 10.1086/501700
   LELOIR Y, 1994, J BACTERIOL, V176, P5135, DOI 10.1128/jb.176.16.5135-5139.1994
   Madsen JM, 2001, CLIN LAB MED, V21, P593
   Medina M, 2008, MICROBIOL IMMUNOL, V52, P399, DOI 10.1111/j.1348-0421.2008.00050.x
   Nanra JS, 2009, VACCINE, V27, P3276, DOI 10.1016/j.vaccine.2009.01.062
   Pocsfalvi G, 2008, PROTEOMICS, V8, P2462, DOI 10.1002/pmic.200700965
   Pouwels PH, 1998, INT J FOOD MICROBIOL, V41, P155, DOI 10.1016/S0168-1605(98)00048-8
   Que YA, 2001, INFECT IMMUN, V69, P6296, DOI 10.1128/IAI.69.10.6296-6302.2001
   Reveneau N, 2002, VACCINE, V20, P1769, DOI 10.1016/S0264-410X(02)00027-0
   Sambrook J., 1989, MOL CLONING LAB MANU
   Schaffer AC, 2009, INFECT DIS CLIN N AM, V23, P153, DOI 10.1016/j.idc.2008.10.005
   Schlievert PM, 2001, J ALLERGY CLIN IMMUN, V108, pS107, DOI 10.1067/mai.2001.117820
   Stiles BG, 2001, INFECT IMMUN, V69, P2031, DOI 10.1128/IAI.69.4.2031-2036.2001
   Streatfield SJ, 2006, METHODS, V38, P150, DOI 10.1016/j.ymeth.2005.09.013
   SWAMINATHAN S, 1992, NATURE, V359, P801, DOI 10.1038/359801a0
   TRILLA A, 1995, J CHEMOTHERAPY, V7, P37
   Tuchscherr LPN, 2008, INFECT IMMUN, V76, P5738, DOI 10.1128/IAI.00874-08
   Ulrich RG, 1998, VACCINE, V16, P1857, DOI 10.1016/S0264-410X(98)00176-5
   VANASSELDONK M, 1990, GENE, V95, P155, DOI 10.1016/0378-1119(90)90428-T
   Vojtov N, 2002, P NATL ACAD SCI USA, V99, P10102, DOI 10.1073/pnas.152152499
   Wells JM, 2008, NAT REV MICROBIOL, V6, P349, DOI 10.1038/nrmicro1840
NR 39
TC 22
Z9 22
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2859
J9 MICROB CELL FACT
JI Microb. Cell. Fact.
PD APR 5
PY 2013
VL 12
AR 32
DI 10.1186/1475-2859-12-32
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 123QA
UT WOS:000317404100001
PM 23561053
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Teixeira-Cunha, MGA
   Figueiredo, RT
   Almeida, PE
   Alves, SC
   Bozza, PT
   Bozza, FA
   Bozza, MT
   Zimmerman, GA
   Castro-Faria-Neto, HC
AF Gomes, Rachel N.
   Teixeira-Cunha, Mariana G. A.
   Figueiredo, Rodrigo T.
   Almeida, Patricia E.
   Alves, Silvio C.
   Bozza, Patricia T.
   Bozza, Fernando A.
   Bozza, Marcelo T.
   Zimmerman, Guy A.
   Castro-Faria-Neto, Hugo C.
TI BACTERIAL CLEARANCE IN SEPTIC MICE IS MODULATED BY MCP-1/CCL2 AND NITRIC
   OXIDE
SO SHOCK
LA English
DT Article
DE Chemokines; nitric oxide; bacterial infection; phagocytosis
ID HOST-DEFENSE; SYNTHASE INHIBITOR; CHEMOKINES; SEPSIS; PROTEIN-1; ROLES;
   RECRUITMENT; MECHANISMS; MORTALITY; DISEASE
AB Bacterial clearance is one of the most important beneficial consequences of the innate immune response. Chemokines are important mediators controlling leukocyte trafficking and activation, whereas reactive oxygen and nitrogen species are effectors in bacterial killing. In the present work, we used in vivo and in vitro models of infections to study the role of monocyte chemoattractant protein 1 (MCP-1)/CCL2 and nitric oxide (NO) in the bacterial clearance in sepsis. Our results show that MCP-1/CCL2 and NO levels are increased in the peritoneal cavity of mice 6 h after sepsis induced by cecal ligation and puncture. Pretreatment with anti-MCP-1/CCL2 monoclonal antibodies increased the number of colony-forming units (CFUs) recovered in the peritoneal lavage fluid. Moreover, CFU counts were increased in the peritoneal fluid of CCR2(-/-) mice subjected to cecal ligation and puncture. In vitro stimulation of peritoneal macrophages with recombinant MCP-1/CCL2 reduced CFU counts in the supematant after challenge with Escherichia coli. Conversely, treatment with anti-MCP-1/CCL2 increased CFU counts under the same experimental condition. Stimulation of cultured macrophages with MCP-1/CCL2 and interferon had a synergistic effect on NO production. Macrophages from CCL2(-/-) mice showed a consistent decrease in NO production when compared with wild-type controls after stimulation with LPS + interferon. Finally, we showed incubation of macrophages with E. coli, and the ERK inhibitor U0126 increased CFU numbers and decreased intracellular levels of NO. In conclusion, we demonstrated for the first time that MCP-1/CCL2 has a crucial role in the clearance of bacteria by mechanisms involving increased expression of inducible NO synthase and production of NO by ERK signaling pathways.
C1 [Gomes, Rachel N.; Teixeira-Cunha, Mariana G. A.; Almeida, Patricia E.; Alves, Silvio C.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Gomes, Rachel N.; Bozza, Fernando A.] Fiocruz MS, Inst Pesquisa Evandro Chagas, Lab Integrado Med Intens, BR-21045900 Rio De Janeiro, Brazil.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio de Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Lab Inflamacao & Imunidade, Rio de Janeiro, Brazil.
   [Zimmerman, Guy A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
RP Castro-Faria-Neto, HC (corresponding author), Fiocruz MS, Dept Fisiol & Farmacodinam, IOC, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM hcastro@ioc.fiocruz.br
RI ; Figueiredo, Rodrigo/F-5176-2016
OI Bozza, Fernando Augusto/0000-0003-4878-0256; Almeida, Patricia Elaine
   de/0000-0002-9081-8601; Figueiredo, Rodrigo/0000-0002-7551-8782; Bozza,
   Patricia/0000-0001-8349-9529; Bozza, Marcelo/0000-0003-3683-7550
FU PAPES-FIOCRUZ; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); National Institutes of
   Health/National Heart, Lung, and Blood InstituteUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [SR37WLO44525]; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525, R37HL044525, R37HL044525,
   R37HL044525, R37HL044525, R37HL044525] Funding Source: NIH RePORTER
FX This work was supported by PAPES-FIOCRUZ, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Fundacao de
   Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil). The funding
   agencies had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. Dr. Zimmerman's
   research activities are in part supported by National Institutes of
   Health/National Heart, Lung, and Blood Institute award SR37WLO44525.
CR Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI [10.1097/00003246-200107000-00002, 10.1097/00003246-200107001-00035]
   Balamayooran G, 2011, INFECT IMMUN, V79, P2567, DOI 10.1128/IAI.00067-11
   Beck PL, 2004, AM J PHYSIOL-GASTR L, V286, pG137, DOI 10.1152/ajpgi.00309.2003
   Biswas SK, 2001, NITRIC OXIDE-BIOL CH, V5, P566, DOI 10.1006/niox.2001.0370
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Cross AS, 2003, ANN INTERN MED, V138, P502, DOI 10.7326/0003-4819-138-6-200303180-00016
   Forslund T, 1997, BIOCHEM BIOPH RES CO, V233, P492, DOI 10.1006/bbrc.1997.6490
   Franchini A, 1995, ADV NEUROIMMUNOL, V5, P463, DOI 10.1016/0960-5428(95)00029-1
   Gaieski DF, 2010, CRIT CARE MED, V38, P1045, DOI 10.1097/CCM.0b013e3181cc4824
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Hauser B, 2004, SHOCK, V22, P588, DOI 10.1097/00024382-200412000-00016
   Jia T, 2008, J IMMUNOL, V180, P6846, DOI 10.4049/jimmunol.180.10.6846
   Kaufmann SHE, 1995, CIBA F SYMP, V195, P239
   Kilbourn RG, 1997, SHOCK, V7, P235, DOI 10.1097/00024382-199704000-00001
   Liew FY, 1995, CIBA F SYMP, V195, P234
   Linares E, 2001, FREE RADICAL BIO MED, V30, P1234, DOI 10.1016/S0891-5849(01)00516-0
   Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323
   Marshall JC, 2003, NAT REV DRUG DISCOV, V2, P391, DOI 10.1038/nrd1084
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   MOILANEN E, 1995, ANN MED, V27, P359, DOI 10.3109/07853899509002589
   MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x
   NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Siddiqui Shahla, 2009, J Ayub Med Coll Abbottabad, V21, P106
   SPAIN DA, 1994, J TRAUMA, V36, P720, DOI 10.1097/00005373-199405000-00021
   Tsai WC, 1997, INFECT IMMUN, V65, P1870, DOI 10.1128/IAI.65.5.1870-1875.1997
   Vromen A, 1996, SHOCK, V6, P248, DOI 10.1097/00024382-199610000-00004
NR 36
TC 39
Z9 41
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JAN
PY 2013
VL 39
IS 1
BP 63
EP 69
DI 10.1097/SHK.0b013e31827802b5
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 063CB
UT WOS:000312972500010
PM 23247123
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Brogliato, AR
   Antunes, CA
   Carvalho, RS
   Monteiro, APT
   Tinoco, RF
   Bozza, MT
   Canetti, C
   Peters-Golden, M
   Kunkel, SL
   Vianna-Jorge, R
   Benjamim, CF
AF Brogliato, Ariane Renno
   Antunes, Carlos A.
   Carvalho, Renato S.
   Monteiro, Ana Paula T.
   Tinoco, Rodrigo F.
   Bozza, Marcelo T.
   Canetti, Claudio
   Peters-Golden, Marc
   Kunkel, Steven L.
   Vianna-Jorge, Rosane
   Benjamim, Claudia Farias
TI KETOPROFEN IMPAIRS IMMUNOSUPPRESSION INDUCED BY SEVERE SEPSIS AND
   REVEALS AN IMPORTANT ROLE FOR PROSTAGLANDIN E-2
SO SHOCK
LA English
DT Article
DE CLP; immunosuppression; ketoprofen; lung; PGE(2); mice; sepsis
ID IMMUNE-RESPONSES; MACROPHAGES; RECEPTOR; CELLS; DIFFERENTIATION;
   INFLAMMATION; INHIBITION; EXERTS; INJURY; PGE(2)
AB The mechanism of immunosuppression induced by severe sepsis is not fully understood. The production of prostaglandin E-2 (PGE(2)) during sepsis is well known, but its role in long-term consequences of sepsis has not been explored. The current study evaluates the role of PGE(2) in the development of immunosuppression secondary to sepsis and its potential as therapeutic target. Cecal ligation and puncture was used as an experimental model for sepsis induction in Balb/c and C57BL/6 mice. Immunosuppression was evaluated by the response to secondary infection with Aspergillus fumigatus in sepsis survivors. The role of prostanoids was evaluated in vivo and in vitro by treatment with the cyclooxygenase inhibitor ketoprofen. Balb/c mice were more susceptible than C57BL/6 to severe sepsis and to secondary infection, with a greater mortality rate. Prostaglandin E-2 concentrations found in bronchoalveolar lavage in sham and cecal ligation and puncture group after fungal challenge were much higher in Balb/c than in C57BL/6 mice. Ketoprofen treatment improved survival of septic Balb/c mice subjected to secondary infection, while also enhancing macrophage phagocytosis and neutrophil recruitment to the lungs. We identified a pivotal role for PGE(2) acting on EP4 receptors in modulating cytokine production differentially by sham and septic macrophages. Furthermore, sepsis also altered key enzymes in PGE(2) synthesis and degradation. Our results indicate the involvement of PGE(2) in severe sepsis-induced immunosuppression. Inhibition of PGE(2) production represents an attractive target to improve innate immune response against secondary infection in the immunocompromised host.
C1 [Benjamim, Claudia Farias] Univ Fed Rio de Janeiro, Inst Ciencias Biomd, CCS, Ilha Fundao, BR-22941902 Rio De Janeiro, RJ, Brazil.
   [Carvalho, Renato S.; Vianna-Jorge, Rosane] Inst Nacl Canc Jose Alencar, Programa Farmacol, Rio De Janeiro, RJ, Brazil.
   [Carvalho, Renato S.; Monteiro, Ana Paula T.; Canetti, Claudio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-22941902 Rio De Janeiro, RJ, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Pedro Paulo Goes, BR-22941902 Rio De Janeiro, RJ, Brazil.
   [Kunkel, Steven L.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Peters-Golden, Marc] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.
RP Benjamim, CF (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomd, CCS, Ilha Fundao, Av Carlos Chagas Filho 373,Bloco J-1,Sala 25, BR-22941902 Rio De Janeiro, RJ, Brazil.
EM cbenjamim@farmaco.ufrj.br
RI Vianna-Jorge, Rosane/AAC-7301-2020; Carvalho, Renato/AAK-3890-2020;
   Vianna-Jorge, Rosane/A-1230-2013; Monteiro, Ana Paula T/L-9540-2013;
   Figueiredo, Rodrigo T./F-5176-2016; Benjamim, Claudia/T-5090-2019;
   Claudio, Canetti A/C-2774-2009
OI Vianna-Jorge, Rosane/0000-0001-5407-4695; Vianna-Jorge,
   Rosane/0000-0001-5407-4695; Figueiredo, Rodrigo T./0000-0002-7551-8782;
   Benjamim, Claudia/0000-0001-6247-9596; Bozza,
   Marcelo/0000-0003-3683-7550
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq); Fundacao Ary Frauzino para Pesquisa e
   Controle do Cancer; CAPESCAPES
FX This work was supported by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico. The fellowships were from
   Fundacao Ary Frauzino para Pesquisa e Controle do Cancer and from CAPES.
CR Bailie MB, 1996, J IMMUNOL, V157, P5221
   BAKER CC, 1983, SURGERY, V94, P331
   Bao YS, 2011, INT IMMUNOPHARMACOL, V11, P1599, DOI 10.1016/j.intimp.2011.05.021
   Benjamim CF, 2003, AM J PATHOL, V163, P2605, DOI 10.1016/S0002-9440(10)63615-2
   Benjamim CF, 2005, BLOOD, V105, P3588, DOI 10.1182/blood-2004-08-3251
   Benjamin CF, 2004, J LEUKOCYTE BIOL, V75, P408, DOI 10.1189/jlb.0503214
   Cavaillon JM, 2006, CRIT CARE, V10, DOI 10.1186/cc5055
   Chian CF, 2012, SHOCK, V38, P196, DOI 10.1097/SHK.0b013e31825a1982
   Costa D, 2006, BIOL PHARM BULL, V29, P1659, DOI 10.1248/bpb.29.1659
   GARRONE P, 1994, J IMMUNOL, V152, P4282
   Harizi H, 2001, CELL IMMUNOL, V209, P19, DOI 10.1006/cimm.2001.1785
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Hedi H, 2004, CELL IMMUNOL, V228, P99, DOI 10.1016/j.cellimm.2004.04.003
   HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112
   KATAMURA K, 1995, J IMMUNOL, V155, P4604
   Lee BPL, 2009, INT IMMUNOPHARMACOL, V9, P534, DOI 10.1016/j.intimp.2009.01.023
   Liclican EL, 2010, INVEST OPHTH VIS SCI, V51, P6311, DOI 10.1167/iovs.10-5455
   Mastino A, 1992, Dev Immunol, V2, P263, DOI 10.1155/1992/80863
   Medeiros AI, 2009, J EXP MED, V206, P61, DOI 10.1084/jem.20082058
   Miceli MH, 2011, LANCET INFECT DIS, V11, P142, DOI 10.1016/S1473-3099(10)70218-8
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Nagamachi M, 2007, J EXP MED, V204, P2865, DOI 10.1084/jem.20070773
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Ness TL, 2004, J IMMUNOL, V173, P6938, DOI 10.4049/jimmunol.173.11.6938
   O'Brien JM, 2007, AM J MED, V120, P1012, DOI 10.1016/j.amjmed.2007.01.035
   Qian XS, 2011, J BIOL CHEM, V286, P2111, DOI 10.1074/jbc.M110.154971
   Ruggeri P, 2000, IMMUNOPHARM IMMUNOT, V22, P117, DOI 10.3109/08923970009016410
   Serezani CH, 2007, AM J RESP CELL MOL, V37, P562, DOI 10.1165/rcmb.2007-0153OC
   Shi J, 2010, J IMMUNOL, V184, P7207, DOI 10.4049/jimmunol.0903487
   Torres-Duenas D, 2006, SHOCK, V25, P267, DOI 10.1097/01.shk.0000208804.34292.38
   Treffkorn L, 2004, PROSTAG OTH LIPID M, V74, P113, DOI 10.1016/j.prostaglandins.2004.07.005
   Trudeau J, 2006, J ALLERGY CLIN IMMUN, V117, P1446, DOI 10.1016/j.jaci.2006.01.049
   Wang TS, 2008, J MOL MED, V86, P495, DOI 10.1007/s00109-007-0300-4
   Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968
   Zhu XO, 2009, MOL ENDOCRINOL, V23, P1839, DOI 10.1210/me.2009-0201
   Zlelinska-Przyjemska M, 2008, CHIRALITY, V20, P159, DOI 10.1002/chir.20516
NR 36
TC 16
Z9 17
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD DEC
PY 2012
VL 38
IS 6
BP 620
EP 629
DI 10.1097/SHK.0b013e318272ff8a
PG 10
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 040QV
UT WOS:000311338900008
PM 23143054
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Feijo, DF
   Dutra, FF
   Carneiro, VC
   Freitas, GB
   Alves, LS
   Mesquita, J
   Fortes, GB
   Figueiredo, RT
   Souza, HSP
   Fantappie, MR
   Lannes-Vieira, J
   Bozza, MT
AF Paiva, Claudia N.
   Feijo, Daniel F.
   Dutra, Fabianno F.
   Carneiro, Vitor C.
   Freitas, Guilherme B.
   Alves, Leticia S.
   Mesquita, Jacilene
   Fortes, Guilherme B.
   Figueiredo, Rodrigo T.
   Souza, Heitor S. P.
   Fantappie, Marcelo R.
   Lannes-Vieira, Joseli
   Bozza, Marcelo T.
TI Oxidative stress fuels Trypanosoma cruzi infection in mice
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HEME OXYGENASE 1; C VIRUS-REPLICATION; CHAGAS-DISEASE; IFN-GAMMA;
   INTRACELLULAR GROWTH; RESPIRATORY BURST; RESPONSE ELEMENTS; LABILE IRON;
   IN-VIVO; MACROPHAGES
AB Oxidative damage contributes to microbe elimination during macrophage respiratory burst. Nuclear factor, erythroid-derived 2, like 2 (NRF2) orchestrates antioxidant defenses, including the expression of heme-oxygenase-1 (HO-1). Unexpectedly, the activation of NRF2 and HO-1 reduces infection by a number of pathogens, although the mechanism responsible for this effect is largely unknown. We studied Trypanosoma cruzi infection in mice in which NRF2/HO-1 was induced with cobalt protoporphyrin (CoPP). CoPP reduced parasitemia and tissue parasitism, while an inhibitor of HO-1 activity increased T. cruzi parasitemia in blood. CoPP-induced effects did not depend on the adaptive immunity, nor were parasites directly targeted. We also found that CoPP reduced macrophage parasitism, which depended on NRF2 expression but not on classical mechanisms such as apoptosis of infected cells, induction of type I IFN, or NO. We found that exogenous expression of NRF2 or HO-1 also reduced macrophage parasitism. Several antioxidants, including NRF2 activators, reduced macrophage parasite burden, while pro-oxidants promoted it. Reducing the intracellular labile iron pool decreased parasitism, and antioxidants increased the expression of ferritin and ferroportin in infected macrophages. Ferrous sulfate reversed the CoPP-induced decrease in macrophage parasite burden and, given in vivo, reversed their protective effects. Our results indicate that oxidative stress contributes to parasite persistence in host tissues and open a new avenue for the development of anti-T. cruzi drugs.
C1 [Paiva, Claudia N.; Feijo, Daniel F.; Dutra, Fabianno F.; Freitas, Guilherme B.; Alves, Leticia S.; Mesquita, Jacilene; Fortes, Guilherme B.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, IMPPG, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [Carneiro, Vitor C.; Fantappie, Marcelo R.] Univ Fed Rio de Janeiro, Programa Biotecnol & Biol Mol, Inst Bioquim Med, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [Souza, Heitor S. P.] Univ Fed Rio de Janeiro, Serv Hematol, Hosp Univ, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [Lannes-Vieira, Joseli] Inst Oswaldo Cruz, Lab Biol Interacoes, BR-20001 Rio De Janeiro, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, CCS Bloco D,Ave Carlos Chagas Filho,373 Cidade Un, BR-21941902 Rio de Janeiro, RJ, Brazil.
EM cnpaiva@iname.com; mtbozza@micro.ufrj.br
RI Dutra, Fabianno F/C-1387-2015; de Souza, Heitor Siffert
   Pereira/G-3297-2012; Figueiredo, Rodrigo T./F-5176-2016; Ferreira Feijo,
   Daniel/Y-6067-2018
OI Dutra, Fabianno F/0000-0003-3106-7585; de Souza, Heitor Siffert
   Pereira/0000-0002-3647-7324; Figueiredo, Rodrigo T./0000-0002-7551-8782;
   Bozza, Marcelo/0000-0003-3683-7550; Carneiro, Vitor/0000-0003-1518-7667;
   De Freitas, Guilherme/0000-0003-4614-4280
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); Pronex; Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES)CAPES
FX This work was supported by CNPq, FAPERJ, Pronex, and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES). C.N. Paiva, R.T.
   Figueiredo, J. Lannes-Vieira, M.R. Fantappie, and M.T. Bozza received
   CNPq grants. We are indebted to Miguel Soares, Leo Otterbein, and Pedro
   Oliveira, who helped us with suggestions and reagents.
CR Arantes JM, 2007, EXP PARASITOL, V117, P43, DOI 10.1016/j.exppara.2007.03.006
   Bergeron M, 2008, PARASITE IMMUNOL, V30, P280, DOI 10.1111/j.1365-3024.2008.01022.x
   Breuer W, 2008, INT J BIOCHEM CELL B, V40, P350, DOI 10.1016/j.biocel.2007.03.010
   Cardoni RL, 1997, AM J TROP MED HYG, V56, P329, DOI 10.4269/ajtmh.1997.56.329
   Chessler ADC, 2008, J IMMUNOL, V181, P7917, DOI 10.4049/jimmunol.181.11.7917
   Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC
   Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730
   Costa VMA, 2006, J IMMUNOL, V177, P3193, DOI 10.4049/jimmunol.177.5.3193
   Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x
   Das NK, 2009, CELL MICROBIOL, V11, P83, DOI 10.1111/j.1462-5822.2008.01241.x
   de Souza EM, 2003, CELL TISSUE RES, V314, P223, DOI 10.1007/s00441-003-0782-5
   Devadas K, 2006, J IMMUNOL, V176, P4252, DOI 10.4049/jimmunol.176.7.4252
   Dhiman M, 2011, J PATHOL, V225, P583, DOI 10.1002/path.2975
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Fraternale A, 2010, VACCINE, V28, P7676, DOI 10.1016/j.vaccine.2010.09.033
   Fraternale A, 2009, MOL ASPECTS MED, V30, P99, DOI 10.1016/j.mam.2008.09.001
   Gong PF, 2002, ANTIOXID REDOX SIGN, V4, P249, DOI 10.1089/152308602753666307
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   Guevara AG, 2000, IMMUNOL LETT, V71, P79, DOI 10.1016/S0165-2478(99)00164-9
   Gupta S, 2009, FREE RADICAL BIO MED, V47, P1414, DOI 10.1016/j.freeradbiomed.2009.08.008
   Hintze KJ, 2005, P NATL ACAD SCI USA, V102, P15048, DOI 10.1073/pnas.0505148102
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Junqueira C, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001560
   Kovrunovych G, 2010, BLOOD, V116, P6054
   LALONDE RG, 1984, J CLIN INVEST, V73, P470, DOI 10.1172/JCI111233
   Larson JA, 2004, MOL MICROBIOL, V53, P807, DOI 10.1111/j.1365-2958.2004.04169.x
   Lee GT, 2010, J BIOL CHEM, V285, P39401, DOI 10.1074/jbc.M110.103705
   Lehmann E, 2010, HEPATOLOGY, V51, P398, DOI 10.1002/hep.23339
   LIMA MF, 1990, MOL BIOCHEM PARASIT, V38, P245, DOI 10.1016/0166-6851(90)90027-J
   Lin QS, 2008, FREE RADICAL BIO MED, V44, P847, DOI 10.1016/j.freeradbiomed.2007.11.012
   Liu XB, 2005, BLOOD CELL MOL DIS, V35, P47, DOI 10.1016/j.bcmd.2005.04.006
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOO VG, 1984, INFECT IMMUN, V45, P726, DOI 10.1128/IAI.45.3.726-730.1984
   Marro S, 2010, HAEMATOL-HEMATOL J, V95, P1261, DOI 10.3324/haematol.2009.020123
   MCCABE RE, 1990, J IMMUNOL, V144, P2384
   McCord JM, 2004, J NUTR, V134, p3171S
   Melo RCN, 2003, CELL BIOL INT, V27, P853, DOI 10.1016/S1065-6995(03)00173-2
   METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x
   Monteiro MC, 2008, PARASITOL RES, V102, P801, DOI 10.1007/s00436-007-0827-x
   MUNOZFERNANDEZ MA, 1992, IMMUNOL LETT, V33, P35, DOI 10.1016/0165-2478(92)90090-B
   MURRAY HW, 1982, J RETICULOENDOTH SOC, V31, P479
   Nagajyothi F, 2012, PARASITOL RES, V110, P2491, DOI 10.1007/s00436-011-2790-9
   NATHAN C, 1979, Journal of Experimental Medicine, V149, P1056, DOI 10.1084/jem.149.5.1056
   Alvarez MN, 2011, J BIOL CHEM, V286, P6627, DOI 10.1074/jbc.M110.167247
   Oberley-Deegan RE, 2010, FREE RADICAL BIO MED, V49, P1666, DOI 10.1016/j.freeradbiomed.2010.08.026
   Padilla AM, 2009, CURR OPIN IMMUNOL, V21, P385, DOI 10.1016/j.coi.2009.07.006
   Portugal S, 2011, NAT MED, V17, P732, DOI 10.1038/nm.2368
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Protzer U, 2007, GASTROENTEROLOGY, V133, P1156, DOI 10.1053/j.gastro.2007.07.021
   Reddy NM, 2009, J IMMUNOL, V183, P4601, DOI 10.4049/jimmunol.0901754
   Rodrigues WF, 2010, MEM I OSWALDO CRUZ, V105, P137, DOI 10.1590/S0074-02762010000200005
   Santello FH, 2007, J PINEAL RES, V42, P359, DOI 10.1111/j.1600-079X.2007.00427.x
   Shan Y, 2007, GASTROENTEROLOGY, V133, P1166, DOI 10.1053/j.gastro.2007.08.002
   Shan Y, 2006, FASEB J, V20, P2651, DOI 10.1096/fj.06-6346fje
   Taille C, 2004, J BIOL CHEM, V279, P28681, DOI 10.1074/jbc.M310661200
   Theurl I, 2008, BLOOD, V111, P2392, DOI 10.1182/blood-2007-05-090019
   Thomson L, 2003, ARCH BIOCHEM BIOPHYS, V412, P55, DOI 10.1016/S0003-9861(02)00745-2
   Tung WH, 2010, CELL SIGNAL, V22, P234, DOI 10.1016/j.cellsig.2009.09.018
   Tzima S, 2009, J EXP MED, V206, P1167, DOI 10.1084/jem.20081582
   Vlahos R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001271
   Wen JJ, 2006, AM J PATHOL, V169, P1953, DOI 10.2353/ajpath.2006.060475
   Wen JJ, 2004, FREE RADICAL BIO MED, V37, P2072, DOI 10.1016/j.freeradbiomed.2004.09.011
   Wen JJ, 2004, FREE RADICAL BIO MED, V37, P1821, DOI 10.1016/j.freeradbiomed.2004.08.018
   WILSON ME, 1994, INFECT IMMUN, V62, P5133, DOI 10.1128/IAI.62.11.5133-5141.1994
   Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163
   Zaki MH, 2009, J IMMUNOL, V182, P3746, DOI 10.4049/jimmunol.0803363
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
   Zhu ZW, 2008, HEPATOLOGY, V48, P1430, DOI 10.1002/hep.22491
NR 70
TC 86
Z9 88
U1 0
U2 15
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2012
VL 122
IS 7
BP 2531
EP 2542
DI 10.1172/JCI58525
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 969GV
UT WOS:000306044600025
PM 22728935
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Fonseca, FL
   Guimaraes, A
   Dutra, FF
   Bozza, M
   Dias, F
   Munoz, JE
   Taborda, C
   Nimrichter, L
   Casadevall, A
   Rodrigues, ML
AF Fonseca, F. L.
   Guimaraes, A.
   Dutra, F. F.
   Bozza, M.
   Dias, F.
   Munoz, J. E.
   Taborda, C.
   Nimrichter, L.
   Casadevall, A.
   Rodrigues, M. L.
TI Chitin-like structures influence in vivo and in vitro interactions of
   Cryptococcus neoformans with host cells
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Fonseca, F. L.; Guimaraes, A.; Dutra, F. F.; Bozza, M.; Nimrichter, L.; Rodrigues, M. L.] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil.
   [Dias, F.; Munoz, J. E.; Taborda, C.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Casadevall, A.] Albert Einstein Coll Med, New York, NY USA.
RI Nimrichter, Leonardo/L-3545-2014; Taborda, Carlos
   Pelleschi/AAH-7031-2020; Taborda, Carlos P/K-1660-2016
OI Nimrichter, Leonardo/0000-0001-9281-6856; Taborda, Carlos
   P/0000-0001-9928-9809
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
J9 MYCOSES
JI Mycoses
PD JUN
PY 2012
VL 55
SU 4
SI SI
BP 301
EP 301
PG 1
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 956DK
UT WOS:000305069801286
DA 2020-12-01
ER

PT J
AU Martinusso, CA
   Araujo, AF
   Duarte, LHG
   Campagnac, M
   Mesquita, JS
   Madi, K
   Bozza, MT
   Souza, HS
   Cavalcanti, MG
AF Martinusso, Cesonia A.
   Araujo, Aline F.
   Duarte, Luiza Helena G.
   Campagnac, Michelle
   Mesquita, Jacilene S.
   Madi, Kalil
   Bozza, Marcelo T.
   Souza, Heitor S.
   Cavalcanti, Marta G.
TI Toxoplasma Gondii-Induced Inflammatory Bowel Disease is Co-Regulated by
   Schistosoma Mansoni Coinfection: Role of Macrophage Migration Inhibitory
   Factor (MIF)
SO GASTROENTEROLOGY
LA English
DT Meeting Abstract
CT Digestive Disease Week (DDW)
CY MAY 19-22, 2012
CL San Diego, CA
RI de Souza, Heitor Siffert Pereira/G-3297-2012
OI de Souza, Heitor Siffert Pereira/0000-0002-3647-7324
NR 0
TC 0
Z9 0
U1 0
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAY
PY 2012
VL 142
IS 5
SU 1
BP S677
EP S678
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 981TT
UT WOS:000306994303594
DA 2020-12-01
ER

PT J
AU Luz, NF
   Andrade, BB
   Feijo, DF
   Araujo-Santos, T
   Carvalho, GQ
   Andrade, D
   Abanades, DR
   Melo, EV
   Silva, AM
   Brodskyn, CI
   Barral-Netto, M
   Barral, A
   Soares, RP
   Ameida, RP
   Bozza, MT
   Borges, VM
AF Luz, Nivea F.
   Andrade, Bruno B.
   Feijo, Daniel F.
   Araujo-Santos, Theo
   Carvalho, Graziele Q.
   Andrade, Daniela
   Abanades, Daniel R.
   Melo, Enaldo V.
   Silva, Angela M.
   Brodskyn, Claudia I.
   Barral-Netto, Manoel
   Barral, Aldina
   Soares, Rodrigo P.
   Ameida, Roque P.
   Bozza, Marcelo T.
   Borges, Valeria M.
TI Heme Oxygenase-1 Promotes the Persistence of Leishmania chagasi
   Infection
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN VISCERAL LEISHMANIASIS; TUMOR-NECROSIS-FACTOR; CARBON-MONOXIDE;
   HEMOPHAGOCYTIC SYNDROME; DIFFERENTIAL-DIAGNOSIS; SUPEROXIDE-DISMUTASE;
   MURINE MACROPHAGES; INTERFERON-GAMMA; VIRULENCE FACTOR; IMMUNE-RESPONSE
AB Visceral leishmaniasis (VL) remains a major public health problem worldwide. This disease is highly associated with chronic inflammation and a lack of the cellular immune responses against Leishmania. It is important to identify major factors driving the successful establishment of the Leishmatzia infection to develop better tools for the disease control. Heme oxygenase-1 (HO-1) is a key enzyme triggered by cellular stress, and its role in VL has not been investigated. In this study, we evaluated the role of HO-1 in the infection by Leishmatzia infantum chagasi, the causative agent of VL cases in Brazil. We found that L. chagasi infection or lipophosphoglycan isolated from promastigotes triggered HO-1 production by murine macrophages. Interestingly, cobalt protoporphyrin IX, an HO-1 inductor, increased the parasite burden in both mouse and human-derived macrophages. Upon L. chagasi infection, macrophages from Hmox1 knockout mice presented significantly lower parasite loads when compared with those from wild-type mice. Furthermore, upregulation of HO-1 by cobalt protoporphyrin IX diminished the production of TNF-alpha and reactive oxygen species by infected murine macrophages and increased Cu/Zn superoxide dismutase expression in human monocytes. Finally, patients with VL presented higher systemic concentrations of HO-1 than healthy individuals, and this increase of HO-1 was reduced after antileishmanial treatment, suggesting that HO-1 is associated with disease susceptibility. Our data argue that HO-1 has a critical role in the L. chagasi infection and is strongly associated with the inflammatory imbalance during VL. Manipulation of HO-1 pathways during VL could serve as an adjunctive therapeutic approach. The Journal of Immunology, 2012, 188: 4460-4467.
C1 [Luz, Nivea F.; Araujo-Santos, Theo; Carvalho, Graziele Q.; Andrade, Daniela; Abanades, Daniel R.; Brodskyn, Claudia I.; Barral-Netto, Manoel; Barral, Aldina; Borges, Valeria M.] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   [Luz, Nivea F.; Araujo-Santos, Theo; Carvalho, Graziele Q.; Andrade, Daniela; Abanades, Daniel R.; Brodskyn, Claudia I.; Barral-Netto, Manoel; Barral, Aldina; Borges, Valeria M.] Univ Fed Bahia, BR-40110060 Salvador, BA, Brazil.
   [Andrade, Bruno B.] NIAID, Immunobiol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Feijo, Daniel F.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
   [Melo, Enaldo V.; Silva, Angela M.; Ameida, Roque P.] Univ Fed Sergipe, Univ Hosp, Dept Med, BR-49010390 Aracaju, Brazil.
   [Brodskyn, Claudia I.; Barral-Netto, Manoel; Barral, Aldina; Ameida, Roque P.; Borges, Valeria M.] Inst Nacl Ciencia & Tecnol Invest Imunol, BR-40110100 Salvador, BA, Brazil.
   [Soares, Rodrigo P.] Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
RP Borges, VM (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM vborges@bahia.fiocruz.br
RI Andrade, Bruno/J-9111-2012; Ferreira Feijo, Daniel/Y-6067-2018; Borges,
   Val/N-6647-2019; Borges, Valeria/G-2009-2014; Barral-Netto,
   Manoel/B-3904-2009; Andrade, Bruno/AAI-2248-2020; Araujo-Santos,
   Theo/F-9807-2014
OI Andrade, Bruno/0000-0001-6833-3811; Borges, Val/0000-0002-2775-5409;
   Barral-Netto, Manoel/0000-0002-5823-7903; Araujo-Santos,
   Theo/0000-0001-9861-6660; Farias Luz, Nivea/0000-0003-1958-7043
FU Fundacao de Amparo a Pesquisa do Estado da Bahia; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Instituto Nacional de
   Ciencia e Tecnologia de Investigacao em Imunologia; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel SuperiorCAPES; National Institute
   for Allergy and Infectious Diseases, National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado da
   Bahia, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), and Instituto Nacional de Ciencia e Tecnologia de Investigacao
   em Imunologia. N.F.L., D.F.F. TA-S., and G.Q.C. are recipients of CNPq
   fellowships. D.A. received a fellowship from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior. C.I.B., R.P.S., M.B.-N.,
   A.B., R.P.A., M.T.B., and V.M.B. are senior investigators from CNPq. The
   work of B.B.A. is supported by the intramural research program of the
   National Institute for Allergy and Infectious Diseases, National
   Institutes of Health.
CR Adapala N, 2008, LAB INVEST, V88, P1329, DOI 10.1038/labinvest.2008.90
   Ahmad M, 2009, AM J PHYSIOL-HEART C, V297, pH1453, DOI 10.1152/ajpheart.00315.2009
   Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588
   Bao W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012371
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9
   Blann AD, 2011, PROSTATE CANCER P D, V14, P114, DOI 10.1038/pcan.2010.56
   Bogdan C, 1999, PARASITOL TODAY, V15, P22, DOI 10.1016/S0169-4758(98)01362-3
   Brittingham A, 1996, PARASITOL TODAY, V12, P444, DOI 10.1016/0169-4758(96)10067-3
   Caldas A, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-113
   Camara NOS, 2005, FREE RADICAL BIO MED, V38, P426, DOI 10.1016/j.freeradbiomed.2004.11.019
   Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
   Chen T, 2011, RHEUMATOL INT, V31, P321, DOI 10.1007/s00296-009-1254-3
   Chung SW, 2008, J CLIN INVEST, V118, P239, DOI 10.1172/JCI32730
   Chung SW, 2009, CELL MICROBIOL, V11, P199, DOI 10.1111/j.1462-5822.2008.01261.x
   Coelho-Finamore JM, 2011, INT J PARASITOL, V41, P333, DOI 10.1016/j.ijpara.2010.10.004
   de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128
   Dermine JF, 2000, CELL MICROBIOL, V2, P115, DOI 10.1046/j.1462-5822.2000.00037.x
   Engwerda CR, 2004, AM J PATHOL, V165, P2123, DOI 10.1016/S0002-9440(10)63262-2
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634
   Gomes NA, 2000, J IMMUNOL, V164, P2001, DOI 10.4049/jimmunol.164.4.2001
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   GREEN SJ, 1990, J IMMUNOL, V145, P4290
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Ke BB, 2002, HUM GENE THER, V13, P1189, DOI 10.1089/104303402320138970
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Kirino Y, 2005, ARTHRITIS RES THER, V7, pR616, DOI 10.1186/ar1721
   Kronke G, 2007, ARTERIOSCL THROM VAS, V27, P1276, DOI 10.1161/ATVBAHA.107.142638
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   LIEW FY, 1990, J IMMUNOL, V144, P4794
   Lodge R, 2006, CELL MICROBIOL, V8, P1922, DOI 10.1111/j.1462-5822.2006.00758.x
   MAINES MD, 1975, J BIOL CHEM, V250, P4171
   Miyazaki T, 2010, INT J HEMATOL, V91, P229, DOI 10.1007/s12185-010-0495-y
   MURRAY HW, 1982, J IMMUNOL, V129, P351
   Nath KA, 2001, AM J PATHOL, V158, P893, DOI 10.1016/S0002-9440(10)64037-0
   Novais FO, 2009, J IMMUNOL, V183, P8088, DOI 10.4049/jimmunol.0803720
   Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Olivier M, 2005, CLIN MICROBIOL REV, V18, P293, DOI 10.1128/CMR.18.2.293-305.2005
   Pae Hyun-Ock, 2009, Immune Netw, V9, P12, DOI 10.4110/in.2009.9.1.12
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Peruhype-Magalhaes V, 2006, CLIN EXP IMMUNOL, V146, P124, DOI 10.1111/j.1365-2249.2006.03171.x
   Pham NK, 2005, INFECT IMMUN, V73, P8322, DOI 10.1128/IAI.73.12.8322-8333.2005
   Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S
   Proudfoot L, 1996, P NATL ACAD SCI USA, V93, P10984, DOI 10.1073/pnas.93.20.10984
   Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3
   Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924
   Saha S, 2006, INDIAN J MED RES, V123, P245
   SALTZMAN BE, 1954, ANAL CHEM, V26, P1949, DOI 10.1021/ac60096a025
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Schneider DS, 2008, NAT REV IMMUNOL, V8, P889, DOI 10.1038/nri2432
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Seldon MP, 2007, J IMMUNOL, V179, P7840, DOI 10.4049/jimmunol.179.11.7840
   Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x
   Shiloh MU, 2008, CELL HOST MICROBE, V3, P323, DOI 10.1016/j.chom.2008.03.007
   Soares MP, 2009, CURR OPIN PHARMACOL, V9, P482, DOI 10.1016/j.coph.2009.05.008
   Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897
   TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748
   Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5
   Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005
   Vivarini AD, 2011, FASEB J, V25, P4162, DOI 10.1096/fj.11-185165
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   YOSHINAGA T, 1982, J BIOL CHEM, V257, P7803
   Zenclussen ML, 2011, J PATHOL, V225, P293, DOI 10.1002/path.2946
NR 67
TC 54
Z9 54
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
IS 9
BP 4460
EP 4467
DI 10.4049/jimmunol.1103072
PG 8
WC Immunology
SC Immunology
GA 932OH
UT WOS:000303299900039
PM 22461696
OA Green Accepted, Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Fortes, GB
   Alves, LS
   de Oliveira, R
   Dutra, FF
   Rodrigues, D
   Fernandez, PL
   Souto-Padron, T
   De Rosa, MJ
   Kelliher, M
   Golenbock, D
   Chan, FKM
   Bozza, MT
AF Fortes, Guilherme B.
   Alves, Leticia S.
   de Oliveira, Rosane
   Dutra, Fabianno F.
   Rodrigues, Danielle
   Fernandez, Patricia L.
   Souto-Padron, Thais
   De Rosa, Maria Jose
   Kelliher, Michelle
   Golenbock, Douglas
   Chan, Francis K. M.
   Bozza, Marcelo T.
TI Heme induces programmed necrosis on macrophages through autocrine TNF
   and ROS production
SO BLOOD
LA English
DT Article
ID NF-KAPPA-B; RECEPTOR-INTERACTING PROTEIN; INDUCED CELL-DEATH; NEUTROPHIL
   MIGRATION; OXIDATIVE STRESS; KINASE RIP; OXYGENASE-1; IRON; ACTIVATION;
   APOPTOSIS
AB Diseases that cause hemolysis or myonecrosis lead to the leakage of large amounts of heme proteins. Free heme has proinflammatory and cytotoxic effects. Heme induces TLR4-dependent production of tumor necrosis factor (TNF), whereas heme cytotoxicity has been attributed to its ability to intercalate into cell membranes and cause oxidative stress. We show that heme caused early macrophage death characterized by the loss of plasma membrane integrity and morphologic features resembling necrosis. Heme-induced cell death required TNFR1 and TLR4/MyD88-dependent TNF production. Addition of TNF to Tlr4(-/-) or to Myd88(-/-) macrophages restored heme-induced cell death. The use of necrostatin-1, a selective inhibitor of receptor-interacting protein 1 (RIP1, also known as RIPK1), or cells deficient in Rip1 or Rip3 revealed a critical role for RIP proteins in heme-induced cell death. Serum, antioxidants, iron chelation, or inhibition of c-Jun N-terminal kinase (JNK) ameliorated heme-induced oxidative burst and blocked macrophage cell death. Macrophages from heme oxygenase-1 deficient mice (Hmox1(-/-)) had increased oxidative stress and were more sensitive to heme. Taken together, these results revealed that heme induces macrophage necrosis through 2 synergistic mechanisms: TLR4/Myd88-dependent expression of TNF and TLR4-independent generation of ROS. (Blood. 2012;119(10):2368-2375)
C1 [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, BR-21941902 Rio de Janeiro, RJ, Brazil.
   [de Oliveira, Rosane; De Rosa, Maria Jose; Kelliher, Michelle; Golenbock, Douglas; Chan, Francis K. M.] Univ Massachusetts, Sch Med, Worcester, MA USA.
   [Fernandez, Patricia L.] Inst Invest Cient & Serv Aita Tecnol, Panama City, Panama.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, CCS Bloco D 36,Ave Carlos Chagas Filho,373 Cidade, BR-21941902 Rio de Janeiro, RJ, Brazil.
EM mbozza@micro.ufrj.br
RI Barbosa de Oliveira, Rosane/E-4399-2012; Chan, Francis
   Ka-Ming/E-9647-2014; Dutra, Fabianno F/C-1387-2015
OI Chan, Francis Ka-Ming/0000-0002-4803-8353; Dutra, Fabianno
   F/0000-0003-3106-7585; Bozza, Marcelo/0000-0003-3683-7550; Rodrigues,
   Danielle/0000-0003-2120-3352; Llanes Fernandez,
   Patricia/0000-0002-0762-0566; DE ROSA, MARIA JOSE/0000-0002-2149-6127
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support
   of the State of Rio de Janeiro (FAPERJ); INCTDengue; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES; Secretaria
   Nacional de Ciencia Tecnologia e Innovacion de Panama (SENACYT);
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI075118, R01AI075118, R01AI075118, R01AI083497, R01AI075118,
   R01AI083497, R01AI075118, R01AI083497, R01AI075118, R01AI075118,
   R01AI083497, R01AI075118, R01AI075118, R01AI075118] Funding Source: NIH
   RePORTER
FX The study received financial support from Conselho Nacional de Pesquisa
   (CNPq), Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ),
   INCTDengue, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), and Secretaria Nacional de Ciencia Tecnologia e Innovacion de
   Panama (SENACYT).
CR Andrade BB, 2010, J IMMUNOL, V185, P1196, DOI 10.4049/jimmunol.0904179
   Antosiewicz J, 2007, FREE RADICAL BIO MED, V43, P265, DOI 10.1016/j.freeradbiomed.2007.04.023
   Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200
   Carneiro LAM, 2009, CELL HOST MICROBE, V5, P123, DOI 10.1016/j.chom.2008.12.011
   Challa S, 2010, CELL MOL LIFE SCI, V67, P3241, DOI 10.1007/s00018-010-0413-8
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Cusson-Hermance N, 2005, J BIOL CHEM, V280, P36560, DOI 10.1074/jbc.M506831200
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Fernandez PL, 2010, J BIOL CHEM, V285, P32844, DOI 10.1074/jbc.M110.146076
   Ferris CD, 1999, NAT CELL BIOL, V1, P152
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600
   He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X
   Kim YS, 2007, MOL CELL, V26, P675, DOI 10.1016/j.molcel.2007.04.021
   Kovtunovych G, 2010, BLOOD, V116, P6054, DOI 10.1182/blood-2010-03-272138
   Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003
   Lamkanfi M, 2010, CELL HOST MICROBE, V8, P44, DOI 10.1016/j.chom.2010.06.007
   Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118
   LASTER SM, 1988, J IMMUNOL, V141, P2629
   Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2
   Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200
   Ma YY, 2005, J BIOL CHEM, V280, P41827, DOI 10.1074/jbc.M510849200
   Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061
   Monteiro APT, 2011, J IMMUNOL, V186, P6562, DOI 10.4049/jimmunol.1002400
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Rushworth SA, 2008, BLOOD, V111, P3793, DOI 10.1182/blood-2007-07-104042
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Shen HM, 2004, MOL CELL BIOL, V24, P5914, DOI 10.1128/MCB.24.13.5914-5922.2004
   Sukumari-Ramesh S, 2010, GLIA, V58, P1858, DOI 10.1002/glia.21055
   Temkin V, 2006, MOL CELL BIOL, V26, P2215, DOI 10.1128/MCB.26.6.2215-2225.2006
   Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004
   Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477
   VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607
   Xu YR, 2006, J BIOL CHEM, V281, P27389, DOI 10.1074/jbc.M602355200
   Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904
NR 51
TC 134
Z9 139
U1 0
U2 20
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAR 8
PY 2012
VL 119
IS 10
BP 2368
EP 2375
DI 10.1182/blood-2011-08-375303
PG 8
WC Hematology
SC Hematology
GA 906OP
UT WOS:000301356000027
PM 22262768
OA Green Published
DA 2020-12-01
ER

PT J
AU Svensjo, E
   Saraiva, EM
   Amendola, RS
   Barja-Fidalgo, C
   Bozza, MT
   Lerner, EA
   Teixeira, MM
   Scharfstein, J
AF Svensjoe, Erik
   Saraiva, Elvira M.
   Amendola, Rafael Silveira
   Barja-Fidalgo, Christina
   Bozza, Marcelo T.
   Lerner, Ethan A.
   Teixeira, Mauro M.
   Scharfstein, Julio
TI Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage
   via PAC1-CXCR1/2-pathway
SO MICROVASCULAR RESEARCH
LA English
DT Article
ID CYCLASE-ACTIVATING POLYPEPTIDE; DEXTRAN SULFATE; VASCULAR-PERMEABILITY;
   POLYMORPHONUCLEAR LEUKOCYTES; LOCAL-ANESTHETICS; HUMAN-NEUTROPHILS;
   INHIBITOR; ADHESION; PEPTIDE; EXPRESSION
AB Experiments were designed to determine if the vasodilatory peptides maxadilan and pituitary adenylate cyclase-activating peptide (PACAP-38) may cause plasma leakage through activation of leukocytes and to what extent these effects could be due to PAC1 and CXCR1/2 receptor stimulation. Intravital microscopy of hamster cheek pouches utilizing FITC-dextran and rhodamine, respectively, as plasma and leukocyte markers was used to measure arteriolar diameter, plasma leakage and leukocyte accumulation in a selected area (5 mm(2)) representative of the hamster cheek pouch microcirculation. Our studies showed that the sand fly vasodilator maxadilan and PACAP-38 induced arteriolar dilation, leukocyte accumulation and plasma leakage in postcapillary venules. The recombinant mutant of maxadilan M65 and an antagonist of CXCR1/2 receptors, reparixin, and an inhibitor of CD11b/CD18 up-regulation, ropivacaine, inhibited all these effects as induced by maxadilan. Dextran sulfate, a complement inhibitor with heparin-like anti-inflammatory effects, inhibited plasma leakage and leukocyte accumulation but not arteriolar dilation as induced by maxadilan and PACAP-38. In vitro studies with isolated human neutrophils showed that maxadilan is a potent stimulator of neutrophil migration comparable with fMLP and leukotriene B-4 and that M65 and reparixin inhibited such migration. The data suggest that leukocyte accumulation and plasma leakage induced by maxadilan involves a mechanism related to PAC1- and CXCR1/2-receptors on leukocytes and endothelial cells. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Svensjoe, Erik; Scharfstein, Julio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio de Janeiro, Brazil.
   [Saraiva, Elvira M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio de Janeiro, Brazil.
   [Amendola, Rafael Silveira; Barja-Fidalgo, Christina] Univ Fed Rio de Janeiro, Dept Farmacol IBRAG, Rio de Janeiro, Brazil.
   [Lerner, Ethan A.] Cutaneous Biol Res Ctr, Boston, MA USA.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
RP Svensjo, E (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio de Janeiro, Brazil.
EM erik.svensjo@gmail.com; esaraiva@micro.ufrj.br;
   rafael.silveira.amendola@gmail.com; barja-fidalgo@uerj.br;
   mbozza@micro.ufrj.br; ethan.lerner@cbrc2.mgh.harvard.edu;
   mmtex.ufmg@gmail.com; jscharf2@gmail.com
RI Svensjo, Erik/B-5026-2008; Saraiva, Elvira M/L-2864-2017; Teixeira,
   Mauro M/A-4587-2008
OI Svensjo, Erik/0000-0002-7356-1787; Saraiva, Elvira
   M/0000-0002-6388-5286; Teixeira, Mauro M/0000-0002-6944-3008; Bozza,
   Marcelo/0000-0003-3683-7550
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ) [E-26/100.938/2007, E-26/110.529/2011];
   PRONEX [26/110.562/2010]; Projeto PensaRio Leishmaniose; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [R01AR057744, R01AR042005, R01AR042005,
   R01AR042005, R01AR057744, R01AR042005, R01AR057744, R01AR057744,
   R01AR042005, R01AR042005, R01AR057744, R01AR042005, R01AR042005] Funding
   Source: NIH RePORTER
FX This research was supported by funds from CNPq and FAPERJ; PRONEX
   (26/110.562/2010), FAPERJ; (E-26/100.938/2007, E-26/110.529/2011) and
   Projeto PensaRio Leishmaniose.
CR BJORK J, 1982, INFLAMMATION, V6, P189, DOI 10.1007/BF00916243
   Brown RA, 2003, BRIT J PHARMACOL, V139, P845, DOI 10.1038/sj.bjp.0705291
   Cassuto J, 2006, ACTA ANAESTH SCAND, V50, P265, DOI 10.1111/j.1399-6576.2006.00936.x
   Coelho ALJ, 2001, FASEB J, V15, P1643, DOI 10.1096/fj.00-0812fje
   Dias MP, 2008, ANAESTHESIA, V63, P151, DOI 10.1111/j.1365-2044.2007.05324.x
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   DOOLEY DC, 1982, EXP HEMATOL, V10, P591
   El Zein N, 2008, CELL CALCIUM, V43, P270, DOI 10.1016/j.ceca.2007.05.017
   Garau A, 2005, CYTOKINE, V30, P125, DOI 10.1016/j.cyto.2004.12.014
   GIDDON DB, 1972, AM J PATHOL, V68, P327
   Harfi I, 2004, J IMMUNOL, V173, P4154, DOI 10.4049/jimmunol.173.6.4154
   Harfi I, 2006, ANN NY ACAD SCI, V1070, P322, DOI 10.1196/annals.1317.037
   Harris AG, 2002, EUR J MED RES, V7, P117
   HOCKING DC, 1991, J APPL PHYSIOL, V70, P1121
   Jones H, 2002, BRIT J PHARMACOL, V135, P469, DOI 10.1038/sj.bjp.0704505
   LERNER EA, 1992, J BIOL CHEM, V267, P1062
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lerner EA, 2007, PEPTIDES, V28, P1651, DOI 10.1016/j.peptides.2007.06.021
   LEY K, 1989, BLOOD, V73, P1324
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   MACGREGOR RR, 1980, BLOOD, V56, P203
   Martinsson T, 1997, J PHARMACOL EXP THER, V283, P59
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   Morimoto H, 1996, JPN J PHARMACOL, V72, P217, DOI 10.1254/jjp.72.217
   Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Pereira P, 2002, PIGM CELL RES, V15, P461, DOI 10.1034/j.1600-0749.2002.02077.x
   Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194
   Peters NC, 2009, CELL MICROBIOL, V11, P1290, DOI 10.1111/j.1462-5822.2009.01348.x
   ROSENGREN S, 1989, MICROVASC RES, V38, P243, DOI 10.1016/0026-2862(89)90003-4
   Saldanha-Gama RF, 2010, BBA-MOL CELL RES, V1803, P848, DOI 10.1016/j.bbamcr.2010.03.012
   Schmitz V, 2009, J LEUKOCYTE BIOL, V85, P1005, DOI 10.1189/jlb.1108693
   SIEBECK M, 1994, J APPL PHYSIOL, V77, P2675
   Souza DG, 2004, BRIT J PHARMACOL, V143, P132, DOI 10.1038/sj.bjp.0705862
   Spirig R, 2008, MOL IMMUNOL, V45, P4084, DOI 10.1016/j.molimm.2008.07.024
   STEWART GJ, 1974, AM J PATHOL, V74, P507
   SVENSJO E, 1978, PROSTAG LEUKOTR ESS, V1, P397, DOI 10.1016/0161-4630(78)90126-X
   Svensjo E, 2009, J VASC RES, V46, P435, DOI 10.1159/000197866
   Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346
   Villa P, 2007, MOL MED, V13, P125, DOI 10.2119/2007-00008.Villa
   WEDMORE CV, 1981, NATURE, V289, P646, DOI 10.1038/289646a0
   Zarbock A, 2008, BRIT J PHARMACOL, V155, P357, DOI 10.1038/bjp.2008.270
   Zhu XQ, 2010, INT IMMUNOPHARMACOL, V10, P662, DOI 10.1016/j.intimp.2010.03.009
NR 44
TC 12
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAR
PY 2012
VL 83
IS 2
BP 185
EP 193
DI 10.1016/j.mvr.2011.10.003
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 899MA
UT WOS:000300818800014
PM 22036674
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Lopes, LCL
   da Silva, MID
   Bittencourt, VCB
   Figueiredo, RT
   Rollin-Pinheiro, R
   Sassaki, GL
   Bozza, MT
   Gorin, PAJ
   Barreto-Bergter, E
AF Lopes, Livia Cristina L.
   da Silva, Mariana Ingrid D.
   Bittencourt, Vera Carolina B.
   Figueiredo, Rodrigo T.
   Rollin-Pinheiro, Rodrigo
   Sassaki, Guilherme L.
   Bozza, Marcelo T.
   Gorin, Philip A. J.
   Barreto-Bergter, Eliana
TI Glycoconjugates and polysaccharides from the
   Scedosporium/Pseudallescheria boydii complex: structural
   characterisation, involvement in cell differentiation, cell recognition
   and virulence
SO MYCOSES
LA English
DT Article; Proceedings Paper
CT 3rd International Workshop on Pseudallescheria/Scedosporium Infections
   (PSI)
CY MAY 06-08, 2010
CL Bonn, GERMANY
DE Scedosporium/Pseudallescheria boydii complex; Scedosporium prolificans;
   peptidorhamnomannans; alpha-glucan; rhamnomannans; cell recognition
ID O-LINKED OLIGOSACCHARIDES; PSEUDALLESCHERIA-BOYDII;
   SCEDOSPORIUM-APIOSPERMUM; HUMAN PATHOGEN; PEPTIDORHAMNOMANNAN;
   RHAMNOMANNANS; CONIDIA
AB Peptidorhamnomannans (PRMs), rhamnomannans and alpha-glucans are especially relevant for the architecture of the Scedosporium/Pseudallescheria boydii cell wall, but many of them are immunologically active, with great potential as regulators of pathogenesis and the immune response of the host. In addition, some of them can be specifically recognised by antibodies from the sera of patients, suggesting that they could also be useful in diagnosis of fungal infections. Their primary structures have been determined, based on a combination of techniques including gas chromatography, electrospray ionization - mass spectrometry (ESI-MS), H-1-COSY and TOCSY, C-13 and H-1/C-13 NMR spectroscopy. Using monoclonal antibodies to PRM, we showed that it is involved in germination and viability of P. boydii conidia, in the phagocytosis of P. boydii conidia by macrophages and non-phagocytic cells and in the survival of mice with P. boydii infection. Also, components of the fungal cell wall, such as alpha-glucans, are involved. Rhamnomannans are immunostimulatory and participate in the recognition and uptake of fungal cells by the immune system. These glycosylated polymers, being present in the fungal cell wall, are mostly absent from mammalian cells, and are excellent targets for the design of new agents capable of inhibiting fungal growth and differentiation of pathogens.
C1 [Lopes, Livia Cristina L.; da Silva, Mariana Ingrid D.; Rollin-Pinheiro, Rodrigo; Barreto-Bergter, Eliana] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Microbiol Geral, BR-21941902 Rio De Janeiro, Brazil.
   [Bittencourt, Vera Carolina B.] Univ Fed Estado Rio de Janeiro UNIRIO, Inst Biomed, Rio De Janeiro, Brazil.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, Brazil.
   [Sassaki, Guilherme L.; Gorin, Philip A. J.] Univ Fed Parana, Dept Bioquim & Biol Mol, BR-80060000 Curitiba, Parana, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941902 Rio De Janeiro, Brazil.
RP Barreto-Bergter, E (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Microbiol Geral, CCS, Bloco 1, BR-21941902 Rio De Janeiro, Brazil.
EM eliana.bergter@micro.ufrj.br
RI Bergter, Eliana Barreto/E-2664-2013; Figueiredo, Rodrigo T./F-5176-2016;
   Sassaki, Guilherme/AAM-1112-2020
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Sassaki,
   Guilherme/0000-0001-7420-168X; bittencourt, vera/0000-0002-7403-9747;
   Bozza, Marcelo/0000-0003-3683-7550
CR ALVER LL, 1994, GLYCOBIOLOGY, V4, P281, DOI 10.1093/glycob/4.3.281
   Baffeto-Bergter E, 2008, INT J BIOL MACROMOL, V42, P93, DOI 10.1016/j.ijbiomac.2007.09.015
   Barreto-Bergter E, 2011, CARBOHYD POLYM, V85, P349, DOI 10.1016/j.carbpol.2011.02.033
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Cimon B, 2000, EUR J CLIN MICROBIOL, V19, P53, DOI 10.1007/s100960050011
   De Hoog GS, 2000, ATLAS CLIN FUNGI
   Figueiredo RT, 2010, J BIOL CHEM, V285, P40714, DOI 10.1074/jbc.M110.181255
   Gilgado F, 2008, J CLIN MICROBIOL, V46, P766, DOI 10.1128/JCM.01122-07
   Gilgado F, 2010, MED MYCOL, V48, P122, DOI 10.3109/13693780902939695
   Gorin PAJ, 2010, CARBOHYD POLYM, V79, P927, DOI 10.1016/j.carbpol.2009.10.015
   Guarro J, 2006, MED MYCOL, V44, P295, DOI 10.1080/13693780600752507
   Harun A, 2009, MED MYCOL, V47, P406, DOI 10.1080/13693780802510240
   Hu CX, 2003, CARBOHYD POLYM, V54, P33, DOI 10.1016/S0144-8617(03)00135-8
   Leitao EA, 2003, GLYCOBIOLOGY, V13, P681, DOI 10.1093/glycob/cwg089
   Lopes LCL, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000853
   Ogawa K, 1997, BIOSCI BIOTECH BIOCH, V61, P539, DOI 10.1271/bbb.61.539
   PATTERSON TF, 1990, MYCOSES, V33, P297
   Pinto MR, 2005, GLYCOBIOLOGY, V15, P895, DOI 10.1093/glycob/cwi084
   Pinto MR, 2004, MICROBES INFECT, V6, P1259, DOI 10.1016/j.micinf.2004.07.006
   Pinto MR, 2001, MICROBIOL-SGM, V147, P1499, DOI 10.1099/00221287-147-6-1499
   Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7
   TRAVASSOS LR, 1973, INFECT IMMUN, V8, P685, DOI 10.1128/IAI.8.5.685-693.1973
NR 22
TC 23
Z9 23
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
PD OCT
PY 2011
VL 54
SU 3
SI SI
BP 28
EP 36
DI 10.1111/j.1439-0507.2011.02105.x
PG 9
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 838BX
UT WOS:000296262600005
PM 21995660
OA Bronze
DA 2020-12-01
ER

PT J
AU Cavalcanti, MG
   Mesquita, JS
   Madi, K
   Feijo, DF
   Assuncao-Miranda, I
   Souza, HSP
   Bozza, MT
AF Cavalcanti, Marta G.
   Mesquita, Jacilene S.
   Madi, Kalil
   Feijo, Daniel F.
   Assuncao-Miranda, Iranaia
   Souza, Heitor S. P.
   Bozza, Marcelo T.
TI MIF Participates in Toxoplasma gondii-Induced Pathology Following Oral
   Infection
SO PLOS ONE
LA English
DT Article
ID MIGRATION-INHIBITORY FACTOR; SMALL-INTESTINE; PERORAL INFECTION;
   HOST-RESISTANCE; C57BL/6 MICE; IFN-GAMMA; MACROPHAGE; CYTOKINE;
   NECROSIS; CELLS
AB Background: Macrophage migration inhibitory factor (MIF) is essential for controlling parasite burden and survival in a model of systemic Toxoplasma gondii infection. Peroral T. gondii infection induces small intestine necrosis and death in susceptible hosts, and in many aspects resembles inflammatory bowel disease (IBD). Considering the critical role of MIF in the pathogenesis of IBD, we hypothesized that MIF participates in the inflammatory response induced by oral infection with T. gondii. Methodology/Principal Findings: Mif deficient (Mif(-/-)) and wild-type mice in the C57Bl/6 background were orally infected with T. gondii strain ME49. Mif(-/-) mice had reduced lethality, ileal inflammation and tissue damage despite of an increased intestinal parasite load compared to wt mice. Lack of MIF caused a reduction of TNF-alpha, IL-12, IFN-gamma and IL-23 and an increased expression of IL-22 in ileal mucosa. Moreover, suppressed pro-inflammatory responses at the ileal mucosa observed in Mif(-/-) mice was not due to upregulation of IL-4, IL-10 or TGF-beta. MIF also affected the expression of matrix metalloproteinase-9 (MMP-9) but not MMP-2 in the intestine of infected mice. Signs of systemic inflammation including the increased concentrations of inflammatory cytokines in the plasma and liver damage were less pronounced in Mif(-/-) mice compared to wild-type mice. Conclusion/Significance: In conclusion, our data suggested that in susceptible hosts MIF controls T. gondii infection with the cost of increasing local and systemic inflammation, tissue damage and death.
C1 [Cavalcanti, Marta G.; Mesquita, Jacilene S.; Feijo, Daniel F.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Assuncao-Miranda, Iranaia] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Cavalcanti, Marta G.] Univ Fed Rio de Janeiro, Serv Doencas Infecciosas & Parasitarias, Rio De Janeiro, Brazil.
   [Souza, Heitor S. P.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Clin Med, Lab Multidisciplinar Pesquisa, Rio De Janeiro, Brazil.
   [Madi, Kalil] Univ Fed Rio de Janeiro, Dept Patol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.
   [Madi, Kalil] Lab Sergio Franco, Rio De Janeiro, Brazil.
RP Cavalcanti, MG (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
EM cavalcanti.marta66@gmail.com; mbozza@micro.ufrj.br
RI Ferreira Feijo, Daniel/Y-6067-2018; de Souza, Heitor Siffert
   Pereira/G-3297-2012
OI de Souza, Heitor Siffert Pereira/0000-0002-3647-7324; Bozza,
   Marcelo/0000-0003-3683-7550
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); Pronex (Programa de Apoio a Nucleos de
   Excelencia - Pronex/FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by CNPq, FAPERJ and Pronex (Programa de Apoio a
   Nucleos de Excelencia - Pronex/FAPERJ
   (www.faperj.br/interna.phtml?ctx_cod = 1.11)). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Aujla SJ, 2009, J MOL MED, V87, P451, DOI 10.1007/s00109-009-0448-1
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Brembilla NC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018741
   Bucala R, 1996, FASEB J, V10, P1607
   Buzoni-Gatel D, 2006, CELL MICROBIOL, V8, P535, DOI 10.1111/j.1462-5822.2006.00692.x
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Chou YT, 2006, ONCOGENE, V25, P5547, DOI 10.1038/sj.onc.1209552
   de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720
   Denkers EY, 1998, CLIN MICROBIOL REV, V11, P569, DOI 10.1128/CMR.11.4.569
   Dunne DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011343
   Flores M, 2008, FASEB J, V22, P3661, DOI 10.1096/fj.08-111666
   Garg P, 2009, AM J PHYSIOL-GASTR L, V296, pG175, DOI 10.1152/ajpgi.90454.2008
   Gazzinelli RT, 1996, J IMMUNOL, V157, P798
   Gomes AD, 2011, AM J PATHOL, V178, P2792, DOI 10.1016/j.ajpath.2011.02.005
   He XX, 2009, MOL MED, V15, P1, DOI 10.2119/molmed.2008.00107
   Heimesaat MM, 2007, GUT, V56, P941, DOI 10.1136/gut.2006.104497
   Heimesaat MM, 2006, J IMMUNOL, V177, P8785, DOI 10.4049/jimmunol.177.12.8785
   Kompalic-Cristo A, 2007, PARASITOL RES, V101, P619, DOI 10.1007/s00436-007-0524-9
   Liesenfeld O, 2002, J INFECT DIS, V185, pS96, DOI 10.1086/338006
   Liesenfeld O, 1999, PARASITE IMMUNOL, V21, P365, DOI 10.1046/j.1365-3024.1999.00237.x
   Liesenfeld O, 1996, J EXP MED, V184, P597, DOI 10.1084/jem.184.2.597
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   McDevitt MA, 2006, J EXP MED, V193, P1
   Mennechet FJD, 2002, J IMMUNOL, V168, P2988, DOI 10.4049/jimmunol.168.6.2988
   Monteleone I, 2011, GASTROENTEROLOGY, V141, P237, DOI 10.1053/j.gastro.2011.04.007
   Mordue DG, 2001, J IMMUNOL, V167, P4574, DOI 10.4049/jimmunol.167.8.4574
   Munoz M, 2011, IMMUNOL REV, V240, P269, DOI 10.1111/j.1600-065X.2010.00992.x
   Munoz M, 2009, J EXP MED, V206, P3047, DOI 10.1084/jem.20090900
   Neves ES, 2009, MEM I OSWALDO CRUZ, V104, P393, DOI 10.1590/S0074-02762009000200039
   Nickdel MB, 2004, PARASITE IMMUNOL, V26, P75, DOI 10.1111/j.0141-9838.2004.00686.x
   Ohkawara T, 2006, IMMUNOL LETT, V107, P148, DOI 10.1016/j.imlet.2006.09.002
   Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009
   Pakozdi A, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2021
   Ramirez JM, 2010, EUR J IMMUNOL, V40, P2450, DOI 10.1002/eji.201040461
   Reischl U, 2003, BMC INFECT DIS, V3, DOI 10.1186/1471-2334-3-7
   Reyes JL, 2006, INFECT IMMUN, V72, P3571
   Roberts CW, 1996, INFECT IMMUN, V64, P897, DOI 10.1128/IAI.64.3.897-904.1996
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   Suzuki Y, 2000, J IMMUNOL, V164, P5375, DOI 10.4049/jimmunol.164.10.5375
   Tait ED, 2009, MEM I OSWALDO CRUZ, V104, P201, DOI 10.1590/S0074-02762009000200013
   Terrazas CA, 2010, EXP PARASITOL, V126, P348, DOI 10.1016/j.exppara.2010.03.009
   Ferro EAV, 2008, AM J PATHOL, V172, P50, DOI 10.2353/ajpath.2008.070432
   Weber C, 2008, P NATL ACAD SCI USA, V105, P16278, DOI 10.1073/pnas.0804017105
   Yap GS, 1999, J EXP MED, V189, P1083, DOI 10.1084/jem.189.7.1083
   Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893
NR 54
TC 26
Z9 26
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2011
VL 6
IS 9
AR e25259
DI 10.1371/journal.pone.0025259
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 825IJ
UT WOS:000295265100077
PM 21977228
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes, RN
   da Cunha, MT
   Figueiredo, RT
   Caetano, S
   Bozza, FA
   Zimmerman, GA
   Bozza, PT
   Bozza, MT
   Castro-Faria-Neto, HC
AF Gomes, R. N.
   da Cunha, M. T.
   Figueiredo, R. T.
   Caetano, S.
   Bozza, F. A.
   Zimmerman, G. A.
   Bozza, P. T.
   Bozza, M. T.
   Castro-Faria-Neto, H. C.
TI INVOLVEMENT OF CCL2 AND NITRIC OXIDE ON BACTERIAL CLEARANCE IN SEPTIC
   MICE
SO INFLAMMATION RESEARCH
LA English
DT Meeting Abstract
CT 10th World Congress on Inflammation
CY JUN 25-29, 2011
CL Paris, FRANCE
SP Int Assoc Inflammation Soc, Grp Res & Study Mediators Inflammat
C1 [Gomes, R. N.; da Cunha, M. T.; Caetano, S.; Bozza, P. T.; Castro-Faria-Neto, H. C.] IOC FIOCRUZ, Oswaldo Cruz Fdn, Lab Immunopharmacol, Rio De Janeiro, Brazil.
   [Figueiredo, R. T.; Bozza, M. T.] Univ Fed Rio de Janeiro, Lab Inflammat & Immun, Rio De Janeiro, Brazil.
   [Bozza, F. A.] Oswaldo Cruz Fdn IPEC FIOCRUZ, Lab Integrated Intens Care Med, Rio De Janeiro, Brazil.
   [Zimmerman, G. A.] Univ Utah, Salt Lake City, UT USA.
RI Bozza, Fernando A/A-2618-2013
OI Bozza, Fernando A/0000-0003-4878-0256
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIRKHAUSER VERLAG AG
PI BASEL
PA VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND
SN 1023-3830
J9 INFLAMM RES
JI Inflamm. Res.
PD JUN
PY 2011
VL 60
SU 1
BP 165
EP 165
PG 1
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 774CM
UT WOS:000291358900448
DA 2020-12-01
ER

PT J
AU Monteiro, APT
   Pinheiro, CS
   Luna-Gomes, T
   Alves, LR
   Maya-Monteiro, CM
   Porto, BN
   Barja-Fidalgo, C
   Benjamim, CF
   Peters-Golden, M
   Bandeira-Melo, C
   Bozza, MT
   Canetti, C
AF Monteiro, Ana Paula T.
   Pinheiro, Carla S.
   Luna-Gomes, Tatiana
   Alves, Liliane R.
   Maya-Monteiro, Clarissa M.
   Porto, Barbara N.
   Barja-Fidalgo, Christina
   Benjamim, Claudia F.
   Peters-Golden, Marc
   Bandeira-Melo, Christianne
   Bozza, Marcelo T.
   Canetti, Claudio
TI Leukotriene B-4 Mediates Neutrophil Migration Induced by Heme
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SICKLE-CELL-DISEASE; MAST-CELLS; TNF-ALPHA; POLYMORPHONUCLEAR
   LEUKOCYTES; VASCULAR ENDOTHELIUM; IMMUNE INFLAMMATION; SEQUENTIAL
   RELEASE; MACROPHAGES; ACTIVATION; EXPRESSION
AB High concentrations of free heme found during hemolytic events or cell damage leads to inflammation, characterized by neutrophil recruitment and production of reactive oxygen species, through mechanisms not yet elucidated. In this study, we provide evidence that heme-induced neutrophilic inflammation depends on endogenous activity of the macrophage-derived lipid mediator leukotriene B-4 (LTB4). In vivo, heme-induced neutrophil recruitment into the peritoneal cavity of mice was attenuated by pretreatment with 5-lipoxygenase (5-LO) inhibitors and leukotriene B-4 receptor 1 (BLT1) receptor antagonists as well as in 5-LO knockout (5-LO-/-) mice. Heme administration in vivo increased peritoneal levels of LTB4 prior to and during neutrophil recruitment. Evidence that LTB4 was synthesized by resident macrophages, but not mast cells, included the following: 1) immunolocalization of heme-induced LTB4 was compartmentalized exclusively within lipid bodies of resident macrophages; 2) an increase in the macrophage population enhanced heme-induced neutrophil migration; 3) depletion of resident mast cells did not affect heme-induced LTB4 production or neutrophil influx; 4) increased levels of LTB4 were found in heme-stimulated peritoneal cavities displaying increased macrophage numbers; and 5) in vitro, heme was able to activate directly macrophages to synthesize LTB4. Our findings uncover a crucial role of LTB4 in neutrophil migration induced by heme and suggest that beneficial therapeutic outcomes could be achieved by targeting the 5-LO pathway in the treatment of inflammation associated with hemolytic processes. The Journal of Immunology, 2011, 186: 6562-6567.
C1 [Canetti, Claudio] Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, Ctr Ciencias & Saude, Ilha Fundao, BR-22541900 Rio De Janeiro, Brazil.
   [Alves, Liliane R.; Maya-Monteiro, Clarissa M.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, Brazil.
   [Porto, Barbara N.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol Prof Paulo de Goes, BR-22541900 Rio De Janeiro, Brazil.
   [Barja-Fidalgo, Christina] Univ Estado Rio De Janeiro, Inst Biol, Dept Pharmacol, BR-20550030 Rio De Janeiro, Brazil.
   [Benjamim, Claudia F.] Univ Fed Rio de Janeiro, Inst Biomed Sci, BR-22541900 Rio De Janeiro, Brazil.
   [Peters-Golden, Marc] Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA.
RP Canetti, C (corresponding author), Univ Fed Rio de Janeiro, Inst Biophys Carlos Chagas Filho, Ctr Ciencias & Saude, Ilha Fundao, Ave Carlos Chagas Filho 373,Bloco C Sala 24, BR-22541900 Rio De Janeiro, Brazil.
EM ccanetti@biof.ufrj.br
RI Benjamim, Claudia/T-5090-2019; Bandeira-Melo, Christianne/X-5619-2019;
   Monteiro, Ana Paula T/L-9540-2013; Claudio, Canetti A/C-2774-2009; de
   Melo, Christianne Bandeira/B-7724-2009
OI Benjamim, Claudia/0000-0001-6247-9596; Bandeira-Melo,
   Christianne/0000-0003-3305-3865; de Melo, Christianne
   Bandeira/0000-0003-3305-3865
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   JaneiroCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Conselho de Desenvolvimento Cientifico e
   TecnologicoNational Council for Scientific and Technological Development
   (CNPq); Fundacao Jose Bonifacio; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL058897, R01HL058897, R01HL058897, R01HL058897,
   R01HL058897, R01HL058897, R01HL058897, R01HL058897, R01HL058897,
   R01HL058897, R01HL058897, R01HL058897, R01HL058897, R01HL058897,
   R01HL058897] Funding Source: NIH RePORTER
FX This work was supported by Fundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio de Janeiro, Conselho de Desenvolvimento
   Cientifico e Tecnologico, and Fundacao Jose Bonifacio.
CR ABRAHAM NG, 1985, EXP GERONTOL, V20, P277, DOI 10.1016/0531-5565(85)90053-1
   ABRAHAM NG, 1988, BIOCHEM BIOPH RES CO, V150, P717, DOI 10.1016/0006-291X(88)90450-0
   Ajuebor MN, 1999, J IMMUNOL, V162, P1685
   BACA L, 1988, AM J MED, V85, P590
   BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700
   Belcher JD, 2000, BLOOD, V96, P2451, DOI 10.1182/blood.V96.7.2451.h8002451_2451_2459
   BERI R, 1993, DRUG METAB REV, V25, P49, DOI 10.3109/03602539308993973
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Canetti C, 2001, BRIT J PHARMACOL, V134, P1619, DOI 10.1038/sj.bjp.0704403
   Cannetti CA, 2003, J IMMUNOL, V171, P1009, DOI 10.4049/jimmunol.171.2.1009
   Croizat H, 1999, AM J HEMATOL, V60, P105, DOI 10.1002/(SICI)1096-8652(199902)60:2<105::AID-AJH4>3.0.CO;2-Z
   Eiam-Ong S, 1998, AM J KIDNEY DIS, V32, P361, DOI 10.1053/ajkd.1998.v32.pm9740151
   Fadlon E, 1998, BLOOD, V91, P266, DOI 10.1182/blood.V91.1.266.266_266_274
   Field JJ, 2009, AM J HEMATOL, V84, P158, DOI 10.1002/ajh.21348
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   HEBBEL RP, 1988, P NATL ACAD SCI USA, V85, P237, DOI 10.1073/pnas.85.1.237
   Hofstra TC, 1996, BLOOD, V87, P4440, DOI 10.1182/blood.V87.10.4440.bloodjournal87104440
   IBE BO, 1994, EUR J CLIN INVEST, V24, P57, DOI 10.1111/j.1365-2362.1994.tb02060.x
   Kasschau MR, 1996, BLOOD, V87, P771, DOI 10.1182/blood.V87.2.771.bloodjournal872771
   Kaul DK, 2004, AM J PHYSIOL-HEART C, V287, pH293, DOI 10.1152/ajpheart.01150.2003
   Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004
   Lard LR, 1999, J LEUKOCYTE BIOL, V66, P411
   LINDBOM L, 1982, ACTA PHYSIOL SCAND, V116, P105, DOI 10.1111/j.1748-1716.1982.tb10607.x
   Mollapour E, 1998, BLOOD, V91, P3423, DOI 10.1182/blood.V91.9.3423.3423_3423_3429
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   Oliveira SHP, 2008, INFLAMMATION, V31, P36, DOI 10.1007/s10753-007-9047-x
   Oliveira SHP, 1997, MEM I OSWALDO CRUZ, V92, P205, DOI 10.1590/S0074-02761997000800028
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   PALMBLAD J, 1982, FEBS LETT, V144, P81, DOI 10.1016/0014-5793(82)80573-5
   Patel N, 2009, BLOOD, V113, P1129, DOI 10.1182/blood-2008-07-169821
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004
   Ramos CDL, 2005, J LEUKOCYTE BIOL, V78, P167, DOI 10.1189/jlb.0404237
   Ramos CDL, 2006, EUR J IMMUNOL, V36, P2025, DOI 10.1002/eji.200636057
   RIBEIRO RA, 1991, IMMUNOLOGY, V73, P472
   Ribeiro RA, 1997, INT ARCH ALLERGY IMM, V112, P27, DOI 10.1159/000237427
   Sassa S, 1996, INT J HEMATOL, V63, P167
   Setty BNY, 2003, LANCET, V362, P1450, DOI 10.1016/S0140-6736(03)14689-2
   Setty BNY, 2002, J LAB CLIN MED, V139, P80, DOI 10.1067/mlc.2002.121200
   Solovey A, 1999, BLOOD, V93, P3824, DOI 10.1182/blood.V93.11.3824.411k10_3824_3830
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
NR 43
TC 40
Z9 40
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2011
VL 186
IS 11
BP 6562
EP 6567
DI 10.4049/jimmunol.1002400
PG 6
WC Immunology
SC Immunology
GA 766BX
UT WOS:000290755700056
PM 21536805
OA Bronze
DA 2020-12-01
ER

PT J
AU Vieira-de-Abreu, A
   Calheiros, AS
   Mesquita-Santos, FP
   Magalhaes, ES
   Mourao-Sa, D
   Castro-Faria-Neto, HC
   Bozza, MT
   Bandeira-Melo, C
   Bozza, PT
AF Vieira-de-Abreu, Adriana
   Calheiros, Andrea S.
   Mesquita-Santos, Fabio P.
   Magalhaes, Elisabeth S.
   Mourao-Sa, Diego
   Castro-Faria-Neto, Hugo C.
   Bozza, Marcelo T.
   Bandeira-Melo, Christianne
   Bozza, Patricia T.
TI Cross-Talk between Macrophage Migration Inhibitory Factor and Eotaxin in
   Allergic Eosinophil Activation Forms Leukotriene C-4-Synthesizing Lipid
   Bodies
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE macrophage migration inhibitory factor; leukotriene C-4; lipid droplets;
   allergic inflammation; asthma
ID ULTRASTRUCTURAL IMMUNOGOLD LOCALIZATION; HUMAN BLOOD EOSINOPHILS; FACTOR
   MIF; 5-LIPOXYGENASE PATHWAY; CYSTEINYL LEUKOTRIENES; EICOSANOID
   FORMATION; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE A(2); C-4 SYNTHESIS;
   MAST-CELLS
AB Recent studies have demonstrated an essential and nonredundant role for macrophage migration inhibitory factor (MIF) in asthma pathogenesis. Here we investigate the mechanisms involved in MIF-induced eosinophil activation. By using a model of allergic pulmonary inflammation, we observed that allergen challenge-elicited eosinophil influx, lipid body (also known as lipid droplets) biogenesis, and leukotriene (LT) C-4 synthesis are markedly reduced in Mif(-/-) compared with wild-type mice. Likewise, in vivo administration of MIF induced formation of new lipid bodies within eosinophils recruited to the inflammatory reaction site that corresponded to the intracellular compartment of increased LTC4 synthesis. MIF-mediated eosinophil activation was at least in part due to a direct effect on eosinophils, because MIF was able to elicit lipid body assembly within human eosinophils in vitro, a phenomenon that was blocked by neutralization of the MIF receptor, CD74. MIF-induced eosinophil lipid body biogenesis, both in vivo and in vitro, was dependent on the cooperation of MIF and eotaxin acting in a positive-feedback loop, because anti-eotaxin and anti-CCR3 antibodies inhibit MIF-elicited lipid body formation, whereas eotaxin-induced lipid body formation is affected by anti-CD74 and MIF expression deficiency. Therefore, allergy-elicited inflammatory MIF acts in concert with eotaxin as a key activator of eosinophils to form LTC4-synthesizing lipid bodies via cross-talk between CD74 and CCR3. Due to the effect of MIF on eosinophils, strategies that inhibit MIF activity might be of therapeutic value in controlling allergic inflammation.
C1 [Vieira-de-Abreu, Adriana; Calheiros, Andrea S.; Mesquita-Santos, Fabio P.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Magalhaes, Elisabeth S.; Mourao-Sa, Diego; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Dept Imunol, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
   [Mesquita-Santos, Fabio P.; Bandeira-Melo, Christianne] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamacao, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI de Melo, Christianne Bandeira/B-7724-2009; Bandeira-Melo,
   Christianne/X-5619-2019
OI de Melo, Christianne Bandeira/0000-0003-3305-3865; Bandeira-Melo,
   Christianne/0000-0003-3305-3865; Bozza, Patricia/0000-0001-8349-9529;
   Mourao, Diego/0000-0001-6618-6969; Bozza, Marcelo/0000-0003-3683-7550
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (Brazil)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Rio de Janeiro (Brazil)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); Programa Nucleos de Excelencia (PRONEX)
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (Brazil), Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (Brazil), and Programa Nucleos de Excelencia (PRONEX). The
   funding organizations had no role in design of the study, data
   collection or analysis, the decision to publish, or preparation of the
   manuscript.
CR Balestrieri B, 2009, J IMMUNOL, V182, P4891, DOI 10.4049/jimmunol.0803776
   Bandeira-Melo C, 2005, MEM I OSWALDO CRUZ, V100, P73, DOI 10.1590/S0074-02762005000900013
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2002, J IMMUNOL, V168, P4756, DOI 10.4049/jimmunol.168.9.4756
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bartemes KR, 1999, J IMMUNOL, V162, P2982
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   Brock TG, 1999, J IMMUNOL, V162, P1669
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815
   Cowburn AS, 1999, J IMMUNOL, V163, P456
   Drazen JM, 1998, AM J RESP CRIT CARE, V158, pS193, DOI 10.1164/ajrccm.158.supplement_2.13tac180
   DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915
   Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712
   Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051
   HODGES MK, 1988, AM REV RESPIR DIS, V138, P799, DOI 10.1164/ajrccm/138.4.799
   Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503
   Kobayashi M, 2006, EUR RESPIR J, V27, P726, DOI 10.1183/09031936.06.00107004
   LAM BK, 1992, P NATL ACAD SCI USA, V89, P11598, DOI 10.1073/pnas.89.23.11598
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   LEWIS RA, 1990, NEW ENGL J MED, V323, P645
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Mesquita-Santos FP, 2006, J IMMUNOL, V176, P1326, DOI 10.4049/jimmunol.176.3.1326
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003
   Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524
   Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x
   Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200
   Vieira-de-Abreu A, 2005, INT IMMUNOPHARMACOL, V5, P1966, DOI 10.1016/j.intimp.2005.06.003
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wardlaw AJ, 1999, J ALLERGY CLIN IMMUN, V104, P917, DOI 10.1016/S0091-6749(99)70069-2
   WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626
   Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244
   Yu WG, 1998, AM J PATHOL, V152, P759
NR 45
TC 16
Z9 16
U1 0
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD APR
PY 2011
VL 44
IS 4
BP 509
EP 516
DI 10.1165/rcmb.2010-0004OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 753KX
UT WOS:000289773400010
PM 20539011
DA 2020-12-01
ER

PT J
AU Svensjo, E
   Saraiva, EM
   Barja-Fidalgo, C
   Bozza, MT
   Lerner, EA
   Teixeira, MM
   Scharfstein, J
AF Svensjoe, Erik
   Saraiva, Elvira M.
   Barja-Fidalgo, Christina
   Bozza, Marcelo T.
   Lerner, Ethan A.
   Teixeira, Mauro M.
   Scharfstein, Julio
TI The vasodilatory peptide maxadilan increases plasma leakage in
   postcapillary venules due to activation of leukocytes via CXCL2-release
SO FASEB JOURNAL
LA English
DT Meeting Abstract
CT Experimental Biology Meeting 2011
CY APR 09-13, 2011
CL Washington, DC
SP Amer Assoc Anatomists (AAA), Amer Physiolog Soc (APS), Amer Soc Biochem & Mol Biol (ASBMB), Amer Soc Investigat Pathol (ASIP), Amer Soc Nutrit (ASN), Amer Soc Pharmacol & Expt Therapeut (ASPET)
C1 [Svensjoe, Erik; Scharfstein, Julio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, BR-21941 Rio De Janeiro, Brazil.
   [Saraiva, Elvira M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Rio de Janeiro, Brazil.
   [Barja-Fidalgo, Christina] Univ Estado Rio de Janeiro, Dept Pharmacol IBRAG, BR-20550011 Rio De Janeiro, Brazil.
   [Lerner, Ethan A.] Cutaneous Biol Res Ctr, Boston, MA USA.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
RI Svensjo, Erik/B-5026-2008; Teixeira, Mauro M/A-4587-2008; Saraiva,
   Elvira M/L-2864-2017
OI Svensjo, Erik/0000-0002-7356-1787; Teixeira, Mauro
   M/0000-0002-6944-3008; Saraiva, Elvira M/0000-0002-6388-5286
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 032IE
UT WOS:000310708400224
DA 2020-12-01
ER

PT J
AU Figueiredo, RT
   Carneiro, LAM
   Bozza, MT
AF Figueiredo, Rodrigo T.
   Carneiro, Leticia A. M.
   Bozza, Marcelo T.
TI Fungal surface and innate immune recognition of filamentous fungi
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE fungi; PRRs; innate immunity; inflammation; signaling; macrophages;
   cytokines
ID C-TYPE LECTIN; ASPERGILLUS-FUMIGATUS CONIDIA; BETA-GLUCAN RECEPTOR;
   NF-KAPPA-B; CANDIDA-ALBICANS PHOSPHOLIPOMANNAN; MACROPHAGE MANNOSE
   RECEPTOR; HEMATOPOIETIC STEM-CELL; TOLL-LIKE RECEPTOR-2; SINGLE-STRANDED
   RNA; CRYPTOCOCCUS-NEOFORMANS
AB The innate immune system performs specific detection of molecules from infectious agents through pattern recognition receptors. This recognition triggers inflammatory responses and activation of microbicidal mechanisms by leukocytes. Infections caused by filamentous fungi have increased in incidence and represent an important cause of mortality and morbidity especially in individuals with immunosuppression. This review will discuss the innate immune recognition of filamentous fungi molecules and its importance to infection control and disease.
C1 [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed Polo Xerem, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Carneiro, Leticia A. M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Figueiredo, RT (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, CCS Bloco F 014,Ave Carlos Chagas Filho, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM rotifi@icb.ufrj.br; mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016; Carneiro, Leticia/T-8978-2019
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Bozza,
   Marcelo/0000-0003-3683-7550
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa no Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); PRONEX; Antonio Luis Vianna Program of the
   PR2-UFRJ
FX Rodrigo T. Figueiredo was supported by grants of Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and Fundacao de Amparo
   a Pesquisa no Estado do Rio de Janeiro (FAPERJ). Marcelo T. Bozza was
   supported by grants of Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), and Fundacao de Amparo a Pesquisa no Estado do Rio
   de Janeiro (FAPERJ), PRONEX. Leticia A. M. Carneiro was supported by
   Fundacao de Amparo a Pesquisa no Estado do Rio de Janeiro (FAPERJ) and
   by the Antonio Luis Vianna Program of the PR2-UFRJ.
CR Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957
   Azad AK, 2008, J LEUKOCYTE BIOL, V84, P1594, DOI 10.1189/jlb.0308192
   Barbosa FM, 2007, CLIN VACCINE IMMUNOL, V14, P94, DOI 10.1128/CVI.00296-06
   Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059
   Bi LK, 2010, J BIOL CHEM, V285, P25969, DOI 10.1074/jbc.M110.131300
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629
   Bretz C, 2008, INFECT IMMUN, V76, P952, DOI 10.1128/IAI.00927-07
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620
   Brunn GJ, 2005, FASEB J, V19, P872, DOI 10.1096/fj.04-3211fje
   Bugarcic A, 2008, GLYCOBIOLOGY, V18, P679, DOI 10.1093/glycob/cwn046
   Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029
   Cambi A, 2008, J BIOL CHEM, V283, P20590, DOI 10.1074/jbc.M709334200
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271
   Chaffin WL, 1998, MICROBIOL MOL BIOL R, V62, P130, DOI 10.1128/MMBR.62.1.130-180.1998
   Chamilos G, 2006, HAEMATOL-HEMATOL J, V91, P986
   Costachel C, 2005, J BIOL CHEM, V280, P39835, DOI 10.1074/jbc.M510163200
   Dan JM, 2008, INFECT IMMUN, V76, P2362, DOI 10.1128/IAI.00095-08
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Debierre-Grockiego F, 2007, J IMMUNOL, V179, P1129, DOI 10.4049/jimmunol.179.2.1129
   Delfino D, 1997, INFECT IMMUN, V65, P2454, DOI 10.1128/IAI.65.6.2454-2456.1997
   DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Dubourdeau M, 2006, J IMMUNOL, V177, P3994, DOI 10.4049/jimmunol.177.6.3994
   Enoch DA, 2006, J MED MICROBIOL, V55, P809, DOI 10.1099/jmm.0.46548-0
   EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Figueiredo RT, 2010, J BIOL CHEM, V285, P40714, DOI 10.1074/jbc.M110.181255
   Fonseca FL, 2010, INFECT IMMUN, V78, P3861, DOI 10.1128/IAI.00111-10
   Fontaine T, 2003, GLYCOBIOLOGY, V13, P169, DOI 10.1093/glycob/cwg004
   Fontaine T, 2000, J BIOL CHEM, V275, P41528
   Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Gersuk GM, 2006, J IMMUNOL, V176, P3717, DOI 10.4049/jimmunol.176.6.3717
   Goodridge HS, 2007, J IMMUNOL, V178, P3107, DOI 10.4049/jimmunol.178.5.3107
   Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071
   Groll AH, 2001, CLIN MICROBIOL INFEC, V7, P8, DOI 10.1111/j.1469-0691.2001.tb00005.x
   Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Hara H, 2007, NAT IMMUNOL, V8, P619, DOI 10.1038/ni1466
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140
   Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002
   Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Hsu TL, 2009, J BIOL CHEM, V284, P34479, DOI 10.1074/jbc.M109.065961
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784
   Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018
   Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kerrigan AM, 2010, IMMUNOL REV, V234, P335, DOI 10.1111/j.0105-2896.2009.00882.x
   Kerrigan AM, 2009, IMMUNOBIOLOGY, V214, P562, DOI 10.1016/j.imbio.2008.11.003
   Kesh S, 2005, ANN NY ACAD SCI, V1062, P95, DOI 10.1196/annals.1358.012
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673
   Kumar H, 2009, J IMMUNOL, V183, P8061, DOI 10.4049/jimmunol.0902477
   Latge JP, 2010, CELL MICROBIOL, V12, P863, DOI 10.1111/j.1462-5822.2010.01474.x
   Latge JP, 2001, TRENDS MICROBIOL, V9, P382, DOI 10.1016/S0966-842X(01)02104-7
   Lee RT, 2011, GLYCOBIOLOGY, V21, P512, DOI 10.1093/glycob/cwq193
   Lee SJ, 2003, INFECT IMMUN, V71, P437, DOI 10.1128/IAI.71.1.437-445.2003
   Leitao EA, 2003, GLYCOBIOLOGY, V13, P681, DOI 10.1093/glycob/cwg089
   Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5
   Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101
   Luther K, 2007, CELL MICROBIOL, V9, P368, DOI 10.1111/j.1462-5822.2006.00796.x
   Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200
   Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202
   Masumoto M, 1999, J IMMUNOL, V163, P5039
   Masuoka J, 2004, CLIN MICROBIOL REV, V17, P281, DOI 10.1128/CMR.17.2.281-310.2004
   McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077
   Means TK, 1999, J IMMUNOL, V163, P6748
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Meersseman W, 2008, AM J RESP CRIT CARE, V177, P27, DOI 10.1164/rccm.200704-606OC
   Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x
   Miyake Yasunobu, 2010, Self Nonself, V1, P310, DOI 10.4161/self.1.4.13736
   Monari C, 2005, J INFECT DIS, V191, P127, DOI 10.1086/426511
   Morgan J, 2005, MED MYCOL, V43, pS49, DOI 10.1080/13693780400020113
   MURATA T, 1987, INFECT IMMUN, V55, P1784, DOI 10.1128/IAI.55.8.1784-1791.1987
   Murray CK, 2008, BURNS, V34, P1108, DOI 10.1016/j.burns.2008.04.007
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Netea MG, 2003, J INFECT DIS, V188, P320, DOI 10.1086/376456
   Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511
   Netea MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830
   Pasqualotto AC, 2006, CLIN MICROBIOL INFEC, V12, P1060, DOI 10.1111/j.1469-0691.2006.01512.x
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Retini C, 1996, INFECT IMMUN, V64, P2897, DOI 10.1128/IAI.64.8.2897-2903.1996
   Rodrigues ML, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00171
   Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004
   Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008
   Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425
   Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001
   Sandor F, 2003, J CELL BIOL, V162, P1099, DOI 10.1083/jcb.200304093
   Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200
   Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683
   Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   Segal BH, 2006, AM J RESP CRIT CARE, V173, P707, DOI 10.1164/rccm.200505-727SO
   Serrano-Gomez D, 2004, J IMMUNOL, V173, P5635, DOI 10.4049/jimmunol.173.9.5635
   Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620
   Singh N, 2001, CLIN INFECT DIS, V33, P1692, DOI 10.1086/323895
   Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932
   Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042
   Swain SD, 2003, INFECT IMMUN, V71, P6213, DOI 10.1128/IAI.71.11.6213-6221.2003
   Syme RM, 2002, INFECT IMMUN, V70, P5972, DOI 10.1128/IAI.70.11.5972-5981.2002
   Tachado SD, 2007, J LEUKOCYTE BIOL, V81, P205, DOI 10.1189/jlb.1005580
   Tada H, 2002, MICROBIOL IMMUNOL, V46, P503, DOI 10.1111/j.1348-0421.2002.tb02727.x
   Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554
   Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10
   Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933
   Tapping RI, 2003, J ENDOTOXIN RES, V9, P264, DOI 10.1179/096805103225001477
   Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200
   Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408
   Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248
   Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200
   Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605
   van de Veerdonk FL, 2008, CURR OPIN MICROBIOL, V11, P305, DOI 10.1016/j.mib.2008.06.002
   van de Veerdonk FL, 2011, EUR J IMMUNOL, V41, P2260, DOI 10.1002/eji.201041226
   van der Graaf CAA, 2006, CLIN VACCINE IMMUNOL, V13, P423, DOI 10.1128/CVI.13.3.423-425.2006
   van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182
   Vecchiarelli A, 1996, INFECT IMMUN, V64, P2846, DOI 10.1128/IAI.64.7.2846-2849.1996
   Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020
   Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001
   Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404
   Werner JL, 2009, J IMMUNOL, V182, P4938, DOI 10.4049/jimmunol.0804250
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Willment JA, 2008, TRENDS MICROBIOL, V16, P27, DOI 10.1016/j.tim.2007.10.012
   WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311
   Xin H, 2008, P NATL ACAD SCI USA, V105, P13526, DOI 10.1073/pnas.0803195105
   Yamasaki S, 2009, P NATL ACAD SCI USA, V106, P1897, DOI 10.1073/pnas.0805177106
   Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651
   Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107
   Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758
   Zhang HJ, 2008, ACTA PHARMACOL SIN, V29, P1202, DOI 10.1111/j.1745-7254.2008.00860.x
   Zhang JM, 2005, MOL BIOL CELL, V16, P824
NR 146
TC 19
Z9 19
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PY 2011
VL 2
AR 248
DI 10.3389/fmicb.2011.00248
PG 14
WC Microbiology
SC Microbiology
GA V31DE
UT WOS:000208863500256
PM 22194732
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Figueiredo, RT
   Fernandez, PL
   Dutra, FF
   Gonzalez, Y
   Lopes, LC
   Bittencourt, VCB
   Sassaki, GL
   Barreto-Bergter, E
   Bozza, MT
AF Figueiredo, Rodrigo T.
   Fernandez, Patricia L.
   Dutra, Fabianno F.
   Gonzalez, Yissett
   Lopes, Livia Cristina
   Bittencourt, Vera Carolina B.
   Sassaki, Guilherme L.
   Barreto-Bergter, Eliana
   Bozza, Marcelo T.
TI TLR4 Recognizes Pseudallescheria boydii Conidia and Purified
   Rhamnomannans
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INVASIVE PULMONARY ASPERGILLOSIS; TOLL-LIKE RECEPTOR-2;
   CANDIDA-ALBICANS; FUNGAL PATHOGENS; HOST-DEFENSE; INFECTIONS; FUMIGATUS;
   DECTIN-1; ALPHA; SCEDOSPORIUM
AB Pseudallescheria boydii (Scedosporium apiospermum) is a saprophytic fungus widespread in the environment, and has recently emerged as an agent of localized as well as disseminated infections, particularly mycetoma, in immunocompromised and immunocompetent hosts. We have previously shown that highly purified alpha-glucan from P. boydii activates macrophages through Toll-like receptor TLR2, however, the mechanism of P. boydii recognition by macrophage is largely unknown. In this work, we investigated the role of innate immune receptors in the recognition of P. boydii. Macrophages responded to P. boydii conidia and hyphae with secretion of proinflammatory cytokines. The activation of macrophages by P. boydii conidia required functional MyD88, TLR4, and CD14, whereas stimulation by hyphae was independent of TLR4 and TLR2 signaling. Removal of peptidorhamnomannans from P. boydii conidia abolished induction of cytokines by macrophages. A fraction highly enriched in rhamnomannans was obtained and characterized by NMR, high performance TLC, and GC-MS. Preparation of rhamnomannans derived from P. boydii triggered cytokine release by macrophages, as well as MAPKs phosphorylation and I kappa B alpha degradation. Cytokine release induced by P. boydii-derived rhamnomannans was dependent on TLR4 recognition and required the presence of non-reducing end units of rhamnose of the rhamnomannan, but not O-linked oligosaccharides from the peptidorhamnomannan. These results imply that TLR4 recognizes P. boydii conidia and this recognition is at least in part due to rhamnomannans expressed on the surface of P. boydii.
C1 [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-941902 Rio De Janeiro, Brazil.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-941902 Rio De Janeiro, Brazil.
   [Fernandez, Patricia L.; Gonzalez, Yissett] Inst Sci Invest & High Technol Serv, INDICASAT, Ciudad De Panama 84301103, Panama.
   [Lopes, Livia Cristina; Bittencourt, Vera Carolina B.; Barreto-Bergter, Eliana] Univ Fed Rio de Janeiro, Dept Microbiol Geral, Inst Microbiol, BR-941902 Rio De Janeiro, Brazil.
   [Bittencourt, Vera Carolina B.] Univ Fed Estado Rio de Janeiro, BR-20211040 Rio De Janeiro, Brazil.
   [Sassaki, Guilherme L.] Univ Fed Parana, Dept Bioquim, BR-81531990 Curitiba, Parana, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, CCS Bloco 1,Ave Carlos Chagas Filho,373 Cidade Un, BR-21941902 Rio de Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016; Sassaki, Guilherme/AAM-1112-2020;
   Dutra, Fabianno F/C-1387-2015; Bergter, Eliana Barreto/E-2664-2013
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Sassaki,
   Guilherme/0000-0001-7420-168X; Dutra, Fabianno F/0000-0003-3106-7585;
   Bozza, Marcelo/0000-0003-3683-7550; Llanes Fernandez,
   Patricia/0000-0002-0762-0566; bittencourt, vera/0000-0002-7403-9747
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Ensino Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Programa de Nucleos de Excelencia
   (Pronex)National Council for Scientific and Technological Development
   (CNPq); Universidade Federal do Rio de Janeiro
FX The work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Ensino Superior (CAPES), Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), Programa de Nucleos de Excelencia
   (Pronex), and Universidade Federal do Rio de Janeiro.
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Ames BN, 1966, METHOD ENZYMOL, V8, P115, DOI DOI 10.1016/0076-6879(66)08014-5
   Baddley JW, 2001, CLIN INFECT DIS, V32, P1319, DOI 10.1086/319985
   Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005
   Barbosa FM, 2007, CLIN VACCINE IMMUNOL, V14, P94, DOI 10.1128/CVI.00296-06
   BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
   BELCHER R, 1954, ANALYST, V79, P201, DOI 10.1039/an9547900201
   Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Chieppa M, 2003, J IMMUNOL, V171, P4552, DOI 10.4049/jimmunol.171.9.4552
   Cortez KJ, 2008, CLIN MICROBIOL REV, V21, P157, DOI 10.1128/CMR.00039-07
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Gersuk GM, 2006, J IMMUNOL, V176, P3717, DOI 10.4049/jimmunol.176.6.3717
   Gilgado F, 2005, J CLIN MICROBIOL, V43, P4930, DOI 10.1128/JCM.43.10.4930-4942.2005
   Gorin P. A. J., 1981, ADV CARBOHYD CHEM BI, V38, P13, DOI DOI 10.1016/S0065-2318(08)60309-1
   Hohl TM, 2006, CURR OPIN IMMUNOL, V18, P465, DOI 10.1016/j.coi.2006.05.003
   Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030
   Hsu TL, 2009, J BIOL CHEM, V284, P34479, DOI 10.1074/jbc.M109.065961
   Leitao EA, 2003, GLYCOBIOLOGY, V13, P681, DOI 10.1093/glycob/cwg089
   Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5
   Levitz SM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000758
   Lopes LCL, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000853
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200
   Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x
   Netea MG, 2004, EUR J CLIN MICROBIOL, V23, P672, DOI 10.1007/s10096-004-1192-7
   Netea MG, 2003, J INFECT DIS, V188, P320, DOI 10.1086/376456
   Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511
   Netea MG, 2006, J CLIN INVEST, V116, P1642, DOI 10.1172/JCI27114
   O'Bryan Thomas A, 2005, Expert Rev Anti Infect Ther, V3, P765, DOI 10.1586/14787210.3.5.765
   Peter E, 2002, CLIN INFECT DIS, V35, pE54, DOI 10.1086/341971
   Pinto MR, 2001, MICROBIOL-SGM, V147, P1499, DOI 10.1099/00221287-147-6-1499
   PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0
   Roilides E, 2009, MED MYCOL, V47, P433, DOI 10.1080/13693780902738006
   Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001
   Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620
   Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042
   Tada H, 2002, MICROBIOL IMMUNOL, V46, P503, DOI 10.1111/j.1348-0421.2002.tb02727.x
   Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605
   Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020
   Warris A, 2001, NEW ENGL J MED, V344, P1099, DOI 10.1056/NEJM200104053441415
   Wieland CW, 2007, MICROBES INFECT, V9, P134, DOI 10.1016/j.micinf.2006.10.018
   Zelante T, 2007, ADV EXP MED BIOL, V590, P209
NR 46
TC 22
Z9 23
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 24
PY 2010
VL 285
IS 52
BP 40714
EP 40723
DI 10.1074/jbc.M110.181255
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 696AN
UT WOS:000285414400035
PM 20959459
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Magalhaes, KG
   Almeida, PE
   Atella, GC
   Maya-Monteiro, CM
   Castro-Faria-Neto, HC
   Pelajo-Machado, M
   Lenzi, HL
   Bozza, MT
   Bozza, PT
AF Magalhaes, Kelly G.
   Almeida, Patricia E.
   Atella, Georgia C.
   Maya-Monteiro, Clarissa M.
   Castro-Faria-Neto, Hugo C.
   Pelajo-Machado, Marcelo
   Lenzi, Henrique L.
   Bozza, Marcelo T.
   Bozza, Patricia T.
TI Schistosomal-Derived Lysophosphatidylcholine Are Involved in Eosinophil
   Activation and Recruitment through Toll-Like Receptor-2-Dependent
   Mechanisms
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID GRANULOMA-FORMATION; LYSOPHOSPHOLIPID RECEPTORS; TISSUE EOSINOPHILIA;
   MANSONI INFECTION; LIVER FIBROSIS; RAPID METHOD; TH2; CYTOKINE; CELLS;
   IL-4
AB Parasite-derived lipids may play important roles in host-pathogen interactions and escape mechanisms. Herein, we evaluated the role of schistosomal-derived lipids in Toll-like receptor (TLR)-2 and eosinophil activation in Schistosoma mansoni infection. Mice lacking TLR2 exhibited reduced liver eosinophilic granuloma, compared with that of wild-type animals, following S. mansoni infection. Decreased eosinophil accumulation and eosinophil lipid body (lipid droplet) formation, at least partially due to reduced production of eotaxin, interleukin (IL)-5, and IL-13 in S. mansoni-infected TLR2(-/-) mice, compared with the corresponding production in wild-type mice, was noted. Although no differences were observed in survival rates during the acute schistosomal infection (up to 50 days), increased survival of TLR2(-/-) mice, compared with survival of wild-type mice, was observed during the chronic phase of infection. Schistosomal lipid extract- and schistosomal-derived lysophosphatidylcholine (lyso-PC)-stimulated macrophages in vitro induced TLR2-dependent NF-kB activation and cytokine production. Furthermore, in vivo schistosomal lyso-PC administration induced eosinophil recruitment and cytokine production, in a mechanism largely dependent on TLR2. Taken together, our results suggest that schistosomal-derived lyso-PC may participate in cytokine production and eosinophil activation through a TLR2-dependent pathway in S. mansoni infection. Moreover, our results suggest that TLR2-dependent inflammatory reaction, cytokine production, and eosinophil recruitment and activation may contribute to the pathogenesis and lethality in the chronic phase of infection.
C1 [Magalhaes, Kelly G.; Almeida, Patricia E.; Maya-Monteiro, Clarissa M.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Lab Imunofarmacol, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Magalhaes, Kelly G.; Pelajo-Machado, Marcelo; Lenzi, Henrique L.] Fiocruz MS, Lab Patol, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Atella, Georgia C.] Univ Fed Rio de Janeiro, Inst Microbiol, Inst Bioquim Med, BR-21941 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fiocruz MS, Lab Imunofarmacol, IOC, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Atella, Georgia/AAK-7897-2020;
   Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Pelajo Machado, Marcelo/0000-0002-7295-7018;
   Almeida, Patricia Elaine de/0000-0002-9081-8601; Bozza,
   Marcelo/0000-0003-3683-7550; Bozza, Patricia/0000-0001-8349-9529
FU PAPES-FIOCRUZ, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX PAPES-FIOCRUZ, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil); Fundacao de Amparo a Pesquisa do Rio de
   Janeiro (FAPERJ, Brazil).
CR Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200
   Akuthota P, 2008, CLIN EXP ALLERGY, V38, P1254, DOI 10.1111/j.1365-2222.2008.03037.x
   Behm CA, 2000, PARASITOL TODAY, V16, P202, DOI 10.1016/S0169-4758(99)01620-8
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   BOZZA PT, 1993, EUR J PHARM-ENVIRON, V248, P41, DOI 10.1016/0926-6917(93)90023-J
   Brouwers JFHM, 1998, MOL BIOCHEM PARASIT, V96, P49, DOI 10.1016/S0166-6851(98)00103-0
   Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026
   Chiaramonte MG, 1999, J IMMUNOL, V162, P920
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842
   Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017
   de Jesus AR, 2004, INFECT IMMUN, V72, P3391, DOI 10.1128/IAI.72.6.3391-3397.2004
   Duraes FV, 2009, IMMUNOL LETT, V125, P72, DOI 10.1016/j.imlet.2009.06.004
   FURLONG ST, 1989, EXP PARASITOL, V69, P65, DOI 10.1016/0014-4894(89)90172-0
   FURLONG ST, 1988, EXP PARASITOL, V65, P222, DOI 10.1016/0014-4894(88)90126-9
   Golodne DM, 2003, J BIOL CHEM, V278, P27766, DOI 10.1074/jbc.M212421200
   Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X
   Herbert DR, 2008, J IMMUNOL, V180, P4948, DOI 10.4049/jimmunol.180.7.4948
   Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x
   Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731
   Jankovic D, 1999, J IMMUNOL, V163, P337
   Jenkins SJ, 2005, INT IMMUNOL, V17, P1409, DOI 10.1093/intimm/dxh319
   Kane CM, 2008, INFECT IMMUN, V76, P5754, DOI 10.1128/IAI.00497-08
   Kaplan MH, 1998, J IMMUNOL, V160, P1850
   Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050
   Layland LE, 2007, EUR J IMMUNOL, V37, P2174, DOI 10.1002/eji.200737063
   Layland LE, 2005, EUR J IMMUNOL, V35, P3248, DOI 10.1002/eji.200526273
   LENZI H L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P67, DOI 10.1590/S0074-02761987000800011
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   MOLONEY NA, 1982, T ROY SOC TROP MED H, V76, P200, DOI 10.1016/0035-9203(82)90274-7
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x
   Penido C, 2001, AM J RESP CELL MOL, V25, P707, DOI 10.1165/ajrcmb.25.6.4401
   Ramalingam TR, 2005, CURR OPIN ALLERGY CL, V5, P392, DOI 10.1097/01.all.0000182542.30100.6f
   Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006
   Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871
   SHER A, 1990, P NATL ACAD SCI USA, V87, P61, DOI 10.1073/pnas.87.1.61
   Silveira-Lemos D, 2008, ACTA TROP, V108, P150, DOI 10.1016/j.actatropica.2008.04.006
   Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103
   Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058
   Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Torkhovskaya TI, 2007, BIOCHEMISTRY-MOSCOW+, V72, P125, DOI 10.1134/S0006297907020010
   van der Kleij D, 2003, EUR J IMMUNOL, V33, P2953, DOI 10.1002/eji.200324340
   van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200
   Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007
   Vanhoutte F, 2007, MICROBES INFECT, V9, P1606, DOI 10.1016/j.micinf.2007.09.013
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x
NR 50
TC 37
Z9 38
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2010
VL 202
IS 9
BP 1369
EP 1379
DI 10.1086/656477
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 656VB
UT WOS:000282367900011
PM 20863227
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Fernandez, PL
   Dutra, FF
   Alves, L
   Figueiredo, RT
   Mourao-Sa, D
   Fortes, GB
   Bergstrand, S
   Lonn, D
   Cevallos, RR
   Pereira, RMS
   Lopes, UG
   Travassos, LH
   Paiva, CN
   Bozza, MT
AF Fernandez, Patricia L.
   Dutra, Fabianno F.
   Alves, Leticia
   Figueiredo, Rodrigo T.
   Mourao-Sa, Diego
   Fortes, Guilherme B.
   Bergstrand, Sophie
   Loenn, David
   Cevallos, Ricardo R.
   Pereira, Renata M. S.
   Lopes, Ulisses G.
   Travassos, Leonardo H.
   Paiva, Claudia N.
   Bozza, Marcelo T.
TI Heme Amplifies the Innate Immune Response to Microbial Molecules through
   Spleen Tyrosine Kinase (Syk)-dependent Reactive Oxygen Species
   Generation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; INCREASES MORTALITY; NLRP3 INFLAMMASOME; SEVERE MALARIA;
   HOST-DEFENSE; ACTIVATION; RECEPTORS; RECOGNITION; DECTIN-1; ALPHA
AB Infectious diseases that cause hemolysis are among the most threatening human diseases, because of severity and/or global distribution. In these conditions, hemeproteins and heme are released, but whether heme affects the inflammatory response to microorganism molecules remains to be characterized. Here, we show that heme increased the lethality and cytokine secretion induced by LPS in vivo and enhanced the secretion of cytokines by macrophages stimulated with various agonists of innate immune receptors. Activation of nuclear factor kappa B (NF-kappa B) and MAPKs and the generation of reactive oxygen species were essential to the increase in cytokine production induced by heme plus LPS. This synergistic effect of heme and LPS was blocked by a selective inhibitor of spleen tyrosine kinase (Syk) and was abrogated in dendritic cells deficient in Syk. Moreover, inhibition of Syk and the downstream molecules PKC and PI3K reduced the reactive oxygen species generation by heme. Our results highlight a mechanism by which heme amplifies the secretion of cytokines triggered by microbial molecule activation and indicates possible pathways for therapeutic intervention during hemolytic infectious diseases.
C1 [Fernandez, Patricia L.; Dutra, Fabianno F.; Alves, Leticia; Figueiredo, Rodrigo T.; Fortes, Guilherme B.; Bergstrand, Sophie; Loenn, David; Travassos, Leonardo H.; Paiva, Claudia N.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, Brazil.
   [Fernandez, Patricia L.; Cevallos, Ricardo R.] Inst Invest Cient & Serv Alta Tecnol, Panama City 084301103, Panama.
   [Figueiredo, Rodrigo T.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, Brazil.
   [Mourao-Sa, Diego] London Res Inst, Lincolns Inn Fields Labs, Immunobiol Lab, London WC2A 3PX, England.
   [Pereira, Renata M. S.; Lopes, Ulisses G.; Travassos, Leonardo H.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Lopes, Ulisses/N-4416-2013; Lopes, Ulisses Gazos/T-6634-2019;
   Figueiredo, Rodrigo T./F-5176-2016; Travassos, Leonardo/G-1925-2012;
   Dutra, Fabianno F/C-1387-2015; Pereira, Renata/V-6194-2019
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Travassos,
   Leonardo/0000-0003-1323-3797; Dutra, Fabianno F/0000-0003-3106-7585;
   Llanes Fernandez, Patricia/0000-0002-0762-0566; Cevallos,
   Ricardo/0000-0001-9759-7859; Mourao, Diego/0000-0001-6618-6969; Bozza,
   Marcelo/0000-0003-3683-7550; Pereira, Renata/0000-0002-7719-8356
FU Conselho de Desenvolvimento Cientifico e TecnologicoNational Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Estado do Rio de JaneiroCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); Fundacao Jose
   Bonifacio; Programa de Nucleos de Excelencia; Secretaria Nacional de
   Ciencia Tecnologia e Innovacion de Panama
FX This work was supported by Conselho de Desenvolvimento Cientifico e
   Tecnologico, Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro,
   Fundacao Jose Bonifacio, and Programa de Nucleos de Excelencia,
   Secretaria Nacional de Ciencia Tecnologia e Innovacion de Panama.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   GRIFFITHS E, 1995, LANCET, V345, P158, DOI 10.1016/S0140-6736(95)90168-X
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002
   Ivashkiv LB, 2009, NAT IMMUNOL, V10, P340, DOI 10.1038/ni.1706
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246
   Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112
   Nathan C, 2003, J CLIN INVEST, V111, P769, DOI 10.1172/JCI200318174
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925
   Powers KA, 2006, J EXP MED, V203, P1951, DOI 10.1084/jem.20060943
   Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004
   SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Shaw MH, 2008, CURR OPIN IMMUNOL, V20, P377, DOI 10.1016/j.coi.2008.06.001
   Su DH, 1997, INFECT IMMUN, V65, P1258, DOI 10.1128/IAI.65.4.1258-1266.1997
   Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   Turnbull IR, 2005, J EXP MED, V202, P363, DOI 10.1084/jem.20050986
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Wang L, 2010, IMMUNITY, V32, P518, DOI 10.1016/j.immuni.2010.03.014
   Yang H, 2002, SHOCK, V17, P485, DOI 10.1097/00024382-200206000-00008
NR 36
TC 52
Z9 52
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 22
PY 2010
VL 285
IS 43
BP 32844
EP 32851
DI 10.1074/jbc.M110.146076
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 665PP
UT WOS:000283048200021
PM 20729208
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Andrade, BB
   Araujo-Santos, T
   Luz, NF
   Khouri, R
   Bozza, MT
   Camargo, LMA
   Barral, A
   Borges, VM
   Barral-Netto, M
AF Andrade, Bruno B.
   Araujo-Santos, Theo
   Luz, Nivea F.
   Khouri, Ricardo
   Bozza, Marcelo T.
   Camargo, Luis M. A.
   Barral, Aldina
   Borges, Valeria M.
   Barral-Netto, Manoel
TI Heme Impairs Prostaglandin E-2 and TGF-beta Production by Human
   Mononuclear Cells via Cu/Zn Superoxide Dismutase: Insight into the
   Pathogenesis of Severe Malaria
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; MIGRATION-INHIBITORY FACTOR;
   GROWTH-FACTOR-BETA; VIVAX MALARIA; OXIDATIVE STRESS; CEREBRAL MALARIA;
   DISEASE SEVERITY; GENE-EXPRESSION; IN-VIVO; BLOOD
AB In many hemolytic disorders, such as malaria, the release of free heme has been involved in the triggering of oxidative stress and tissue damage. Patients presenting with severe forms of malaria commonly have impaired regulatory responses. Although intriguing, there is scarce data about the involvement of heme on the regulation of immune responses. In this study, we investigated the relation of free heme and the suppression of anti-inflammatory mediators such as PGE(2) and TGF-beta in human vivax malaria. Patients with severe disease presented higher hemolysis and higher plasma concentrations of Cu/Zn superoxide dismutase (SOD-1) and lower concentrations of PGE(2) and TGF-beta than those with mild disease. In addition, there was a positive correlation between SOD-1 concentrations and plasma levels of TNF-alpha. During antimalaria treatment, the concentrations of plasma SOD-1 reduced whereas PGE(2) and TGF-beta increased in the individuals severely ill. Using an in vitro model with human mononuclear cells, we demonstrated that the heme effect on the impairment of the production of PGE(2) and TGF-beta partially involves heme binding to CD14 and depends on the production of SOD-1. Aside from furthering the current knowledge about the pathogenesis of vivax malaria, the present results may represent a general mechanism for hemolytic diseases and could be useful for future studies of therapeutic approaches. The Journal of Immunology, 2010, 185: 1196-1204.
C1 [Andrade, Bruno B.; Araujo-Santos, Theo; Luz, Nivea F.; Barral, Aldina; Borges, Valeria M.; Barral-Netto, Manoel] Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, BR-40295001 Salvador, BA, Brazil.
   [Andrade, Bruno B.; Araujo-Santos, Theo; Luz, Nivea F.; Barral, Aldina; Barral-Netto, Manoel] Univ Fed Bahia, Fac Med Bahia, Salvador, BA, Brazil.
   [Camargo, Luis M. A.] Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biol, BR-05508 Sao Paulo, Brazil.
   [Barral, Aldina; Borges, Valeria M.; Barral-Netto, Manoel] Inst Nacl Ciencia & Tecnol, Inst Invest Imunol, Sao Paulo, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
   [Khouri, Ricardo] Katholieke Univ Leuven, Rega Inst, Leuven, Belgium.
RP Barral-Netto, M (corresponding author), Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Moniz, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.
EM mbarral@bahia.fiocruz.br
RI Barral, Aldina/B-4191-2009; Borges, Valeria/G-2009-2014; Inagemp,
   Inct/J-9451-2013; Andrade, Bruno/AAI-2248-2020; Barral-Netto,
   Manoel/B-3904-2009; Andrade, Bruno/J-9111-2012; CAMARGO,
   LMA/B-4156-2009; Borges, Val/N-6647-2019; Araujo-Santos,
   Theo/F-9807-2014; Khouri, Ricardo/M-3184-2018
OI Barral, Aldina/0000-0002-7177-464X; Barral-Netto,
   Manoel/0000-0002-5823-7903; Andrade, Bruno/0000-0001-6833-3811; CAMARGO,
   LMA/0000-0001-9486-6195; Borges, Val/0000-0002-2775-5409; Araujo-Santos,
   Theo/0000-0001-9861-6660; Khouri, Ricardo/0000-0001-5664-4436; Farias
   Luz, Nivea/0000-0003-1958-7043
FU Fundo Nacional de Desenvolvimento Cientifico e Tecnologico Amazonia
   [010409605]; Brazilian National Research Council (Conselho Nacional de
   Pesquisa e Tecnologia)National Council for Scientific and Technological
   Development (CNPq)
FX This work was supported by Financiadora de Estudos e Projetos (Grant
   010409605)/Fundo Nacional de Desenvolvimento Cientifico e Tecnologico
   Amazonia. B. B. A., T. A. S., and N.F.L. received fellowships from the
   Brazilian National Research Council (Conselho Nacional de Pesquisa e
   Tecnologia). M. T. B., V. M. B., A. B., and M.B.-N. are senior
   investigators from the Conselho Nacional de Pesquisa e Tecnologia.
CR Ahmad M, 2009, AM J PHYSIOL-HEART C, V297, pH1453, DOI 10.1152/ajpheart.00315.2009
   Andrade BB, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000650
   Andrade BB, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-13
   [Anonymous], 2000, T R SOC TROP MED S1, V94, pS1
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155
   Ataga KI, 2007, HAEMATOLOGICA, V93, P20, DOI 10.3324/haematol.11763
   Awandare GA, 2007, INFECT IMMUN, V75, P201, DOI 10.1128/IAI.01327-06
   Bueno LL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009623
   Campos EG, 2005, GENET MOL RES, V4, P409
   Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010
   Clark IA, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-85
   Clark Ian A, 2008, Travel Med Infect Dis, V6, P67, DOI 10.1016/j.tmaid.2007.07.002
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003
   COCCO D, 1981, J BIOL CHEM, V256, P8983
   Covas MI, 1997, CLIN CHEM, V43, P1991
   DELMASBEAUVIEUX MC, 1995, CLIN BIOCHEM, V28, P163, DOI 10.1016/0009-9120(94)00071-3
   Dodoo D, 2002, J INFECT DIS, V185, P971, DOI 10.1086/339408
   Ekvall H, 2001, T ROY SOC TROP MED H, V95, P611, DOI 10.1016/S0035-9203(01)90095-1
   Emerit J, 2006, BIOMED PHARMACOTHER, V60, P1, DOI 10.1016/j.biopha.2005.09.002
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Golenser J, 1998, FREE RADICAL BIO MED, V24, P1504, DOI 10.1016/S0891-5849(98)00026-4
   Griffith JW, 2009, J IMMUNOL, V183, P5208, DOI 10.4049/jimmunol.0713552
   Hanscheid T, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-109
   HILL HAO, 1980, BIOCHEM J, V185, P245, DOI 10.1042/bj1850245
   Hod EA, 2008, BLOOD, V112, P891, DOI 10.1182/blood-2008-01-132092
   Hoshino T, 2008, ANTIOXID REDOX SIGN, V10, P769, DOI 10.1089/ars.2007.1936
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Keller CC, 2006, J INFECT DIS, V193, P1384, DOI 10.1086/503047
   Keller CC, 2004, MOL MED, V10, P45, DOI 10.2119/2004-00035.Perkins
   Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
   Lamikanra AA, 2007, BLOOD, V110, P18, DOI 10.1182/blood-2006-09-018069
   Marikovsky M, 2003, J IMMUNOL, V170, P2993, DOI 10.4049/jimmunol.170.6.2993
   Newton CRJC, 1998, AM J TROP MED HYG, V58, P673, DOI 10.4269/ajtmh.1998.58.673
   Ocana-Morgner C, 2007, EUR J IMMUNOL, V37, P1562, DOI 10.1002/eji.200737068
   Omer FM, 1998, J EXP MED, V188, P39, DOI 10.1084/jem.188.1.39
   Pabon A, 2003, CLIN BIOCHEM, V36, P71, DOI 10.1016/S0009-9120(02)00423-X
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pamplona A, 2009, INT J BIOCHEM CELL B, V41, P711, DOI 10.1016/j.biocel.2008.09.020
   Perkins DJ, 2003, BIOCHEM BIOPH RES CO, V311, P839, DOI 10.1016/j.bbrc.2003.10.073
   Perkins DJ, 2001, J INFECT DIS, V183, P113, DOI 10.1086/317660
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Qi SF, 2009, TOXICOL APPL PHARM, V237, P111, DOI 10.1016/j.taap.2009.02.019
   REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C
   Schofield L, 2007, IMMUNOL CELL BIOL, V85, P130, DOI 10.1038/sj.icb.7100040
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344
   Soares MP, 2009, CURR OPIN PHARMACOL, V9, P482, DOI 10.1016/j.coph.2009.05.008
   Song YS, 2007, J CEREBR BLOOD F MET, V27, P764, DOI 10.1038/sj.jcbfm.9600379
   Tranquilli AL, 2007, CYTOKINE, V40, P82, DOI 10.1016/j.cyto.2007.08.010
   TRAPE JF, 1985, T ROY SOC TROP MED H, V79, P430, DOI 10.1016/0035-9203(85)90053-7
   Turkseven S, 2005, AM J PHYSIOL-HEART C, V289, pH701, DOI 10.1152/ajpheart.00024.2005
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Yeo TW, 2009, J INFECT DIS, V200, P1522, DOI 10.1086/644641
NR 57
TC 35
Z9 36
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2010
VL 185
IS 2
BP 1196
EP 1204
DI 10.4049/jimmunol.0904179
PG 9
WC Immunology
SC Immunology
GA 622PH
UT WOS:000279675200048
PM 20562262
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Svensjo, E
   Cruz, V
   Saraiva, EM
   Bozza, MT
   Lerner, EA
   Scharfstein, J
AF Svensjo, Erik
   Cruz, Vanessa
   Saraiva, Elvira M.
   Bozza, Marcelo T.
   Lerner, Ethan A.
   Scharfstein, Julio
TI The vasodilatory peptide maxadilan increases vascular permeability due
   to activation of leukocytes in postcapillary venules
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 [Svensjo, Erik; Cruz, Vanessa; Scharfstein, Julio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, BR-21941 Rio De Janeiro, Brazil.
   [Saraiva, Elvira M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio de Janeiro, Brazil.
   [Lerner, Ethan A.] Cutaneous Biol Res Ctr, Boston, MA USA.
RI Svensjo, Erik/B-5026-2008; Saraiva, Elvira M/L-2864-2017
OI Svensjo, Erik/0000-0002-7356-1787; Saraiva, Elvira M/0000-0002-6388-5286
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2010
VL 24
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA V28IW
UT WOS:000208675503164
DA 2020-12-01
ER

PT J
AU Regis, EG
   Barreto-de-Souza, V
   Morgado, MG
   Bozza, MT
   Leng, L
   Bucala, R
   Bou-Habib, DC
AF Regis, Eduardo G.
   Barreto-de-Souza, Victor
   Morgado, Mariza G.
   Bozza, Marcelo T.
   Leng, Lin
   Bucala, Richard
   Bou-Habib, Dumith C.
TI Elevated levels of macrophage migration inhibitory factor (MIF) in the
   plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: A
   relevant role on viral replication
SO VIROLOGY
LA English
DT Article
DE MIF; HIV-1; AIDS; LTR; gp120
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TUMOR-NECROSIS-FACTOR; PRODUCTIVE
   INFECTION; REGULATORY ROLE; HIV-1; ACTIVATION; EXPRESSION; INDUCTION;
   RECEPTOR; DISEASE
AB The cytokine macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of inflammatory and infectious diseases, however its role in HIV-1 infection is unknown. Here we show that HIV-1-infected patients present elevated plasma levels of MIF, that HIV-1-infected peripheral blood mononuclear cells (PBMCs) release a greater amount of MIF, and that the HIV-1 envelope glycoprotein gp120 induces MIF secretion from uninfected PBMCs. The HIV-1 replication in PBMCs declines when these cells are treated with anti-MIF antibodies, and exposure of HIV-1-infected cells to the ABC-transporter inhibitor probenecid results in inhibition of MIF secretion. The addition of recombinant MIF (rhMIF) to HIV-1-infected PBMCs enhances viral replication of CCR5- or CXCR4-tropic HIV-1 isolates. Using a T CD4(+) cell lineage containing an HIV long terminal repeats (LTR)-Luciferase construct, we detected that rhMIF promotes transcription from HIV-1 LTR. Our results show that HIV-1 induces MIF secretion and suggest that MIF influences the HIV-1 biology through activation of HIV-1 LTR. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Regis, Eduardo G.; Barreto-de-Souza, Victor; Bou-Habib, Dumith C.] Fiocruz MS, Inst Oswaldo Cruz, Lab Thymus Res, BR-21045900 Rio De Janeiro, Brazil.
   [Morgado, Mariza G.] Fiocruz MS, Inst Oswaldo Cruz, Lab AIDS & Mol Immunol, BR-21045900 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
   [Leng, Lin; Bucala, Richard] Yale Univ, Sch Med, New Haven, CT 06520 USA.
RP Bou-Habib, DC (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Thymus Res, Av Brasil,4365,Manguinhos Pav Leonidas Deane 506, BR-21045900 Rio De Janeiro, Brazil.
EM dumith@ioc.fiocruz.br
OI Bozza, Marcelo/0000-0003-3683-7550; Leng, Lin/0000-0002-0605-358X
FU PAPES/Fiocruz; CNPqNational Council for Scientific and Technological
   Development (CNPq); FaperjCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); CAPESCAPES; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [2 RO1 AI42310]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI042310, R01AI042310,
   R01AI042310, R01AI042310, R01AI042310, R01AI042310, R01AI042310,
   R01AI042310, R01AI042310, R01AI042310, R01AI042310, R01AI042310,
   R01AI042310, R01AI042310, R01AI042310, R01AI042310] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R01AR049610, R01AR049610,
   R01AR049610, R01AR049610, R01AR049610, R01AR049610, R01AR049610,
   R01AR049610, R01AR049610, R01AR049610, R01AR049610, R01AR049610,
   R01AR049610, R01AR049610, R01AR049610, R01AR049610] Funding Source: NIH
   RePORTER
FX We thank the Hemotherapy Service of the Hospital Clementino Fraga Filho
   (UFRJ) for providing buffy coats. This work was supported by grants from
   PAPES/Fiocruz, CNPq, Faperj and CAPES. The HIV-1 isolates Ba-L and Tybe,
   the recombinant HIV-1 proteins Tat and gp120, and the 1G5 cells were
   kindly donated by NIH AIDS Research and Reference Reagent Program
   (Division of AIDS, MAID, NIH, Bethesda, MD). Eduardo G. Regis is
   presently a Ph.D. Student of the Cellular and Molecular Biology
   Post-graduation Program at the Oswaldo Cruz Institute/FIOCRUZ, Rio de
   Janeiro, RJ, Brazil, and this paper is a partial fulfillment for
   obtaining his PhD title. Lin Leng and Richard Bucala are supported by
   NIH grant 2 RO1 AI42310.
CR AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295
   Alfano Massimo, 2008, Curr HIV/AIDS Rep, V5, P27, DOI 10.1007/s11904-008-0005-5
   Amano T, 2007, INFLAMM RES, V56, P24, DOI 10.1007/s00011-007-5184-9
   Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011
   Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218
   Arndt U, 2002, J VIROL, V76, P9298, DOI 10.1128/JVI.76.18.9298-9306.2002
   Awandare GA, 2007, AM J TROP MED HYG, V76, P1033, DOI 10.4269/ajtmh.2007.76.1033
   Ayoub S, 2008, NAT CLIN PRACT RHEUM, V4, P98, DOI 10.1038/ncprheum0701
   Bacher M, 2002, VIROLOGY, V299, P32, DOI 10.1006/viro.2002.1464
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Capobianchi MR, 1996, J BIOL REG HOMEOS AG, V10, P83
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   CHIODI F, 1987, AIDS RES HUM RETROV, V3, P165, DOI 10.1089/aid.1987.3.165
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621
   Copeland KFT, 2005, MINI-REV MED CHEM, V5, P1093, DOI 10.2174/138955705774933383
   DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974
   Emonts M, 2007, CLIN INFECT DIS, V44, P1321, DOI 10.1086/514344
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Finnegan A, 1996, J IMMUNOL, V156, P841
   Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1
   Gando S, 2007, INFLAMMATION, V30, P118, DOI 10.1007/s10753-007-9027-1
   Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200
   He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Hoi Alberta Y., 2007, Inflammation & Allergy Drug Targets, V6, P183, DOI 10.2174/187152807781696455
   Ichiyama H, 2004, CYTOKINE, V26, P187, DOI 10.1016/j.cyto.2004.02.007
   Javeed A, 2008, INFLAMM RES, V57, P45, DOI 10.1007/s00011-007-7110-6
   Kedzierska Katherine, 2001, Antiviral Chemistry and Chemotherapy, V12, P133
   Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x
   Klasse PJ, 2004, VIROLOGY, V323, P1, DOI 10.1016/j.virol.2004.03.003
   Kleemann R, 2000, NATURE, V408, P211
   Larson DF, 2006, CRIT CARE, V10, DOI 10.1186/cc4899
   Lee PI, 2009, J INFECT DIS, V199, P1664, DOI 10.1086/598953
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Lima RG, 2002, J INFECT DIS, V185, P1561, DOI 10.1086/340412
   Meazza C, 2002, ARTHRITIS RHEUM, V46, P232, DOI 10.1002/1529-0131(200201)46:1<232::AID-ART10059>3.0.CO;2-B
   Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599
   Munoz-Fernandez MA, 1997, J ALLERGY CLIN IMMUN, V100, P838, DOI 10.1016/S0091-6749(97)70282-3
   Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553
   Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857
   Ortigao-deo-Sampaio MB, 1998, AIDS, V12, pF145, DOI 10.1097/00002030-199814000-00001
   Schols D, 1996, J VIROL, V70, P4953, DOI 10.1128/JVI.70.8.4953-4960.1996
   Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020
   Stanley SK, 1996, NEW ENGL J MED, V334, P1222, DOI 10.1056/NEJM199605093341903
   Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853
   Stopak KS, 2007, J BIOL CHEM, V282, P3539, DOI 10.1074/jbc.M610138200
   Toh ML, 2006, J IMMUNOL, V177, P4818, DOI 10.4049/jimmunol.177.7.4818
   TOOSSI Z, 1993, J EXP MED, V177, P1511, DOI 10.1084/jem.177.5.1511
   Varthakavi V, 2008, NAT MED, V14, P641, DOI 10.1038/nm1778
   Wahl SM, 1999, J INFECT DIS, V179, pS457, DOI 10.1086/314814
   Zhang YJ, 1997, AIDS, V11, P1219, DOI 10.1097/00002030-199710000-00004
NR 64
TC 28
Z9 28
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD MAR 30
PY 2010
VL 399
IS 1
BP 31
EP 38
DI 10.1016/j.virol.2009.12.018
PG 8
WC Virology
SC Virology
GA 568AB
UT WOS:000275491600004
PM 20085845
OA Green Accepted
DA 2020-12-01
ER

PT J
AU Assuncao-Miranda, I
   Amaral, FA
   Bozza, FA
   Fagundes, CT
   Sousa, LP
   Souza, DG
   Pacheco, P
   Barbosa-Lima, G
   Gomes, RN
   Bozza, PT
   Da Poian, AT
   Teixeira, MM
   Bozza, MT
AF Assuncao-Miranda, Iranaia
   Amaral, Flavio A.
   Bozza, Fernando A.
   Fagundes, Caio T.
   Sousa, Lirlandia P.
   Souza, Danielle G.
   Pacheco, Patricia
   Barbosa-Lima, Giselle
   Gomes, Rachel N.
   Bozza, Patricia T.
   Da Poian, Andrea T.
   Teixeira, Mauro M.
   Bozza, Marcelo T.
TI Contribution of macrophage migration inhibitory factor to the
   pathogenesis of dengue virus infection
SO FASEB JOURNAL
LA English
DT Article
DE MIF; cytokine; lipid droplets; inflammation; hemorrhagic fever; sepsis
ID FACTOR MIF; HEMORRHAGIC-FEVER; JAPANESE ENCEPHALITIS; CHEMOKINE
   RECEPTORS; DISEASE SEVERITY; INNATE IMMUNITY; REGULATORY ROLE;
   SHOCK-SYNDROME; SEPTIC SHOCK; SERUM-LEVELS
AB Dengue fever is an emerging viral disease transmitted by arthropods to humans in tropical countries. Dengue hemorrhagic fever (DHF) is escalating in frequency and mortality rates. Here we studied the involvement of macrophage migration inhibitory factor (MIF) in dengue virus (DENV) infection and its pathogenesis. Patients with DHF had elevated plasma concentrations of MIF. Both leukocytes from these patients and macrophages from healthy donors infected in vitro with DENV showed a substantial amount of MIF within lipid droplets. The secretion of MIF by macrophages and hepatocytes required a productive infection and occurred without an increase in gene transcription or cell death, thus indicating active secretion from preformed stocks. In vivo infection of wildtype and mif-deficient (Mif(-/-)) mice demonstrated a role of MIF in dengue pathogenesis. Clinical disease was less severe in Mif(-/-) mice, and they exhibited a significant delay in lethality, lower viremia, and lower viral load in the spleen than wild-type mice. This reduction in all parameters of severity on DENV infection in Mif(-/-) mice correlated with reduced proinflammatory cytokine concentrations. These results demonstrated the contribution of MIF to the pathogenesis of dengue and pointed to a possible beneficial role of neutralizing MIF as an adjunctive therapeutic approach to treat the severe forms of the disease.-Assuncao-Miranda, I., Amaral, F. A., Bozza, F. A., Fagundes, C. T., Sousa, L. P., Souza, D. G., Pacheco, P., Barbosa-Lima, G., Gomes, R. N., Bozza, P. T., Da Poian, A. T., Teixeira, M. M., Bozza, M. T. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J. 24, 218-228 (2010). www.fasebj.org
C1 [Teixeira, Mauro M.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Assuncao-Miranda, Iranaia; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Programa Biol Estrutural, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Assuncao-Miranda, Iranaia; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
   [Amaral, Flavio A.; Fagundes, Caio T.; Souza, Danielle G.] Univ Fed Minas Gerais, Dept Microbiol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Intens Care Unit, Rio De Janeiro, Brazil.
   [Pacheco, Patricia; Barbosa-Lima, Giselle; Gomes, Rachel N.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Teixeira, MM (corresponding author), Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Ave Antonio Carlos,6627 Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM mmtex@icb.ufmg.br; mtbozza@gmail.com
RI Da Poian, Andrea T./V-1699-2019; Gomes, Rachel N/I-7643-2013; Fagundes,
   Caio/AAK-9336-2020; Teixeira, Mauro M/A-4587-2008; Bozza, Fernando
   A/A-2618-2013; Amaral, Flavio/D-5489-2014; souza, danielle/D-3378-2014;
   Amaral, Flavio Almeida/C-3768-2018
OI Fagundes, Caio/0000-0002-6747-5233; Teixeira, Mauro
   M/0000-0002-6944-3008; Bozza, Fernando A/0000-0003-4878-0256; Amaral,
   Flavio/0000-0002-1695-0612; Amaral, Flavio Almeida/0000-0002-1695-0612;
   Bozza, Marcelo/0000-0003-3683-7550; Bozza, Patricia/0000-0001-8349-9529;
   Da Poian, Andrea/0000-0002-3969-704X
FU Conselho de Desenvolvimento Cientifico e Tecnologico (CNPq;
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Brazil)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); National Institute of Science and
   Technology in Dengue (INCT-Dengue; Brazil)
FX This work was supported by Conselho de Desenvolvimento Cientifico e
   Tecnologico (CNPq;Brazil), Fundacao de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ; Brazil), and National Institute of Science and
   Technology in Dengue (INCT-Dengue; Brazil).
CR Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011
   Arjona A, 2007, J CLIN INVEST, V117, P3059, DOI 10.1172/JCI32218
   Armstrong ME, 2008, J IMMUNOL, V180, P7125, DOI 10.4049/jimmunol.180.11.7125
   Arndt U, 2002, J VIROL, V76, P9298, DOI 10.1128/JVI.76.18.9298-9306.2002
   Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Bacher M, 2002, VIROLOGY, V299, P32, DOI 10.1006/viro.2002.1464
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza FA, 2007, CRIT CARE, V11, DOI 10.1186/cc5783
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   BOZZA PT, 2009, BIOCHIM BIOPHYS ACTA, V1791, P40
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Chen LC, 2006, AM J TROP MED HYG, V74, P142, DOI 10.4269/ajtmh.2006.74.142
   Chen ST, 2008, NATURE, V453, P672, DOI 10.1038/nature07013
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   El-Bacha T, 2007, BBA-MOL BASIS DIS, V1772, P1158, DOI 10.1016/j.bbadis.2007.08.003
   Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1
   Flores M, 2008, FASEB J, V22, P3661, DOI 10.1096/fj.08-111666
   Frascaroli G, 2009, J IMMUNOL, V182, P477, DOI 10.4049/jimmunol.182.1.477
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guzman MG, 2008, T ROY SOC TROP MED H, V102, P522, DOI 10.1016/j.trstmh.2008.03.001
   Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2
   Higa LM, 2008, BBA-PROTEINS PROTEOM, V1784, P1607, DOI 10.1016/j.bbapap.2008.06.015
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Kimura K, 2006, CLIN VACCINE IMMUNOL, V13, P415, DOI 10.1128/CVI.13.3.415-419.2006
   Koebernick H, 2002, P NATL ACAD SCI USA, V99, P13681, DOI 10.1073/pnas.212488699
   La Braga E, 2001, MEM I OSWALDO CRUZ, V96, P229, DOI 10.1590/S0074-02762001000200015
   Leng L, 2005, CRIT CARE MED, V33, pS475, DOI 10.1097/01.CCM.0000191278.04636.D8
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   McDevitt MA, 2006, J EXP MED, V203, P1185, DOI 10.1084/jem.20052398
   Merk M, 2009, J IMMUNOL, V182, P6896, DOI 10.4049/jimmunol.0803710
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009
   Pan American Health Organization, 2007, NUMB REP CAS DENG DE
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Souza DG, 2002, AM J PATHOL, V160, P1755, DOI 10.1016/S0002-9440(10)61122-4
   Sprong T, 2007, SHOCK, V27, P482, DOI 10.1097/01.shk.0000246898.65692.34
   Suharti C, 2002, THROMB HAEMOSTASIS, V87, P42
   Suzuki T, 2000, BBA-GENE STRUCT EXPR, V1517, P100, DOI 10.1016/S0167-4781(00)00262-1
   Umareddy I, 2008, J GEN VIROL, V89, P3052, DOI 10.1099/vir.0.2008/001594-0
   *WHO, 2002, 117 WHO
   Zhang Wei, 2002, Hepatobiliary Pancreat Dis Int, V1, P577
NR 62
TC 89
Z9 90
U1 0
U2 11
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2010
VL 24
IS 1
BP 218
EP 228
DI 10.1096/fj.09-139469
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 539DL
UT WOS:000273233600023
PM 19776337
DA 2020-12-01
ER

PT J
AU Assuncao-Miranda, I
   Bozza, MT
   Da Poian, AT
AF Assuncao-Miranda, Iranaia
   Bozza, Marcelo T.
   Da Poian, Andrea T.
TI Pro-Inflammatory Response Resulting From Sindbis Virus Infection of
   Human Macrophages: Implications for the Pathogenesis of Viral Arthritis
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE Sindbis virus; arthritis; macrophage; inflammatory response; macrophage
   migration inhibitory factor
ID MIGRATION-INHIBITORY FACTOR; ROSS-RIVER-VIRUS; ANTI-INTERLEUKIN-6
   RECEPTOR ANTIBODY; RHEUMATOID-ARTHRITIS; OSTEOCLAST DIFFERENTIATION;
   MATRIX METALLOPROTEINASES; SYNOVIAL FIBROBLASTS; POGOSTA DISEASE;
   OCKELBO DISEASE; NECROSIS-FACTOR
AB Several viruses cause acute and chronic joint inflammation in humans, and among them, the alphaviruses are of special interest due to the increasing number of outbreaks in which they are the etiological factor. Sindbis virus (SinV), a member of the Alphavirus genus, is the most widely distributed of all known arboviruses. Although SinV causes arthritis in humans, the molecular and cellular factors that contribute to the pathogenesis of this disease are almost completely unknown. Despite the crucial role of macrophages in the development of arthritis, these cells have not been recognized as potential targets for viruses causing arthritis. In this study, replication of SinV in human macrophages was demonstrated. The infection promoted macrophage activation, leading to the release of macrophage migration inhibitor factor (MIF) from intracellular stores and inducing the expression and secretion of TNF-alpha, IL-1 beta, and IL-6. Production of these cytokines was followed by the expression of matrix metalloproteinases (MMPs) 1 and 3, which could be involved in the articular damage that has been observed in disease induced by SinV. The use of different strategies to block MIF action, including an anti-MIF antibody, the MIF inhibitor ISO-1 and knockout mice for the MIF gene, showed that cytokine secretion and MMP expression during infection were regulated by MIF, suggesting that this cytokine acts in autocrine and paracrine manner upstream in the macrophage activation cascade. Thus, these are remarkable similarities between macrophage responses induced by SinV infection and those observed in rheumatoid arthritis, despite the different etiologies of infectious and autoimmune arthritides. J. Med. Virol. 82:164-174, 2010. (C) 2009 Wiley-Liss, Inc.
C1 [Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Bioquim Med, Program Struct Biol, BR-21941590 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Immunol, BR-21941590 Rio De Janeiro, Brazil.
RP Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Bioquim Med, Program Struct Biol, Bloco H,2 Andar,Sala 22, BR-21941590 Rio De Janeiro, Brazil.
EM dapoian@bioqmed.ufrj.br
RI Da Poian, Andrea T./V-1699-2019
OI Da Poian, Andrea/0000-0002-3969-704X; Bozza, Marcelo/0000-0003-3683-7550
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX Grant sponsor: Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ); Grant sponsor: Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq).
CR Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Bokarewa M, 2007, SCAND J IMMUNOL, V66, P192, DOI 10.1111/j.1365-3083.2007.01977.x
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Brennan F, 2007, CURR OPIN RHEUMATOL, V19, P296, DOI 10.1097/BOR.0b013e32805e87f1
   Brentano F, 2005, ARTHRITIS RHEUM-US, V52, P2656, DOI 10.1002/art.21273
   Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817
   Calabrese LH, 2008, NAT CLIN PRACT RHEUM, V4, P2, DOI 10.1038/ncprheum0679
   Calabrese LH, 2005, INFECT DIS CLIN N AM, V19, P963, DOI 10.1016/j.idc.2005.09.002
   CALISHER CH, 1985, J CLIN MICROBIOL, V22, P566, DOI 10.1128/JCM.22.4.566-571.1985
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   CLARRIS BJ, 1975, AUST NZ J MED, V5, P450, DOI 10.1111/j.1445-5994.1975.tb03056.x
   Dayer JM, 2003, RHEUMATOLOGY, V42, P3, DOI 10.1093/rheumatology/keg326
   Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165
   ESPMARK A, 1984, AM J TROP MED HYG, V33, P1203, DOI 10.4269/ajtmh.1984.33.1203
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5
   FRASER JRE, 1981, AUST NZ J MED, V11, P168, DOI 10.1111/j.1445-5994.1981.tb04226.x
   Heise MT, 2000, J VIROL, V74, P9294, DOI 10.1128/JVI.74.19.9294-9299.2000
   Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313
   Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743
   Javeed A, 2008, INFLAMM RES, V57, P45, DOI 10.1007/s00011-007-7110-6
   KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x
   Kudrin A, 2006, J BIOL CHEM, V281, P29641, DOI 10.1074/jbc.M601103200
   Kurkela S, 2004, EMERG INFECT DIS, V10, P889, DOI 10.3201/eid1005.030689
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X
   Laine M, 2000, RHEUMATOLOGY, V39, P1272, DOI 10.1093/rheumatology/39.11.1272
   Laine M, 2004, J INTERN MED, V256, P457, DOI 10.1111/j.1365-2796.2004.01413.x
   Levine Beth, 1994, Trends in Microbiology, V2, P25, DOI 10.1016/0966-842X(94)90341-7
   Lidbury BA, 2000, J INFECT DIS, V181, P27, DOI 10.1086/315164
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   LVOV DK, 1984, LANCET, V2, P399
   Maini RN, 2000, ANNU REV MED, V51, P207, DOI 10.1146/annurev.med.51.1.207
   Mateo L, 2000, INTERVIROLOGY, V43, P55, DOI 10.1159/000025023
   Matsuyama M, 2007, INTERNAL MED, V46, P771, DOI 10.2169/internalmedicine.46.6262
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Mitchell KL, 2007, CURR OPIN RHEUMATOL, V19, P278, DOI 10.1097/BOR.0b013e32805e87bf
   Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029
   Morrison TE, 2006, J VIROL, V80, P737, DOI 10.1128/JVI.80.2.737-749.2006
   Morrison TE, 2008, J VIROL, V82, P11263, DOI 10.1128/JVI.01352-08
   Morrison TE, 2007, J VIROL, V81, P5132, DOI 10.1128/JVI.02799-06
   Nishimoto N, 2004, ARTHRITIS RHEUM-US, V50, P1761, DOI 10.1002/art.20303
   Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444
   Onodera S, 1999, CYTOKINE, V11, P163, DOI 10.1006/cyto.1998.0402
   Park JY, 2007, BULL HOSP JT DIS, V65, pS4
   Radstake TRDJ, 2005, ARTHRITIS RHEUM, V52, P3020, DOI 10.1002/art.21285
   Rulli NE, 2005, PHARMACOL THERAPEUT, V107, P329, DOI 10.1016/j.pharmthera.2005.03.006
   Santos LL, 2006, WIEN MED WOCHENSCHR, V156, P11, DOI 10.1007/s10354-005-0243-8
   Santos LL, 2009, CLIN CHIM ACTA, V399, P1, DOI 10.1016/j.cca.2008.09.014
   SKOGH M, 1982, LANCET, V1, P795
   Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089
   Suhrbier A, 2004, CURR OPIN RHEUMATOL, V16, P374, DOI 10.1097/01.bor.0000130537.76808.26
   Szekanecz Z, 2007, CURR OPIN RHEUMATOL, V19, P289, DOI 10.1097/BOR.0b013e32805e87ae
   TAYLOR RM, 1955, AM J TROP MED HYG, V4, P844, DOI 10.4269/ajtmh.1955.4.844
   Toivanen A, 2008, CURR OPIN RHEUMATOL, V20, P486, DOI 10.1097/BOR.0b013e328303220b
   VANDERSTRAETEN EF, 1995, DIS COLON RECTUM, V38, P172, DOI 10.1007/BF02052446
   Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697
   Zare F, 2004, J IMMUNOL, V172, P5656, DOI 10.4049/jimmunol.172.9.5656
NR 60
TC 36
Z9 36
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD JAN
PY 2010
VL 82
IS 1
BP 164
EP 174
DI 10.1002/jmv.21649
PG 11
WC Virology
SC Virology
GA 533GZ
UT WOS:000272813000021
PM 19950249
DA 2020-12-01
ER

PT J
AU Carneiro, VC
   Maciel, RD
   da Silva, ICD
   da Costa, RFM
   Paiva, CN
   Bozza, MT
   Fantappie, MR
AF Carneiro, Vitor Coutinho
   Maciel, Renata de Moraes
   de Abreu da Silva, Isabel Caetano
   Madeira da Costa, Rodrigo Furtado
   Paiva, Claudia Neto
   Bozza, Marcelo Torres
   Fantappie, Marcelo Rosado
TI The extracellular release of Schistosoma mansoni HMGB1 nuclear protein
   is mediated by acetylation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Schistosoma mansoni; HMGB1; Acetylation; Secretion; Inflammation
ID DNA-BINDING; CHROMOSOMAL-PROTEINS; IN-VIVO; INFLAMMATION; RECEPTOR;
   CLONING; SEPSIS
AB Schistosoma mansoni HMGB1 (SmHMGB1) was revealed to be a substrate for the parasite histone acetyltransferases SmGCN5 and SmCBP1. We found that full-length SmHMGB1, as well as its HMG-box B (but not HMG-box A) were acetylated in vitro by SmGCN5 and SmCBP1. However, SmCBP1 was able to acetylate both substrates more efficiently than SmGCN5. Interestingly, the removal of the C-terminal acidic tail of SmHMGB1 (SmHMGB1 Delta C) resulted in increased acetylation of the protein. We showed by mammalian cell transfection assays that SmHMGB1 and SmHMGB1 Delta C were transported from the nucleus to the cytoplasm after sodium butyrate (NaB) treatment. Importantly, after NaB treatment, SmHMGB1 was also present outside the cell. Together, our data suggest that acetylation of SmHMGB1 plays a role in cellular trafficking, culminating with its secretion to the extracellular milieu. The possible role of SmHMGB1 acetylation in the pathogenesis of schistosomiasis is discussed. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Carneiro, Vitor Coutinho; Maciel, Renata de Moraes; de Abreu da Silva, Isabel Caetano; Madeira da Costa, Rodrigo Furtado; Fantappie, Marcelo Rosado] Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biotecnol & Biol Mol, CCS,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
   [Paiva, Claudia Neto; Bozza, Marcelo Torres] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
RP Fantappie, MR (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biotecnol & Biol Mol, CCS,Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
EM fantappie@bioqmed.ufrj.br
RI Madeiro, Rodrigo/M-6433-2017; de Moraes Maciel, Renata/E-1426-2014
OI Madeiro, Rodrigo/0000-0001-5646-8858; Carneiro,
   Vitor/0000-0003-1518-7667; Bozza, Marcelo/0000-0003-3683-7550
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and Fundacao Carlos
   Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)
   to M.R.F. We wish to thank Dr. Ana Lucia Giannini for helpful
   Suggestions and for providing the pEGFP vector and Vanessa Sandim, for
   critical feedback.
CR Assenberg R, 2008, BIOCHEM J, V411, P553, DOI 10.1042/BJ20071613
   de Oliveira FMB, 2006, GENE, V377, P33, DOI 10.1016/j.gene.2006.03.001
   Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516
   Bustin M, 1999, MOL CELL BIOL, V19, P5237
   DYSON M, 1984, INT J PEPT PROT RES, V24, P201
   El Gazzar M, 2007, INFLAMM RES, V56, P162, DOI 10.1007/s00011-006-6112-0
   Engers HD, 1996, DEV BIOL STAND, V87, P73
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   Gnanasekar M, 2006, MOL BIOCHEM PARASIT, V145, P137, DOI 10.1016/j.molbiopara.2005.09.013
   Grasser KD, 2003, PLANT MOL BIOL, V53, P281, DOI 10.1023/B:PLAN.0000007002.99408.ba
   Maciel RD, 2004, MOL BIOCHEM PARASIT, V133, P131, DOI 10.1016/j.molbiopara.2003.09.005
   Nagaki S, 1998, BIOCHEM BIOPH RES CO, V246, P137, DOI 10.1006/bbrc.1998.8589
   Pasheva E, 2004, BIOCHEMISTRY-US, V43, P2935, DOI 10.1021/bi035615y
   Pisetsky DS, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2440
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   STERNER R, 1979, BIOCHEM BIOPH RES CO, V89, P129, DOI 10.1016/0006-291X(79)90953-7
   STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044
   Travers AA, 2003, EMBO REP, V4, P131, DOI 10.1038/sj.embor.embor741
   Ugrinova I, 2001, BIOCHEMISTRY-US, V40, P14655, DOI 10.1021/bi0113364
   van Zoelen MAD, 2009, SHOCK, V31, P280, DOI 10.1097/SHK.0b013e318186262d
   Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x
   Wang HC, 2009, SHOCK, V32, P348, DOI 10.1097/SHK.0b013e3181a551bd
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
NR 23
TC 24
Z9 25
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 25
PY 2009
VL 390
IS 4
BP 1245
EP 1249
DI 10.1016/j.bbrc.2009.10.129
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 531GB
UT WOS:000272650800031
PM 19879244
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Figueiredo, RT
   Kroll-Palhares, K
   Silva, AA
   Silverio, JC
   Gibaldi, D
   Pyrrho, AD
   Benjamim, CF
   Lannes-Vieira, J
   Bozza, MT
AF Paiva, Claudia N.
   Figueiredo, Rodrigo T.
   Kroll-Palhares, Karina
   Silva, Andrea A.
   Silverio, Jaline C.
   Gibaldi, Daniel
   Pyrrho, Alexandre dos S.
   Benjamim, Claudia F.
   Lannes-Vieira, Joseli
   Bozza, Marcelo T.
TI CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear
   activation during acute Trypanosoma cruzi infection
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE heart; liver; myocarditis; flow cytometry; recruitment; CD8; monocytes;
   Chagas' disease
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PERIPHERAL-BLOOD MONOCYTES;
   HEART-FAILURE; IFN-GAMMA; CARDIAC INFLAMMATION; T-CELLS; EXPRESSION;
   MYOCARDITIS; MCP-1; MICE
AB CCL2/MCP-1 has emerged recently as a critical factor in infectious and autoimmune myocarditis. In fact, this chemokine is produced in great amounts in hearts from Trypanosoma cruzi-infected mice and is known to enhance parasite uptake and destruction by macrophages. Herein, we studied the involvement of CCL2 in tissue inflammation and resistance to T. cruzi. Infected CCL2(-/-) mice developed higher parasitemias and died earlier than WT mice. Close to their death, T. cruzi-infected CCL2(-/-) presented greater amounts of TNF, IFN-gamma, and IL-10 in plasma than WTs and clinical signs of systemic inflammatory response. Amastigote nests were more frequent in hearts and livers from infected CCL2(-/-) tissues than in WTs, and reduced numbers of leukocytes infiltrated their tissues. Leukocytes formed diffuse but not focal infiltrates in hearts from infected CCL2(-/-) mice, and perivascular cuffs could still be found in their livers. Infected CCL2(-/-) mice had smaller percentages of activated CD11b (Mac-1)(+)CD107b (Mac-3)(+) macrophages and CD8(+)CD69(hi) cells among heart and liver infiltrates than WTs (flow cytometry), indicating that CCL2 controls subset migration/activation. CCL2 accumulated among focal heart infiltrates, suggesting that this chemokine is involved in retention of mononuclear cells in particular spots. Peritoneal macrophages from CCL2(-/-) mice displayed decreased trypanocidal activity. Our results demonstrate that CCL2 contributes to reduce parasite growth and indicate that it does so by controlling the distribution, cellular composition, and state of activation of inflammatory infiltrates in acute T. cruzi infection. J. Leukoc. Biol. 86: 1239-1246; 2009.
C1 [Paiva, Claudia N.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Imunol, Ilha Fundao, BR-21941902 Rio de Janeiro, Brazil.
   [Pyrrho, Alexandre dos S.] Univ Fed Rio de Janeiro, Anal Clin & Toxicol, Fac Farm, BR-21941902 Rio de Janeiro, Brazil.
   [Benjamim, Claudia F.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Farmacol Basica & Clin, BR-21941902 Rio de Janeiro, Brazil.
   [Kroll-Palhares, Karina; Silva, Andrea A.; Silverio, Jaline C.; Gibaldi, Daniel; Lannes-Vieira, Joseli] Inst Oswaldo Cruz, Lab Pesquisa Autoimunidade & Imunoregulacao, BR-20001 Rio De Janeiro, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Imunol, Ilha Fundao, Av Carlos Chagas Filho 373,CCS Bloco I, BR-21941902 Rio de Janeiro, Brazil.
EM cnpaiva@iname.com; mbozza@micro.ufrj.br
RI Gibaldi, Daniel/K-7352-2012; Silva, Andrea Alice/J-6729-2012; Benjamim,
   Claudia/T-5090-2019; Figueiredo, Rodrigo T./F-5176-2016
OI Silva, Andrea Alice/0000-0001-5856-6128; Benjamim,
   Claudia/0000-0001-6247-9596; Figueiredo, Rodrigo T./0000-0002-7551-8782;
   Bozza, Marcelo/0000-0003-3683-7550
FU FAPERJCarlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); CNPqNational Council for Scientific and
   Technological Development (CNPq); Pronex; Fiocruz
FX Financial support was from FAPERJ, CNPq, Pronex, and Fiocruz. We thank
   Dr. Barret J. Rollins from the Dana-Farber Cancer Institute for kindly
   providing mcp-1/ccl-2-/- mice and their WT controls. We are grateful to
   the computer expert Rafael F. M. Mores for his assistance with the
   graphics and statistical analyses.
CR Aliberti JCS, 1999, INFECT IMMUN, V67, P4819, DOI 10.1128/IAI.67.9.4819-4826.1999
   Benevides L, 2008, AM J PATHOL, V173, P741, DOI 10.2353/ajpath.2008.080129
   BRENER Z., 1962, REV INST MED TROP SAO PAULO, V4, P389
   CELENTANO AM, 1993, ACTA TROP, V55, P171, DOI 10.1016/0001-706X(93)90075-M
   Coelho PS, 2002, J LEUKOCYTE BIOL, V71, P837
   de Oliveira GM, 2007, AM J PATHOL, V171, P79, DOI 10.2353/ajpath.2007.060643
   DENHOLM EM, 1991, J IMMUNOL METHODS, V144, P247, DOI 10.1016/0022-1759(91)90092-T
   Diaz-Guerra E, 2007, J IMMUNOL, V179, P7352, DOI 10.4049/jimmunol.179.11.7352
   dos Santos PVA, 2001, MICROBES INFECT, V3, P971, DOI 10.1016/S1286-4579(01)01461-7
   Froberg MK, 2001, CIRC RES, V89, P1224, DOI 10.1161/hh2401.100601
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072
   Goser S, 2005, CIRCULATION, V112, P3400, DOI 10.1161/CIRCULATIONAHA.105.572396
   Hardison JL, 2006, J INFECT DIS, V193, P1584, DOI 10.1086/503812
   Hardison JL, 2006, INFECT IMMUN, V74, P135, DOI 10.1128/IAI.74.1.135-143.2006
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   Kolattukudy PE, 1998, AM J PATHOL, V152, P101
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LOETSCHER P, 1994, FASEB J, V8, P1055
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Marino APMP, 2004, CIRCULATION, V110, P1443, DOI 10.1161/01.CIR.0000141561.15939.EC
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Matsumoto Y, 2004, J IMMUNOL, V173, P3535, DOI 10.4049/jimmunol.173.5.3535
   Medeiros GA, 2009, MICROBES INFECT, V11, P264, DOI 10.1016/j.micinf.2008.11.012
   Melo RCN, 2001, EXP PARASITOL, V97, P15, DOI 10.1006/expr.2000.4576
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Niu J, 2006, CARDIOVASC RES, V71, P139, DOI 10.1016/j.cardiores.2006.03.008
   Niu JL, 2006, J MOL CELL CARDIOL, V40, P810, DOI 10.1016/j.yjmcc.2006.03.010
   Paiva CN, 2007, EUR J IMMUNOL, V37, P1355, DOI 10.1002/eji.200636705
   Ramasawmy R, 2006, CLIN INFECT DIS, V43, P305, DOI 10.1086/505395
   Robben PM, 2005, J EXP MED, V201, P1761, DOI 10.1084/jem.20050054
   Rodrigues V, 2008, MICROBES INFECT, V10, P29, DOI 10.1016/j.micinf.2007.09.015
   Roffe E, 2006, MICROBES INFECT, V8, P2745, DOI 10.1016/j.micinf.2006.08.004
   Russo M, 1996, IMMUNOL LETT, V49, P163, DOI 10.1016/0165-2478(96)02498-4
   Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326
   Shen Y, 2004, J VIROL, V78, P12548, DOI 10.1128/JVI.78.22.12548-12556.2004
   Shiratsuchi Y, 2007, J LEUKOCYTE BIOL, V81, P412, DOI 10.1189/jlb.0606399
   Shireman PK, 2006, J SURG RES, V134, P145, DOI 10.1016/j.jss.2005.12.003
   Talvani A, 2000, MICROBES INFECT, V2, P851, DOI 10.1016/S1286-4579(00)00388-9
   Talvani A, 2004, MEM I OSWALDO CRUZ, V99, P645, DOI 10.1590/S0074-02762004000600020
   Talvani A, 2003, MICROBES INFECT, V5, P789, DOI 10.1016/S1286-4579(03)00146-1
   Tarleton RL, 2007, CURR OPIN IMMUNOL, V19, P430, DOI 10.1016/j.coi.2007.06.003
   TARLETON RL, 1994, INFECT IMMUN, V62, P1820, DOI 10.1128/IAI.62.5.1820-1829.1994
   Waeckel L, 2005, CIRC RES, V96, P576, DOI 10.1161/01.RES.0000159389.55544.20
   Wang T, 2008, J IMMUNOL, V180, P2886, DOI 10.4049/jimmunol.180.5.2886
NR 45
TC 30
Z9 31
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD NOV
PY 2009
VL 86
IS 5
BP 1239
EP 1246
DI 10.1189/jlb.0309187
PG 8
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 512SJ
UT WOS:000271270600025
PM 19641038
OA Bronze
DA 2020-12-01
ER

PT J
AU Carlos, D
   Frantz, FG
   Souza, DA
   Jamur, MC
   Oliver, C
   Ramos, SG
   Quesniaux, VF
   Ryffel, B
   Silva, CL
   Bozza, MT
   Faccioli, LH
AF Carlos, Daniela
   Frantz, Fabiani G.
   Souza-Junior, Devandir A.
   Jamur, Maria C.
   Oliver, Constance
   Ramos, Simone G.
   Quesniaux, Valerie F.
   Ryffel, Bernhard
   Silva, Celio L.
   Bozza, Marcelo T.
   Faccioli, Lucia H.
TI TLR2-dependent mast cell activation contributes to the control of
   Mycobacterium tuberculosis infection
SO MICROBES AND INFECTION
LA English
DT Article
DE Mast cells; TLR2; Mycobacterium tuberculosis; Cytokines; Inflammation; T
   cells; Host defence
ID TOLL-LIKE RECEPTOR; IMMUNE-RESPONSE; INNATE IMMUNITY; CUTTING EDGE;
   MURINE MODEL; TLR2; MICE; EXPRESSION; RESISTANCE; DISTINCT
AB Mast Cells (MCs) express toll-like receptor 2 (TLR2), a receptor known to be triggered by several major mycobacterial ligands and involved in resistance against Mycobacterium tuberculosis (MTB) infection. This study investigated whether adoptive transfer of TLR2 positive MCs (TLR2(+/+)) corrects the increased susceptibility of TLR2(-/-) mice to MTB infection. TLR2(-/-) mice displayed increased mycobacterial burden, diminished myeloid cell recruitment and proinflammatory cytokine production accompanied by defective granuloma formation. The reconstitution of these mice with TLR2(+/+) MCs, but not TLR2(-/-), confers better control of the infection, promotes the normalization of myeloid cell recruitment associated with reestablishment of the granuloma formation. In addition, adoptive transfer of TLR2(+/+) MC to TLR2(-/-) mice resulted in regulation of the pulmonary levels of IL-beta, IL-6, TNF-alpha, enhanced Th1 response and activated CD8(+) T cell homing to the lungs. Our results suggest that activation of MCs via TLR2 is required to compensate the defect in protective immunity and inability of TLR2(-/-) mice to control MTB infection. (C) 2009 Elsevier Masson SAS. All rights reserved.
C1 [Carlos, Daniela; Frantz, Fabiani G.; Faccioli, Lucia H.] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Souza-Junior, Devandir A.; Jamur, Maria C.; Oliver, Constance] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular & Mol & Bioagentes Patogen, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Ramos, Simone G.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Patol, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Quesniaux, Valerie F.; Ryffel, Bernhard] CNRS, F-45071 Orleans, France.
   [Silva, Celio L.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Bioquim & Imunol, BR-14040903 Ribeirao Preto, SP, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
RP Faccioli, LH (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, Dept Anal Clin Toxicol & Bromatol, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM faccioli@fcfrp.usp.br
RI Silva, Celio/C-4639-2012; Lucia, Faccioli/G-8976-2015; Frantz,
   Fabiani/B-9204-2016; Ramos, Simone G./C-4720-2012; Jamur, Maria
   Celia/L-5520-2016
OI Silva, Celio/0000-0002-0043-4568; Lucia, Faccioli/0000-0002-4999-8305;
   Frantz, Fabiani/0000-0001-6960-2438; Ramos, Simone
   G./0000-0002-1981-5248; Jamur, Maria Celia/0000-0001-7065-8543; Bozza,
   Marcelo/0000-0003-3683-7550
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [03/12885-5]
FX The authors would like to thank Elaine Medeiros Floriano from the
   Laboratorio de Histologia, Departamento de Patologia, Faculdade de
   Medicinade Ribeirao Preto for their technical assistance with
   histological material. We also wish to thank Dr. Carlos Arterio Sorgi
   for his technical assistance with the cytokine assay and Walter M.
   Turato for FACS analysis. This study was supported by a grant from
   FAPESP (no. 03/12885-5).
CR AbouZeid C, 1997, INFECT IMMUN, V65, P1856, DOI 10.1128/IAI.65.5.1856-1862.1997
   Applequist SE, 2002, INT IMMUNOL, V14, P1065, DOI 10.1093/intimm/dxf069
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782
   Bonato VLD, 2004, IMMUNOLOGY, V113, P130, DOI 10.1111/j.1365-2567.2004.01931.x
   Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987
   Carlos D, 2007, J INFECT DIS, V196, P1361, DOI 10.1086/521830
   da Fonseca DPAJ, 1998, INFECT IMMUN, V66, P3190, DOI 10.1128/IAI.66.7.3190-3197.1998
   Drennan MB, 2004, AM J PATHOL, V164, P49, DOI 10.1016/S0002-9440(10)63095-7
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fremond CM, 2004, J CLIN INVEST, V114, P1790, DOI 10.1172/JCI200421027
   Fricke I, 2006, J IMMUNOL, V176, P5173, DOI 10.4049/jimmunol.176.9.5173
   Gregory GD, 2005, EUR J IMMUNOL, V35, P3478, DOI 10.1002/eji.200535271
   Grivennikov SI, 2005, IMMUNITY, V22, P93, DOI 10.1016/j.immuni.2004.11.016
   Grodzki ACG, 2003, BRAZ J MED BIOL RES, V36, P1101, DOI 10.1590/S0100-879X2003000800017
   Heldwein KA, 2003, J LEUKOCYTE BIOL, V74, P277, DOI 10.1189/jlb.0103026
   Holscher C, 2008, EUR J IMMUNOL, V38, P680, DOI 10.1002/eji.200736458
   Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0
   Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045
   McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625
   McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005
   Metcalfe DD, 1997, PHYSIOL REV, V77, P1033
   Munoz S, 2003, J IMMUNOL, V170, P5590, DOI 10.4049/jimmunol.170.11.5590
   Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480
   Scanga CA, 2004, INFECT IMMUN, V72, P2400, DOI 10.1128/IAI.72.4.2400-2404.2004
   Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P327, DOI 10.1111/j.1348-0421.2003.tb03404.x
   Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704
   Tanzola MB, 2003, J IMMUNOL, V171, P4385, DOI 10.4049/jimmunol.171.8.4385
   Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2
   Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605
   van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002
NR 30
TC 29
Z9 30
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD JUL-AUG
PY 2009
VL 11
IS 8-9
BP 770
EP 778
DI 10.1016/j.micinf.2009.04.025
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 487QX
UT WOS:000269291000007
PM 19442756
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Arras, RH
   Magalhaes, ES
   Alves, LS
   Lessa, LP
   Silva, MH
   Ejzemberg, R
   Canetti, U
   Bozza, MT
AF Paiva, Claudia N.
   Arras, Rosa H.
   Magalhaes, Elisabeth S.
   Alves, Leticia S.
   Lessa, Luiz Paulo
   Silva, Maria Helena
   Ejzemberg, Regina
   Canetti, Udio
   Bozza, Marcelo T.
TI Migration inhibitory factor (MIF) released by macrophages upon
   recognition of immune complexes is critical to inflammation in Arthus
   reaction
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE monocytes; cytokines; Fc receptors
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA;
   TOLL-LIKE RECEPTOR-4; FC-GAMMA-RECEPTORS; RHEUMATOID-ARTHRITIS; JOINT
   INFLAMMATION; CELL RECRUITMENT; LEISHMANIA-MAJOR; LUPUS NEPHRITIS;
   REGULATORY ROLE
AB Deposition of immune complexes (IC) triggers Fc gamma R-dependent inflammation, leading to tissue damage in rheumatoid arthritis, systemic lupus erythematous, immune glomerulonephritis, and several immune vasculitides. Evidences support a role for macrophage migration inhibitory factor (MIF) in a number of inflammatory diseases, but the triggering of its secretion and its physiopathological role upon IC deposition remain elusive. Herein, we show that human macrophages secreted MIF after IC recognition, which in turn controlled the secretion of TNF. Macrophages from Mif(-/-) mice produced smaller amounts of TNF when stimulated with IgG-opsonized erythrocytes than wild-type (WT) cells. Using passive reverse Arthus reaction in the peritoneum and lungs as a model for IC-induced inflammation, we demonstrated that Mif(-/-) mice had a milder response, observed by reduced neutrophil recruitment, vascular leakage, and secretion of TNF, MIP-2, and keratinocyte-derived chemokine compared with WT controls. Adoptive transfer of alveolar macrophages from WT to Mif(-/-) mice rescued pulmonary neutrophil recruitment and TNF production upon passive reverse Arthus reaction. Our study indicates that Arthus inflammatory reaction is largely dependent on MIF and poses macrophages as a source of the MIF released upon IC recognition. These results give experimental support to the proposition that blockade of MIF might constitute an adjunctive, therapeutic approach to IC disease. J. Leukoc. Biol. 85: 855-861; 2009.
C1 [Paiva, Claudia N.; Arras, Rosa H.; Magalhaes, Elisabeth S.; Alves, Leticia S.; Lessa, Luiz Paulo; Silva, Maria Helena; Ejzemberg, Regina; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Imunol, BR-21941902 Rio De Janeiro, Brazil.
   [Canetti, Udio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, CCS Bloco I,Ave Carlos Chagas Filho,373 Cidade, BR-21941902 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Claudio, Canetti A/C-2774-2009
OI Bozza, Marcelo/0000-0003-3683-7550
FU Conselho de Desenvolvimento Cientifico e Tecnologico ( CNPq)National
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro ( FAPERJ)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Fundacao Jose Bonifacio ( FuJB), Programa de Nucleos de
   Excelencia ( Pronex)
FX This work was supported in part by grants from Conselho de
   Desenvolvimento Cientifico e Tecnologico ( CNPq), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro ( FAPERJ), Fundacao Jose Bonifacio
   ( FuJB), Programa de Nucleos de Excelencia ( Pronex), and Programa Pensa
   Rio ( FAPERJ). The authors thank Patricia Bozza, Andrea Pons, and
   Claudia Benjamim for kindly providing reagents.
CR Al-Abed Y, 2005, J BIOL CHEM, V280, P36541, DOI 10.1074/jbc.C500243200
   Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011
   Bao L, 2007, SEMIN NEPHROL, V27, P69, DOI 10.1016/j.semnephrol.2006.09.009
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065
   Bergtold A, 2006, J IMMUNOL, V177, P7287, DOI 10.4049/jimmunol.177.10.7287
   Bernhagen J, 1995, BIOTHERAPY, V8, P123, DOI 10.1007/BF01878495
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2003, J INFECT DIS, V187, pS385, DOI 10.1086/374752
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Chouchakova N, 2001, J IMMUNOL, V166, P5193, DOI 10.4049/jimmunol.166.8.5193
   Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179
   Daryadel A, 2006, J BIOL CHEM, V281, P27653, DOI 10.1074/jbc.M604051200
   de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720
   Denkinger CM, 2003, J IMMUNOL, V170, P1274, DOI 10.4049/jimmunol.170.3.1274
   Gao HW, 2006, ANNU REV PATHOL-MECH, V1, P215, DOI 10.1146/annurev.pathol.1.110304.100155
   Heller T, 1999, J IMMUNOL, V162, P5657
   Hoi AY, 2006, J IMMUNOL, V177, P5687, DOI 10.4049/jimmunol.177.8.5687
   ISSEKUTZ AC, 1994, CLIN EXP IMMUNOL, V97, P26
   Juttner S, 1998, J IMMUNOL, V161, P2383
   Kim HR, 2007, J RHEUMATOL, V34, P927
   Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X
   Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455
   Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   MAGALHAES ES, 2008, FASEB J
   Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086
   Matsui Y, 2004, J MOL CELL CARDIOL, V37, P557, DOI 10.1016/j.yjmcc.2004.05.016
   Mikulowska A, 1997, J IMMUNOL, V158, P5514
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Morand EF, 2005, INTERN MED J, V35, P419, DOI 10.1111/j.1445-5994.2005.00853.x
   Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002
   Okroj M, 2007, ANN MED, V39, P517, DOI 10.1080/07853890701477546
   Onodera S, 2000, J BIOL CHEM, V275, P444, DOI 10.1074/jbc.275.1.444
   Paiva CN, 2007, EUR J IMMUNOL, V37, P1355, DOI 10.1002/eji.200636705
   Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2
   Powell ND, 2005, J IMMUNOL, V175, P5611, DOI 10.4049/jimmunol.175.9.5611
   Riedemann NC, 2004, J IMMUNOL, V173, P1355, DOI 10.4049/jimmunol.173.2.1355
   Roger T, 2003, J ENDOTOXIN RES, V9, P119, DOI 10.1179/096805103125001513
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   Skokowa J, 2005, J IMMUNOL, V174, P3041, DOI 10.4049/jimmunol.174.5.3041
   Suzuki Y, 2003, J IMMUNOL, V170, P3243, DOI 10.4049/jimmunol.170.6.3243
   Van Lent PL, 2006, ARTHRITIS RHEUM-US, V54, P3868, DOI 10.1002/art.22253
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385
NR 52
TC 20
Z9 20
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD MAY 1
PY 2009
VL 85
IS 5
BP 855
EP 861
DI 10.1189/jlb.0108009
PG 7
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 453TM
UT WOS:000266635800013
PM 19188484
OA Bronze
DA 2020-12-01
ER

PT J
AU Magalhaes, ES
   Paiva, CN
   Souza, HSP
   Pyrrho, AS
   Mourao-Sa, D
   Figueiredo, RT
   Vieira-De-Abreu, A
   Dutra, HS
   Silveira, MS
   Gaspar-Elsas, MIC
   Xavier-Elsas, P
   Bozza, PT
   Bozza, MT
AF Magalhaes, Elizabeth S.
   Paiva, Claudia N.
   Souza, Heitor S. P.
   Pyrrho, Alexandre S.
   Mourao-Sa, Diego
   Figueiredo, Rodrigo T.
   Vieira-de-Abreu, Adriana
   Dutra, Helio S.
   Silveira, Mariana S.
   Gaspar-Elsas, Maria Ignez C.
   Xavier-Elsas, Pedro
   Bozza, Patricia T.
   Bozza, Marcelo T.
TI Macrophage migration inhibitory factor is critical to
   interleukin-5-driven eosinophilopoiesis and tissue eosinophilia
   triggered by Schistosoma mansoni infection
SO FASEB JOURNAL
LA English
DT Article
DE Th2 response; apoptosis; inflammation; granuloma; MIF
ID FACTOR MIF; GRANULOMA-FORMATION; REGULATORY ROLE; ASTHMA; MICE;
   APOPTOSIS; SURVIVAL; INFLAMMATION; RECRUITMENT; ACTIVATION
AB Macrophage migration inhibitory factor (MIF) participates in the pathogenesis of inflammatory diseases, including asthma, in which it enhances airway hypersensitivity and tissue eosinophilia. Herein, we investigated the role of MIF in eosinophilopoiesis and tissue eosinophilia using Schistosoma mansoni infection. MIF-deficient (Mif(-/-)) mice had similar numbers of adult worms, eggs, and granulomas compared to wildtype mice, but the size of granulomas was strikingly reduced due to smaller numbers of eosinophils. MIF did not affect the acquired response to infection, as Mif(-/-) mice produced normal amounts of Th2 cytokines and IgE. Nevertheless, recombinant MIF (rMIF) behaved as a chemoattractant for eosinophils, what could partially explain the reduced eosinophilia in infected Mif(-/-) mice. Moreover, the percentage of eosinophils was reduced in bone marrows of Mif(-/-) mice chronically infected with S. mansoni compared to wild type. Mif(-/-) had impaired eosinophilopoiesis in response to interleukin (IL)-5 and addition of rMIF to bone marrow cultures from IL-5 transgenic mice enhanced the generation of eosinophils. In the absence of MIF, eosinophil precursors were unable to survive the IL-5-supplemented cell culture, and were ingested by macrophages. Treatment with pancaspase inhibitor z-VAD or rMIF promoted the survival of eosinophil progenitors. Together, these results indicate that MIF participates in IL-5-driven maturation of eosinophils and in tissue eosinophilia associated with S. mansoni infection.-Magalhaes, E. S., Paiva, C. N., Souza, H. S. P., Pyrrho, A. S., Mourao-Sa, D., Figueiredo, R. T., Vieira-de-Abreu, A., Dutra, H. S., Silveira, M. S., Gaspar-Elsas, M. I. C., Xavier-Elsas, P., Bozza, P. T., Bozza, M. T. Macrophage migration inhibitory factor is critical to IL-5-driven eosinophilopoiesis and tissue eosinophilia triggered by Schistosoma mansoni infection. FASEB J. 23, 1262-1271 (2009)
C1 [Magalhaes, Elizabeth S.; Paiva, Claudia N.; Mourao-Sa, Diego; Figueiredo, Rodrigo T.; Xavier-Elsas, Pedro; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, BR-21941902 Rio De Janeiro, Brazil.
   [Souza, Heitor S. P.] Univ Fed Rio de Janeiro, Dept Clin Med, Fac Med, BR-21941902 Rio De Janeiro, Brazil.
   [Pyrrho, Alexandre S.] Univ Fed Rio de Janeiro, Dept Farm, Inst Biol, BR-21941902 Rio De Janeiro, Brazil.
   [Dutra, Helio S.] Univ Fed Rio de Janeiro, Dept Histol & Embriol, Inst Ciencias Biomed, BR-21941902 Rio De Janeiro, Brazil.
   [Silveira, Mariana S.] Univ Fed Rio de Janeiro, Lab Neurogenese, Inst Biofisca, BR-21941902 Rio De Janeiro, Brazil.
   [Vieira-de-Abreu, Adriana] Inst Oswaldo Cruz, Lab Imunofarmacol, BR-20001 Rio De Janeiro, Brazil.
   [Gaspar-Elsas, Maria Ignez C.] Fiocruz MS, Dept Pediat, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, CCS Bloco 1,UFRJ Ave Carlos Chagas Filho,373 Cida, BR-21941902 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016; Mourao-Sa, Diego/C-5977-2009;
   Xavier-Elsas, Pedro/Q-9070-2019; Silveira, Mariana/M-4865-2013; de
   Souza, Heitor Siffert Pereira/G-3297-2012
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Xavier-Elsas,
   Pedro/0000-0003-3057-6062; Silveira, Mariana/0000-0002-0496-1517; de
   Souza, Heitor Siffert Pereira/0000-0002-3647-7324; Bozza,
   Marcelo/0000-0003-3683-7550; Bozza, Patricia/0000-0001-8349-9529;
   Mourao, Diego/0000-0001-6618-6969
FU Howard Hughes Medical InstituteHoward Hughes Medical Institute Funding
   Source: Medline
CR Amano T, 2007, INFLAMM RES, V56, P24, DOI 10.1007/s00011-007-5184-9
   Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com
   Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567
   Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325
   DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842
   Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017
   Davies SJ, 2004, INT J PARASITOL, V34, P27, DOI 10.1016/j.ijpara.2003.10.010
   Denkinger CM, 2004, ARCH IMMUNOL THER EX, V52, P389
   DOLBER PC, 1993, J HISTOCHEM CYTOCHEM, V41, P465, DOI 10.1177/41.3.7679127
   Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404, DOI 10.1165/ajrcmb.17.4.2691
   Falcone FH, 2001, J IMMUNOL, V167, P5348, DOI 10.4049/jimmunol.167.9.5348
   Fallon PG, 2000, J IMMUNOL, V164, P2585, DOI 10.4049/jimmunol.164.5.2585
   Farahi N, 2007, J IMMUNOL, V179, P1264, DOI 10.4049/jimmunol.179.2.1264
   Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065
   Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145
   HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524
   Hoontrakoon R, 2002, AM J RESP CELL MOL, V26, P404, DOI 10.1165/ajrcmb.26.4.4517
   Hu JS, 2006, AM J PATHOL, V169, P424, DOI 10.2353/ajpath.2006.051234
   Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   KARIYAWASAM HH, 2007, CURR OPIN IMMUNOL
   Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472
   Leeto M, 2006, AM J PATHOL, V169, P1701, DOI 10.2353/ajpath.2006.060346
   LENZI H L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P67, DOI 10.1590/S0074-02761987000800011
   Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X
   Magalhaes ES, 2007, EUR J IMMUNOL, V37, P1097, DOI 10.1002/eji.200635968
   Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   Nagase H, 2001, INT ARCH ALLERGY IMM, V125, P29, DOI 10.1159/000053849
   Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002
   Ohnmacht C, 2007, J IMMUNOL, V179, P4766, DOI 10.4049/jimmunol.179.7.4766
   Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05
   Petering H, 1999, BLOOD, V93, P694, DOI 10.1182/blood.V93.2.694.402k31_694_702
   Powell ND, 2005, J IMMUNOL, V175, P5611, DOI 10.4049/jimmunol.175.9.5611
   Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006
   Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003
   Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Sabroe I, 2000, CLIN EXP ALLERGY, V30, P1194
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   SHER A, 1990, P NATL ACAD SCI USA, V87, P61, DOI 10.1073/pnas.87.1.61
   Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x
   Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933
   Vermeire JJ, 2008, TRENDS PARASITOL, V24, P355, DOI 10.1016/j.pt.2008.04.007
   Wang FZ, 2005, MED HYPOTHESES, V65, P1082, DOI 10.1016/j.mehy.2005.05.047
   Wilson MS, 2007, IMMUNOL CELL BIOL, V85, P148, DOI 10.1038/sj.icb.7100014
   Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244
   YAMAGUCHI Y, 1991, BLOOD, V78, P2542
   Yousefi S, 1997, INT ARCH ALLERGY IMM, V112, P9, DOI 10.1159/000237424
NR 53
TC 32
Z9 34
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2009
VL 23
IS 4
BP 1262
EP 1271
DI 10.1096/fj.08-124248
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 453ZO
UT WOS:000266651600030
PM 19088181
DA 2020-12-01
ER

PT J
AU Carneiro, LAM
   Travassos, LH
   Soares, F
   Tattoli, I
   Magalhaes, JG
   Bozza, MT
   Plotkowski, MC
   Sansonetti, PJ
   Molkentin, JD
   Philpott, DJ
   Girardin, SE
AF Carneiro, Leticia A. M.
   Travassos, Leonardo H.
   Soares, Fraser
   Tattoli, Ivan
   Magalhaes, Joao G.
   Bozza, Marcelo T.
   Plotkowski, Maria C.
   Sansonetti, Philippe J.
   Molkentin, Jeffery D.
   Philpott, Dana J.
   Girardin, Stephen E.
TI Shigella Induces Mitochondrial Dysfunction and Cell Death in Nonmyleoid
   Cells
SO CELL HOST & MICROBE
LA English
DT Article
ID NF-KAPPA-B; NOD-LIKE PROTEINS; PERMEABILITY TRANSITION; ACTIVATION;
   CASPASE-1; INFLAMMASOME; APOPTOSIS; INTERLEUKIN-1-BETA; INFECTION;
   ADAPTERS
AB Shigella rapidly kills myeloid cells via a caspase-1 inflammasome-dependent cell death mechanism. However, despite a critical role for nonmyeloid cells in the physiopathology of Shigella infection, the mechanism by which Shigella kills nonmyeloid cells remains uncharacterized. Here we demonstrate that, in nonmyeloid cells, Shigella infection induces loss of mitochondrial inner membrane potential, mitochondrial damage, and necrotic cell death through a pathway dependent on Bnip3 and cyclophilin D, two molecules implicated in the host oxidative stress responses. This mitochondrial cell death mechanism was potently counterbalanced by a Nod1-dependent Rip2/IKK beta/NF-kappa B signaling pathway activated by the pathogen in the first hours of infection. Our results suggest that in nonmyeloid cells, oxidative stress pathways and signaling triggered by an intracellular bacterial pathogen are tightly linked and demonstrate the existence of specific Shigella-induced prodeath and prosurvival pathways converging at the mitochondria to control a necrotic cell death program.
C1 [Carneiro, Leticia A. M.; Soares, Fraser; Tattoli, Ivan; Girardin, Stephen E.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
   [Travassos, Leonardo H.; Magalhaes, Joao G.; Philpott, Dana J.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
   [Carneiro, Leticia A. M.; Travassos, Leonardo H.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil.
   [Plotkowski, Maria C.] Univ Estado Rio de Janeiro, Disciplina Microbiol & Imunol, BR-20551030 Rio De Janeiro, Brazil.
   [Sansonetti, Philippe J.] Inst Pasteur, INSERM, U786, Unite Pathogenie Microbienne Mol, F-75724 Paris 05, France.
   [Molkentin, Jeffery D.] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.
RP Girardin, SE (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg, Toronto, ON M5S 1A8, Canada.
EM stephen.girardin@utoronto.ca
RI Travassos, Leonardo/G-1925-2012; Magalhaes, Joao/AAK-2686-2020;
   Carneiro, Leticia/T-8978-2019; Tattoli, Ivan/H-2600-2017
OI Travassos, Leonardo/0000-0003-1323-3797; Tattoli,
   Ivan/0000-0001-7925-4609; Molkentin, Jeffery/0000-0002-3558-6529;
   Soares, Fraser/0000-0002-3977-7939; Bozza, Marcelo/0000-0003-3683-7550
FU Canadian Institutes for Health ResearchCanadian Institutes of Health
   Research (CIHR); Howard Hughes International Scholar Program; Strategic
   Program for Asthma Research (SPAR).; Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR); Crohn's and
   Colitis Foundation of Canada; Burroughs Wellcome FundBurroughs Wellcome
   Fund
FX We would like to thank Doctor S.D. Ha and Doctor S.O. Kim (University of
   Western Ontario) for Bnip3-GFP constructs, Doctor M. May (University of
   Pennsylvania) and Doctor I. Verma (University of San Diego) for IKK
   alpha<SUP>-/-</SUP> and IKK beta<SUP>-/-</SUP> MEFs, Doctor T. Mak
   (University of Toronto) for NEMO<SUP>-/-</SUP> MEFs, and all those
   individuals who provided the plasmids used in this study. We are also
   grateful to Steven Doyle (University of Toronto) for assistance with
   electron microscopy. L.A.M.C. and L.H.T. were partially supported by a
   studentship and a fellowship from CNPq (Brazil), respectively, and are
   currently supported by fellowships from the Canadian Institutes of
   Health Research. J.G.M. is supported by a fellowship from Fundacao para
   a Ciencia e Tecnologia (Portugal). P.J.S. is a Howard Hughes
   International Scholar. D.J.P. is supported by grants from the Canadian
   Institutes for Health Research and funding from the Howard Hughes
   International Scholar Program and the Strategic Program for Asthma
   Research (SPAR). Research in the laboratory of S.E.G. is funded by
   Canadian Institutes of Health Research, Crohn's and Colitis Foundation
   of Canada, and Burroughs Wellcome Fund.
CR Armstrong JS, 2006, MITOCHONDRION, V6, P225, DOI 10.1016/j.mito.2006.07.006
   Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271
   Charlot JF, 2004, APOPTOSIS, V9, P333, DOI 10.1023/B:APPT.0000025810.58981.4c
   Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x
   Correia JD, 2007, CELL DEATH DIFFER, V14, P830, DOI 10.1038/sj.cdd.4402070
   Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103
   Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393
   Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104
   Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346
   Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412
   Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Graham RA, 2004, J EXP BIOL, V207, P3189, DOI 10.1242/jeb.01109
   Ha SD, 2007, J BIOL CHEM, V282, P26275, DOI 10.1074/jbc.M703668200
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Mantis N, 1996, INFECT IMMUN, V64, P2474, DOI 10.1128/IAI.64.7.2474-2482.1996
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997
   May MJ, 2007, J BIOL CHEM, V282, P16105, DOI 10.1074/jbc.M611115200
   Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Park JH, 2007, J IMMUNOL, V179, P514, DOI 10.4049/jimmunol.179.1.514
   Phalipon A, 2007, IMMUNOL CELL BIOL, V85, P119, DOI 10.1038/sj.icb7100025
   Sansonetti PJ, 2000, IMMUNITY, V12, P581, DOI 10.1016/S1074-7613(00)80209-5
   Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111
   Ting JPY, 2008, NAT REV IMMUNOL, V8, P372, DOI 10.1038/nri2296
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Willingham SB, 2007, CELL HOST MICROBE, V2, P147, DOI 10.1016/j.chom.2007.07.009
   XU J, 2005, CURRENT PROTOCOLS MO
   Yao MZ, 2007, J NEUROSCI, V27, P1422, DOI 10.1523/JNEUROSCI.2382-06.2007
   ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0
NR 34
TC 101
Z9 102
U1 3
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD FEB 19
PY 2009
VL 5
IS 2
BP 123
EP 136
DI 10.1016/j.chom.2008.12.011
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 413SY
UT WOS:000263814000005
PM 19218084
DA 2020-12-01
ER

PT J
AU Svensjo, E
   Saraiva, EM
   Bozza, MT
   Oliveira, SMP
   Lerner, EA
   Scharfstein, J
AF Svensjoe, Erik
   Saraiva, Elvira M.
   Bozza, Marcelo T.
   Oliveira, Sandra M. P.
   Lerner, Ethan A.
   Scharfstein, Julio
TI Salivary Gland Homogenates of Lutzomyia longipalpis and Its Vasodilatory
   Peptide Maxadilan Cause Plasma Leakage via PAC1 Receptor Activation
SO JOURNAL OF VASCULAR RESEARCH
LA English
DT Article
DE Arteriolar dilation; Lutzomyia longipalpis; Maxadilan; PAC1 receptor;
   Pituitary adenylate cyclase-activating peptide; Plasma leakage;
   Postcapillary venules; Salivary glands
ID HAMSTER-CHEEK POUCH; SAND FLY SALIVA; ADENYLATE-CYCLASE; POLYPEPTIDE
   PACAP; IMMUNOMODULATORY FACTORS; PERMEABILITY INCREASE;
   LEISHMANIA-DONOVANI; POTENT VASODILATOR; MOUSE MACROPHAGES; ARTHROPOD
   SALIVA
AB Objectives: Experiments were designed to determine if salivary gland homogenates (SGH) of the sand fly Lutzomyia longipalpis, the vasodilatory peptides maxadilan and pituitary adenylate cyclase-activating peptide (PACAP-38) may cause plasma leakage and to what extent these effects could be due to PAC1 receptor stimulation. Methods: Using FITC-dextran as a plasma marker, intravital microscopy of the hamster cheek pouch (HCP) and a digital camera were used to assess arteriolar diameter and fluorescence of a selected area (5 mm(2)) representative of the HCP microcirculation. Results: Cheek pouches prepared for intravital microscopy and exposed to topical application of SGH, maxadilan or PACAP-38 developed maximal dilation of arterioles in the range of 20-60 mu m within 10 min, and this effect lasted for 30-90 min. The increase in fluorescence intensity induced by each of these compounds was due to plasma leakage from postcapillary venules. The mutant peptide of maxadilan (M-65), a PAC1 receptor antagonist, inhibited both dilation and plasma leakage induced by SGH or maxadilan. Plasma leakage induced by SGH was modestly inhibited by the bradykinin B(2) receptor antagonist HOE-140, but not by the antihistamine mepyramine or the nitric oxide synthase inhibitor L-NA. Conclusions: SGH of L. longipalpis and its vasodilatory peptide maxadilan caused long-lasting arteriolar dilation and plasma leakage in the cheek pouch via PAC1 receptor activation. Copyright (C) 2009 S. Karger AG, Basel
C1 [Svensjoe, Erik] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, BR-21944900 Rio De Janeiro, Brazil.
   [Saraiva, Elvira M.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21944900 Rio De Janeiro, Brazil.
   [Oliveira, Sandra M. P.] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Lerner, Ethan A.] Cutaneous Biol Res Ctr, Boston, MA USA.
RP Svensjo, E (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, CCS Cidade Univ, BR-21944900 Rio De Janeiro, Brazil.
EM erik.svensjo@gmail.com
RI Svensjo, Erik/B-5026-2008; Saraiva, Elvira M/L-2864-2017
OI Svensjo, Erik/0000-0002-7356-1787; Saraiva, Elvira
   M/0000-0002-6388-5286; Bozza, Marcelo/0000-0003-3683-7550
FU CNPq (National Council for Scientific and Technological
   Development)National Council for Scientific and Technological
   Development (CNPq) [410552/2006-2]; FAPERJ (Foundation for Research
   Support of the Rio de Janeiro State)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/100.938/2007]
FX Our study was supported by grants from CNPq (National Council for
   Scientific and Technological Development) project no. 410552/2006-2 and
   FAPERJ (Foundation for Research Support of the Rio de Janeiro State)
   E-26/100.938/2007.
CR Andrade BB, 2007, SCAND J IMMUNOL, V66, P122, DOI 10.1111/j.1365-3083.2007.01964.x
   ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003
   ARIMURA A, 1992, REGUL PEPTIDES, V37, P287
   ARMENANTE PM, 1991, MICROVASC RES, V42, P198, DOI 10.1016/0026-2862(91)90087-R
   Bozza M, 1998, EUR J IMMUNOL, V28, P3120, DOI 10.1002/(SICI)1521-4141(199810)28:10<3120::AID-IMMU3120>3.0.CO;2-3
   Brodie TM, 2007, INFECT IMMUN, V75, P2359, DOI 10.1128/IAI.01812-06
   Cardell LO, 1997, REGUL PEPTIDES, V71, P67, DOI 10.1016/S0167-0115(97)00027-X
   El Zein N, 2007, CELL SIGNAL, V19, P152, DOI 10.1016/j.cellsig.2006.05.031
   ERLANSSON M, 1991, PROSTAGLANDINS, V41, P157, DOI 10.1016/0090-6980(91)90028-E
   ERLANSSON M, 1989, INFLAMMATION, V13, P693, DOI 10.1007/BF00914313
   GAWLOWSKI DM, 1986, CIRC RES, V58, P348, DOI 10.1161/01.RES.58.3.348
   Ghosh KN, 1998, INT J PARASITOL, V28, P275, DOI 10.1016/S0020-7519(97)00152-5
   Gillespie RD, 2000, PARASITE IMMUNOL, V22, P319, DOI 10.1046/j.1365-3024.2000.00309.x
   GREGA GJ, 1972, AM J PHYSIOL, V223, P1165
   Harfi I, 2004, J IMMUNOL, V173, P4154, DOI 10.4049/jimmunol.173.6.4154
   Kinhult J, 2003, CLIN EXP ALLERGY, V33, P942, DOI 10.1046/j.1365-2222.2003.01721.x
   LERNER EA, 1992, J BIOL CHEM, V267, P1062
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Lerner EA, 2007, PEPTIDES, V28, P1651, DOI 10.1016/j.peptides.2007.06.021
   Lima HC, 1996, INFECT IMMUN, V64, P5442, DOI 10.1128/IAI.64.12.5442-5445.1996
   MAYHAN WG, 1984, MICROVASC RES, V28, P159
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9
   Monteiro AC, 2006, J IMMUNOL, V177, P6325, DOI 10.4049/jimmunol.177.9.6325
   Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966
   Morris RV, 2001, J IMMUNOL, V167, P5226, DOI 10.4049/jimmunol.167.9.5226
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Pereira P, 2002, PIGM CELL RES, V15, P461, DOI 10.1034/j.1600-0749.2002.02077.x
   PERSSON NH, 1985, INT J MICROCIRC, V4, P257
   Reddy VB, 2006, J BIOL CHEM, V281, P16197, DOI 10.1074/jbc.M509429200
   Reglodi D, 2008, J MOL NEUROSCI, V36, P270, DOI 10.1007/s12031-008-9089-z
   RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335
   Rohousova I, 2006, FOLIA PARASIT, V53, P161, DOI 10.14411/fp.2006.022
   Scharfstein J, 2007, SCAND J IMMUNOL, V66, P128, DOI 10.1111/j.1365-3083.2007.01983.x
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   Soares RPP, 2003, AN ACAD BRAS CIENC, V75, P301, DOI 10.1590/S0001-37652003000300005
   Svensjo E, 2006, MICROBES INFECT, V8, P206, DOI 10.1016/j.micinf.2005.06.016
   SVENSJO E, 1993, AGENTS ACTIONS, V39, P35, DOI 10.1007/BF01975712
   SVENSJO E, 1979, AM J PHYSIOL, V236, pH600
   SVENSJO E, 1978, PROSTAG LEUKOTR ESS, V1, P397, DOI 10.1016/0161-4630(78)90126-X
   SVENSJO E, 2006, MICROVASCULAR RES BI, P195
   SVENSJO E, 1990, EUR RESPIR J, V3, P595
   Teixeira MJ, 2006, TRENDS PARASITOL, V22, P32, DOI 10.1016/j.pt.2005.11.010
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Titus RG, 2006, PARASITE IMMUNOL, V28, P131, DOI 10.1111/j.1365-3024.2006.00807.x
   Valenzuela JG, 2004, J EXP BIOL, V207, P3717, DOI 10.1242/jeb.01185
   WARBURG A, 1994, PHILOS T R SOC B, V345, P223, DOI 10.1098/rstb.1994.0097
   WARREN JB, 1993, FASEB J, V7, P1394
   WARREN JB, 1992, BRIT J PHARMACOL, V106, P331, DOI 10.1111/j.1476-5381.1992.tb14336.x
   Wheat WH, 2008, J IMMUNOL, V180, P8286, DOI 10.4049/jimmunol.180.12.8286
   WHO, 2008, LEISHM BACKGR INF
   Winzell MS, 2007, PEPTIDES, V28, P1805, DOI 10.1016/j.peptides.2007.04.024
NR 52
TC 13
Z9 13
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1018-1172
J9 J VASC RES
JI J. Vasc. Res.
PY 2009
VL 46
IS 5
BP 435
EP 446
DI 10.1159/000197866
PG 12
WC Physiology; Peripheral Vascular Disease
SC Physiology; Cardiovascular System & Cardiology
GA 485DW
UT WOS:000269102100006
PM 19176972
OA Bronze
DA 2020-12-01
ER

PT J
AU Mesquita, RD
   Carneiro, AB
   Bafica, A
   Gazos-Lopes, F
   Takiya, CM
   Souto-Padron, T
   Vieira, DP
   Ferreira-Pereira, A
   Almeida, IC
   Figueiredo, RT
   Porto, BN
   Bozza, MT
   Graca-Souza, AV
   Lopes, AHCS
   Atella, GC
   Silva-Neto, MAC
AF Mesquita, Rafael D.
   Carneiro, Alan Brito
   Bafica, Andre
   Gazos-Lopes, Felipe
   Takiya, Christina M.
   Souto-Padron, Thais
   Vieira, Danielle P.
   Ferreira-Pereira, Antonio
   Almeida, Igor C.
   Figueiredo, Rodrigo T.
   Porto, Barbara N.
   Bozza, Marcelo T.
   Graca-Souza, Aurelio V.
   Lopes, Angela H. C. S.
   Atella, Georgia C.
   Silva-Neto, Mario A. C.
TI Trypanosoma cruzi Infection Is Enhanced by Vector Saliva through
   Immunosuppressant Mechanisms Mediated by Lysophosphatidylcholine
SO INFECTION AND IMMUNITY
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE PRODUCTION; BUG RHODNIUS-PROLIXUS;
   SAND FLY SALIVA; CHAGAS-DISEASE; IMMUNOMODULATORY PROPERTIES;
   LEISHMANIA-AMAZONENSIS; OXIDIZED PHOSPHOLIPIDS; DENDRITIC CELLS;
   REACTIVE OXYGEN
AB Trypanosoma cruzi, the etiological agent of Chagas disease, is transmitted by bug feces deposited on human skin during a blood meal. However, parasite infection occurs through the wound produced by insect mouth-parts. Saliva of the Triatominae bug Rhodnius prolixus is a source of lysophosphatidylcholine (LPC). Here, we tested the role of both triatomine saliva and LPC on parasite transmission. We show that vector saliva is a powerful inducer of cell chemotaxis. A massive number of inflammatory cells were found at the sites where LPC or saliva was inoculated into the skin of mice. LPC is a known chemoattractant for monocytes, but neutrophil recruitment induced by saliva is LPC independent. The preincubation of peritoneal macrophages with saliva or LPC increased fivefold the association of T. cruzi with these cells. Moreover, saliva and LPC block nitric oxide production by T. cruzi-exposed macrophages. The injection of saliva or LPC into mouse skin in the presence of the parasite induces an up-to-sixfold increase in blood parasitemia. Together, our data suggest that saliva of the Triatominae enhances T. cruzi transmission and that some of its biological effects are attributed to LPC. This is a demonstration that a vector-derived lysophospholipid may act as an enhancing factor of Chagas disease.
C1 [Mesquita, Rafael D.; Carneiro, Alan Brito; Gazos-Lopes, Felipe; Graca-Souza, Aurelio V.; Atella, Georgia C.; Silva-Neto, Mario A. C.] Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21940590 Rio De Janeiro, Brazil.
   [Takiya, Christina M.] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Histol & Embriol, BR-21940590 Rio De Janeiro, Brazil.
   [Souto-Padron, Thais; Vieira, Danielle P.; Ferreira-Pereira, Antonio; Figueiredo, Rodrigo T.; Porto, Barbara N.; Bozza, Marcelo T.; Lopes, Angela H. C. S.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, BR-21940590 Rio De Janeiro, Brazil.
   [Bafica, Andre] Univ Fed Santa Catarina, Div Imunol, Dept Microbiol & Parasitol, BR-88040900 Florianopolis, SC, Brazil.
   [Almeida, Igor C.] Univ Texas El Paso, Dept Biol Sci, Border Biomed Res Ctr, El Paso, TX 79968 USA.
RP Silva-Neto, MAC (corresponding author), Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21940590 Rio De Janeiro, Brazil.
EM maneto@bioqmed.ufrj.br
RI Ferreira-Pereira, Antonio/A-2910-2011; Atella, Georgia/AAK-7897-2020;
   Almeida, Igor C./AAF-9409-2019; Vieira, Danielle/N-1254-2014; Bafica,
   Andre/ABF-5986-2020; Figueiredo, Rodrigo T./F-5176-2016; Silva-Neto,
   Mario A C/C-1211-2013
OI Ferreira-Pereira, Antonio/0000-0002-0474-8388; Almeida, Igor
   C./0000-0002-2443-8213; Bafica, Andre/0000-0002-5148-600X; Figueiredo,
   Rodrigo T./0000-0002-7551-8782; Silva-Neto, Mario A
   C/0000-0003-2273-194X; Bozza, Marcelo/0000-0003-3683-7550; Mesquita,
   Rafael D/0000-0002-2882-3362
FU International Foundation for ScienceInternational Foundation for Science
   [F/3619-1, F/2887-3]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa Carlos Chagas Filho do
   Estado do Rio de JaneiroCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ) [E-26/110.401/2007];
   NIH/NCRRUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [5G12RR008124, 1R01AI070655, 2506GM00812-37]; NATIONAL
   CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI070655, R01AI070655,
   R01AI070655, R01AI070655, R01AI070655, R01AI070655] Funding Source: NIH
   RePORTER
FX We thank Helo sa L. Coelho, Lilian Gomes, and Cleuza Alexandre Silva for
   technical assistance. We are indebted to Alan Sher (NIAID/ NIH) for
   insightful scientific advice and Pat Casper (NIAID/NIH) for technical
   assistance.; This work was supported by two grants provided by the
   International Foundation for Science (IFS) to G. C. Atella (F/3619-1)
   and to M. A. C. Silva-Neto (F/2887-3), by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and by Fundacao de
   Amparo a Pesquisa Carlos Chagas Filho do Estado do Rio de Janeiro
   (FAPERJ-PENSA RIO, E-26/110.401/2007). I. C. A. is supported by NIH/NCRR
   grants 5G12RR008124, 1R01AI070655 and 2506GM00812-37 (to the Border
   Biomedical Research Center/University of Texas at El Paso). We are
   grateful to the Biomolecule Analysis Core Facility/BBRC/ UTEP, supported
   by NIH/NCRR grant 5G12RR008124.
CR Agusti R, 2000, MEM I OSWALDO CRUZ, V95, P97, DOI 10.1590/S0074-02762000000100016
   Aliberti JCS, 1996, INFECT IMMUN, V64, P1961, DOI 10.1128/IAI.64.6.1961-1967.1996
   Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476
   Amura CR, 1998, J IMMUNOL, V161, P2552
   Andrade LO, 2005, NAT REV MICROBIOL, V3, P819, DOI 10.1038/nrmicro1249
   Aprahamian T, 2004, J EXP MED, V199, P1121, DOI 10.1084/jem.20031557
   Ashton AW, 2007, J EXP MED, V204, P929, DOI 10.1084/jem.20062432
   Atella GC, 2000, ARCH INSECT BIOCHEM, V43, P99, DOI 10.1002/(SICI)1520-6327(200003)43:3&lt;99::AID-ARCH1&gt;3.0.CO;2-3
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1084/jem.20051782
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Bisaggio DFR, 2003, PARASITOL RES, V91, P273, DOI 10.1007/s00436-003-0965-8
   Burleigh BA, 2002, CELL MICROBIOL, V4, P701, DOI 10.1046/j.1462-5822.2002.00226.x
   CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Chagas C., 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008
   Chagas Carlos, 1909, Archiv Schiffshyg Leipzig, V13
   Chagas Carlos, 1909, Bulletin de la Societe de Pathologie Exotique Paris, V2
   Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791
   Chen L, 2001, EUR J IMMUNOL, V31, P265, DOI 10.1002/1521-4141(200101)31:1<265::AID-IMMU265>3.3.CO;2-C
   CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8
   Dias JCP, 2002, MEM I OSWALDO CRUZ, V97, P603, DOI 10.1590/S0074-02762002000500002
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Golodne DM, 2003, J BIOL CHEM, V278, P27766, DOI 10.1074/jbc.M212421200
   Gomes MT, 2006, INT J PARASITOL, V36, P165, DOI 10.1016/j.ijpara.2005.09.016
   HALL LR, 1995, J IMMUNOL, V155, P3501
   Huang AN, 1999, FREE RADICAL BIO MED, V26, P526, DOI 10.1016/S0891-5849(98)00236-6
   Itabe H, 1998, PROG LIPID RES, V37, P181, DOI 10.1016/S0163-7827(98)00009-5
   Kalvachova P, 1999, J MED ENTOMOL, V36, P341, DOI 10.1093/jmedent/36.3.341
   Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9
   Koga R, 2006, J IMMUNOL, V177, P7059, DOI 10.4049/jimmunol.177.10.7059
   Kollien AH, 2000, PARASITOL TODAY, V16, P381, DOI 10.1016/S0169-4758(00)01724-5
   KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0
   Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7
   Lee YK, 2006, BIOCHEM BIOPH RES CO, V348, P1116, DOI 10.1016/j.bbrc.2006.07.164
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mbow ML, 1998, J IMMUNOL, V161, P5571
   McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189
   MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605
   Mesquita RD, 2005, BIOCHEM BIOPH RES CO, V335, P690, DOI 10.1016/j.bbrc.2005.07.133
   Montgomery RR, 2004, INFECT IMMUN, V72, P2989, DOI 10.1128/IAI.72.5.2989-2994.2004
   Norsworthy NB, 2004, INFECT IMMUN, V72, P1240, DOI 10.1128/IAI.72.3.1240-1247.2004
   Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805
   Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665
   Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100
   Ribeiro JMC, 2004, INSECT BIOCHEM MOLEC, V34, P61, DOI 10.1016/j.ibmb.2003.09.004
   Rigoni M, 2005, SCIENCE, V310, P1678, DOI 10.1126/science.1120640
   Rogers ME, 2007, PLOS PATHOG, V3, P818, DOI 10.1371/journal.ppat.0030091
   Rosa MDS, 2001, CURR MICROBIOL, V43, P33, DOI 10.1007/s002840010256
   Ryborg AK, 2000, ACTA DERM-VENEREOL, V80, P242
   Sa-Nunes A, 2007, J IMMUNOL, V179, P1497, DOI 10.4049/jimmunol.179.3.1497
   Saiga A, 2001, BBA-MOL CELL BIOL L, V1530, P67, DOI 10.1016/S1388-1981(00)00167-0
   Schneider BS, 2004, VIRAL IMMUNOL, V17, P565, DOI 10.1089/vim.2004.17.565
   Schuster JP, 2000, INT J PARASITOL, V30, P1475, DOI 10.1016/S0020-7519(00)00119-3
   Scott GA, 2007, J INVEST DERMATOL, V127, P668, DOI 10.1038/sj.jid.5700567
   Takahara N, 1996, METABOLISM, V45, P559, DOI 10.1016/S0026-0495(96)90024-4
   Tarleton RL, 2007, CURR OPIN IMMUNOL, V19, P430, DOI 10.1016/j.coi.2007.06.003
   TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436
   Urbina JA, 2003, TRENDS PARASITOL, V19, P495, DOI 10.1016/j.pt.2003.09.001
   VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994
   Werling D, 2004, IMMUNOLOGY, V111, P41, DOI 10.1111/j.1365-2567.2004.01781.x
   Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414
   Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989
   zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026
NR 68
TC 42
Z9 44
U1 1
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD DEC
PY 2008
VL 76
IS 12
BP 5543
EP 5552
DI 10.1128/IAI.00683-08
PG 10
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 373WJ
UT WOS:000261003900012
PM 18794282
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Silva, PL
   Passaro, CR
   Cagidob, VR
   Bozza, M
   Dolhnikoff, M
   Negri, EA
   Morales, MMB
   Capelozzi, VL
   Zin, WA
   Rocco, PRM
AF Silva, Pedro L.
   Passaro, Caroline R.
   Cagidob, Viviane R.
   Bozza, Marcelo
   Dolhnikoff, Marisa
   Negri, Elnara A.
   Morales, Maina M. B.
   Capelozzi, Vera L.
   Zin, Walter A.
   Rocco, Patricia R. M.
TI Impact of lung remodelling on respiratory mechanics in a model of severe
   allergic inflammation
SO RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
LA English
DT Article
DE mammals; mice; mechanics of breathing; elastance; lung viscoelasticity;
   pathology; lung histology; eosinophil; extracellular matrix; collagen
   fibres
ID AIRWAY SMOOTH-MUSCLE; SEVERE ASTHMA; INDUCED CONSTRICTION; PERSISTENT
   ASTHMA; MURINE MODEL; GUINEA-PIG; MICE; TISSUE; PATHOGENESIS;
   DYSFUNCTION
AB We developed a model of severe allergic inflammation and investigated the impact of airway and lung parenchyma remodelling on in vivo and in vitro respiratory mechanics. BALB/c mice were sensitized and challenged with ovalbumin in severe allergic inflammation (SA) group. The control group (C) received saline using the same protocol. Light and electron microscopy showed eosinophil and neutrophil infiltration and fibrosis in airway and lung parenchyma, mucus gland hyperplasia, and airway smooth muscle hypertrophy and hyperplasia in SA group. These morphological changes led to in vivo (resistive and viscoelastic pressures, and static elastance) and in vitro (tissue elastance and resistance) lung mechanical alterations. Airway responsiveness to methacholine was markedly enhanced in SA as compared with C group. Additionally, IL-4, IL-5, and IL-13 levels in the bronchoalveolar lavage fluid were higher in SA group. In conclusion, this model of severe allergic lung inflammation enabled us to directly assess the role of airway and lung parenchyma inflammation and remodelling on respiratory mechanics. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Silva, Pedro L.; Passaro, Caroline R.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Edificio Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho CCS, Lab Invest Pulmonar, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Cagidob, Viviane R.; Zin, Walter A.] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Ctr Chagas Filho Biophys Inst, Physiol Resp Lab, BR-21941902 Rio De Janeiro, Brazil.
   [Bozza, Marcelo] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Microbiol, Inst Microbiol, BR-21941902 Rio De Janeiro, Brazil.
   [Dolhnikoff, Marisa; Negri, Elnara A.; Morales, Maina M. B.; Capelozzi, Vera L.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Rocco, PRM (corresponding author), Univ Fed Rio de Janeiro, Edificio Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho CCS, Lab Invest Pulmonar, Bloco G-014 Av Carlos Chagas Filho S-N,Cidade Uni, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM prmrocco@biof.ufrj.br
RI Negri, Elnara M/F-3643-2019; Capelozzi, Vera Luiza/C-6363-2013;
   CAPELOZZI, VERA LUIZA/N-1737-2019; Zin, Walter/H-8220-2013; Dolhnikoff,
   Marisa/B-9019-2013; Silva, Pedro Leme/AAD-8236-2019
OI Negri, Elnara M/0000-0002-6428-6066; CAPELOZZI, VERA
   LUIZA/0000-0001-9732-5853; Zin, Walter/0000-0001-8226-9123; Silva, Pedro
   Leme/0000-0001-5838-4949; delmonte, samuel/0000-0002-3289-4577; Passaro,
   Caroline/0000-0003-2980-1015; Dolhnikoff, Marisa/0000-0002-9073-9989;
   Bozza, Marcelo/0000-0003-3683-7550
CR Adler A, 1998, J APPL PHYSIOL, V85, P231
   An SS, 2007, EUR RESPIR J, V29, P834, DOI 10.1183/09031936.00112606
   Arantes-Costa FM, 2002, EUR RESPIR J, V19, P1008, DOI 10.1183/09031936.02.00232402
   Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC
   Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.02.00261102
   BATES JHT, 1988, J APPL PHYSIOL, V65, P408
   Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867
   Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC
   BURKHARDT A, 1989, AM REV RESPIR DIS, V140, P513, DOI 10.1164/ajrccm/140.2.513
   Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292
   Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109
   Dolhnikoff M, 1999, AM J RESP CRIT CARE, V160, P1750, DOI 10.1164/ajrccm.160.5.9812040
   FREDBERG JJ, 1989, J APPL PHYSIOL, V67, P2408
   Hamid Qutayba, 2003, J Allergy Clin Immunol, V111, P431
   Ingram JL, 2003, CHEST, V123, p422S, DOI 10.1378/chest.123.3_suppl.422S
   Jarjour NN, 1999, AM J RESP CRIT CARE, V160, P336, DOI 10.1164/ajrccm.160.1.9806155
   Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532, DOI 10.1164/ajrccm.160.5.9806170
   JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890
   KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555
   KATZENSTEIN ALA, 1985, HUM PATHOL, V16, P1015, DOI 10.1016/S0046-8177(85)80279-3
   Kay AB, 1996, AM J RESP CRIT CARE, V154, pS66, DOI 10.1164/ajrccm/154.2_Pt_2.S66
   Kobayashi SD, 2005, ARCH IMMUNOL THER EX, V53, P505
   Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248
   Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734
   LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771
   Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC
   LIU M, 1995, CLIN EXP ALLERGY, V25, P1053, DOI 10.1111/j.1365-2222.1995.tb03251.x
   Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC
   Lopez-Aguilar J, 1998, RESP PHYSIOL, V113, P239, DOI 10.1016/S0034-5687(98)00054-1
   Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC
   Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x
   Mojtabavi N, 2002, J IMMUNOL, V169, P4788, DOI 10.4049/jimmunol.169.9.4788
   Montes GS, 1996, CELL BIOL INT, V20, P15, DOI 10.1006/cbir.1996.0004
   Mukaiyama O, 2004, EUR J PHARMACOL, V498, P287, DOI 10.1016/j.ejphar.2004.07.071
   NAGASE T, 1994, J APPL PHYSIOL, V76, P830
   NAGASE T, 1992, J APPL PHYSIOL, V73, P1900
   Ochkur SI, 2007, J IMMUNOL, V178, P7879, DOI 10.4049/jimmunol.178.12.7879
   PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167, DOI 10.1164/ajrccm.149.5.8173756
   Rocco PRM, 2001, AM J RESP CRIT CARE, V164, P1067, DOI 10.1164/ajrccm.164.6.2007062
   Seow CY, 1998, AM J RESP CRIT CARE, V158, pS179, DOI 10.1164/ajrccm.158.supplement_2.13tac160
   Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x
   Wagers S, 2002, J APPL PHYSIOL, V92, P1802, DOI 10.1152/japplphysiol.00883.2001
   Wagers SS, 2007, J APPL PHYSIOL, V102, P221, DOI 10.1152/japplphysiol.01385.2005
   Ward C, 2001, AM J RESP CRIT CARE, V164, P1718, DOI 10.1164/ajrccm.164.9.2102039
   Weibel E.R., 1990, MODELS LUNG DIS MICR, V47, P199
   Weigert C., 1898, Z ALLG PATHOL, V9, P289
   Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP
   Xisto DG, 2005, AM J RESP CRIT CARE, V171, P829, DOI 10.1164/rccm.200408-997OC
   YING S, 2002, ACI INT, V14, P64
   Yuan HC, 1997, J APPL PHYSIOL, V83, P1420
   Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909
NR 51
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1569-9048
EI 1878-1519
J9 RESP PHYSIOL NEUROBI
JI Respir. Physiol. Neuro.
PD FEB 29
PY 2008
VL 160
IS 3
BP 239
EP 248
DI 10.1016/j.resp.2007.10.009
PG 10
WC Physiology; Respiratory System
SC Physiology; Respiratory System
GA 285IN
UT WOS:000254770600001
PM 18055276
DA 2020-12-01
ER

PT J
AU Pacheco, P
   Vieira-De-Abreu, A
   Gomes, RN
   Barbosa-Lima, G
   Wermelinger, LB
   Maya-Monteiro, CM
   Silva, AR
   Bozza, MT
   Castro-Faria-Neto, HC
   Bandeira-Melo, C
   Bozza, PT
AF Pacheco, Patricia
   Vieira-de-Abreu, Adriana
   Gomes, Rachel N.
   Barbosa-Lima, Giselle
   Wermelinger, Leticia B.
   Maya-Monteiro, Clarissa M.
   Silva, Adriana R.
   Bozza, Marcelo T.
   Castro-Faria-Neto, Hugo C.
   Bandeira-Melo, Christianne
   Bozza, Patricia T.
TI Monocyte chemoattractarit protein-1/CC chemokine ligand 2 controls
   microtubule-driven biogenesis leukotriene B-4-synthesizing function of
   macrophage lipid bodies elicited by innate immune response
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; FOAM CELL-FORMATION; IN-VIVO; EICOSANOID
   FORMATION; BODY FORMATION; INTRACELLULAR DOMAINS; SIGNALING PATHWAYS;
   ENDOTOXIC-SHOCK; MICE; ACTIVATION
AB Lipid bodies (also known as lipid droplets) are emerging as inflammatory organelles with roles in the innate immune response to infections and inflammatory processes. In this study, we identified MCP-1 as a key endogenous mediator of lipid body biogenesis in infection-driven inflammatory disorders and we described the cellular mechanisms and signaling pathways involved in the ability of MCP-1 to regulate the biogenesis and leukotriene B-4 (LTB4) synthetic function of lipid bodies. In vivo assays in MCP-1(-/-) mice revealed that endogenous MCP-1 produced during polymicrobial infection or LPS-driven inflammatory responses has a critical role on the activation of lipid body-assembling machinery, as well as on empowering enzymatically these newly formed lipid bodies with LTB4 synthetic function within macrophages. MCP-1 triggered directly the rapid biogenesis of distinctive LTB4-synthesizing lipid bodies via CCR2-driven ERK- and PI3K-dependent intracellular signaling in in vitro-stimulated macrophages. Disturbance of microtubule organization by microtubule-active drugs demonstrated that MCP-1-induced lipid body biogenesis also signals through a pathway dependent on microtubular dynamics. Besides biogenic process, microtubules control LTB4-synthesizing function of MCP-1-elicited lipid bodies, in part by regulating the compartmentalization of key proteins, as adipose differentiation-related protein and 5-lipoxygenase. Therefore, infection-elicited MCP-1, besides its known CCR2-driven chemotactic function, appears as a key activator of lipid body biogenic and functional machineries, signaling through a microtubule-dependent manner.
C1 [Pacheco, Patricia; Vieira-de-Abreu, Adriana; Gomes, Rachel N.; Barbosa-Lima, Giselle; Wermelinger, Leticia B.; Maya-Monteiro, Clarissa M.; Silva, Adriana R.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Bozza, Patricia T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
   [Bandeira-Melo, Christianne] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamacao, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Ave Brasil 4365,Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM cbmelo@biof.ufd.br; pbozza@ioc.fiocruz.br
RI Silva, Adriana/C-5931-2014; Gomes, Rachel N/I-7643-2013; Silva, Adriana
   Ribeiro/U-7811-2019; de Melo, Christianne Bandeira/B-7724-2009;
   Bandeira-Melo, Christianne/X-5619-2019; maya-monteiro,
   clarissa/A-9091-2010
OI Silva, Adriana/0000-0002-5137-4251; Silva, Adriana
   Ribeiro/0000-0002-5137-4251; de Melo, Christianne
   Bandeira/0000-0003-3305-3865; Bandeira-Melo,
   Christianne/0000-0003-3305-3865; Bozza, Patricia/0000-0001-8349-9529
CR Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593
   Andersson L, 2006, J CELL SCI, V119, P2246, DOI 10.1242/jcs.02941
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bostrom P, 2005, ARTERIOSCL THROM VAS, V25, P1945, DOI 10.1161/01.ATV.0000179676.41064.d4
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2005, MEM I OSWALDO CRUZ, V100, P113, DOI 10.1590/S0074-02762005000900020
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   de Assis EF, 2003, J IMMUNOL, V171, P2090, DOI 10.4049/jimmunol.171.4.2090
   Dvorak A.M., 1991, BLOOD CELL BIOCH, V4, P27
   Etienne-Manneville S, 2004, TRAFFIC, V5, P470, DOI 10.1111/j.1600-0854.2004.00196.x
   FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Jimenez-Sainz MC, 2003, MOL PHARMACOL, V64, P773, DOI 10.1124/mol.64.3.773
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Leite MS, 2005, SHOCK, V23, P173, DOI 10.1097/01.shk.0000148072.12094.77
   Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Mermelstein CS, 2001, CELL TISSUE RES, V306, P75, DOI 10.1007/s004410100428
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7
   Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007
   Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   TERASAKI M, 1994, CELL MOTIL CYTOSKEL, V29, P291, DOI 10.1002/cm.970290402
   TUMER SJ, 1998, J BIOL CHEM, V273, P25987
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wan HC, 2007, FASEB J, V21, P167, DOI 10.1096/fj.06-6711com
   Wittmann T, 2001, J CELL SCI, V114, P3795
   Wolins NE, 2006, FEBS LETT, V580, P5484, DOI 10.1016/j.febslet.2006.08.040
   Yu WG, 1998, AM J PATHOL, V152, P759
   Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085
NR 45
TC 69
Z9 70
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2007
VL 179
IS 12
BP 8500
EP 8508
DI 10.4049/jimmunol.179.12.8500
PG 9
WC Immunology
SC Immunology
GA 240LV
UT WOS:000251590000060
PM 18056397
OA Bronze
DA 2020-12-01
ER

PT J
AU Andrade, PMM
   Ribeiro, BG
   Bozza, MT
   Rosa, LFBC
   do Carmo, MGT
AF Andrade, Priscila M. M.
   Ribeiro, Beatriz G.
   Bozza, Marcelo T.
   Rosa, Luiz Fernando B. Costa
   do Carmo, Maria G. Tavares
TI Effects of the fish-oil supplementation on the immune and inflammatory
   responses in elite swimmers
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; STRENUOUS EXERCISE; NUTRITIONAL MODULATION;
   GENE-EXPRESSION; CYTOKINES; OMEGA-3-FATTY-ACIDS; PARAMETERS; STRESS;
   LIPIDS
AB The effect of fish-oil supplementation (FO-S) on the immune responses of elite swimmers was investigated. In a randomized placebo-controlled trial, swimmers received either fish-oil capsules (n = 10) containing long chain polyunsaturated fatty acids (FA) of n-3 (LCPUFA n-3) or placebo capsules (n = 10), both for 6 weeks. Plasma FA, immunological markers, insulin and cortisol were evaluated. The FO-S resulted in an increase in LCPUFA n-3 and a decrease in arachidonic n-6 FA in plasma and a reduction in the production of interferon-gamma by cultured cells. A reduction in the production of tumor necrosis factor-a was observed in both groups. An increase in interleukin-2 production and no significant difference in interleukin-4 were also observed. FO-S was able to attenuate the exercise-induced increases in prostaglandin E2. Circulating concentrations of insulin did not change, while cortisol and glucose showed increase after the study period. These results suggest that FO-S influence exercise-associated immune responses in competitive swimmers. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Andrade, Priscila M. M.; Ribeiro, Beatriz G.; do Carmo, Maria G. Tavares] Univ Fed Rio de Janeiro, Inst Nutricao, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Microbiol, Rio De Janeiro, Brazil.
   [Rosa, Luiz Fernando B. Costa] Univ Sao Paulo, Inst Ciencias Biomed, Dept Histol & Embriol, BR-05508 Sao Paulo, Brazil.
RP do Carmo, MGT (corresponding author), Univ Fed Rio de Janeiro, Inst Nutricao, Ctr Ciencias Saude, Inst Nutricao Bloco J-2 Andar, BR-21941590 Rio De Janeiro, Brazil.
EM tcarmo@pesquisador.cnpq.br
OI Bozza, Marcelo/0000-0003-3683-7550
CR Andrade PDM, 2004, NUTRITION, V20, P243, DOI 10.1016/j.nut.2003.10.016
   Bortolotti M, 2007, CLIN NUTR, V26, P225, DOI 10.1016/j.clnu.2006.11.006
   Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166
   Calder PC, 2001, WORLD REV NUTR DIET, V88, P109
   Coyle EF, 2000, AM J CLIN NUTR, V72, p512S, DOI 10.1093/ajcn/72.2.512S
   Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5
   Grimble RF, 1998, NUTRITION, V14, P634, DOI 10.1016/S0899-9007(98)00010-0
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Kelley DS, 1998, LIPIDS, V33, P559, DOI 10.1007/s11745-998-0240-8
   Kelley DS, 2001, NUTRITION, V17, P669, DOI 10.1016/S0899-9007(01)00576-7
   Lapillonne A, 2004, CURR OPIN CLIN NUTR, V7, P151, DOI 10.1097/00075197-200403000-00008
   LEPAGE G, 1986, J LIPID RES, V27, P114
   MEYDANI SN, 1993, J CLIN INVEST, V92, P105, DOI 10.1172/JCI116537
   Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC
   Moreira A, 2007, EUR J CLIN NUTR, V61, P443, DOI 10.1038/sj.ejcn.1602549
   Morel PA, 1998, CRIT REV IMMUNOL, V18, P275, DOI 10.1615/CritRevImmunol.v18.i4.10
   Nielsen HB, 1997, EUR J APPL PHYSIOL O, V75, P375, DOI 10.1007/s004210050175
   NORTHOFF H, 1991, INT J SPORTS MED, V12, pS9, DOI 10.1055/s-2007-1024743
   Northoff H., 1995, EXERC IMMUNOL REV, V1, P1
   Pedersen BK, 2000, BRIT J SPORT MED, V34, P246, DOI 10.1136/bjsm.34.4.246
   PENDERSEN BK, 2000, PHYSIOL REV, V80, P1055
   Price PT, 2000, CURR OPIN LIPIDOL, V11, P3, DOI 10.1097/00041433-200002000-00002
   RIVIER A, 1994, INT J SPORTS MED, V15, P192, DOI 10.1055/s-2007-1021046
   Seematter G, 2004, CURR OPIN CLIN NUTR, V7, P169, DOI 10.1097/00075197-200403000-00011
   Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248
   *SOC BRAS MED ESP, 2003, REV BRAS MED ESPORTE, V9, P43
   TOMASI TB, 1982, J CLIN IMMUNOL, V2, P173, DOI 10.1007/BF00915219
   TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158
   ULLUM H, 1994, J APPL PHYSIOL, V77, P93
   Yaqoob P, 2000, EUR J CLIN INVEST, V30, P260, DOI 10.1046/j.1365-2362.2000.00623.x
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
NR 31
TC 27
Z9 27
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD OCT-NOV
PY 2007
VL 77
IS 3-4
BP 139
EP 145
DI 10.1016/j.plefa.2007.08.010
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA 246KD
UT WOS:000252005000002
PM 17923401
DA 2020-12-01
ER

PT J
AU Porto, BN
   Alves, LS
   Fernandez, PL
   Dutra, TP
   Figueiredo, RT
   Graca-Souza, AV
   Bozza, MT
AF Porto, Barbara N.
   Alves, Leticia S.
   Fernandez, Patricia L.
   Dutra, Tatiana P.
   Figueiredo, Rodrigo T.
   Graca-Souza, Aurelio V.
   Bozza, Marcelo T.
TI Heme induces neutrophil migration and reactive oxygen species generation
   through signaling pathways characteristic of chemotactic receptors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PROTEIN-KINASE-C; ACTIVATION; IDENTIFICATION; INFLAMMATION; TRANSPORTER;
   INDUCTION; CHANNELS; ALPHA; CELLS; MAPK
AB Hemolysis or extensive cell damage can lead to high concentrations of free heme, causing oxidative stress and inflammation. Considering that heme induces neutrophil chemotaxis, we hypothesize that heme activates a G protein-coupled receptor. Here we show that similar to heme, several heme analogs were able to induce neutrophil migration in vitro and in vivo. Mesoporphyrins, molecules lacking the vinyl groups in their rings, were not chemotactic for neutrophils and selectively inhibited heme-induced migration. Moreover, migration of neutrophils induced by heme was abolished by pretreatment with pertussis toxin, an inhibitor of G alpha inhibitory protein, and with inhibitors of phosphoinositide 3-kinase, phospholipase C beta, mitogen-activated protein kinases, or Rho kinase. The induction of reactive oxygen species by heme was dependent of G beta, inhibitory protein and phosphoinositide 3-kinase and partially dependent of phospholipase C beta, protein kinase C, mitogen-activated protein kinases, and Rho kinase. Together, our results indicate that heme activates neutrophils through signaling pathways that are characteristic of chemoattractant molecules and suggest that mesoporphyrins might prove valuable in the treatment of the inflammatory consequences of hemorrhagic and hemolytic disorders.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, BR-21941590 Rio De Janeiro, Brazil.
   Inst Adv Sci Invest & High Technol Serv, Panama City 081602852, Panama.
   Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Biotecnol & Biol Mol, BR-21941590 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco 1,Ave Carlos Chagas Filho,337 Cidade Un, BR-21941590 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Bozza,
   Marcelo/0000-0003-3683-7550; Llanes Fernandez,
   Patricia/0000-0002-0762-0566
CR Arruda MA, 2004, J IMMUNOL, V173, P2023, DOI 10.4049/jimmunol.173.3.2023
   Balla J, 2000, BLOOD, V95, P3442, DOI 10.1182/blood.V95.11.3442.011k51_3442_3450
   BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285
   Coxon PY, 2003, CELL SIGNAL, V15, P993, DOI 10.1016/S0898-6568(03)00074-3
   Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099
   DAVENPORT RD, 1994, TRANSFUS MED REV, V8, P157, DOI 10.1016/S0887-7963(94)70108-5
   DAVENPORT RD, 1990, BLOOD, V76, P2439
   DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   GALBRAITH RA, 1990, J HEPATOL, V10, P305, DOI 10.1016/0168-8278(90)90137-G
   GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Gudi SRP, 1998, AM J PHYSIOL-CELL PH, V274, pC1424
   Haeger M, 1996, ACTA OBSTET GYN SCAN, V75, P695, DOI 10.3109/00016349609065729
   Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114
   JACOB HS, 1994, J LAB CLIN MED, V123, P808
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499
   Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   MULLEREBERHARD U, 1993, AM J HEMATOL, V42, P59, DOI 10.1002/ajh.2830420112
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550
   Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Suchyna TM, 2004, PHYS BIOL, V1, P1, DOI 10.1088/1478-3967/1/1/001
   Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Wakasugi K, 2003, J BIOL CHEM, V278, P36505, DOI 10.1074/jbc.M305519200
   Worthington MT, 2001, AM J PHYSIOL-GASTR L, V280, pG1172
NR 34
TC 98
Z9 98
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 17
PY 2007
VL 282
IS 33
BP 24430
EP 24436
DI 10.1074/jbc.M703570200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 199HK
UT WOS:000248686600069
PM 17581818
OA Bronze
DA 2020-12-01
ER

PT J
AU Porto, BN
   Telli, CA
   Dutra, TP
   Alves, LS
   Bozza, MT
   Fin, CA
   Thiesen, FV
   Renner, MF
AF Porto, Barbara N.
   Telli, Caliandra A.
   Dutra, Tatiana P.
   Alves, Leticia S.
   Bozza, Marcelo T.
   Fin, Cyntia A.
   Thiesen, Flavia V.
   Renner, Marcia F.
TI Biochemical and biological characterization of the venoms of Bothriopsis
   bilineata and Bothriopsis taeniata (Serpentes : Viperidae)
SO TOXICON
LA English
DT Article
DE enzymes; neutrophil migration; pharmacological mediators; snake venoms;
   Bothriopsis bilineata; Bothriopsis taeniata
ID BOTHROPS-ASPER; SNAKE-VENOMS; IN-VIVO; INFLAMMATION; MIGRATION; ATROX
AB Snake venom is a complex mixture containing diverse protein components with different structures and functions that are used for prey immobilization and death. Snake venoms from the family Viperidae cause pronounced local and systemic effects, such as pain, edema, hemorrhage and necrosis. Here, we investigated the enzymatic and biological activities of venoms from two Amazonian snakes, Bothriopsis bilineata and Bothriopsis taeniata. Both venoms presented high enzymatic activities for proteases kallikrein, thrombin and plasmin, low levels of trypsin, cathepsin C and leucine aminopeptidase activities, while lacked acetylcholinesterase activity. R taeniata and B. bilineata crude venoms caused inflammation inducing neutrophil recruitment into peritoneal cavity of mice 4h after injection. Neutrophil recruitment induced by B. taeniata venom was accompanied by hemorrhage. EDTA treatment profoundly impaired neutrophil recruitment, suggesting the involvement of a metalloproteinase on venoms-induced neutrophil recruitment. Pretreatment with dexamethasone and zileuton, a 5-lipoxygenase inhibitor, significantly reduced neutrophil migration, but indomethacin and montelukast, a cysteinyl leukotriene receptor antagonist, had no effect, suggesting the involvement of lipoxygenase-derived metabolites, probably LTB4. Together, these results show that B. bilineata and R taeniata venoms induce a marked inflammatory reaction, with leukocyte recruitment, and hemorrhage, which parallels to a high proteolytic activity found in these venoms. (c) 2007 Elsevier Ltd. All rights reserved.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21741902 Rio De Janeiro, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Fac Farm, Porto Alegre, RS, Brazil.
   Pontificia Univ Catolica Rio Grande do Sul, Inst Toxicol, Porto Alegre, RS, Brazil.
   Fundacao Fac Fed Ciencias Med Porto Alegre, Dept Ciencias Fisiol, Porto Alegre, RS, Brazil.
   Ctr Univ Metodista IPA, Porto Alegre, RS, Brazil.
RP Porto, BN (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Av Carlos Chagas Filho 373,CCS Bloco I,Sala 059, BR-21741902 Rio De Janeiro, Brazil.
EM bnporto@hotmail.com
RI thiesen, flavia/A-3470-2017
OI thiesen, flavia/0000-0003-4907-6789; Bozza, Marcelo/0000-0003-3683-7550
CR AIRD SD, 1991, COMP BIOCHEM PHYS B, V99, P287, DOI 10.1016/0305-0491(91)90043-D
   Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4
   Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559
   Arruda VA, 2003, TOXICON, V41, P99, DOI 10.1016/S0041-0101(02)00238-6
   ASSAKURA MT, 1992, COMP BIOCHEM PHYS B, V102, P727, DOI 10.1016/0305-0491(92)90071-X
   BJARNASON JB, 1983, J BIOL CHEM, V258, P2566
   Braud S, 2000, BIOCHIMIE, V82, P851, DOI 10.1016/S0300-9084(00)01178-0
   CAMPBELL J.A. W. LAMAR, 1989, VENOMOUS REPTILES LA
   Chacur M, 2001, TOXICON, V39, P1173, DOI 10.1016/S0041-0101(00)00254-3
   Dodd C.K. Jr, 1987, P478
   Farsky SHP, 1997, TOXICON, V35, P185, DOI 10.1016/S0041-0101(96)00135-3
   FLORES CA, 1993, TOXICON, V31, P1551, DOI 10.1016/0041-0101(93)90339-K
   GIORGI R, 1993, TOXICON, V31, P1257, DOI 10.1016/0041-0101(93)90399-4
   GUTIERREZ J M, 1989, Memorias do Instituto Butantan (Sao Paulo), V51, P211
   GUTIERREZ JM, 1986, REV BIOL TROP, V34, P209
   Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9
   GUTIERREZ JM, 1995, HDB CLIN TOXICOLOGY, P644
   IWANAGA S, 1979, HDB EXPT PHARMACOLOG, V52, P61
   KAMIGUTI AS, 1995, J TOXICOL-TOXIN REV, V14, P359, DOI 10.3109/15569549509019469
   Kuch U, 1996, TOXICON, V34, P714, DOI 10.1016/0041-0101(96)00016-5
   LEITE LCC, 1992, COMP BIOCHEM PHYS B, V102, P515, DOI 10.1016/0305-0491(92)90042-P
   LEWIS RA, 1988, INFLAMMATION BASIC P, P121
   LIMAVERDE JS, 1994, HERPETOLOGIA BRASIL, V1, P92
   Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275
   Markland FS, 1998, TOXICON, V36, P1749, DOI 10.1016/S0041-0101(98)00126-3
   Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X
   *MIN SAUD BRAS, 1990, AC OF CONTR EST MORB
   MOURADASILVA AM, 1991, TOXICON, V29, P713, DOI 10.1016/0041-0101(91)90063-W
   NAHAS L, 1979, THROMB HAEMOSTASIS, V41, P314
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   PIPER PJ, 1983, BRIT MED BULL, V39, P255, DOI 10.1093/oxfordjournals.bmb.a071829
   SILVA M V D, 1983, Memorias do Instituto Butantan (Sao Paulo), V47-48, P121
   Simon SI, 2005, ANNU REV BIOMED ENG, V7, P151, DOI 10.1146/annurev.bioeng.7.060804.100423
   TAN NH, 1988, COMP BIOCHEM PHYS B, V90, P745, DOI 10.1016/0305-0491(88)90329-X
   Teixeira CDP, 2005, MEM I OSWALDO CRUZ, V100, P181, DOI 10.1590/S0074-02762005000900031
   TU AT, 1996, NAT TOXINS, V2, P33
   Zamuner SR, 2005, TOXICON, V46, P806, DOI 10.1016/j.toxicon.2005.08.011
NR 37
TC 19
Z9 19
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD AUG
PY 2007
VL 50
IS 2
BP 270
EP 277
DI 10.1016/j.toxicon.2007.03.020
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 203GZ
UT WOS:000248964400011
PM 17537475
DA 2020-12-01
ER

PT J
AU Figueiredo, RT
   Fernandez, PL
   Mourao-Sa, DS
   Porto, BN
   Dutra, FF
   Alves, LS
   Oliveira, MF
   Oliveira, PL
   Graca-Souza, AV
   Bozza, MT
AF Figueiredo, Rodrigo T.
   Fernandez, Patricia L.
   Mourao-Sa, Diego S.
   Porto, Barbara N.
   Dutra, Fabianno F.
   Alves, Leticia S.
   Oliveira, Marcus F.
   Oliveira, Pedro L.
   Graca-Souza, Aurelio V.
   Bozza, Marcelo T.
TI Characterization of heme as activator of toll-like receptor 4
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-4; TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES;
   DENDRITIC CELLS; ENDOTOXIN CONTAMINATION; CUTTING EDGE; TLR4; MICE;
   LIPOPOLYSACCHARIDE; IDENTIFICATION
AB Heme is an ancient and ubiquitous molecule present in organisms of all kingdoms, composed of an atom of iron linked to four ligand groups of porphyrin. A high amount of free heme, a potential amplifier of the inflammatory response, is a characteristic feature of diseases with increased hemolysis or extensive cell damage. Here we demonstrate that heme, but not its analogs/ precursors, induced tumor necrosis factor-alpha (TNF-alpha) secretion by macrophages dependently on MyD88, TLR4, and CD14. The activation of TLR4 by heme is exquisitely strict, requiring its coordinated iron and the vinyl groups of the porphyrin ring. Signaling of heme through TLR4 depended on an interaction distinct from the one established between TLR4 and lipopolysaccharide (LPS) since anti-TLR4/MD2 antibody or a lipid A antagonist inhibited LPS-induced TNF-alpha secretion but not heme activity. Conversely, protoporphyrin IX antagonized heme without affecting LPS-induced activation. Moreover, heme induced TNF-alpha and keratinocyte chemokine but was ineffective to induce interleukin-6, interleukin-12, and interferon-inducible protein-10 secretion or co-stimulatory molecule expression. These findings support the concept that the broad ligand specificity of TLR4 and the different activation profiles might in part reside in its ability to recognize different ligands in different binding sites. Finally, heme induced oxidative burst, neutrophil recruitment, and heme oxygenase-1 expression independently of TLR4. Thus, our results presented here reveal a previous unrecognized role of heme as an extracellular signaling molecule that affects the innate immune response through a receptor-mediated mechanism.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco I, BR-21941 Rio De Janeiro, RJ, Brazil.
   Inst Adv Sci Invest & High Technol Serv, Panama City 0816, Panama.
   Univ Fed Rio de Janeiro, Inst Med Biochem, Program Biotechnol & Biol Mol, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, CCS Bloco I, Avenida Carlos Chagas Filho,373 Cidade Univ, BR-21941 Rio De Janeiro, RJ, Brazil.
EM mbozza@micro.ufrj.br
RI Oliveira, Marcus/G-3158-2011; Dutra, Fabianno F/C-1387-2015; Figueiredo,
   Rodrigo T./F-5176-2016; Mourao-Sa, Diego/C-5977-2009; Oliveira,
   Pedro/A-9438-2010
OI Oliveira, Marcus/0000-0002-9890-8425; Dutra, Fabianno
   F/0000-0003-3106-7585; Figueiredo, Rodrigo T./0000-0002-7551-8782;
   Bozza, Marcelo/0000-0003-3683-7550; Mourao, Diego/0000-0001-6618-6969;
   Llanes Fernandez, Patricia/0000-0002-0762-0566; Oliveira,
   Pedro/0000-0003-0307-354X
CR Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8
   Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200
   ASEA A, 2001, J IMMUNOL, V167, P2887
   Balla J, 2000, BLOOD, V95, P3442, DOI 10.1182/blood.V95.11.3442.011k51_3442_3450
   Barsness KA, 2004, AM J PHYSIOL-REG I, V287, pR592, DOI 10.1152/ajpregu.00412.2003
   Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C
   Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761
   Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565
   Bittencourt VCB, 2006, J BIOL CHEM, V281, P22614, DOI 10.1074/jbc.M511417200
   CHOU AC, 1980, J CLIN INVEST, V66, P856, DOI 10.1172/JCI109925
   Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836
   Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099
   GALBRAITH RA, 1990, J HEPATOL, V10, P305, DOI 10.1016/0168-8278(90)90137-G
   Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200
   Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   Guillot L, 2002, J IMMUNOL, V168, P5989, DOI 10.4049/jimmunol.168.12.5989
   Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Jeney V, 2002, BLOOD, V100, P879, DOI 10.1182/blood.V100.3.879
   Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207
   Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047
   Krishnamurthy PC, 2006, NATURE, V443, P586, DOI 10.1038/nature05125
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Mullarkey M, 2003, J PHARMACOL EXP THER, V304, P1093, DOI 10.1124/jpet.102.044487
   MULLEREBERHARD U, 1968, BLOOD, V32, P811, DOI 10.1182/blood.V32.5.811.811
   Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558
   Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200
   Oyama J, 2004, CIRCULATION, V109, P784, DOI 10.1161/01.CIR.0000112575.66565.84
   Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574
   Perera PY, 1997, J IMMUNOL, V158, P4422
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Quigley JG, 2004, CELL, V118, P757, DOI 10.1016/j.cell.2004.08.014
   Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200
   Rossignol Daniel P, 2005, Curr Opin Investig Drugs, V6, P496
   Saemann MD, 2005, J CLIN INVEST, V115, P468, DOI 10.1172/JCI200522720
   Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JCI23755
   SCHMITT TH, 1993, ARCH BIOCHEM BIOPHYS, V307, P96, DOI 10.1006/abbi.1993.1566
   Shayeghi M, 2005, CELL, V122, P789, DOI 10.1016/j.cell.2005.06.025
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003
   Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858
   Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127
   Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200
   Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200
   Visintin A, 2005, J IMMUNOL, V175, P6465, DOI 10.4049/jimmunol.175.10.6465
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
NR 55
TC 302
Z9 315
U1 0
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 13
PY 2007
VL 282
IS 28
BP 20221
EP 20229
DI 10.1074/jbc.M610737200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 187AI
UT WOS:000247819300024
PM 17502383
OA Bronze
DA 2020-12-01
ER

PT J
AU Paiva, CN
   Arras, RH
   Lessa, LP
   Gibaldi, D
   Alves, L
   Metz, CN
   Gazzinelli, R
   Pyrrho, AS
   Lannes-Vieira, J
   Bozza, MT
AF Paiva, Claudia N.
   Arras, Rosa H.
   Lessa, Luiz P.
   Gibaldi, Daniel
   Alves, Leticia
   Metz, Christine N.
   Gazzinelli, Ricardo
   Pyrrho, Alexandre S.
   Lannes-Vieira, Joseli
   Bozza, Marcelo T.
TI Unraveling the lethal synergism between Trypanosoma cruzi infection and
   LPS: A role for increased macrophage reactivity
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE endotoxemia; macrophage; septic shock; Trypanosoma cruzi
ID MIGRATION-INHIBITORY FACTOR; EXPERIMENTAL CHAGAS-DISEASE;
   TUMOR-NECROSIS-FACTOR; IFN-GAMMA PRODUCTION; SEPTIC SHOCK;
   PROPIONIBACTERIUM-ACNES; SHWARTZMAN REACTION; CYTOKINE PRODUCTION;
   IMMUNE-RESPONSES; INTERFERON-GAMMA
AB Various infections sensitize to lethal shock by promoting hyperactivation of macrophages to LPS stimulation. Although macrophages are thought to be deactivated upon contact with apoptotic cells during Trypanosoma cruzi infection, T. cruzi infection also sensitizes mice to endotoxemia. Herein, we studied the mechanisms of sensitization to endotoxemia in T cruzi-infected mice in order to solve the paradox. Live (but not fixed) trypomastigotes from various stocks sensitized mice to endotoxemia. Mice deficient in glycolipid recognition (TLR2(-/-) and CD1d(-/-)) were sensitized by infection to challenge with LPS. Infected mice hyperproduced TNF and IL-10 upon LPS challenge. Infected TNF-R1(-/-), macrophage migration inhibitory factor (MIF)(-/-) and IFN-gamma(-/-) mice were lethally sensitized, but infected TNF-R1(-/-) mice administered anti-MIF survived shock with LPS. Macrophages from infected mice hyperproduced TNF in response to LPS stimulation and displayed increased expression of TLR4 compared to non-infected controls. Treatment with the PGE(2) synthesis inhibitor acetylsalicylic acid (AAS) in vivo reduced parasitemia and enhanced LPS-stimulated production of TNF by macrophages, but the effect was less in infected mice than in normal mice. Nevertheless, AAS treatment did not increase the susceptibility of infected mice to sublethal shock with LPS. Our results point to independent MIF and TNF/TNF-R1 lethal pathways and suggest a role for hyperactivated macrophages in T cruzi-sensitized LPS-induced shock.
C1 Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Dept Immunol, BR-21941902 Rio De Janeiro, Brazil.
   Fiocruz MS, Inst Oswaldo Cruz, Dept Immunol, BR-21045900 Rio De Janeiro, Brazil.
   N Shore LIJ Hlth Syst, Feinstein Inst Med Res, Lab Med Biochem, New York, NY USA.
   Univ Fed Minas Gerais, Dept Imunol & Bioquim, Belo Horizonte, MG, Brazil.
   Univ Fed Rio de Janeiro, Fac Farm, Dept Analises Clin & Toxicol, BR-21941 Rio De Janeiro, Brazil.
RP Paiva, CN (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Dept Immunol, CCS Bloco 1,Ave Carlos Chagas Filho,373 Cidade Un, BR-21941902 Rio De Janeiro, Brazil.
EM cnpaiva@iname.com
RI Gibaldi, Daniel/K-7352-2012
OI Gazzinelli, Ricardo/0000-0003-2427-7699; Bozza,
   Marcelo/0000-0003-3683-7550; Christine, Metz/0000-0002-1013-1691
CR Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467
   Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8
   Bambirra E A, 1984, Mem Inst Oswaldo Cruz, V79, P433, DOI 10.1590/S0074-02761984000400006
   BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290
   BLACK CM, 1989, IMMUNOLOGY, V68, P570
   Borges MM, 1998, IMMUNOL LETT, V63, P1, DOI 10.1016/S0165-2478(98)00034-0
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8
   Cowdery J, 1996, J IMMUNOL, V156, P4570
   Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fehniger TA, 2000, J IMMUNOL, V164, P1643, DOI 10.4049/jimmunol.164.4.1643
   Fejer G, 2005, J IMMUNOL, V175, P1498, DOI 10.4049/jimmunol.175.3.1498
   Fijen, 2000, Eur J Intern Med, V11, P89, DOI 10.1016/S0953-6205(00)00068-6
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z
   HEREMANS H, 1990, J EXP MED, V171, P1853, DOI 10.1084/jem.171.6.1853
   Holscher C, 2000, INFECT IMMUN, V68, P4075, DOI 10.1128/IAI.68.7.4075-4083.2000
   Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638
   Jacobs F, 1996, CLIN EXP IMMUNOL, V103, P233, DOI 10.1046/j.1365-2249.1996.d01-632.x
   Kalis C, 2005, J IMMUNOL, V174, P4295, DOI 10.4049/jimmunol.174.7.4295
   Lopes MF, 2000, IMMUNOL TODAY, V21, P489, DOI 10.1016/S0167-5699(00)01713-8
   LOPES MF, 1995, J IMMUNOL, V154, P744
   Merlin T, 2001, J ENDOTOXIN RES, V7, P157, DOI 10.1177/09680519010070021001
   NABORS GS, 1991, J IMMUNOL, V146, P3591
   Nansen A, 1997, J INFECT DIS, V176, P151, DOI 10.1086/514017
   Nansen A, 2001, J IMMUNOL, V166, P982, DOI 10.4049/jimmunol.166.2.982
   Nguyen KB, 1999, J IMMUNOL, V162, P5238
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Paiva CN, 2003, SHOCK, V19, P163, DOI 10.1097/00024382-200302000-00013
   Peschon JJ, 1998, J IMMUNOL, V160, P943
   PETRAY P, 1994, PARASITE IMMUNOL, V16, P193, DOI 10.1111/j.1365-3024.1994.tb00340.x
   Planelles L, 2003, CLIN EXP IMMUNOL, V131, P41, DOI 10.1046/j.1365-2249.2003.02022.x
   Procopio DO, 2002, J IMMUNOL, V169, P3926, DOI 10.4049/jimmunol.169.7.3926
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456
   RUSSO M, 1991, RES IMMUNOL, V142, P144, DOI 10.1016/0923-2494(91)90026-F
   SMITH SR, 1993, J LEUKOCYTE BIOL, V54, P23
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Yang H, 2002, SHOCK, V17, P485, DOI 10.1097/00024382-200206000-00008
NR 42
TC 19
Z9 19
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0014-2980
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAY
PY 2007
VL 37
IS 5
BP 1355
EP 1364
DI 10.1002/eji.200636705
PG 10
WC Immunology
SC Immunology
GA 168XY
UT WOS:000246558500024
PM 17390393
OA Bronze
DA 2020-12-01
ER

PT J
AU Magalhaes, ES
   Mourao-Sa, DS
   Vieira-de-Abreu, A
   Figueiredo, RT
   Pires, AL
   Farias, FA
   Fonseca, BPF
   Viola, JPB
   Metz, C
   Martins, MA
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
AF Magalhaes, Elizabeth S.
   Mourao-Sa, Diego S.
   Vieira-de-Abreu, Adriana
   Figueiredo, Rodrigo T.
   Pires, Ana L.
   Farias-Filho, Francisco A.
   Fonseca, Bruna P. F.
   Viola, Joao P. B.
   Metz, Christine
   Martins, Marco A.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
   Bozza, Marcelo T.
TI Macrophage migration inhibitory factor is essential for allergic asthma
   but not for Th2 differentiation
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE airway hyper-responsiveness; asthma; eosinophils; inflammation; Th1-Th2
ID INDUCED AIRWAY INFLAMMATION; FACTOR MIF; REGULATORY ROLE; MURINE MODEL;
   DEFICIENT; MOUSE; LEUKOTRIENES; EOSINOPHILS; CYTOKINE; MICE
AB Macrophage migration inhibitory factor (MIF) is increased in asthmatic patients and plays a critical role in the pathogenesis of asthma. We show here that mice lacking MIF failed to develop airway hyper-responsiveness (AHR), tissue eosinophilia, and mucus metaplasia. Analysis of the bronchoalveolar fluids revealed a substantial reduction of IL-13, eotaxin and cysteinyl-leukotrienes. The lack of these cardinal features of asthma in MIF-/- mice occurs regardless of high concentrations of IL-4 in the lung and OVA-specific IgE in the serum. Antigen-specific lymphocyte proliferation and IL-13 production were similarly increased in the draining lymph nodes of OVA-immunized and challenged MIF-/- mice compared to WT, but were reduced in the spleen of MIF-/-, thus indicating differential roles of MIF in these compartments. Stimulation of naive CD4(+) cells with anti-CD3 antibody demonstrated that MIF-/- cells produced increased amounts of IFN-gamma and IL-4 compared to WT CD4(+) cells. Finally, treatment of sensitized BALB/c mice with neutralizing anti-MIF antibody abrogated the development of ARH and airway inflammation without affecting the production of Th2 cytokines or IgE. The present study demonstrates that MIF is required for allergic inflammation, adding important elements to our knowledge of asthma pathogenesis and suggesting that neutralization of MIF might be of therapeutic value in asthma.
C1 Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, BR-21941902 Rio De Janeiro, Brazil.
   IOC Fiocruz, Dept Fisiol & Farmacodinam, Rio De Janeiro, Brazil.
   Inst Nacl Canc, Div Biol Celular, Rio De Janeiro, Brazil.
   Inst Med Res N Shore LIJ, Lab Med Biochem, Manhasset, NY USA.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Immunol, Inst Microbiol, CCS Bloco 1,Ave Carlos Chagas Filho,373 Cidade Un, BR-21941902 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Viola, Joao/AAP-4125-2020; Mourao-Sa, Diego/C-5977-2009; Figueiredo,
   Rodrigo T./F-5176-2016
OI Viola, Joao/0000-0002-0698-3146; Figueiredo, Rodrigo
   T./0000-0002-7551-8782; Christine, Metz/0000-0002-1013-1691; Bozza,
   Marcelo/0000-0003-3683-7550; Mourao, Diego/0000-0001-6618-6969; Bozza,
   Patricia/0000-0001-8349-9529; Fonseca, Bruna de
   Paula/0000-0002-8795-2578
CR Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Bacher M, 1997, AM J PATHOL, V150, P235
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109
   de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720
   Denkinger CM, 2003, J IMMUNOL, V170, P1274, DOI 10.4049/jimmunol.170.3.1274
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748
   Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195
   Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157
   Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261
   Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011
   Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051
   Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483
   Hua ZX, 1998, HUM PATHOL, V29, P1441, DOI 10.1016/S0046-8177(98)90013-2
   Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283
   Kobayashi M, 2006, EUR RESPIR J, V27, P726, DOI 10.1183/09031936.06.00107004
   Korsgren M, 2000, MEDIAT INFLAMM, V9, P15, DOI 10.1080/09629350050024339
   Lan HY, 1997, J EXP MED, V185, P1455, DOI 10.1084/jem.185.8.1455
   Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472
   Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO;2-B
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286
   Lloyd CM, 2001, J IMMUNOL, V166, P2033, DOI 10.4049/jimmunol.166.3.2033
   Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100
   Mizue Y, 2005, P NATL ACAD SCI USA, V102, P14410, DOI 10.1073/pnas.0507189102
   NAGAI H, 1993, LIFE SCI, V53, pPL243
   Nakamaru Y, 2005, CYTOKINE, V31, P103, DOI 10.1016/j.cyto.2005.04.002
   Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2
   Qiang Y, 2003, J IMMUNOL, V170, P1473, DOI 10.4049/jimmunol.170.3.1473
   Rodriguez-Sosa M, 2003, INFECT IMMUN, V71, P1247, DOI 10.1128/IAI.71.3.1247-1254.2003
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524
   Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001
   Stavitsky AB, 2003, PARASITE IMMUNOL, V25, P369, DOI 10.1046/j.1365-3024.2003.00641.x
   Topilski I, 2002, J IMMUNOL, V168, P1610, DOI 10.4049/jimmunol.168.4.1610
   Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC
   Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V284, pL260, DOI 10.1152/ajplung.00226.2002
   Walter DM, 2001, J IMMUNOL, V167, P4668, DOI 10.4049/jimmunol.167.8.4668
   Wang B, 2006, J IMMUNOL, V177, P5779, DOI 10.4049/jimmunol.177.9.5779
   Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255
   Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258
   Yamaguchi E, 2000, CLIN EXP ALLERGY, V30, P1244
   Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909
NR 52
TC 27
Z9 28
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD APR
PY 2007
VL 37
IS 4
BP 1097
EP 1106
DI 10.1002/eji.200635968
PG 10
WC Immunology
SC Immunology
GA 159HX
UT WOS:000245857300023
PM 17373669
OA Bronze
DA 2020-12-01
ER

PT J
AU Barbosa, FM
   Fonseca, FL
   Figueiredo, RT
   Bozza, MT
   Casadevall, A
   Nimrichter, L
   Rodrigues, ML
AF Barbosa, Fabiane M.
   Fonseca, Fernanda L.
   Figueiredo, Rodrigo T.
   Bozza, Marcelo T.
   Casadevall, Arturo
   Nimrichter, Leonardo
   Rodrigues, Marcio L.
TI Binding of glucuronoxylomannan to the CD14 receptor in human A549
   alveolar cells induces interleukin-8 production
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-4; CRYPTOCOCCUS-NEOFORMANS; EPITHELIAL-CELLS;
   MONOCLONAL-ANTIBODIES; PULMONARY INFECTION; LIPOPOLYSACCHARIDE;
   POLYSACCHARIDE; MACROPHAGES; MENINGITIS; EXPRESSION
AB Glucuronoxylomarman (GXM) is the major capsular polysaccharide of Cryptococcus neoformans. GXM receptors have been characterized in phagocytes and endothelial cells, but epithelial molecules recognizing the polysaccharide remain unknown. In the current study, we demonstrate that GXM binds to the CD14 receptor in human type II alveolar epithelial cells, resulting in the production of the proinflammatory chemokine interleukin-8.
C1 Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo De Goes, CCS, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Lab Estudos Integrados Bioquim Microbiana, Dept Microbiol Geral, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Immunol, BR-21941590 Rio De Janeiro, Brazil.
   Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
   Albert Einstein Coll Med, Div Infect Dis, Dept Med, Bronx, NY 10461 USA.
RP Rodrigues, ML (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo De Goes, CCS, Bloco 1, BR-21941590 Rio De Janeiro, Brazil.
EM marcio@micro.ufrj.br
RI Nimrichter, Leonardo/L-3545-2014; Fonseca, Fernanda/V-3446-2019;
   Figueiredo, Rodrigo T./F-5176-2016; Rodrigues, Marcio/J-3727-2013
OI Nimrichter, Leonardo/0000-0001-9281-6856; Figueiredo, Rodrigo
   T./0000-0002-7551-8782; Rodrigues, Marcio/0000-0002-6081-3439; Bozza,
   Marcelo/0000-0003-3683-7550
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842, R01HL059842, R01HL059842,
   R01HL059842, R01HL059842, R01HL059842] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052733, R37AI033142, R01AI052733, R01AI052733, R01AI033142,
   R01AI033142, R01AI052733, R01AI052733, R37AI033142, R01AI033774,
   R01AI033774, R01AI052733, R01AI052733, R37AI033142, R01AI052733,
   R01AI033142, R37AI033142, R01AI052733, R01AI033774, R01AI033774,
   R37AI033142, R37AI033142, R37AI033142, R01AI033142, R01AI033142,
   R01AI033774, R37AI033142, R01AI052733, R01AI033774, R01AI033774,
   R01AI033142, R01AI033774, R01AI033774, R01AI033142, R01AI033774,
   R01AI033774, R01AI033774, R01AI033774, R37AI033142, R01AI033142,
   R37AI033142, R01AI033774, R01AI033142, R01AI033142, R01AI033774,
   R01AI052733, R01AI052733, R01AI033774, R01AI033774, R01AI033142,
   R37AI033142, R01AI052733, R01AI033774, R37AI033142, R37AI033142,
   R01AI052733, R01AI033142, R01AI052733, R37AI033142, R01AI033142,
   R01AI033774, R01AI033774, R01AI033774, R01AI033774] Funding Source: NIH
   RePORTER; NHLBI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [HL059842, R01 HL059842] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI033774, R01 AI033142,
   R37 AI033142, AI052733, R01 AI052733, AI033142, AI033774] Funding
   Source: Medline
CR Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803
   Barbosa FM, 2006, MICROBES INFECT, V8, P493, DOI 10.1016/j.micinf.2005.07.027
   Casadevall A, 1998, ANTIMICROB AGENTS CH, V42, P1437, DOI 10.1128/AAC.42.6.1437
   CHANG YC, 1994, MOL CELL BIOL, V14, P4912, DOI 10.1128/MCB.14.7.4912
   CHERNIAK R, 1991, INFECT IMMUN, V59, P59, DOI 10.1128/IAI.59.1.59-64.1991
   Cleare W, 1998, CLIN DIAGN LAB IMMUN, V5, P125, DOI 10.1128/CDLI.5.2.125-129.1998
   Feldmesser M, 2000, INFECT IMMUN, V68, P4225, DOI 10.1128/IAI.68.7.4225-4237.2000
   Ganendren R, 2006, MICROBES INFECT, V8, P1006, DOI 10.1016/j.micinf.2005.10.018
   Jersmann HPA, 2005, IMMUNOL CELL BIOL, V83, P462, DOI 10.1111/j.1440-1711.2005.01370.x
   Kawakami K, 2004, JPN J INFECT DIS, V57, P137
   Larsen RA, 2005, ANTIMICROB AGENTS CH, V49, P952, DOI 10.1128/AAC.49.3.952-958.2005
   LEVITZ SM, 1991, J CLIN INVEST, V87, P528, DOI 10.1172/JCI115027
   Levitz Stuart M, 2002, Nihon Ishinkin Gakkai Zasshi, V43, P133, DOI 10.3314/jjmm.43.133
   MacRedmond R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-116
   Monari C, 2005, J IMMUNOL, V174, P3461, DOI 10.4049/jimmunol.174.6.3461
   Monari C, 2006, FEMS YEAST RES, V6, P537, DOI 10.1111/j.1567-1364.2006.00072.x
   Oscarson S, 2005, VACCINE, V23, P3961, DOI 10.1016/j.vaccine.2005.02.029
   Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x
   PIROFSKI L, 1995, INFECT IMMUN, V63, P3005, DOI 10.1128/IAI.63.8.3005-3014.1995
   Reddi K, 2003, PEDIATR RES, V54, P297, DOI 10.1203/01.PDR.0000076661.85928.1D
   Riederer I, 2002, TRANSPLANTATION, V74, P1515, DOI 10.1097/00007890-200212150-00007
   Siddiqui AA, 2005, J IMMUNOL, V174, P1746, DOI 10.4049/jimmunol.174.3.1746
   Tsutsumi-Ishii Y, 2003, J IMMUNOL, V170, P4226, DOI 10.4049/jimmunol.170.8.4226
   Wormley FL, 2005, METH MOLEC MED, V118, P193
   YANCH LE, 2004, INFECT IMMUN, V72, P5373
   Zhang ZH, 2005, J INFECTION, V51, P375, DOI 10.1016/j.jinf.2004.12.012
NR 26
TC 19
Z9 20
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JAN
PY 2007
VL 14
IS 1
BP 94
EP 98
DI 10.1128/CVI.00296-06
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 126WL
UT WOS:000243546100013
PM 17093102
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Salluh, JI
   Japiassu, AM
   Soares, M
   Assis, EF
   Gomes, RN
   Bozza, MT
   Castro-Faria-Neto, HC
   Bozza, PT
AF Bozza, Fernando A.
   Salluh, Jorge I.
   Japiassu, Andre M.
   Soares, Marcio
   Assis, Edson F.
   Gomes, Rachel N.
   Bozza, Marcelo T.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
TI Cytokine profiles as markers of disease severity in sepsis: a multiplex
   analysis
SO CRITICAL CARE
LA English
DT Article
ID MCP-1 PROTECTS MICE; ORGAN FAILURE; SEPTIC SHOCK; SYSTEM; DEFINITIONS;
   GUIDELINES; PROTEIN-1; ASSAYS; SCORE
AB Introduction The current shortage of accurate and readily available, validated biomarkers of disease severity in sepsis is an important limitation when attempting to stratify patients into homogeneous groups, in order to study pathogenesis or develop therapeutic interventions. The aim of the present study was to determine the cytokine profile in plasma of patients with severe sepsis by using a multiplex system for simultaneous detection of 17 cytokines.
   Methods This was a prospective cohort study conducted in four tertiary hospitals. A total of 60 patients with a recent diagnosis of severe sepsis were included. Plasma samples were collected for measurement of cytokine concentrations. A multiplex analysis was performed to evaluate levels of 17 cytokines ( IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-17, interferon-gamma, granulocyte colony-stimulating factor [ G-CSF], granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein [ MCP]-1, macrophage inflammatory protein-1 and tumour necrosis factor-alpha). Cytokine concentrations were related to the presence of severe sepsis or septic shock, the severity and evolution of organ failure, and early and late mortality.
   Results Concentrations of IL-1 beta, IL-6, IL-7, IL-8, IL-10, IL-13, interferon-gamma, MCP-1 and tumour necrosis factor-alpha were significantly higher in septic shock patients than in those with severe sepsis. Cytokine concentrations were associated with severity and evolution of organ dysfunction. With regard to the severity of organ dysfunction on day 1, IL-8 and MCP-1 exhibited the best correlation with Sequential Organ Failure Assessment score. In addition, IL-6, IL-8 and G-CSF concentrations during the first 24 hours were predictive of worsening organ dysfunction or failure of organ dysfunction to improve on day three. In terms of predicting mortality, the cytokines IL-1 beta, IL-4, IL-6, IL-8, MCP-1 and G-CSF had good accuracy for predicting early mortality (< 48 hours), and IL-8 and MCP-1 had the best accuracy for predicting mortality at 28 days. In multivariate analysis, only MCP-1 was independently associated with prognosis.
   Conclusion In this exploratory analysis we demonstrated that use of a multiple cytokine assay platform allowed identification of distinct cytokine profiles associated with sepsis severity, evolution of organ failure and death.
C1 Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Frago Filho, ICU, Rio De Janeiro, Brazil.
   Hosp Barra Or, ICU, BR-22775001 Rio De Janeiro, Brazil.
   Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
   Hosp Quinta Or, ICU, BR-20941150 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, ICU, Av Brasil 4365, Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Gomes, Rachel N/I-7643-2013; dantas, vicente c souza/L-2648-2013;
   Salluh, Jorge IF/F-6779-2012; Bozza, Fernando A/A-2618-2013; Soares,
   Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Patricia/0000-0001-8349-9529; Salluh,
   Jorge/0000-0002-8164-1453; Bozza, Marcelo/0000-0003-3683-7550
CR BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Brueckmann M, 2003, THROMB HAEMOSTASIS, V89, P149
   Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003
   Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Gerlach H, 2003, CRIT CARE, V7, P256, DOI 10.1186/cc2195
   Gibot S, 2004, ANN INTERN MED, V141, P9, DOI 10.7326/0003-4819-141-1-200407060-00009
   Gomes RN, 2006, SHOCK, V26, P457, DOI 10.1097/01.shk.0000228801.56223.92
   Goodman RB, 1996, AM J RESP CRIT CARE, V154, P602, DOI 10.1164/ajrccm.154.3.8810593
   Hosmer DW, 2000, APPL LOGISTIC REGRES
   Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Knight PR, 2004, SHOCK, V21, P26, DOI 10.1097/01.shk.0000101668.49265.19
   Levy MM, 2005, CRIT CARE MED, V33, P2194, DOI 10.1097/01.CCM.0000182798.39709.84
   Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B
   Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A
   Marshall John C, 2006, Curr Infect Dis Rep, V8, P351, DOI 10.1007/s11908-006-0045-1
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59
   Oliver KG, 1998, CLIN CHEM, V44, P2057
   Prabhakar U, 2002, J IMMUNOL METHODS, V260, P207, DOI 10.1016/S0022-1759(01)00543-9
   Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523
   Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699
   Sennikov SV, 2003, J IMMUNOL METHODS, V275, P81, DOI 10.1016/S0022-1759(03)00007-3
   Simon L, 2004, CLIN INFECT DIS, V39, P206, DOI 10.1086/421997
   Tam SW, 2002, J IMMUNOL METHODS, V261, P157, DOI 10.1016/S0022-1759(01)00572-5
   Tjardes T, 2002, SHOCK, V17, P1, DOI 10.1097/00024382-200201000-00001
   Ulloa L, 2005, TRENDS MOL MED, V11, P56, DOI 10.1016/j.molmed.2004.12.007
   Vermont CL, 2006, CRIT CARE, V10, DOI 10.1186/cc4836
   Vignali DAA, 2000, J IMMUNOL METHODS, V243, P243, DOI 10.1016/S0022-1759(00)00238-6
   Vincent JL, 2006, AM J RESP CRIT CARE, V173, P256, DOI 10.1164/rccm.200510-1604OE
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 38
TC 423
Z9 457
U1 0
U2 49
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1466-609X
J9 CRIT CARE
JI Crit. Care
PY 2007
VL 11
IS 2
AR R49
DI 10.1186/cc5783
PG 8
WC Critical Care Medicine
SC General & Internal Medicine
GA 185OV
UT WOS:000247721200019
PM 17448250
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Figueiredo, RT
   Bozza, FA
   Pacheco, P
   Amancio, RT
   Laranjeira, AP
   Castro-Faria, HC
   Bozza, PT
   Bozza, MT
AF Gomes, Rachel N.
   Figueiredo, Rodrigo T.
   Bozza, Fernando A.
   Pacheco, Patricia
   Amancio, Rodrigo T.
   Laranjeira, Andrea P.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
   Bozza, Marcelo T.
TI Increased susceptibility to septic and endotoxic shock in monocyte
   chemoattractant protein 1/CC chemokine ligand 2-deficient mice
   correlates with reduced interleukin 10 and enhanced macrophage migration
   inhibitory factor production
SO SHOCK
LA English
DT Article
DE MCP-1; CCL2; CLP; endotoxin; sepsis; cytokines
ID INFLAMMATORY RESPONSE SYNDROME; LETHAL ENDOTOXEMIA; HOST-DEFENSE; MURINE
   MODEL; CHEMOTACTIC PROTEIN-1; BACTERIAL-INFECTION; ACTIVATING-FACTOR;
   SEPSIS; MCP-1; PERITONITIS
AB The chemokine monocyte chemoattractant protein 1/CC chemokine ligand 2 (MCP-1/CCL2) is a potent chemoattractant of mononuclear cells and a regulatory mediator involved in a variety of inflammatory diseases. In the present study, we demonstrate that mcp-1/ccl2-deficient mice are more susceptible to systemic inflammatory response syndrome induced by lipopolysaccharide and to polymicrobial sepsis induced by cecum ligation and puncture (CLP) when compared with wild-type mice. Interestingly, in the CLP model, mcp-1/ccl2 deficient mice efficiently cleared the bacteria despite an impaired recruitment of leukocytes, especially mononuclear cells. The increased lethality rate in these models correlates with an impaired production of interleukin (IL) 10 in vivo. Furthermore, macrophages from mcp-1/ccl2-deficient mice activated with lipopolysaccharide also produced lower amounts of IL-10 and similar tumor necrosis factor compared with wild-type mice. We observed a drastic increase in the amounts of macrophage migration inhibitory factor at 6 and 24 h after CLP in mcp-1/ccl2-deficient mice. These results indicate that endogenous MCP-1/CCL2 positively regulates IL-10 but negatively controls macrophage migration inhibitory factor during peritoneal sepsis, thus suggesting an important immunomodulatory role for MCP-1/CCL2 in controlling the balance between proinflammatory and anti-inflammatory factors in sepsis.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941590 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, LATEB, BR-21045900 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Ctr Tratamento Intens, BR-21045900 Rio De Janeiro, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Lab Inflamacao & Imunidade, Av Brigadeiro Trompowsky S-N CCS Bloco I, BR-21941590 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br; mbozza@micro.ufrj.br
RI Figueiredo, Rodrigo T./F-5176-2016; Bozza, Fernando A/A-2618-2013;
   Gomes, Rachel N/I-7643-2013
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Bozza, Fernando
   A/0000-0003-4878-0256; Bozza, Patricia/0000-0001-8349-9529
CR Amano H, 2004, J IMMUNOL, V172, P398, DOI 10.4049/jimmunol.172.1.398
   BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   BOSSINK AWJ, 1995, BLOOD, V86, P3841, DOI 10.1182/blood.V86.10.3841.bloodjournal86103841
   Bozza FA, 2004, SHOCK, V22, P309, DOI 10.1097/01.shk.0000140305.01641.c8
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   Chensue SW, 1996, J IMMUNOL, V157, P4602
   Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0
   ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
   Feterowski C, 2004, EUR J IMMUNOL, V34, P3664, DOI 10.1002/eji.200425294
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   Gomes RN, 2005, SHOCK, V24, P590, DOI 10.1097/01.shk.0000183395.29014.7c
   GREENBERGER MJ, 1995, J IMMUNOL, V155, P722
   Held KS, 2004, VIROLOGY, V329, P251, DOI 10.1016/j.virol.2004.09.006
   Hokeness KL, 2005, J IMMUNOL, V174, P1549, DOI 10.4049/jimmunol.174.3.1549
   JANSEN PM, 1995, J INFECT DIS, V171, P1640, DOI 10.1093/infdis/171.6.1640
   LEONARD EJ, 1990, IMMUNOL TODAY, V11, P97, DOI 10.1016/0167-5699(90)90035-8
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Matsukawa A, 2000, EXP MOL PATHOL, V68, P77, DOI 10.1006/exmp.1999.2296
   NAKANO Y, 1994, INFECT IMMUN, V62, P377, DOI 10.1128/IAI.62.2.377-383.1994
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Penido C, 2003, J IMMUNOL, V171, P6788, DOI 10.4049/jimmunol.171.12.6788
   Raghavendran K, 2005, AM J PHYSIOL-LUNG C, V289, pL134, DOI 10.1152/ajplung.00390.2004
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Sewnath ME, 2001, J IMMUNOL, V166, P6323, DOI 10.4049/jimmunol.166.10.6323
   Speyer CL, 2004, AM J PATHOL, V165, P2187, DOI 10.1016/S0002-9440(10)63268-3
   Steinhauser ME, 1999, J IMMUNOL, V162, P392
   STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365
   Tsuda Y, 2004, J LEUKOCYTE BIOL, V76, P368, DOI 10.1189/jlb.1203645
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Zisman DA, 1997, J CLIN INVEST, V99, P2832, DOI 10.1172/JCI119475
NR 39
TC 37
Z9 39
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD NOV
PY 2006
VL 26
IS 5
BP 457
EP 463
DI 10.1097/01.shk.0000228801.56223.92
PG 7
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 104BU
UT WOS:000241931700005
PM 17047515
DA 2020-12-01
ER

PT J
AU Bittencourt, VCB
   Figueiredo, RT
   da Silva, RB
   Mourao-Sa, DS
   Fernandez, PL
   Sassaki, GL
   Mulloy, B
   Bozza, MT
   Barreto-Bergter, E
AF Bittencourt, Vera Carolina B.
   Figueiredo, Rodrigo T.
   da Silva, Rosana B.
   Mourao-Sa, Diego S.
   Fernandez, Patricia L.
   Sassaki, Guilherme L.
   Mulloy, Barbara
   Bozza, Marcelo T.
   Barreto-Bergter, Eliana
TI An alpha-glucan of Pseudallescheria boydii is involved in fungal
   phagocytosis and toll-like receptor activation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNE CELLS; CANDIDA; TLR4; RECOGNITION; DECTIN-1; MICE; CD14;
   SUSCEPTIBILITY; INDUCTION; RESPONSES
AB The host response to fungi is in part dependent on activation of evolutionarily conserved receptors, including toll-like receptors and phagocytic receptors. However, the molecular nature of fungal ligands responsible for this activation is largely unknown. Herein, we describe the isolation and structural characterization of an alpha-glucan from Pseudallescheria boydii cell wall and evaluate its role in the induction of innate immune response. These analyses indicate that alpha-glucan of P. boydii is a glycogen-like polysaccharide consisting of linear 4-linked alpha-D-Glcp residues substituted at position 6 with alpha-D-Glcp branches. Soluble alpha-glucan, but not alpha-glucan, led to a dose-dependent inhibition of conidia phagocytosis. Furthermore, a significant decrease in the phagocytic index occurred when alpha-glucan from conidial surface was removed by enzymatic treatment with alpha-amyloglucosidase, thus indicating an essential role of alpha-glucan in P. boydii internalization by macrophages. alpha-Glucan stimulates the secretion of inflammatory cytokines by macrophages and dendritic cells; again this effect is abolished by treatment with alpha-amyloglucosidase. Finally, alpha-glucan induces cytokine secretion by cells of the innate immune system in a mechanism involving toll-like receptor 2, CD14, and MyD88. These results might have relevance in the context of infections with P. boydii and other fungi, and alpha-glucan could be a target for intervention during fungal infections.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Microbiol Geral, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Parana, Dept Bioquim, BR-81531990 Curitiba, Parana, Brazil.
   Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Ave Brigadeiro Trompowsky S-N,CCS Bloco 1, BR-21941590 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br; eliana.bergter@micro.ufrj.br
RI Bergter, Eliana Barreto/E-2664-2013; Figueiredo, Rodrigo T./F-5176-2016;
   Mourao-Sa, Diego/C-5977-2009; Sassaki, Guilherme/AAM-1112-2020
OI Figueiredo, Rodrigo T./0000-0002-7551-8782; Sassaki,
   Guilherme/0000-0001-7420-168X; bittencourt, vera/0000-0002-7403-9747;
   Llanes Fernandez, Patricia/0000-0002-0762-0566; Mourao,
   Diego/0000-0001-6618-6969
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Bahia MCFD, 1997, MYCOPATHOLOGIA, V137, P17
   Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005
   Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059
   BJORNDAL H, 1967, U STOCKOL CHEM COMMU, V8, P1
   Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470
   Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890
   Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Cano LE, 1998, INFECT IMMUN, V66, P800, DOI 10.1128/IAI.66.2.800-806.1998
   Cenci E, 1998, J IMMUNOL, V161, P3543
   Cenci E, 1999, J INFECT DIS, V180, P1957, DOI 10.1086/315142
   CHEETHAM NWH, 1991, CARBOHYD RES, V215, P59, DOI 10.1016/0008-6215(91)84007-2
   CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8
   Dinadayala P, 2004, J BIOL CHEM, V279, P12369, DOI 10.1074/jbc.M308908200
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200
   Flo TH, 2000, INFECT IMMUN, V68, P6770, DOI 10.1128/IAI.68.12.6770-6776.2000
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Gil-Lamaignere C, 2003, INFECT IMMUN, V71, P6472, DOI 10.1128/IAI.71.11.6472-6478.2003
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784
   Kataoka K, 2002, J BIOL CHEM, V277, P36825, DOI 10.1074/jbc.M206756200
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x
   Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200
   Means TK, 1999, J IMMUNOL, V163, P6748
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x
   Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207
   Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734
   Netea MG, 2002, J INFECT DIS, V185, P1483, DOI 10.1086/340511
   NEWMAN SL, 1995, J IMMUNOL, V154, P753
   Park JM, 2004, J EXP MED, V200, P1647, DOI 10.1084/jem.20041215
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Popi AF, 2002, CELL IMMUNOL, V218, P87, DOI 10.1016/S0008-8749(02)00576-2
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255
   SASADA M, 1980, J EXP MED, V152, P85, DOI 10.1084/jem.152.1.85
   SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048
   Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554
   Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544
   Tischer CA, 2002, CARBOHYD POLYM, V47, P151, DOI 10.1016/S0144-8617(01)00173-4
   Villamon E, 2004, MICROBES INFECT, V6, P1, DOI 10.1016/j.micinf.2003.09.020
   WANG RH, 1995, BIOCHEM J, V311, P867, DOI 10.1042/bj3110867
   WASHBURN RG, 1987, INFECT IMMUN, V55, P2088, DOI 10.1128/IAI.55.9.2088-2092.1987
   ZANG LH, 1991, CARBOHYD RES, V220, P1, DOI 10.1016/0008-6215(91)80001-4
NR 53
TC 101
Z9 104
U1 0
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 11
PY 2006
VL 281
IS 32
BP 22614
EP 22623
DI 10.1074/jbc.M511417200
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 070RY
UT WOS:000239542600022
PM 16766532
OA Bronze
DA 2020-12-01
ER

PT J
AU Correa-De-Santana, E
   Paez-Pereda, M
   Theodoropoulou, M
   Nihei, OK
   Gruebler, Y
   Bozza, M
   Arzt, E
   Villa-Verde, DMS
   Renner, U
   Stalla, J
   Stalla, GK
   Savino, W
AF Correa-De-Santana, E
   Paez-Pereda, M
   Theodoropoulou, M
   Nihei, OK
   Gruebler, Y
   Bozza, M
   Arzt, E
   Villa-Verde, DMS
   Renner, U
   Stalla, J
   Stalla, GK
   Savino, W
TI Hypothalamus-pituitary-adrenal axis during Trypanosoma cruzi acute
   infection in mice
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE HPA axis; Trypanosoma cruzi; ACTH; cytokines; transcription factors;
   neuroimmunoendocrine interactions
ID LEUKEMIA-INHIBITORY FACTOR; EXTRACELLULAR-MATRIX COMPONENTS; THYMIC
   NURSE CELLS; CHAGAS-DISEASE; ENDOCRINE INTERACTIONS; HORMONE-RELEASE;
   TUMOR-CELLS; MODULATION; CYTOKINES; INTERLEUKIN-6
AB Functional interactions between neuroendocrine and immune systems are mediated by similar ligands and receptors, which establish a bidirectional communication that is relevant for homeostasis. We investigated herein the hypothalamus-pituitary-adrenal (HPA) axis in mice acutely infected by Trypanosoma cruzi, the causative agent of Chagas' disease. Parasites were seen in the adrenal gland, whereas T cruzi specific PCR gene amplification product was found in both adrenal and pituitary glands of infected mice. Histological and immunohistochemical analyses of pituitary and adrenal glands of infected animals revealed several alterations including vascular stasis, upregulation of the extracellular matrix proteins fibronectin and laminin, as well as T cell and macrophage infiltration. Functionally, we detected a decrease in CRH and an increase in corticosterone contents, in hypothalamus and serum respectively. In contrast, we did not find significant changes in the amounts of ACTH in sera of infected animals, whereas the serum levels of the glucocorticoid-stimulating cytokine, IL-6 (interleukin-6), were increased as compared to controls. When we analyzed the effects of T cruzi in ACTH-producing AtT-20 cell line, infected cultures presented lower levels of ACTH and pro-opiomelanocortin production when compared to controls. In these cells we observed a strong phosphorylation of STAT-3, together with an increased synthesis of IL-6, suppressor of cytokine signaling 3 (SOCS-3) and inhibitor of activated STAT-3 (PIAS-3), which could explain the partial blockage of ACTH production. In conclusion, our data reveal that the HPA axis is altered during acute T cruzi infection.. suggesting direct and indirect influences of the parasite in the endocrine homeostasis. (c) 2005 Elsevier B.V. All rights reserved.
C1 Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Immunol, Lab Thymus Res, BR-21045900 Rio De Janeiro, Brazil.
   Max Planck Inst Psychiat, Dept Endocrinol, D-80804 Munich, Germany.
   Univ Buenos Aires, Lab Physiol & Mol Biol, Buenos Aires, DF, Argentina.
   Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Lab Inflammat & Immun, Rio De Janeiro, Brazil.
RP Savino, W (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Dept Immunol, Lab Thymus Res, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM savino@fiocruz.br
RI Villa-Verde, Dea M.S./Q-1238-2016
OI Villa-Verde, Dea M.S./0000-0002-2685-5512; Paez-Pereda,
   Marcelo/0000-0001-6029-0706; Bozza, Marcelo/0000-0003-3683-7550
CR ABEBE G, 1993, ACTA ENDOCRINOL-COP, V129, P75, DOI 10.1530/acta.0.1290075
   Arzt E, 2001, J CLIN INVEST, V108, P1729
   Arzt E, 1999, FRONT NEUROENDOCRIN, V20, P71, DOI 10.1006/frne.1998.0176
   Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954
   Auernhammer CJ, 2001, J CLIN INVEST, V108, P1735, DOI 10.1172/JCI200114662
   AZAR ST, 1993, AM J MED SCI, V305, P321, DOI 10.1097/00000441-199305000-00012
   Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64
   Bousquet C, 1999, J BIOL CHEM, V274, P10723, DOI 10.1074/jbc.274.16.10723
   Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924
   Brener Z, 1997, INT ARCH ALLERGY IMM, V114, P103, DOI 10.1159/000237653
   CALABRESE KS, 1994, INT J EXP PATHOL, V75, P453
   Chesnokova V, 2002, ENDOCRINOLOGY, V143, P1571, DOI 10.1210/en.143.5.1571
   Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803
   CottaDeAlmeida V, 1997, CLIN IMMUNOL IMMUNOP, V82, P125, DOI 10.1006/clin.1996.4283
   Davis TME, 1997, J CLIN ENDOCR METAB, V82, P3029, DOI 10.1210/jc.82.9.3029
   DEMORAES MCL, 1991, SCAND J IMMUNOL, V33, P267, DOI 10.1111/j.1365-3083.1991.tb01772.x
   GWOSDOW AR, 1993, ENDOCRINOLOGY, V132, P710, DOI 10.1210/en.132.2.710
   Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   HERMUS ARMM, 1990, J STEROID BIOCHEM, V37, P867, DOI 10.1016/0960-0760(90)90434-M
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   Kuchenbauer F, 2001, MOL CELL ENDOCRINOL, V175, P141, DOI 10.1016/S0303-7207(01)00390-2
   McCann Samuel M., 1994, Neuroimmunomodulation, V1, P2, DOI 10.1159/000095948
   Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219
   Nakamura Y, 1998, VET PARASITOL, V80, P117, DOI 10.1016/S0304-4017(98)00200-3
   Reincke Martin, 1994, Neuroimmunomodulation, V1, P14, DOI 10.1159/000095930
   RENNER U, 1995, ENDOCRINOLOGY, V136, P3186, DOI 10.1210/en.136.8.3186
   Renner U, 1997, EXP CLIN ENDOCR DIAB, V105, P345, DOI 10.1055/s-0029-1211777
   SAVINO W, 1999, CYTOKINES STRESS IMM, P187
   Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522
   SILEGHEM M, 1989, IMMUNOLOGY, V68, P137
   Silva AA, 1999, CLIN IMMUNOL, V92, P56, DOI 10.1006/clim.1999.4716
   SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575
   Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206
   Szabo S, 1998, ANN NY ACAD SCI, V851, P19, DOI 10.1111/j.1749-6632.1998.tb08972.x
   Theodoropoulou M, 2000, J ENDOCRINOL, V167, P7, DOI 10.1677/joe.0.1670007
   Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642
   VILLAVERDE DMS, 1994, EUR J IMMUNOL, V24, P659, DOI 10.1002/eji.1830240326
   Webster EL, 1997, MOL PSYCHIATR, V2, P368, DOI 10.1038/sj.mp.4000305
NR 39
TC 60
Z9 62
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD APR
PY 2006
VL 173
IS 1-2
BP 12
EP 22
DI 10.1016/j.jneuroim.2005.08.015
PG 11
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 033CO
UT WOS:000236824200003
PM 16494952
DA 2020-12-01
ER

PT J
AU Gomes, RN
   Castro-Faria-Neto, HC
   Bozza, PT
   Soares, MBP
   Shoemaker, CB
   David, JR
   Bozza, MT
AF Gomes, RN
   Castro-Faria-Neto, HC
   Bozza, PT
   Soares, MBP
   Shoemaker, CB
   David, JR
   Bozza, MT
TI Calcitonin gene-related peptide inhibits local acute inflammation and
   protects mice against lethal endotoxemia
SO SHOCK
LA English
DT Article
DE LPS; CGRP; cytokines; inflammation; enclotoxemia
ID SAND FLY SALIVA; MOUSE PERITONEAL-MACROPHAGES;
   PLATELET-ACTIVATING-FACTOR; NECROSIS-FACTOR-ALPHA; SUBSTANCE-P;
   TNF-ALPHA; LIPOPOLYSACCHARIDE; RECEPTOR; CELLS; ACCUMULATION
AB Calcitonin gene-related peptide (CGRP), a potent vasodilatory peptide present in central and peripheral neurons, is released at inflammatory sites and inhibits several macrophage, dendritic cell, and lymphocyte functions. In the present study, we investigated the role of CGRP in models of local and systemic acute inflammation and on macrophage activation induced by lipopolysaccharide (LPS). Intraperitoneal pretreatment with synthetic CGRP reduces in approximately 50% the number of neutrophils in the blood and into the peritoneal cavity 4 h after LPS injection. CGRP failed to inhibit neutrophil recruitment induced by the direct chemoattractant platelet-activating factor, whereas it significantly inhibited LPS-induced KC generation, suggesting that the effect of CGRP on neutrophil recruitment is indirect, acting on chemokine production by resident cells. Pretreatment of mice with 1 mu g of CGRP protects against a lethal dose of LPS. The CGRP-induced protection is receptor mediated because it is completely reverted by the CGRP receptor antagonist, CGRP 8-37. The protective effect of CGRP correlates with an inhibition of TNF-alpha and an induction of IL-6 and IL-10 in mice sera 90 min after LPS challenge. Finally, CGRP significantly inhibits LPS-induced TNF-alpha released from mouse peritoneal macrophages. These results suggest that activation of the CGRP receptor on macrophages during acute inflammation could be part of the negative feedback mechanism controlling the extension of acute inflammatory responses.
C1 Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, Lab Inflamacao & Imunidade, BR-21941590 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, Ctr Pesquisas Goncalo Muniz, BR-40295001 Salvador, BA, Brazil.
   Tufts Univ, Sch Vet Med, Div Infect Dis, Dept Biomed Sci, North Grafton, MA 01536 USA.
   Harvard Univ, Sch Publ Hlth, Dept Trop Publ Hlth, Boston, MA 02115 USA.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol, Lab Inflamacao & Imunidade, Av Brigadeiro Trompwski S-N,CCS Bloco 1, BR-21941590 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Gomes, Rachel N/I-7643-2013
OI Soares, Milena/0000-0001-7549-2992; Bozza, Patricia/0000-0001-8349-9529
CR AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0
   ARNALICH F, 1994, LIFE SCI, V56, P75, DOI 10.1016/0024-3205(94)00927-9
   ASAHINA A, 1995, P NATL ACAD SCI USA, V92, P8323, DOI 10.1073/pnas.92.18.8323
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   Boudet R, 1999, FOUND PHYS, V29, P29, DOI 10.1023/A:1018861019202
   Bozza M, 1998, EUR J IMMUNOL, V28, P3120, DOI 10.1002/(SICI)1521-4141(199810)28:10<3120::AID-IMMU3120>3.0.CO;2-3
   BOZZA PT, 1994, EUR J PHARM-ENVIRON, V270, P143, DOI 10.1016/0926-6917(94)90056-6
   BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x
   BUCKLEY TL, 1991, J IMMUNOL, V146, P3424
   Bulger EM, 2002, SHOCK, V17, P173, DOI 10.1097/00024382-200203000-00003
   CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867
   Feng Y, 1997, LIFE SCI, V61, pPL281, DOI 10.1016/S0024-3205(97)00866-7
   FLEMING I, 1992, J CARDIOVASC PHARM, V20, pS135, DOI 10.1097/00005344-199204002-00038
   GIBBINS IL, 1985, NEUROSCI LETT, V57, P125, DOI 10.1016/0304-3940(85)90050-3
   Holmes MC, 2002, SHOCK, V18, P555, DOI 10.1097/00024382-200212000-00012
   HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0
   HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205
   Larangeira AP, 2001, INFLAMM RES, V50, P309, DOI 10.1007/PL00000249
   Liu J, 2000, IMMUNOLOGY, V101, P61, DOI 10.1046/j.1365-2567.2000.00082.x
   LU B, 1995, J EXP MED, V181, P2271, DOI 10.1084/jem.181.6.2271
   LUBERNAROD J, 1994, J IMMUNOL, V152, P819
   LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X
   MCGILLIS JP, 1991, J IMMUNOL, V147, P3482
   Monneret G, 2000, CYTOKINE, V12, P762, DOI 10.1006/cyto.1999.0607
   MOVAT HZ, 1997, FASEB J, V46, P97
   NONG YH, 1989, J IMMUNOL, V143, P45
   Peng J, 2000, EUR J PHARMACOL, V407, P303, DOI 10.1016/S0014-2999(00)00702-0
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Soares MBP, 1998, J IMMUNOL, V160, P1811
   THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991
   Torii H, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P82, DOI 10.1038/jidsymp.1997.16
   UMEDA Y, 1988, BIOCHEM BIOPH RES CO, V154, P227, DOI 10.1016/0006-291X(88)90674-2
   UMEDA Y, 1989, NEUROPEPTIDES, V14, P237, DOI 10.1016/0143-4179(89)90052-8
   Wagner JG, 1999, J LEUKOCYTE BIOL, V66, P10
   WORTHEN GS, 1986, FED PROC, V45, P7
NR 35
TC 92
Z9 96
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD DEC
PY 2005
VL 24
IS 6
BP 590
EP 594
DI 10.1097/01.shk.0000183395.29014.7c
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 990HT
UT WOS:000233734500016
PM 16317392
OA Green Published
DA 2020-12-01
ER

PT J
AU Travassos, LH
   Carneiro, LAM
   Girardin, SE
   Boneca, IG
   Lemos, R
   Bozza, MT
   Domingues, RCP
   Coyle, AJ
   Bertin, J
   Philpott, DJ
   Plotkowski, MC
AF Travassos, LH
   Carneiro, LAM
   Girardin, SE
   Boneca, IG
   Lemos, R
   Bozza, MT
   Domingues, RCP
   Coyle, AJ
   Bertin, J
   Philpott, DJ
   Plotkowski, MC
TI Nod1 participates in the innate immune response to Pseudomonas
   aeruginosa
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID AIRWAY EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-5; NF-KAPPA-B; PEPTIDOGLYCAN
   RECOGNITION; HOST RESPONSE; EXOTOXIN-A; INFLAMMATION; ACTIVATION;
   FLAGELLIN; LIPOPOLYSACCHARIDE
AB The mammalian innate immune system recognizes pathogen-associated molecular patterns through pathogen recognition receptors. Nod1 has been described recently as a cytosolic receptor that detects specifically diaminopimelate-containing muropeptides from Gram-negative bacteria peptidoglycan. In the present study we investigated the potential role of Nod1 in the innate immune response against the opportunistic pathogen Pseudomonas aeruginosa. We demonstrate that Nod1 detects the P. aeruginosa peptidoglycan leading to NF-kappa B activation and that this activity is diminished in epithelial cells expressing a dominant-negative Nod1 construct or in mouse embryonic fibroblasts from Nod1 knock-out mice infected with P. aeruginosa. Finally, we demonstrate that the cytokine secretion kinetics and bacterial killing are altered in Nod1-deficient cells infected with P. aeruginosa in the early stages of infection.
C1 Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, BR-21941590 Rio De Janeiro, Brazil.
   Univ Estado Rio de Janeiro, Fac Ciencias Med, BR-20551030 Rio De Janeiro, Brazil.
   Inst Pasteur, Unite Pathogenie Microbienne Mol, F-75724 Paris, France.
   Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris, France.
   Inst Pasteur, Grp Immun Innee & Signalisat, F-75724 Paris, France.
   Millenium Pharmaceut, Cambridge, MA 02139 USA.
RP Travassos, LH (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Microbiol, Bloco 1,Prof Paulo de Goes Ctr Cidade Univ,Ilha F, BR-21941590 Rio De Janeiro, Brazil.
EM lhtravassos@ufrj.br
RI Carneiro, Leticia/T-8978-2019; Domingues, Regina/V-3046-2019; Boneca,
   Ivo G/H-1677-2014; Travassos, Leonardo/G-1925-2012
OI Boneca, Ivo G/0000-0001-8122-509X; Travassos,
   Leonardo/0000-0003-1323-3797; Bozza, Marcelo/0000-0003-3683-7550
CR Agramonte-Hevia J, 2002, FEMS IMMUNOL MED MIC, V34, P255, DOI 10.1016/S0928-8244(02)00408-X
   Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013
   CRIPPS AW, 1995, IMMUNOL CELL BIOL, V73, P418, DOI 10.1038/icb.1995.65
   deBentzmann S, 1996, AM J RESP CRIT CARE, V154, pS155, DOI 10.1164/ajrccm/154.4_Pt_2.S155
   Endlich B, 2002, J IMMUNOL, V168, P3586, DOI 10.4049/jimmunol.168.7.3586
   Fritz JH, 2005, EUR J IMMUNOL, V35, P2459, DOI 10.1002/eji.200526286
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200
   Girardin SE, 2004, EUR J IMMUNOL, V34, P1777, DOI 10.1002/eji.200425095
   Girardin SE, 2003, EMBO REP, V4, P932, DOI 10.1038/sj.embor.embor940
   Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Greene CM, 2005, J IMMUNOL, V174, P1638, DOI 10.4049/jimmunol.174.3.1638
   Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200
   Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200
   JOHNSON DA, 1982, AM REV RESPIR DIS, V126, P1070
   Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004
   Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a
   Kooguchi K, 1998, INFECT IMMUN, V66, P3164, DOI 10.1128/IAI.66.7.3164-3169.1998
   Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100
   Plotkowski MC, 2002, AM J RESP CELL MOL, V26, P617, DOI 10.1165/ajrcmb.26.5.4489
   Plotkowski MC, 1999, AM J RESP CELL MOL, V20, P880, DOI 10.1165/ajrcmb.20.5.3408
   Power MR, 2004, J BIOL CHEM, V279, P49315, DOI 10.1074/jbc.M402111200
   Sato H, 2004, MOL MICROBIOL, V53, P1279, DOI 10.1111/j.1365-2958.2004.04194.x
   Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011
   Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200
   Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248
   Tsai WC, 2000, INFECT IMMUN, V68, P4289, DOI 10.1128/IAI.68.7.4289-4296.2000
   van Heel DA, 2005, EUR J IMMUNOL, V35, P2471, DOI 10.1002/eji.200526296
   VANHEIJENOORT J, 1975, EUR J BIOCHEM, V58, P611
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Wieland CW, 2002, INFECT IMMUN, V70, P1352, DOI 10.1128/IAI.70.3.1352-1358.2002
   Zhang J, 2003, INVEST OPHTH VIS SCI, V44, P4247, DOI 10.1167/iovs.03-0219
NR 36
TC 111
Z9 117
U1 0
U2 16
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 4
PY 2005
VL 280
IS 44
BP 36714
EP 36718
DI 10.1074/jbc.M501649200
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 978VT
UT WOS:000232901800024
PM 16150702
OA Bronze
DA 2020-12-01
ER

PT J
AU Bozza, FA
   Gomes, RN
   Japiassu, AM
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
AF Bozza, FA
   Gomes, RN
   Japiassu, AM
   Soares, M
   Castro-Faria-Neto, HC
   Bozza, PT
   Bozza, MT
TI Macrophage migration inhibitory factor levels correlate with fatal
   outcome in sepsis
SO SHOCK
LA English
DT Article
DE sepsis; MIF; IL-6; cytokine; mortality; markers
ID RESPIRATORY-DISTRESS-SYNDROME; SEPTIC SHOCK; FACTOR MIF; CRITICAL
   MEDIATOR; REGULATORY ROLE; PLASMA-LEVELS; INTERLEUKIN-6; ACTIVATION;
   CYTOKINE; SEVERITY
AB Macrophage migration inhibitory factor (MIF) is a cytokine playing a critical role in the pathophysiology of experimental sepsis. The purpose of this study was to determine the levels of MIF and to compare those to interleukin-6 (IL-6) levels in predicting mortality among critically ill patients with sepsis. The levels of MIF and IL-6 were measured in 25 patients with septic shock, 17 patients with sepsis, and 11 healthy volunteers. The median plasma concentrations of MIF and IL-6 were significantly higher in patients with septic shock and in patients with sepsis than in healthy controls. MIF levels were significantly different between survivors and nonsurvivors, as were IL-6 levels. Discriminatory power in predicting mortality, as assessed by the areas under receiver operating characteristic curves (AUROC), was 0.793 for MIF and 0.680 for IL-6. Finally, high plasma levels of MIF (>1100 pg/mL) had a sensitivity of 100% and a specificity of 64% to identify the patients who eventually would evolve to a fatal outcome. Thus, our data suggest that an elevated MIF level in recently diagnosed septic patients appears to be an early indicator of poor outcome and a potential entry criterion for future studies with therapeutic intervention aiming at MIF neutralization.
C1 Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementino Grafa Filho, ICU, BR-21941590 Rio De Janeiro, Brazil.
   Hosp Espanol, ICU, Rio De Janeiro, Brazil.
   Fundacao Oswaldo Cruz, IOC, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   Inst Nacl Canc, ICU, Rio De Janeiro, Brazil.
RP Bozza, FA (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, Av Brigadeiro Trompowsky,S-N CCS Bloco 1,Ilha Fun, BR-21941590 Rio De Janeiro, Brazil.
EM mbozza@micro.ufrj.br
RI Bozza, Fernando A/A-2618-2013; Gomes, Rachel N/I-7643-2013; Soares,
   Marcio/B-3083-2013
OI Bozza, Fernando A/0000-0003-4878-0256; Soares,
   Marcio/0000-0003-2503-6088; Bozza, Patricia/0000-0001-8349-9529
CR Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849
   Bacher M, 1997, AM J PATHOL, V150, P235
   Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004
   Beishuizen A, 2001, J CLIN ENDOCR METAB, V86, P2811, DOI 10.1210/jc.86.6.2811
   Bergmann M, 2003, SHOCK, V20, P575, DOI 10.1097/01.shk.0000095934.86703.83
   BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A
   Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383
   Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262
   CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0
   CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001
   DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320
   Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC
   Gando S, 2001, INTENS CARE MED, V27, P1187, DOI 10.1007/s001340000818
   GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296
   HERRIOTT MJ, 1993, J IMMUNOL, V150, P4524
   Joshi PC, 2000, RES COMMUN MOL PATH, V107, P13
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lai KN, 2003, J PATHOL, V199, P496, DOI 10.1002/path.1291
   Lehmann LE, 2001, INTENS CARE MED, V27, P1412, DOI 10.1007/s001340101022
   Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5
   Makita H, 1998, AM J RESP CRIT CARE, V158, P573, DOI 10.1164/ajrccm.158.2.9707086
   Opal SM, 2003, SHOCK, V20, P295, DOI 10.1097/01.shk.0000084343.58020.57
   Pettila V, 2002, INTENS CARE MED, V28, P1220, DOI 10.1007/s00134-002-1416-1
   Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004
   Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517
   Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a
   Turnbull IR, 2004, SHOCK, V21, P121, DOI 10.1097/01.shk.0000108399.56565.e7
   Vianna RCS, 2004, SHOCK, V21, P115, DOI 10.1097/01.shk.0000111828.07309.26
   Vincent JL, 2002, CLIN INFECT DIS, V34, P1084, DOI 10.1086/339549
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Yang SL, 2001, AM J PHYSIOL-GASTR L, V281, pG1014
NR 39
TC 123
Z9 135
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1073-2322
J9 SHOCK
JI Shock
PD OCT
PY 2004
VL 22
IS 4
BP 309
EP 313
DI 10.1097/01.shk.0000140305.01641.c8
PG 5
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA 859LF
UT WOS:000224264300002
PM 15377884
DA 2020-12-01
ER

PT J
AU Penido, C
   Vieira-de-Abreu, A
   Bozza, MT
   Castro-Faria-Neto, HC
   Bozza, PT
AF Penido, C
   Vieira-de-Abreu, A
   Bozza, MT
   Castro-Faria-Neto, HC
   Bozza, PT
TI Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma
   delta T lymphocyte trafficking during inflammation induced by
   lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guerin
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ESCHERICHIA-COLI INFECTION; PLEURAL MESOTHELIAL CELLS; IN-VIVO;
   EOSINOPHIL ACCUMULATION; CHEMOATTRACTANT PROTEIN-1; CC-CHEMOKINES;
   EXPRESSION; MICE; LPS; MIGRATION
AB gammadelta T lymphocytes are involved in a great variety of inflammatory and infectious responses. However, the mechanisms by which gammadelta T lymphocytes migrate to inflamed sites are poorly understood. In this study we investigate the role of monocyte chemotactic protein (MCP)-1 in regulating gammadelta T cell migration after LPS or Mycobacterium bovis bacille Calmette-Guerin (BCG) challenge. LPS-induced gammadelta T cell influx was significantly inhibited by either pretreatment with dexamethasone or vaccinia virus Lister 35-kDa chemokine binding protein, vCKBP, a CC chemokine neutralizing protein, suggesting a role for CC chemokines in this phenomenon. LPS stimulation increased the expression of MCP-1 mRNA and protein at the inflammation site within 6 h. It is noteworthy that LPS was unable to increase MCP-1 production or gammadelta T cell recruitment in C3H/HeJ, indicative of the involvement of Toll-like receptor 4. gammadelta T cells express MCP-1 receptor CCR2. Pretreatment with anti-MCP-1 mAb drastically inhibited LPS-induced in vivo gammadelta T cell mobilization. Indeed, MCP-1 knockout mice were unable to recruit gammadelta T cells to the pleural cavity after LPS stimulation, effect that could be restored by coadministration of MCP-1. In addition, BCG-induced gammadelta lymphocyte accumulation was significantly reduced in MCP-1 knockout mice when compared with wild-type mice. In conclusion, our results indicate that LPS-induced gammadelta T lymphocyte migration is dependent on Toll-like receptor 4 and sensitive to both dexamethasone and CC chemokine-binding protein inhibition. Moreover, by using MCP-1 neutralizing Abs and genetically deficient mice we show that LPS- and BCG-induced gammadelta T lymphocyte influx to the pleural cavity of mice is mainly orchestrated by the CC chemokine MCP-1.
C1 Fdn Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Dept Fisiol & Farmacol, BR-21045900 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Immunol, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fdn Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Dept Fisiol & Farmacol, Avenida Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI Penido, Carmen/V-3371-2019
OI Bozza, Patricia/0000-0001-8349-9529
CR Ajuebor MN, 1998, BRIT J PHARMACOL, V125, P319, DOI 10.1038/sj.bjp.0702071
   Alcami A, 1998, J IMMUNOL, V160, P624
   ALLAVENA P, 1994, EUR J IMMUNOL, V24, P3233, DOI 10.1002/eji.1830241249
   ANTONIN V, 1993, LIBRI BOT, V8, P1
   Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985
   Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315
   Biswas P, 1998, BLOOD, V91, P258, DOI 10.1182/blood.V91.1.258.258_258_265
   BOZZA PT, 1994, J LEUKOCYTE BIOL, V56, P151
   BOZZA PT, 1993, EUR J PHARM-ENVIRON, V248, P41, DOI 10.1016/0926-6917(93)90023-J
   BOZZA PT, 1991, BRAZ J MED BIOL RES, V24, P957
   Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797
   CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652
   Castro-Faria-Neto HC, 1997, MEM I OSWALDO CRUZ, V92, P197, DOI 10.1590/S0074-02761997000800026
   Dabbagh K, 2000, J IMMUNOL, V165, P3418, DOI 10.4049/jimmunol.165.6.3418
   Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1
   FACCIOLI LH, 1990, AGENTS ACTIONS, V30, P344, DOI 10.1007/BF01966298
   FOLLOWS GA, 1992, INFECT IMMUN, V60, P1229, DOI 10.1128/IAI.60.3.1229-1231.1992
   Glatzel A, 2002, J IMMUNOL, V168, P4920, DOI 10.4049/jimmunol.168.10.4920
   Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157
   GRIFFIN JP, 1991, INFECT IMMUN, V59, P4263, DOI 10.1128/IAI.59.11.4263-4265.1991
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Hsieh B, 1996, J IMMUNOL, V156, P232
   HUFFNAGLE GB, 1995, J IMMUNOL, V155, P4790
   Imlach S, 2003, VIROLOGY, V305, P415, DOI 10.1006/viro.2002.1759
   INOUE T, 1991, J IMMUNOL, V146, P2754
   Johnston CJ, 1998, TOXICOL SCI, V46, P300, DOI 10.1093/toxsci/46.2.300
   Kaufmann SHE, 1996, P NATL ACAD SCI USA, V93, P2272, DOI 10.1073/pnas.93.6.2272
   Kopydlowski KM, 1999, J IMMUNOL, V163, P1537
   Kunstfeld R, 1998, J INVEST DERMATOL, V111, P1040, DOI 10.1046/j.1523-1747.1998.00410.x
   LECLERCQ G, 1995, J IMMUNOL, V154, P5313
   Loetscher P, 1996, J IMMUNOL, V156, P322
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506
   Menezes-de-Lima-Junior O, 1997, MEM I OSWALDO CRUZ, V92, P227, DOI 10.1590/S0074-02761997000800033
   MenezesdeLimaJunior O, 1997, J LEUKOCYTE BIOL, V62, P778
   Miyamasu M, 1998, J ALLERGY CLIN IMMUN, V101, P75, DOI 10.1016/S0091-6749(98)70196-4
   Mohammed KA, 1998, J INFECT DIS, V178, P1450, DOI 10.1086/314442
   Mohammed KA, 1999, AM J RESP CRIT CARE, V159, P1653, DOI 10.1164/ajrccm.159.5.9810011
   Mokuno Y, 2000, J IMMUNOL, V165, P931, DOI 10.4049/jimmunol.165.2.931
   MORRISON DC, 1979, J IMMUNOL METHODS, V27, P83, DOI 10.1016/0022-1759(79)90241-2
   Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219
   Penido C, 2001, AM J RESP CELL MOL, V25, P707, DOI 10.1165/ajrcmb.25.6.4401
   Penido C, 1997, J IMMUNOL, V159, P853
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660
   Roth SJ, 1998, EUR J IMMUNOL, V28, P104, DOI 10.1002/(SICI)1521-4141(199801)28:01<104::AID-IMMU104>3.0.CO;2-F
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   Smith JB, 1997, METHOD ENZYMOL, V287, P250
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   TAKADA H, 1993, J IMMUNOL, V151, P2062
   Takano M, 1998, INFECT IMMUN, V66, P3270, DOI 10.1128/IAI.66.7.3270-3278.1998
   Uehara S, 2002, J IMMUNOL, V168, P2811, DOI 10.4049/jimmunol.168.6.2811
   VILA LM, 1995, INFECT IMMUN, V63, P1211, DOI 10.1128/IAI.63.4.1211-1217.1995
   Wilson E, 2002, J IMMUNOL, V169, P4970, DOI 10.4049/jimmunol.169.9.4970
   Young JL, 1997, IMMUNOLOGY, V91, P503, DOI 10.1046/j.1365-2567.1997.00289.x
   Zuany-Amorim C, 2002, NAT REV DRUG DISCOV, V1, P797, DOI 10.1038/nrd914
NR 58
TC 51
Z9 51
U1 1
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2003
VL 171
IS 12
BP 6788
EP 6794
DI 10.4049/jimmunol.171.12.6788
PG 7
WC Immunology
SC Immunology
GA 753JF
UT WOS:000187227700062
PM 14662884
OA Bronze
DA 2020-12-01
ER

PT J
AU Rozenfeld, C
   Martinez, R
   Figueiredo, RT
   Bozza, MT
   Lima, FRS
   Pires, AL
   Silva, PM
   Bonomo, A
   Lannes-Vieira, J
   De Souza, W
   Moura-Neto, V
AF Rozenfeld, C
   Martinez, R
   Figueiredo, RT
   Bozza, MT
   Lima, FRS
   Pires, AL
   Silva, PM
   Bonomo, A
   Lannes-Vieira, J
   De Souza, W
   Moura-Neto, V
TI Soluble factors released by Toxoplasma gondii-infected astrocytes
   down-modulate nitric oxide production by gamma interferon-activated
   microglia and prevent neuronal degeneration
SO INFECTION AND IMMUNITY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; PROSTAGLANDIN E-2;
   IFN-GAMMA; SYNTHASE EXPRESSION; BRAIN-INJURY; INTRACELLULAR PATHOGEN;
   MULTIPLE-SCLEROSIS; HOST-RESISTANCE; POTENTIAL ROLE
AB The maintenance of a benign chronic Toxoplasma gondii infection is mainly dependent on the persistent presence of gamma interferon (IFN-gamma) in the central nervous system (CNS). However, IFN-gamma-activated microglia are paradoxically involved in parasitism control and in tissue damage during a broad range of CNS pathologies. In this way, nitric oxide (NO), the main toxic metabolite produced by IFN-gamma-activated microglia, may cause neuronal injury, during T. gondii infection. Despite the potential NO toxicity, neurodegeneration is not a common finding during chronic T. gondii infection. In this work, we describe a significant down-modulation of NO production by IFN-gamma-activated microglia in the presence of conditioned medium of T. gondii-infected astrocytes (CMi). The inhibition of NO production was paralleled with recovery of neurite outgrowth when neurons were cocultured with IFN-gamma-activated microglia in the presence of CMi. Moreover, the modulation of NO secretion and the neuroprotective effect were shown to be dependent on prostaglandin E-2 (PGE(2)) production by T. gondii-infected astrocytes and autocrine secretion of interleukin-10 (IL-10) by microglia. These events were partially eliminated when infected astrocytes were treated with aspirin and cocultures were treated with anti-IL-10 neutralizing antibodies and RP-8-Br cyclic AMP (cAMP), a protein kinase A inhibitor. Further, the modulatory effects of CMi were mimicked by the presence of exogenous PGE(2) and by forskolin, an adenylate cyclase activator. Altogether, these data point to a T. gondii-triggered regulatory mechanism involving PGE(2) secretion by astrocytes and cAMP-dependent IL-10 secretion by microglia. This may reduce host tissue inflammation, thus avoiding neuron damage during an established Th1 protective immune response.
C1 Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Ultraestrutura Celular Hertha Meyer, CCS, BR-21944590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Anat, ICB, BR-21944590 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Dept Imunol, BR-21944590 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Dept Expt Med, INCa, BR-20001 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Dept Imunol, BR-20001 Rio De Janeiro, Brazil.
   Inst Oswaldo Cruz, Dept Farmacol & Farmacodinam, BR-20001 Rio De Janeiro, Brazil.
RP Rozenfeld, C (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Ultraestrutura Celular Hertha Meyer, CCS, Bloco G, BR-21944590 Rio De Janeiro, Brazil.
EM rozen@biof.ufrj.br
RI Moura-Neto, VIVALDO/V-9913-2019; Figueiredo, Rodrigo T./F-5176-2016
OI Moura-Neto, VIVALDO/0000-0002-6266-043X; Figueiredo, Rodrigo
   T./0000-0002-7551-8782; Bozza, Marcelo/0000-0003-3683-7550; Souza Lima,
   Flavia Regina/0000-0003-0799-9235
CR Aloisi F, 2001, ANN MED, V33, P510, DOI 10.3109/07853890108995960
   Aloisi F, 1999, J NEUROSCI RES, V56, P571
   Aloisi F, 1997, J IMMUNOL, V159, P1604
   Aloisi F, 1999, ADV EXP MED BIOL, V468, P123
   Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001
   BOHNE W, 1994, INFECT IMMUN, V62, P1761, DOI 10.1128/IAI.62.5.1761-1767.1994
   Bolanos J P, 2001, Prog Brain Res, V132, P441
   Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173
   BURKE JM, 1994, PARASITE IMMUNOL, V16, P305, DOI 10.1111/j.1365-3024.1994.tb00353.x
   Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x
   Carlson NG, 1999, J IMMUNOL, V163, P3963
   Channon JY, 1996, INFECT IMMUN, V64, P1181, DOI 10.1128/IAI.64.4.1181-1189.1996
   CHAO CC, 1992, J IMMUNOL, V149, P2736
   CHAO CC, 1995, CRIT REV NEUROBIOL, V9, P189
   CHAO CC, 1994, J IMMUNOL, V152, P1246
   Chuenkova MV, 2001, NEUROREPORT, V12, P3715, DOI 10.1097/00001756-200112040-00022
   Chuenkova MV, 2000, MOL BIOL CELL, V11, P1487, DOI 10.1091/mbc.11.4.1487
   DELEMARRE FGA, 1995, AIDS, V9, P441, DOI 10.1097/00002030-199509050-00005
   DING AH, 1988, J IMMUNOL, V141, P2407
   DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700
   Fischer HG, 1997, EUR J IMMUNOL, V27, P1539, DOI 10.1002/eji.1830270633
   FRETLAND DJ, 1992, PROSTAG LEUKOTR ESS, V45, P249, DOI 10.1016/0952-3278(92)90080-3
   Freund YR, 2001, INFECT IMMUN, V69, P765, DOI 10.1128/IAI.69.2.765-772.2001
   GAZZINELLI RT, 1991, J IMMUNOL, V146, P286
   GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792
   Gazzinelli RT, 1996, J IMMUNOL, V157, P798
   Giovannoni G, 1998, MULT SCLER J, V4, P212, DOI 10.1177/135245859800400323
   Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x
   Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x
   Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004
   Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001
   Hewett SJ, 1999, J NEUROIMMUNOL, V94, P134, DOI 10.1016/S0165-5728(98)00240-9
   HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607
   Israelski D M, 1993, Curr Clin Top Infect Dis, V13, P322
   JAMRA LMF, 1991, REV I MED TROP, V33, P435, DOI 10.1590/S0036-46651991000600003
   JUN CD, 1993, IMMUNOL INVEST, V22, P487, DOI 10.3109/08820139309084178
   KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0
   Kang H, 2001, INFECT IMMUN, V69, P2920, DOI 10.1128/IAI.69.5.2920-2927.2001
   Khan IA, 1997, P NATL ACAD SCI USA, V94, P13955, DOI 10.1073/pnas.94.25.13955
   Kikuchi S, 2002, NEUROPHARMACOLOGY, V42, P714, DOI 10.1016/S0028-3908(02)00020-5
   Levi G, 1998, BIOCHIMIE, V80, P899, DOI 10.1016/S0300-9084(00)88886-0
   Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001
   Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001
   Luder CGK, 1998, CLIN EXP IMMUNOL, V112, P308
   Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8
   MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415
   MCMILLIAN M, 1995, BIOCHEM BIOPH RES CO, V215, P572, DOI 10.1006/bbrc.1995.2503
   MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642
   Minghetti L, 1998, J NEUROIMMUNOL, V82, P31, DOI 10.1016/S0165-5728(97)00185-9
   Minghetti L, 1997, ADV EXP MED BIOL, V433, P181
   Minghetti L, 1997, GLIA, V19, P152, DOI 10.1002/(SICI)1098-1136(199702)19:2<152::AID-GLIA6>3.3.CO;2-2
   Penkowa M, 1999, GLIA, V25, P343
   PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z
   ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4
   Rostasy K, 1999, ANN NEUROL, V46, P207, DOI 10.1002/1531-8249(199908)46:2<207::AID-ANA10>3.3.CO;2-W
   SchartonKersten TM, 1997, J EXP MED, V185, P1261, DOI 10.1084/jem.185.7.1261
   Schluter D, 1999, J IMMUNOL, V162, P3512
   Schluter D, 1997, AM J PATHOL, V150, P1021
   Silva NM, 2002, MICROBES INFECT, V4, P261, DOI 10.1016/S1286-4579(02)01537-X
   Stoll G, 2000, J NEURAL TRANSM-SUPP, P81
   SUZUKI Y, 1988, SCIENCE, V240, P516, DOI 10.1126/science.3128869
   Suzuki Y, 2000, MICROBES INFECT, V2, P455, DOI 10.1016/S1286-4579(00)00318-X
   Suzuki Y, 1999, IMMUNOBIOLOGY, V201, P255, DOI 10.1016/S0171-2985(99)80066-7
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   THERY C, 1994, GLIA, V11, P383, DOI 10.1002/glia.440110411
   Trentin AG, 2001, AM J PHYSIOL-ENDOC M, V281, pE1088
   Tsacopoulos M, 1996, J NEUROSCI, V16, P877
   Vane JR, 2002, SCIENCE, V296, P474, DOI 10.1126/science.1071702
   Villegas EN, 2000, INFECT IMMUN, V68, P2837, DOI 10.1128/IAI.68.5.2837-2844.2000
   Williams K, 2001, EUR CHILD ADOLES PSY, V10, P96
   Yap GS, 1999, J EXP MED, V189, P1083, DOI 10.1084/jem.189.7.1083
   Zhang J, 2001, J NEUROCHEM, V76, P855, DOI 10.1046/j.1471-4159.2001.00080.x
   Zhang SC, 2001, GLIA, V34, P101, DOI 10.1002/glia.1045
NR 73
TC 53
Z9 56
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2003
VL 71
IS 4
BP 2047
EP 2057
DI 10.1128/IAI.71.4.2047-2057.2003
PG 11
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 662BQ
UT WOS:000181926200054
PM 12654825
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Saraiva, VB
   Gibaldi, D
   Previato, JO
   Mendonca-Previato, L
   Bozza, MT
   Freire-de-Lima, CG
   Heise, N
AF Saraiva, VB
   Gibaldi, D
   Previato, JO
   Mendonca-Previato, L
   Bozza, MT
   Freire-de-Lima, CG
   Heise, N
TI Proinflammatory and cytotoxic effects of hexadecylphosphocholine
   (miltefosine) against drug-resistant strains of Trypanosoma cruzi
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; VISCERAL LEISHMANIASIS; ORAL MILTEFOSINE;
   CHAGAS-DISEASE; CUTANEOUS LEISHMANIASIS; ACTIVATED MACROPHAGES;
   NITRIC-OXIDE; FACTOR-ALPHA; IN-VITRO; MICE
AB The increased resistance of the protozoan parasite Trypanosoma cruzi to nitro derivatives is one of the major problems for the successful treatment of Chagas' disease. In the present study, we have tested the effects of 1-O-hexadecylphosphocholine (miltefosine) against strains of T. cruzi that are partially resistant (strain Y) and highly resistant (strain Colombiana) to the drugs in clinical use. As expected, epimastigotes of strain Colombiana showed higher levels of resistance to benznidazole than those of strain Y. However, the level of resistance to miltefosine was the same for both strains. This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains. This ether-lipid analogue induced in a dose-dependent manner the production of tumor necrosis factor alpha and nitric oxide (NO) radicals by infected and noninfected macrophages, suggesting that miltefosine may activate macrophages in vitro. Nevertheless, the cytotoxic effect of miltefosine against intracellular amastigotes was independent of the amount of NO produced by the infected macrophages since the same dose-response curves for miltefosine were observed when the NO production was blocked by the NO synthase inhibitor N-G-monomethyl-L-arginine monoacetate. Preliminary in vivo studies with BALB/c mice infected with strain Y indicated that oral miltefosine promoted survival and reduced the parasitemia to levels comparable to those observed when benznidazole was used. Four months after treatment, no parasites were detected in the blood or spleen tissue sections maintained in culture. Together, these results support the hypothesis that miltefosine may be used for the treatment of Chagas' disease, including cases caused by resistant strains of T. cruzi.
C1 UFRJ, IBCCF, Lab Glicobiol, BR-21944970 Rio De Janeiro, RJ, Brazil.
   UFRJ, Dept Imunol, Inst Microbiol, BR-21944970 Rio De Janeiro, RJ, Brazil.
RP Heise, N (corresponding author), UFRJ, IBCCF, Lab Glicobiol, CCS Bloco G, BR-21944970 Rio De Janeiro, RJ, Brazil.
RI de Lima, Celio Geraldo Freire/A-9057-2012; Gibaldi, Daniel/K-7352-2012;
   Heise, Norton/I-4098-2013
OI Barbosa, Victor/0000-0002-9130-8902; Bozza, Marcelo/0000-0003-3683-7550;
   Mendonca Previato, Lucia/0000-0003-3927-3244; Heise,
   Norton/0000-0003-0154-7406; Previato, Jose Osvaldo/0000-0002-9233-9954
CR ANDREWS NW, 1985, EXP PARASITOL, V60, P255, DOI 10.1016/0014-4894(85)90029-3
   Arana B, 2001, MED MICROBIOL IMMUN, V190, P93, DOI 10.1007/s004300100089
   CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8
   Croft SL, 1996, J ANTIMICROB CHEMOTH, V38, P1041, DOI 10.1093/jac/38.6.1041
   CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0
   Escobar P, 2002, ACTA TROP, V81, P151, DOI 10.1016/S0001-706X(01)00197-8
   Escobar P, 2001, ANTIMICROB AGENTS CH, V45, P1872, DOI 10.1128/AAC.45.6.1872-1875.2001
   EUE I, 1995, J CANCER RES CLIN, V121, P350, DOI 10.1007/BF01225687
   Eue I, 2001, INT J CANCER, V92, P426, DOI 10.1002/ijc.1201
   FILARDI LS, 1987, T ROY SOC TROP MED H, V81, P755, DOI 10.1016/0035-9203(87)90020-4
   Fischer C, 2001, MED MICROBIOL IMMUN, V190, P85, DOI 10.1007/s004300100087
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Gantt KR, 2001, J IMMUNOL, V167, P893, DOI 10.4049/jimmunol.167.2.893
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608
   HOCHHUTH CH, 1992, CELL IMMUNOL, V141, P161, DOI 10.1016/0008-8749(92)90135-C
   Jha TK, 1999, NEW ENGL J MED, V341, P1795, DOI 10.1056/NEJM199912093412403
   Konstantinov SM, 1997, ACTA TROP, V64, P145, DOI 10.1016/S0001-706X(96)00628-6
   KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630, DOI 10.1128/AAC.36.8.1630
   Leonard R, 2001, J CLIN ONCOL, V19, P4150, DOI 10.1200/JCO.2001.19.21.4150
   Lira R, 2001, J ANTIMICROB CHEMOTH, V47, P537, DOI 10.1093/jac/47.5.537
   Lux H, 1996, ADV EXP MED BIOL, V416, P201
   Lux H, 2000, MOL BIOCHEM PARASIT, V111, P1, DOI 10.1016/S0166-6851(00)00278-4
   Martinez-Diaz RA, 2001, MEM I OSWALDO CRUZ, V96, P53, DOI 10.1590/S0074-02762001000100006
   MEIRELLES MNL, 1986, EUR J CELL BIOL, V41, P198
   Michailowsky V, 1998, ANTIMICROB AGENTS CH, V42, P2549, DOI 10.1128/AAC.42.10.2549
   Moncayo A, 1999, MEM I OSWALDO CRUZ, V94, P401, DOI 10.1590/S0074-02761999000700079
   Murray HW, 2000, INFECT IMMUN, V68, P6289, DOI 10.1128/IAI.68.11.6289-6293.2000
   Murray HW, 2000, ANTIMICROB AGENTS CH, V44, P3235, DOI 10.1128/AAC.44.11.3235-3236.2000
   Murray HW, 2000, J INFECT DIS, V181, P795, DOI 10.1086/315268
   Murray HW, 2001, ANTIMICROB AGENTS CH, V45, P2185, DOI 10.1128/AAC.45.8.2185-2197.2001
   Murta SMF, 1998, MOL BIOCHEM PARASIT, V93, P203, DOI 10.1016/S0166-6851(98)00037-1
   NEAL RA, 1988, T ROY SOC TROP MED H, V82, P709, DOI 10.1016/0035-9203(88)90208-8
   PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151
   Rybczynska M, 2001, BIOCHEM PHARMACOL, V62, P765, DOI 10.1016/S0006-2952(01)00715-8
   Santa-Rita RM, 2000, ACTA TROP, V75, P219, DOI 10.1016/S0001-706X(00)00052-8
   SCHMIDT HHHW, 1989, BIOCHEM BIOPH RES CO, V165, P284, DOI 10.1016/0006-291X(89)91067-X
   Seifert K, 2001, ANTIMICROB AGENTS CH, V45, P1505, DOI 10.1128/AAC.45.5.1505-1510.2001
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995
   Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0
   Sundar S, 2000, CLIN INFECT DIS, V31, P1110, DOI 10.1086/318122
   Urbina JA, 1999, MEM I OSWALDO CRUZ, V94, P349, DOI 10.1590/S0074-02761999000700068
   Walochnik J, 2002, ANTIMICROB AGENTS CH, V46, P695, DOI 10.1128/AAC.46.3.695-701.2002
   ZEISIG R, 1995, J CANCER RES CLIN, V121, P69, DOI 10.1007/BF01202215
NR 44
TC 35
Z9 36
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2002
VL 46
IS 11
BP 3472
EP 3477
DI 10.1128/AAC.46.11.3472-3477.2002
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 606BK
UT WOS:000178712800020
PM 12384352
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Silveira, MS
   Costa, MR
   Bozza, M
   Linden, R
AF Silveira, MS
   Costa, MR
   Bozza, M
   Linden, R
TI Pituitary adenylyl cyclase-activating polypeptide prevents induced cell
   death in retinal tissue through activation of cyclic AMP-dependent
   protein kinase
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RAT RETINA; ULTRASTRUCTURAL-LOCALIZATION; VASODILATORY PEPTIDE; PACAP
   RECEPTOR; APOPTOSIS; EXPRESSION; MAXADILAN; NEUROTOXICITY; INHIBITION;
   OUTGROWTH
AB Multiple neuroactive substances are secreted by neurons and/or glial cells and modulate the sensitivity to cell death. In the developing retina, it has been shown that increased intracellular levels of cAMP protect cells from degeneration. We tested the hypothesis that the neuroactive peptide pituitary adenylyl cyclase-activating polypeptide (PACAP) has neuroprotective effects upon the developing rat retina. PACAP38 prevented anisomycin-induced cell death in the neuroblastic layer (NBL) of retinal explants, and complete inhibition of induced cell death was obtained with 1 nM. A similar protective effect was observed with PACAP27 and with the specific PAC1 receptor agonist maxadilan but not with glucagon. Photoreceptor cell death induced by thapsigargin was also prevented by PACAP38. The neuroprotective effect of PACAP38 upon the NBL could be reverted by the competitive PACAP receptor antagonist PACAP6-38 and by the specific PAC1 receptor antagonist Maxd.4. Molecular and immunohistochemical analysis demonstrated PAC1 receptors, and treatment with PACAP38 induced phospho-cAMP-response element-binding protein immunoreactivity in the anisomycin-sensitive undifferentiated postmitotic cells within the NBL. PACAP38 produced an increase in cAMP but not inositol triphosphate, and treatment with the cAMP-dependent protein kinase inhibitor R-p-cAMPS blocked the protective effect of PACAP38. The results indicate that activation of PAC1 receptors by PACAP38 modulates cell death in the developing retina through the intracellular cAMP/cAMP-dependent protein kinase pathway.
C1 Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Neurogenese, BR-21949900 Rio de Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21949900 Rio de Janeiro, Brazil.
RP Silveira, MS (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Neurogenese, Bloco G,Cidade Univ, BR-21949900 Rio de Janeiro, Brazil.
EM silveira@biof.ufrj.br
RI Linden, Rafael/F-2275-2011; Silveira, Mariana/M-4865-2013
OI Linden, Rafael/0000-0003-3287-336X; Silveira,
   Mariana/0000-0002-0496-1517; Bozza, Marcelo/0000-0003-3683-7550
CR Alexiades MR, 1997, DEVELOPMENT, V124, P1119
   AryPires R, 1997, INT J DEV NEUROSCI, V15, P239
   BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473
   Braas KM, 1999, J BIOL CHEM, V274, P27702, DOI 10.1074/jbc.274.39.27702
   Casaccia-Bonnefil P, 1999, ADV EXP MED BIOL, V468, P275
   Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226
   Chiarini LB, 2000, CELL DEATH DIFFER, V7, P272, DOI 10.1038/sj.cdd.4400639
   Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098
   CRAFT JL, 1982, CURR EYE RES, V2, P295, DOI 10.3109/02713688209000773
   Cui Q, 2000, NEUROREPORT, V11, P3921, DOI 10.1097/00001756-200011270-00062
   D'Agata V, 1998, MOL BRAIN RES, V54, P161, DOI 10.1016/S0169-328X(97)00335-5
   DEARAUJO EG, 1993, EUR J NEUROSCI, V5, P1181
   GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305
   Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3
   Guimaraes CA, 2001, J NEUROCHEM, V76, P1233, DOI 10.1046/j.1471-4159.2001.00126.x
   Hefti F, 1997, ANNU REV PHARMACOL, V37, P239, DOI 10.1146/annurev.pharmtox.37.1.239
   ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I
   Izumi S, 2000, ANN NY ACAD SCI, V921, P317
   Journot L, 1998, ANN NY ACAD SCI, V865, P100, DOI 10.1111/j.1749-6632.1998.tb11168.x
   KATER SB, 1995, TRENDS NEUROSCI, V18, P71, DOI 10.1016/0166-2236(95)93877-Z
   LERNER EA, 1991, J BIOL CHEM, V266, P11234
   Linden R, 1999, PROG RETIN EYE RES, V18, P133, DOI 10.1016/S1350-9462(98)00020-2
   Linden R, 2000, BRAIN RES REV, V32, P146, DOI 10.1016/S0165-0173(99)00073-9
   LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135
   Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357
   Lu NR, 1998, J NEUROSCI RES, V53, P651, DOI 10.1002/(SICI)1097-4547(19980915)53:6<651::AID-JNR3>3.0.CO;2-4
   LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9
   MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U
   Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966
   Moro O, 1999, J BIOL CHEM, V274, P23103, DOI 10.1074/jbc.274.33.23103
   Namura S, 1998, J NEUROSCI, V18, P3659
   Olianas MC, 1997, J NEUROCHEM, V69, P1213
   ONALI P, 1994, BRAIN RES, V641, P132, DOI 10.1016/0006-8993(94)91825-2
   Rehen SK, 1996, DEVELOPMENT, V122, P1439
   Rehen SK, 1999, EUR J NEUROSCI, V11, P4349, DOI 10.1046/j.1460-9568.1999.00868.x
   REIS RAM, 1995, NEUROCHEM INT, V26, P375, DOI 10.1016/0197-0186(94)00143-I
   Rocha M, 1999, BRAIN RES, V827, P79, DOI 10.1016/S0006-8993(99)01307-4
   Seki T, 1998, ANN NY ACAD SCI, V865, P408, DOI 10.1111/j.1749-6632.1998.tb11205.x
   Seki T, 1997, NEUROSCI LETT, V238, P127, DOI 10.1016/S0304-3940(97)00869-0
   Seki T, 2000, PEPTIDES, V21, P109, DOI 10.1016/S0196-9781(99)00180-1
   Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X
   SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0
   Suh JH, 2001, NAT NEUROSCI, V4, P123, DOI 10.1038/83936
   Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5
   Varella MH, 1999, J NEUROCHEM, V73, P485, DOI 10.1046/j.1471-4159.1999.0730485.x
   Vaudry D, 2000, PHARMACOL REV, V52, P269
   Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415
NR 49
TC 56
Z9 57
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 3
PY 2002
VL 277
IS 18
BP 16075
EP 16080
DI 10.1074/jbc.M110106200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 550PA
UT WOS:000175510400114
PM 11847214
OA Bronze
DA 2020-12-01
ER

PT J
AU Silva, AR
   de Assis, EF
   Caiado, LFC
   Marathe, GK
   Bozza, MT
   McIntyre, TM
   Zimmerman, GA
   Prescott, SM
   Bozza, PT
   Castro-Faria-Neto, HC
AF Silva, AR
   de Assis, EF
   Caiado, LFC
   Marathe, GK
   Bozza, MT
   McIntyre, TM
   Zimmerman, GA
   Prescott, SM
   Bozza, PT
   Castro-Faria-Neto, HC
TI Monocyte chemoattractant protein-1 and 5-lipoxygenase products recruit
   leukocytes in response to platelet-activating factor-like lipids in
   oxidized low-density lipoprotein
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID HUMAN-ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC LESIONS;
   CHEMOTACTIC PROTEIN-1; STRUCTURAL IDENTIFICATION; LYSOPHOSPHATIDIC ACID;
   EICOSANOID FORMATION; INTRACELLULAR SITES; FACTOR RECEPTOR; DEFICIENT
   MICE
AB Oxidized low-density lipoprotein (LDL) contains inflammatory agents, including oxidatively fragmented phospholipids that activate the platelet-activating factor (PAF) receptor, but in vivo events caused by these pathologically generated agents are not well defined. Injection of PAF-like lipids derived from oxidized LDL, or C-4-PAF that is a major PAF-like lipid in these particles, into the pleural cavity of mice resulted in rapid monocyte, neutrophil, and eosinophil accumulation. Increased numbers of intracellular lipid bodies in these cells show they were in an inflammatory environment. Leukocyte recruitment was abolished by a PAF receptor antagonist, as expected. PAF-like lipids induced 5-lipoxygenase expression in leukocytes, mRNA expression for monocyte chemoattractant protein-1 (MCP-1) and other chemokines, synthesis of MCP-1, and leukotriene B-4. The 5-lipoxygenase Inhibitor zileuton impaired neutrophil influx, while MCP-1 had a more global role, as determined with MCP-1(-/-) mice. The lack of MCP-1 abrogated leukocyte accumulation and lipid body formation both in vivo and in vitro and chemokine transcription in vivo, and reduced in vivo leukotriene B-4 production. Thus, PAF-like phospholipids in oxidized LDL induce an inflammatory infiltrate through the PAF receptor, chemokine transcription, lipid body formation, and 5-lipoxygenase expression in leukocytes. MCP-1 has a key role in this inflammatory response, and 5-lipoxygenase products are essential for neutrophil recruitment into the inflamed pleural cavity.
C1 Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Fdn Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   Fed Univ Rio De Janeiro, Inst Microbiol, Dept Imunol, Lab Imflamacao & Imunidade, Rio De Janeiro, Brazil.
   Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.
RP Castro-Faria-Neto, HC (corresponding author), Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, Lab Imunofarmacol, Fdn Oswaldo Cruz, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
RI Silva, Adriana/C-5931-2014; Silva, Adriana Ribeiro/U-7811-2019
OI Silva, Adriana/0000-0002-5137-4251; Silva, Adriana
   Ribeiro/0000-0002-5137-4251; Bozza, Patricia/0000-0001-8349-9529;
   Marathe, Gopal/0000-0002-0025-6677
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL44513, HL44252] Funding Source: Medline; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [R01HL044513, R01HL044513,
   R01HL044513, R43HL044252, R01HL044513, R01HL044513, R01HL044513,
   R01HL044513, R01HL044513, R01HL044513, R01HL044513, R01HL044513,
   R01HL044513, R01HL044513, R01HL044513, R44HL044252, R01HL044513,
   R01HL044513, R01HL044513, R01HL044513, R01HL044513, R44HL044252,
   R01HL044513, R01HL044513] Funding Source: NIH RePORTER
CR Aiello RJ, 1999, ARTERIOSCL THROM VAS, V19, P1518, DOI 10.1161/01.ATV.19.6.1518
   Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BONNET J, 1983, PROSTAGLANDINS, V26, P457, DOI 10.1016/0090-6980(83)90180-6
   Boren J, 2000, CURR OPIN LIPIDOL, V11, P451, DOI 10.1097/00041433-200010000-00002
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515
   CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0
   CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134
   Cuzzocrea S, 2001, FASEB J, V15, P1187, DOI 10.1096/fj.00-0526hyp
   Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200
   DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511
   GILMAN M, 1993, CURRENT PROTOCOLS MO, V1
   Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624
   Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288
   HUFFNAGLE GB, 1995, J IMMUNOL, V155, P4790
   Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133
   Johnston B, 1999, J CLIN INVEST, V103, P1269, DOI 10.1172/JCI5208
   KALUZNY MA, 1985, J LIPID RES, V26, P135
   Kroegel C, 1997, EUR RESPIR J, V10, P2411, DOI 10.1183/09031936.97.10102411
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620
   Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Nagase T, 1997, AM J RESP CRIT CARE, V156, P1621, DOI 10.1164/ajrccm.156.5.9703016
   NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532
   ODA M, 1990, AM REV RESPIR DIS, V141, P1469, DOI 10.1164/ajrccm/141.6.1469
   Ohtsuki K, 2001, CIRCULATION, V104, P203, DOI 10.1161/01.CIR.104.2.203
   Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419
   Rayner K, 2000, J VASC RES, V37, P93, DOI 10.1159/000025720
   Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9
   Rizza C, 1999, LAB INVEST, V79, P1227
   SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055
   Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931
   SILVA PMRE, 1991, J PHARMACOL EXP THER, V257, P1039
   Suga M, 1999, EUR RESPIR J, V14, P376, DOI 10.1034/j.1399-3003.1999.14b23.x
   Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837
   WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765
   Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787
   Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597
   WELLER PF, 1994, J ALLERGY CLIN IMMUN, V94, P1151, DOI 10.1016/0091-6749(94)90325-5
   WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921
   YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252
   YOUNG JM, 1985, PROSTAGLANDINS, V30, P545, DOI 10.1016/0090-6980(85)90018-8
   ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232
NR 51
TC 64
Z9 66
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD APR 15
PY 2002
VL 168
IS 8
BP 4112
EP 4120
DI 10.4049/jimmunol.168.8.4112
PG 9
WC Immunology
SC Immunology
GA 540DJ
UT WOS:000174913300056
PM 11937571
OA Bronze
DA 2020-12-01
ER

PT J
AU Barros, JCD
   Pinheiro, SR
   Bozza, M
   Gueiros, FJ
   Bello, AR
   Lopes, UG
   Pereira, JAA
AF Barros, JCD
   Pinheiro, SR
   Bozza, M
   Gueiros, FJ
   Bello, AR
   Lopes, UG
   Pereira, JAA
TI Evidences of gentamicin resistance amplification in Klebsiella
   pneumoniae isolated from faeces of hospitalized newborns
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE resistance amplification; aminoglycosides modifying enzymes; Klebsiella
   pneumoniae
ID ANTIBIOTIC-RESISTANCE; DNA; 6'-N-ACETYLTRANSFERASE; MECHANISMS; PLASMIDS
AB The intestinal microbiota, a barrier to the establishment of pathogenic bacteria, is also an important reservoir of opportunistic pathogens. It plays a key role in the process of resistance-genes dissemination, commonly carried by specialized genetic elements, like plasmids, phages, and conjugative transposons.
   We obtained from strains of enterobacteria, isolated from faeces of newborns bl a university hospital nursery indication of phenothypical gentamicin resistance amplification (frequencies of 10(-3) to 10(-5) compatible with transposition frequencies). Southern blotting assays showed strong hybridization signals for both plasmidial and chromossomal regions in DNA extracted from variants selected at high gentamicin concentrations, using as a probe a labeled cloned insert containing aminoglycoside modifying enzyme (AME) gene sequence originated from a plasmid of a Klebsiella pneumoniae strain previously isolated in the same hospital. Further we found indications of inactivation to other resistance genes in variants selected under similar conditions, as well as, indications of co-amplification of other AME markers (amikacin).
   Since the intestinal environment is a scenario of selective processes due to the therapeutic and prophylactic use of antimicrobial agents, the processes of amplification of low level antimicrobial resistance (not usually detected or sought by common methods used for antibiotic resistance surveillance) might compromise the effectiveness of antibiotic chemotherapy.
C1 UREJ, Fac Ciencias Med, Dept Patol Labs, BR-20551030 Rio De Janeiro, Brazil.
   Far Manguinhos, Lab Farmacol Aplicada, BR-20551030 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Mol Parasitol Lab, BR-21941 Rio De Janeiro, Brazil.
RP Pereira, JAA (corresponding author), UREJ, Fac Ciencias Med, Dept Patol Labs, Av 28 Setembro,87 Fundos, BR-20551030 Rio De Janeiro, Brazil.
RI Lopes, Ulisses Gazos/T-6634-2019; Bello, Alexandre/Y-7410-2019; Lopes,
   Ulisses/N-4416-2013; Gueiros-Filho, Frederico J./D-2160-2013; Bello,
   Alexandre/H-1293-2012
OI Bello, Alexandre/0000-0003-1391-9967; Gueiros-Filho, Frederico
   J./0000-0001-5425-2439; Bello, Alexandre/0000-0003-1391-9967; Bozza,
   Marcelo/0000-0003-3683-7550
CR Baquero F, 1997, CIBA F SYMP, V207, P93
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   BENNETT PM, 1991, J HOSP INFECT, V18, P211, DOI 10.1016/0195-6701(91)90026-5
   CASEWELL M, 1977, BRIT MED J, V2, P1315, DOI 10.1136/bmj.2.6098.1315
   CHOPRA I, 1992, J ANTIMICROB CHEMOTH, V30, P737, DOI 10.1093/jac/30.6.737
   DATTA N, 1983, NATURE, V306, P616, DOI 10.1038/306616a0
   FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9
   Hariharan R, 1996, HOSP EPIDEMIOLOGY IN, P345
   JACOBY GA, 1991, NEW ENGL J MED, V324, P601, DOI 10.1056/NEJM199102283240906
   KADO CI, 1981, J BACTERIOL, V145, P1365, DOI 10.1128/JB.145.3.1365-1373.1981
   LAMBERT T, 1994, FEMS MICROBIOL LETT, V115, P297, DOI 10.1111/j.1574-6968.1994.tb06654.x
   Maniatis T, 1982, MOL CLONING LAB MANU
   MARTINEZSALAZAR JM, 1986, ANTIMICROB AGENTS CH, V30, P630, DOI 10.1128/AAC.30.4.630
   NIES BA, 1986, J ANTIMICROB CHEMOTH, V18, P35, DOI 10.1093/jac/18.Supplement_C.35
   Panaite DM, 1998, PLASMID, V39, P123, DOI 10.1006/plas.1997.1330
   PEREIRA JAA, 1990, THESIS UFRJ
   PETERSON BC, 1985, J BACTERIOL, V161, P1042, DOI 10.1128/JB.161.3.1042-1048.1985
   PHILLIPS I, 1996, HOSP EPIDEMIOLOGY IN, P980
   SCHMITT R, 1986, J ANTIMICROB CHEMOTH, V18, P25, DOI 10.1093/jac/18.Supplement_C.25
   SHALAES DM, 1996, HOSP EPIDEMIOLOGY IN, P965
   SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993
   SILVER LL, 1993, ANTIMICROB AGENTS CH, V37, P377, DOI 10.1128/AAC.37.3.377
   THOMPSON R, 1986, J ANTIMICROB CHEMOTH, V18, P13, DOI 10.1093/jac/18.Supplement_C.13
   TOLMASKY ME, 1988, ANTIMICROB AGENTS CH, V32, P1416, DOI 10.1128/AAC.32.9.1416
   Vieira L A, 1999, J Pediatr (Rio J), V75, P83
   WIEDEMANN B, 1986, J ANTIMICROB CHEMOTH, V18, P85, DOI 10.1093/jac/18.Supplement_C.85
NR 26
TC 2
Z9 2
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD NOV-DEC
PY 1999
VL 94
IS 6
BP 795
EP 802
PG 8
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 256YL
UT WOS:000083754000016
PM 10585658
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU BOZZA, M
   KOLAKOWSKI, LF
   JENKINS, NA
   GILBERT, DJ
   COPELAND, NG
   DAVID, JR
   GERARD, C
AF BOZZA, M
   KOLAKOWSKI, LF
   JENKINS, NA
   GILBERT, DJ
   COPELAND, NG
   DAVID, JR
   GERARD, C
TI STRUCTURAL CHARACTERIZATION AND CHROMOSOMAL LOCATION OF THE MOUSE
   MACROPHAGE-MIGRATION INHIBITORY FACTOR GENE AND PSEUDOGENES
SO GENOMICS
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; LYMPHOCYTE MEDIATORS; LINKAGE
   MAP; INTERSPECIFIC BACKCROSS; LOCALIZATION; EXPRESSION; CELLS;
   HYPERSENSITIVITY; ORGANIZATION
AB Macrophage migration inhibitory factor, MIF, is a cytokine released by T-lymphocytes, macrophages, and the pituitary gland that serves to integrate peripheral and central inflammatory responses. Ubiquitous expression and developmental regulation suggest that MIF may have additional roles outside of the immune system. Here we report the structure and chromosomal location of the mouse Mif gene and the partial characterization of five Mif pseudogenes. The mouse Mif gene spans less than 0.7 kb of chromosomal DNA and is composed of three exons. A comparison between the mouse and the human genes shows a similar gene structure and common regulatory elements in both promoter regions. The mouse Mif gene maps to the middle region of chromosome 10, between Ber and S100b, which have been mapped to human chromosomes 22q11 and 21q22.3, respectively. The entire sequence of two pseudogenes demonstrates the absence of introns, the presence of the 5' untranslated region of the cDNA, a 3' poly(A) tail, and the lack of sequence similarity with untranscribed regions of the gene. The five pseudogenes are highly homologous to the cDNA, but contain a variable number of mutations that would produce mutated or truncated MIF-like proteins. Phylogenetic analyses of MIF genes and pseudogenes indicate several independent genetic events that can account for multiple genomic integrations. Three of the Mif pseudogenes were also mapped by interspecific backcross to chromosomes 1, 9, and 17. These results suggest that Mif pseudogenes originated by retrotransposition (C) 1995 Academic Press, Inc.
C1 HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115.
   CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115.
   NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,BETHESDA,MD 21702.
OI Bozza, Marcelo/0000-0003-3683-7550
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI022532, R01AI022532, R01AI022532, R01AI022532, R01AI022532,
   R01AI022532, R01AI022532, R01AI022532, R01AI022532, R01AI022532,
   R01AI022532, R01AI022532, R01AI022532] Funding Source: NIH RePORTER;
   OFFICE OF THE DIRECTOR, NCIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [N01CO046000, N01CO046000, N01CO046000, N01CO046000,
   N01CO046000, N01CO046000, N01CO046000, N01CO046000, N01CO046000,
   N01CO046000] Funding Source: NIH RePORTER; NCI NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [N01-CO-46000] Funding Source:
   Medline; NIAID NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI22532] Funding Source:
   Medline
CR BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0
   Bernhagen Juergen, 1994, Trends in Microbiology, V2, P198, DOI 10.1016/0966-842X(94)90111-H
   BLOCKI FA, 1993, PROTEIN SCI, V2, P2095, DOI 10.1002/pro.5560021210
   BLOCKI FA, 1992, NATURE, V360, P269, DOI 10.1038/360269a0
   BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80
   BOURBON HM, 1991, GENE, V101, P273, DOI 10.1016/0378-1119(91)90423-9
   BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025
   BROSIUS J, 1991, SCIENCE, V15, P753
   BUDARF M, 1990, GENOMICS, V8, P575, DOI 10.1016/0888-7543(90)90047-X
   CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895
   CHURCHILL WH, 1975, J IMMUNOL, V115, P781
   COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y
   COX RD, 1991, GENOMICS, V10, P375, DOI 10.1016/0888-7543(91)90322-6
   DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72
   DAVID JR, 1972, PROG ALLERGY, V16, P300, DOI 10.1159/000313176
   DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I
   DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X
   FOWLES RE, 1973, J EXP MED, V138, P952, DOI 10.1084/jem.138.4.952
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   GOMI H, 1994, P NATL ACAD SCI USA, V91, P2824, DOI 10.1073/pnas.91.7.2824
   GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037
   Green EL, 1981, GENETICS PROBABILITY, P77
   HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189
   HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463
   ISHIZAKA K, 1988, ANNU REV IMMUNOL, V6, P513
   JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982
   JUSTICE MJ, 1990, GENETICS, V125, P855
   KINGSLEY DM, 1989, GENETICS, V123, P165
   LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919
   MIKAYAMA T, 1993, P NATL ACAD SCI USA, V90, P10056, DOI 10.1073/pnas.90.21.10056
   NATHAN CF, 1973, J EXP MED, V137, P275, DOI 10.1084/jem.137.2.275
   NATHAN CF, 1971, J EXP MED, V133, P1356, DOI 10.1084/jem.133.6.1356
   OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477
   PARALKAR V, 1994, GENOMICS, V19, P48, DOI 10.1006/geno.1994.1011
   PEREZ JL, 1994, ONCOGENE, V9, P211
   PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C
   PIESSENS WF, 1975, J IMMUNOL, V114, P293
   ROCKLIN RE, 1970, NEW ENGL J MED, V282, P1340, DOI 10.1056/NEJM197006112822404
   Sambrook J, 1989, MOL CLONING LABORATO
   SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664
   SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN
   TAYLOR BA, 1993, MAMM GENOME, V4, pS154, DOI 10.1007/BF00360836
   TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421
   WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.biochem.55.1.631
   WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522
   WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272
NR 46
TC 31
Z9 35
U1 0
U2 0
PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS
PI SAN DIEGO
PA 525B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495
SN 0888-7543
J9 GENOMICS
JI Genomics
PD JUN 10
PY 1995
VL 27
IS 3
BP 412
EP 419
DI 10.1006/geno.1995.1071
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA RG981
UT WOS:A1995RG98100004
PM 7558021
DA 2020-12-01
ER

EF